-DOCSTART-

Whether	O
PPAR	O
activators	O
influence	O
the	O
inflammatory	O
responses	O
of	O
ECs	B-cell_type
is	O
unknown	O
.	O

Recent	O
reports	O
have	O
suggested	O
a	O
previously	O
unexpected	O
variability	O
in	O
the	O
expression	O
of	O
the	O
dominant	B-cell_line
neoplastic	I-cell_line
clone	I-cell_line
in	O
myeloproliferative	O
disorders	O
(	O
MPD	O
)	O
.	O

The	O
second	O
(	O
-365/-264	O
)	O
binds	O
to	O
nuclear	B-protein
factors	I-protein
,	O
which	O
appear	O
to	O
be	O
different	O
in	O
basophils	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
acts	O
as	O
a	O
negative	O
element	O
in	O
basophils	B-cell_type
and	O
as	O
a	O
positive	O
one	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
present	O
evidence	O
indicating	O
that	O
signal	O
transduction	O
pathways	O
induced	O
by	O
PGE2	O
necessitate	O
the	O
participation	O
of	O
cyclic	O
AMP	O
,	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
and	O
Ca2+	O
.	O

Specific	O
lymphocytes	B-cell_type
were	O
induced	O
by	O
in	O
vitro	O
peptide	O
sensitization	O
and	O
screened	O
by	O
thymidine	O
uptake	O
or	O
cellular	O
cytotoxic	O
assays	O
.	O

We	O
used	O
our	O
monoclonal	O
model	O
of	O
germinal	O
center	O
maturation	O
,	O
CL-01	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
to	O
investigate	O
the	O
role	O
of	O
CD30	B-protein
in	O
human	O
B	O
cell	O
differentiation	O
.	O

The	O
loss	O
of	O
TNFRp55	B-protein
function	O
renders	O
mice	O
resistant	O
to	O
lethal	O
dosages	O
of	O
either	O
lipopolysaccharides	O
or	O
S.	B-protein
aureus	I-protein
enterotoxin	I-protein
B	I-protein
.	O

In	O
this	O
paper	O
,	O
we	O
studied	O
the	O
molecular	O
consequences	O
of	O
PF	O
treatment	O
during	O
lymphocyte	O
activation	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
activation	O
of	O
JAK	B-protein
/STAT	B-protein
pathway	O
upon	O
human	B-protein
interleukin-5	I-protein
(	O
hIL-5	B-protein
)	O
stimulation	O
of	O
two	O
different	O
hIL-5-responsive	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
hIL-5	B-cell_line
receptor	I-cell_line
alpha-subunit	I-cell_line
(	I-cell_line
hIL-5R	I-cell_line
alpha	I-cell_line
)	I-cell_line
cDNA-transfected	I-cell_line
TF-1	I-cell_line
(	O
TF-h5R	B-cell_line
alpha	I-cell_line
)	O
and	O
butyric-acid-treated	B-cell_line
YY-1	I-cell_line
(	O
YY-Bu	B-cell_line
)	O
,	O
and	O
peripheral	B-cell_line
eosinophils	I-cell_line
.	O

Finally	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
increased	O
the	O
activity	O
of	O
both	O
the	O
core	O
and	O
the	O
969-bp	B-DNA
promoter	I-DNA
fragments	I-DNA
,	O
and	O
this	O
increase	O
was	O
abrogated	O
by	O
mutations	O
at	O
the	O
CRE	B-DNA
site	I-DNA
.	O

We	O
have	O
cloned	O
the	O
gene	O
for	O
a	O
new	O
ets-related	B-protein
transcription	I-protein
factor	I-protein
,	O
ERP	B-protein
(	O
ets-related	B-protein
protein	I-protein
)	O
,	O
from	O
the	O
murine	B-cell_line
pre-B	I-cell_line
cell	I-cell_line
line	I-cell_line
BASC	B-cell_line
6C2	I-cell_line
and	O
from	O
mouse	O
lung	O
tissue	O
.	O

In	O
contrast	O
to	O
neutrophils	B-cell_type
,	O
p38	B-protein
was	O
constitutively	O
phosphorylated	O
and	O
agonist-dependent	O
phosphorylation	O
and	O
activation	O
was	O
not	O
detected	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

An	O
exogenously	O
expressed	O
Cbf	B-protein
alpha	I-protein
2-encoded	I-protein
subunit	I-protein
(	O
CBF	B-protein
alpha	I-protein
2-451	I-protein
)	O
stimulated	O
transcription	O
from	O
the	O
SL3	B-DNA
enhancer	I-DNA
in	O
P19	B-protein
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Specific	O
receptors	O
for	O
1	O
,	O
25	O
Dihydroxyvitamin	O
D3	O
have	O
been	O
described	O
in	O
human	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O

All	O
these	O
motifs	O
are	O
strikingly	O
conserved	O
in	O
sequence	O
and	O
placement	O
relative	O
to	O
the	O
previously	O
characterized	O
murine	B-DNA
B29	I-DNA
promoter	I-DNA
.	O

The	O
novel	O
Ets	B-protein
protein	I-protein
was	O
most	O
closely	O
related	O
to	O
PU.1	B-protein
and	O
Spi-B	B-protein
within	O
the	O
DNA	B-DNA
binding	I-DNA
Ets	I-DNA
domain	I-DNA
and	O
was	O
therefore	O
named	O
Spi-C	B-protein
.	O

These	O
data	O
demonstrate	O
that	O
the	O
15-amino	B-protein
acid	I-protein
sequence	I-protein
of	O
NFATx1	B-protein
is	O
a	O
major	B-protein
transactivation	I-protein
sequence	I-protein
required	O
for	O
induction	O
of	O
genes	O
by	O
NFATx1	B-protein
in	O
T	B-cell_type
cells	I-cell_type
and	O
possibly	O
regulates	O
NFAT	B-protein
activity	O
through	O
tissue-specific	O
alternative	O
splicing	O
.	O

Thus	O
,	O
depending	O
on	O
the	O
cellular	O
environment	O
,	O
the	O
short-	O
and	O
long-term	O
effects	O
of	O
Tax	B-protein
expression	O
can	O
be	O
quite	O
different	O
.	O

Hepatic	B-cell_type
microsomes	I-cell_type
and	O
isolated	B-cell_type
hepatocytes	I-cell_type
in	O
short	O
term	O
culture	O
desulfate	O
T3	O
sulfate	O
(	O
T3SO4	O
)	O
.	O

The	O
resolution	O
of	O
immune	O
responses	O
is	O
characterized	O
by	O
extensive	O
apoptosis	O
of	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

LPMC	B-cell_type
exhibited	O
increased	O
IL-2	B-protein
production	O
in	O
response	O
to	O
CD28	B-protein
costimulation	O
,	O
compared	O
with	O
cells	O
activated	O
through	O
CD2	B-protein
alone	O
.	O

T	B-cell_type
cells	I-cell_type
lack	O
active	O
NF-kappa	B-protein
B	I-protein
but	O
express	O
Sp1	B-protein
as	O
expected	O
.	O

In	O
August	O
,	O
1992	O
,	O
we	O
established	O
a	O
leukemic	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
NS-Meg	B-cell_line
)	O
from	O
a	O
patient	O
in	O
megakaryoblastic	O
transformation	O
of	O
Philadelphia	O
chromosome-positive	O
chronic	O
myeloid	O
leukemia	O
.	O

By	O
contrast	O
,	O
memory	O
cells	O
,	O
either	O
in	O
vitro	B-cell_line
activated	I-cell_line
helper	I-cell_line
T	I-cell_line
cells	I-cell_line
reverting	O
to	O
a	O
resting	O
state	O
,	O
or	O
CD4+	B-cell_line
T	I-cell_line
(	I-cell_line
memory	I-cell_line
)	I-cell_line
clones	I-cell_line
,	O
or	O
CD4+CD45RO+	B-cell_line
T	I-cell_line
cells	I-cell_line
isolated	O
ex	O
vivo	O
,	O
no	O
longer	O
have	O
a	O
silencer	B-DNA
.	O

Tissue	O
and	O
cell-type	O
specific	O
expression	O
of	O
the	O
tuberous	B-DNA
sclerosis	I-DNA
gene	I-DNA
,	O
TSC2	B-DNA
,	O
in	O
human	O
tissues	O
.	O

The	O
gC2-	B-cell_line
and	I-cell_line
gD2-specific	I-cell_line
CD4+	I-cell_line
clones	I-cell_line
had	O
cytotoxic	O
activity	O
.	O

Nonetheless	O
,	O
only	O
a	O
limited	O
portion	O
of	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
is	O
necessary	O
for	O
IL-7R	B-protein
signal	O
transduction	O
.	O

Oestradiol	O
has	O
mitogenic	O
and	O
regulatory	O
effects	O
on	O
various	O
organs	O
and	O
cells	O
,	O
mediated	O
mainly	O
by	O
its	O
nuclear	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
.	O

The	O
Tax	B-protein
protein	I-protein
of	O
HTLV-I	O
,	O
a	O
positive	B-protein
transcriptional	I-protein
activator	I-protein
of	O
HTLV-I	O
gene	O
expression	O
,	O
is	O
a	O
viral	O
oncogene	O
that	O
also	O
increases	O
transcription	O
of	O
cellular	B-DNA
genes	I-DNA
including	O
GM-CSF	B-protein
,	O
IL-2R	B-protein
alpha	I-protein
and	O
IL-2	B-protein
.	O

The	O
importance	O
of	O
TNF-alpha	B-protein
release	O
in	O
NF-kappaB	B-protein
induction	O
by	O
HOCl	O
or	O
H2O2	O
was	O
demonstrated	O
by	O
the	O
fact	O
that	O
:	O
(	O
1	O
)	O
the	O
nuclear	O
appearance	O
of	O
NF-kappaB	B-protein
was	O
promoted	O
in	O
untreated	B-cell_line
cells	I-cell_line
;	O
and	O
(	O
2	O
)	O
synergism	O
between	O
TNF-alpha	B-protein
and	O
HOCl	O
was	O
detected	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
coexpression	O
of	O
constitutively	O
active	O
forms	O
of	O
Raf-1	B-protein
and	O
calcineurin	B-protein
synergistically	O
induced	O
kappaB	B-protein
-dependent	O
reporter	O
activity	O
,	O
suggesting	O
a	O
physiologically	O
relevant	O
functional	O
interaction	O
between	O
the	O
kinase	B-protein
and	O
the	O
phosphatase	B-protein
.	O

A	O
cDNA	B-DNA
clone	I-DNA
,	O
B4-2	B-DNA
,	O
was	O
isolated	O
from	O
a	O
natural	B-DNA
killer	I-DNA
(	I-DNA
NK	I-DNA
)	I-DNA
minus	I-DNA
T	I-DNA
cell	I-DNA
subtractive	I-DNA
library	I-DNA
.	O

These	O
results	O
suggest	O
the	O
possible	O
use	O
of	O
combinations	O
between	O
IFNs	B-protein
and	O
retinoic	O
acid	O
in	O
the	O
cyto-differentiating	O
treatment	O
of	O
APL	O
patients	O
.	O

Circular	O
permutation	O
and	O
phasing	O
analyses	O
demonstrated	O
that	O
PU.1	B-protein
binding	O
but	O
not	O
TFE3	B-protein
or	O
Ets-1	B-protein
bends	O
mu	B-DNA
enhancer	I-DNA
DNA	I-DNA
toward	O
the	O
major	O
groove	O
.	O

These	O
interactions	O
require	O
ATP/Mg2+	O
and	O
when	O
ATP	O
is	O
limiting	O
the	O
PR	B-protein
complex	O
is	O
altered	O
to	O
one	O
containing	O
the	O
proteins	O
p60	B-protein
and	O
p48	B-protein
,	O
but	O
lacking	O
immunophilins	B-protein
and	O
p23	B-protein
.	O

Our	O
experiments	O
also	O
show	O
that	O
activated	O
PR	B-protein
does	O
not	O
confer	O
direct	O
transcriptional	O
control	O
on	O
the	O
dPRL	B-DNA
promoter	I-DNA
.	O

We	O
have	O
studied	O
the	O
regulation	O
of	O
sialoadhesin	B-protein
expression	O
in	O
vitro	O
and	O
show	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
induce	O
sialoadhesin	B-protein
expression	O
on	O
freshly	O
isolated	O
rat	B-cell_type
macrophages	I-cell_type
and	O
the	O
rat	B-cell_line
macrophage	I-cell_line
cell	I-cell_line
line	I-cell_line
R2	I-cell_line
.	O

IFN-gamma	B-protein
pre-treatment	O
affected	O
the	O
magnitude	O
rather	O
than	O
the	O
sensitivity	O
of	O
the	O
LPS	O
response	O
.	O

Because	O
the	O
GATA-1	B-DNA
gene	I-DNA
is	O
known	O
to	O
transactivate	O
several	O
genes	O
specific	O
for	O
the	O
erythroid	B-cell_type
,	I-cell_type
megakaryocytic	I-cell_type
,	I-cell_type
and	I-cell_type
mastocytic/basophilic	I-cell_type
lineages	I-cell_type
,	O
we	O
studied	O
GATA-1	B-protein
expression	O
in	O
these	O
purified	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

The	O
concentration	O
of	O
the	O
VDR	B-RNA
mRNA	I-RNA
was	O
10	O
(	O
-8	O
)	O
to	O
10	O
(	O
-7	O
)	O
g/g	O
of	O
total	O
RNA	O
in	O
cell-sorted	B-cell_type
monocytes	I-cell_type
and	O
in	O
in	B-cell_type
vitro	I-cell_type
activated	I-cell_type
lymphocytes	I-cell_type
,	O
but	O
only	O
10	O
(	O
-12	O
)	O
g/g	O
of	O
total	O
mRNA	O
in	O
resting	O
lymphocytes	B-cell_type
,	O
establishing	O
that	O
the	O
VDR	B-RNA
mRNA	I-RNA
determined	O
by	O
our	O
method	O
in	O
PBMCs	B-cell_type
is	O
due	O
to	O
constitutive	O
expression	O
in	O
monocytes	B-cell_type
.	O

These	O
results	O
suggest	O
that	O
clinical	O
glucocorticoid	O
resistance	O
in	O
chronic	O
asthma	O
does	O
not	O
reflect	O
abnormal	O
glucocorticoid	O
clearance	O
but	O
may	O
be	O
due	O
at	O
least	O
partly	O
to	O
a	O
relative	O
insensitivity	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
to	O
glucocorticoids	O
.	O

Induction	O
of	O
this	O
distal	B-DNA
IL-2	I-DNA
enhancer	I-DNA
differs	O
from	O
induction	O
of	O
the	O
proximal	B-DNA
IL-2	I-DNA
promoter-enhancer	I-DNA
,	O
since	O
it	O
is	O
induced	O
by	O
phorbol	O
esters	O
alone	O
and	O
independent	O
from	O
Ca2+	O
signals	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
a	O
portion	O
of	O
the	O
ER	B-protein
upstream	B-DNA
regulatory	I-DNA
region	I-DNA
from	O
the	O
ER-positive	B-cell_line
MCF-7	I-cell_line
and	O
the	O
ER-negative	B-cell_line
MDA-MB-231	I-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
to	O
determine	O
if	O
sequence	O
alterations	O
in	O
this	O
region	O
account	O
for	O
the	O
ER	B-protein
-negative	O
phenotype	O
of	O
some	O
tumors	O
.	O

Thirteen	O
preterms	O
of	O
the	O
latter	O
group	O
received	O
prenatal	O
steroid	O
treatment	O
.	O

These	O
involve	O
activation	O
of	O
the	O
sodium/proton-exchanger	B-protein
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1-2	O
minutes	O
.	O

The	O
T/NK	B-cell_type
subsets	I-cell_type
in	O
the	O
BM	O
of	O
MRD-negative	O
(	O
MRD-	O
)	O
LT	O
(	O
MRD-/LT	O
)	O
patients	O
showed	O
similar	O
numbers	O
of	O
cells	O
as	O
normal	O
volunteers	O
.	O

Differential	O
phosphorylation	O
and	O
consequent	O
differential	O
activation	O
of	O
both	O
separate	O
and	O
overlapping	O
STAT	B-protein
proteins	I-protein
by	O
IL-2	B-protein
,	O
IL-12	B-protein
,	O
and	O
IFN-alpha	B-protein
may	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
similarities	O
and	O
differences	O
in	O
the	O
actions	O
of	O
these	O
cytokines	B-protein
on	O
NK	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
we	O
used	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
to	O
determine	O
whether	O
such	O
mutations	O
occur	O
naturally	O
in	O
rhabdomyosarcomas	O
.	O

Although	O
the	O
activating	O
signals	O
leading	O
to	O
Egr-1	B-protein
induction	O
have	O
been	O
studied	O
extensively	O
,	O
little	O
is	O
known	O
about	O
the	O
genes	O
that	O
are	O
placed	O
further	O
downstream	O
within	O
this	O
activation	O
cascade	O
and	O
that	O
are	O
transcriptionally	O
regulated	O
by	O
Egr-1	B-protein
.	O

One	O
of	O
the	O
isolated	O
genes	O
,	O
that	O
for	O
retinaldehyde	B-protein
dehydrogenase	I-protein
2	I-protein
(	O
RALDH2	B-protein
)	O
,	O
was	O
regularly	O
expressed	O
in	O
most	O
of	O
the	O
T-ALL	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
coexpressed	O
TAL1	B-protein
and	O
LMO	B-protein
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
corresponding	O
mutations	O
in	O
murine	O
calcineurin	B-protein
render	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
signal	O
transduction	O
cascade	O
CsA	O
resistant	O
in	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
NF90	B-protein
was	O
phosphorylated	O
in	O
a	O
double-stranded	B-RNA
RNA	I-RNA
-dependent	O
manner	O
likely	O
by	O
the	O
interferon-induced	O
,	O
double-stranded	B-protein
RNA-dependent	I-protein
protein	I-protein
kinase	I-protein
,	O
PKR	B-protein
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
indicate	O
that	O
MS-2beta	B-protein
and	O
MS-2gamma	B-protein
interact	O
with	O
nuclear	B-protein
factors	I-protein
that	O
are	O
induced	O
during	O
U937	B-cell_line
differentiation	O
.	O

This	O
was	O
evidenced	O
by	O
the	O
ability	O
of	O
the	O
AP-1	B-DNA
site	I-DNA
to	O
compete	O
with	O
the	O
NF-AT	B-protein
site	O
for	O
binding	O
to	O
NF-AT	B-protein
and	O
by	O
the	O
capacity	O
of	O
immobilized	B-protein
anti-Jun	I-protein
and	O
anti-Fos	B-protein
antibodies	O
to	O
deplete	O
NF-AT	B-protein
-binding	O
activity	O
from	O
nuclear	O
extracts	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Transcriptional	O
basis	O
for	O
hyporesponsiveness	O
of	O
the	O
human	B-DNA
inducible	I-DNA
nitric	I-DNA
oxide	I-DNA
synthase	I-DNA
gene	I-DNA
to	O
lipopolysaccharide/interferon-gamma	O
.	O

Inhibition	O
of	O
T	B-cell_type
cell	I-cell_type
and	O
promotion	O
of	O
natural	O
killer	O
cell	O
development	O
by	O
the	O
dominant	B-protein
negative	I-protein
helix	I-protein
loop	I-protein
helix	I-protein
factor	I-protein
Id3	B-protein
.	O

Two	O
well-characterized	O
Ets	B-protein
family	I-protein
members	I-protein
,	O
Ets-1	B-protein
and	O
Ets-2	B-protein
,	O
are	O
reciprocally	O
expressed	O
during	O
T-cell	O
activation	O
.	O

Similar	O
results	O
have	O
been	O
obtained	O
by	O
our	O
own	O
group	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
from	O
patients	O
with	O
secondary	O
hyperparathyroidism	O
to	O
chronic	O
renal	O
failure	O
.	O

In	O
parallel	O
with	O
such	O
differentiation	O
,	O
HIV	O
transcription	O
,	O
monitored	O
using	O
an	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
reporter	I-DNA
gene	I-DNA
construct	I-DNA
,	O
is	O
activated	O
in	O
such	O
cells	O
under	O
the	O
influence	O
of	O
enhanced	O
NF-kappa	B-protein
B	I-protein
expression	O
.	O

Tyrosine	O
phosphorylation	O
of	O
p38	B-protein
and	O
p63	B-protein
is	O
also	O
observed	O
in	O
platelets	B-cell_type
stimulated	O
by	O
the	O
tyrosine	B-protein
kinase	I-protein
-linked	O
receptor	O
agonist	O
collagen	B-protein
and	O
by	O
the	O
G	B-protein
protein	I-protein
-coupled	O
receptor	O
agonist	O
thrombin	B-protein
,	O
although	O
phosphorylation	O
of	O
SLP-76	B-protein
is	O
only	O
observed	O
in	O
collagen	B-protein
-stimulated	O
platelets	B-cell_type
.	O

In	O
contrast	O
,	O
C3H	O
mice	O
inoculated	O
with	O
wild-type	O
Ad	O
recognized	O
an	O
epitope	O
mapping	O
within	O
E1B	B-DNA
.	O
When	O
inoculated	O
twice	O
with	O
Ad	O
vectors	O
lacking	O
both	O
E1A	B-DNA
and	O
E1B	B-DNA
,	O
no	O
immunorecessive	B-protein
epitopes	I-protein
were	O
recognized	O
.	O

IkappaB	B-protein
levels	O
in	O
MNC	B-cell_type
homogenates	O
increased	O
at	O
1	O
hr	O
,	O
peaked	O
at	O
2-4	O
hr	O
,	O
started	O
to	O
decrease	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O

We	O
show	O
here	O
that	O
helenalin	O
,	O
and	O
,	O
to	O
a	O
much	O
lesser	O
degree	O
,	O
11alpha	O
,	O
13-dihydrohelenalin	O
and	O
chamissonolid	O
,	O
inhibit	O
activation	O
of	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O

Previous	O
studies	O
using	O
antisense	O
oligonucleotides	O
implicated	O
the	O
c-Myc	B-protein
protein	I-protein
in	O
the	O
phenomenon	O
of	O
activation-induced	O
apoptosis	O
.	O

All	O
three	O
proteins	O
show	O
the	O
same	O
sequence	O
specificity	O
and	O
binding	O
affinity	O
.	O

Terminal	O
differentiation	O
of	O
the	O
leukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
U-937	B-cell_line
and	O
HL-60	B-cell_line
by	O
12-O-tetradecanoylphorbol-13-acetate	O
is	O
accompanied	O
by	O
marked	O
changes	O
in	O
gene	O
expression	O
.	O

Interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
protects	O
animals	O
from	O
lethal	O
endotoxemia	O
.	O

NF-kappa	B-protein
B	I-protein
,	O
a	O
50	B-protein
kDa/65	I-protein
kDa	I-protein
(	I-protein
p50/p65	I-protein
)	I-protein
heterodimer	I-protein
,	O
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
involved	O
in	O
the	O
positive	O
regulation	O
of	O
various	O
immune	B-DNA
genes	I-DNA
.	O

Our	O
data	O
suggest	O
that	O
SAC	O
may	O
act	O
via	O
antioxidant	O
mechanisms	O
to	O
block	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

These	O
redox-regulated	B-protein
enzymes	I-protein
trigger	O
signal	O
cascades	O
for	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
and	O
transduce	O
signals	O
from	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
,	O
from	O
CD4	B-protein
and	O
CD8	B-protein
molecules	I-protein
,	O
and	O
from	O
the	O
IL-2	B-protein
receptor	I-protein
beta-chain	I-protein
.	O

These	O
mutations	O
paralleled	O
those	O
in	O
other	O
viral	O
strains	O
passaged	O
in	O
vitro	O
.	O

Cytokine	B-protein
-modulating	O
activity	O
of	O
tepoxalin	O
,	O
a	O
new	O
potential	O
antirheumatic	O
.	O

Both	O
sites	O
showed	O
activation	O
by	O
Sp3	B-protein
;	O
however	O
,	O
the	O
-70	B-DNA
to	I-DNA
-65	I-DNA
region	I-DNA
was	O
more	O
responsive	O
to	O
Sp3	B-protein
than	O
to	O
Sp1	B-protein
.	O

Both	O
c-Rel	B-protein
and	O
RelA	B-protein
induced	O
jagged1	O
gene	O
expression	O
,	O
whereas	O
a	O
mutant	O
defective	O
for	O
transactivation	O
did	O
not	O
.	O

Coexpression	O
of	O
alpha	B-protein
B1	I-protein
and	O
alpha	B-protein
B2	I-protein
showed	O
that	O
the	O
promoter	O
activity	O
could	O
be	O
determined	O
by	O
the	O
alpha	B-protein
B1	I-protein
/alpha	B-protein
B2	I-protein
ratio	O
.	O

The	O
absence	O
of	O
BSAP	B-protein
,	O
TCF-1	B-protein
,	O
and	O
GATA-3	B-protein
clearly	O
indicates	O
an	O
underlying	O
difference	O
between	O
H-RS	B-cell_line
cells	I-cell_line
and	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

In	O
fact	O
,	O
cellular	O
NF-kappa	B-protein
B	I-protein
activity	O
was	O
phosphorylation-dependent	O
and	O
the	O
DNA	O
binding	O
activity	O
of	O
p65-containing	B-protein
NF-kappa	I-protein
B	I-protein
was	O
enhanced	O
by	O
phosphorylation	O
in	O
vitro	O
.	O

The	O
inhibition	O
is	O
exerted	O
specifically	O
on	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
activation	O
induced	O
by	O
mAb	B-protein
OKT3	I-protein
,	O
and	O
not	O
that	O
produced	O
by	O
PMA	O
.	O

Using	O
antibodies	O
against	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
NF-kappaB	B-protein
in	O
EMSAs	O
,	O
the	O
involvement	O
of	O
both	O
p50	B-protein
and	O
p65	B-protein
proteins	I-protein
was	O
further	O
demonstrated	O
.	O

During	O
the	O
differentiation	O
process	O
of	O
cells	O
from	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	I-cell_line
we	O
observed	O
a	O
transient	O
transcriptional	O
upregulation	O
of	O
a	O
human	B-protein
carboxylesterase	I-protein
analyzed	O
by	O
means	O
of	O
Northern	O
blots	O
.	O

This	O
study	O
concerns	O
9	O
iv	O
drug	O
abusers	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
who	O
developed	O
hypercortisolism	O
without	O
the	O
clinical	O
signs	O
or	O
metabolic	O
consequences	O
of	O
hypercortisolism	O
.	O

Analysis	O
of	O
DNA	O
failed	O
to	O
show	O
genomic	O
rearrangements	O
corresponding	O
to	O
transcripts	O
containing	O
deletions	O
in	O
the	O
same	O
samples	O
.	O

We	O
report	O
that	O
two	O
20-epi	O
analogues	O
,	O
MC1627	O
and	O
MC1288	O
,	O
induced	O
differentiation	O
and	O
transcription	O
of	O
p21	B-DNA
(	O
Waf1	B-DNA
,	O
Cip1	B-DNA
)	O
,	O
a	O
key	O
VDR	B-DNA
target	I-DNA
gene	I-DNA
involved	O
in	O
growth	O
inhibition	O
,	O
at	O
a	O
concentration	O
100-fold	O
lower	O
than	O
that	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

Further	O
,	O
Tax1	B-protein
coimmunoprecipitated	O
with	O
NF-Y	B-protein
from	O
nuclear	O
extracts	O
of	O
HTLV-1-transformed	B-cell_type
cells	I-cell_type
,	O
providing	O
evidence	O
for	O
in	O
vivo	O
interaction	O
of	O
Tax1	B-protein
and	O
NF-YB	B-protein
.	O

Cross-linking	O
of	O
CD30	B-protein
induces	O
HIV	O
expression	O
in	O
chronically	O
infected	O
T	B-cell_type
cells	I-cell_type
.	O

Monocytes	O
were	O
isolated	O
from	O
human	O
donors	O
.	O

Patients	O
with	O
AD	O
(	O
n	O
=	O
15	O
)	O
exhibited	O
significantly	O
more	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
per	O
cell	O
than	O
the	O
control	O
group	O
(	O
n	O
=	O
22	O
)	O
,	O
while	O
the	O
GR	B-protein
affinity	O
did	O
not	O
differ	O
.	O

Our	O
finding	O
that	O
Vpr	B-protein
can	O
regulate	O
NF-kappa	B-protein
B	I-protein
supports	O
the	O
hypothesis	O
that	O
some	O
aspects	O
of	O
viral	O
pathogenesis	O
are	O
the	O
consequence	O
of	O
cell	O
dysregulation	O
by	O
Vpr	B-protein
.	O

The	O
murine	O
BCL6	B-DNA
gene	I-DNA
is	O
induced	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
as	O
an	O
immediate	B-DNA
early	I-DNA
gene	I-DNA
.	O

Copyright	O
1997	O
Academic	O
Press	O
.	O

C/EBPepsilon	B-RNA
mRNA	I-RNA
was	O
greatly	O
induced	O
during	O
in	O
vitro	O
granulocytic	O
differentiation	O
of	O
human	B-cell_type
primary	I-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

NF-kappa	B-protein
B	I-protein
was	O
not	O
activated	O
by	O
retinoic	O
acid	O
,	O
which	O
induced	O
morphological	O
differentiation	O
of	O
all	O
the	O
neuroblastoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
used	O
in	O
the	O
present	O
study	O
.	O

Lysis	O
is	O
mediated	O
by	O
any	O
steroid	O
that	O
allows	O
for	O
activation	O
of	O
the	O
receptor	O
containing	O
such	O
a	O
region	O
.	O

Interleukin	B-protein
12	I-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
STAT4	B-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

This	O
result	O
indicates	O
the	O
involvement	O
of	O
either	O
a	O
B-cell-specific	B-protein
cofactor	I-protein
or	O
a	O
specific	O
modification	O
of	O
a	O
cofactor	B-protein
or	O
the	O
Oct2	B-protein
protein	I-protein
in	O
Oct2	B-protein
-mediated	O
enhancer	O
activation	O
.	O

This	O
review	O
will	O
cover	O
the	O
molecular	O
mechanisms	O
that	O
are	O
utilized	O
by	O
mammalian	O
oncogenic	O
viruses	O
to	O
affect	O
the	O
activity	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
and	O
the	O
role	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
in	O
the	O
regulation	O
of	O
viral	O
gene	O
expression	O
and	O
replication	O
.	O

Intriguingly	O
,	O
surface	O
expression	O
of	O
LT-alpha1beta2	B-protein
is	O
up-regulated	O
on	O
a	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
acutely	O
infected	O
with	O
HIV-1	O
,	O
suggesting	O
a	O
positive	O
feedback	O
loop	O
between	O
HIV-1	O
infection	O
,	O
LT-alpha1beta2	B-protein
expression	O
,	O
and	O
HIV-1	O
replication	O
.	O

This	O
model	O
is	O
of	O
particular	O
value	O
for	O
exploring	O
physical	O
stress-induced	O
signaling	O
pathways	O
,	O
as	O
well	O
as	O
for	O
testing	O
the	O
effects	O
of	O
novel	O
ventilatory	O
strategies	O
or	O
adjunctive	O
substances	O
aimed	O
at	O
modulating	O
cell	O
activation	O
induced	O
by	O
mechanical	O
ventilation	O
.	O

The	O
appearance	O
of	O
the	O
CMAT	B-protein
binding	I-protein
complex	I-protein
was	O
inhibited	O
by	O
both	O
cyclosporin	O
A	O
and	O
rapamycin	O
.	O

A	O
role	O
for	O
retinoic	O
acid	O
during	O
neutrophil	B-cell_type
maturation	O
has	O
been	O
suggested	O
from	O
a	O
variety	O
of	O
sources.	O
Here	O
we	O
present	O
a	O
review	O
of	O
the	O
mechanism	O
of	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
action	O
and	O
the	O
major	O
evidence	O
showing	O
that	O
normal	O
retinoid	O
signaling	O
is	O
required	O
for	O
neutrophil	B-cell_type
maturation	O
.	O

NF-kappa	B-protein
B	I-protein
is	O
composed	O
of	O
distinct	O
subunits	O
;	O
five	O
independent	O
genes	O
,	O
NFKB1	B-DNA
(	O
p105	B-protein
)	O
,	O
NFKB2	B-DNA
(	O
p100	B-protein
)	O
,	O
RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
,	O
c-rel	B-DNA
and	O
relB	B-DNA
,	O
that	O
encode	O
related	O
proteins	O
that	O
bind	O
to	O
kappa	B-DNA
B	I-DNA
DNA	I-DNA
elements	I-DNA
have	O
been	O
isolated	O
.	O

High	O
levels	O
of	O
Sp140	B-RNA
mRNA	I-RNA
were	O
detected	O
in	O
human	O
spleen	O
and	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
,	O
but	O
not	O
other	O
human	O
tissues	O
.	O

Activation	O
of	O
distinct	O
transcription	B-protein
factors	I-protein
in	O
neutrophils	B-cell_type
by	O
bacterial	O
LPS	O
,	O
interferon-gamma	B-protein
,	O
and	O
GM-CSF	B-protein
and	O
the	O
necessity	O
to	O
overcome	O
the	O
action	O
of	O
endogenous	B-protein
proteases	I-protein
.	O

The	O
effect	O
of	O
constitutive	O
Tax	B-protein
expression	O
on	O
the	O
interaction	O
of	O
NF-kappa	B-protein
B	I-protein
with	O
its	O
recognition	B-DNA
sequence	I-DNA
and	O
on	O
NF-kappa	B-protein
B	I-protein
-dependent	O
gene	O
expression	O
was	O
examined	O
in	O
T	B-cell_line
lymphoid	I-cell_line
Jurkat	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
19D	B-cell_line
and	O
9J	B-cell_line
)	O
stably	O
transformed	O
with	O
a	O
Tax	B-DNA
expression	I-DNA
vector	I-DNA
.	O

No	O
receptor	O
abnormalities	O
were	O
detected	O
in	O
the	O
MDD	O
group	O
;	O
thus	O
any	O
cellular	O
defect	O
leading	O
to	O
a	O
lack	O
of	O
responsiveness	O
to	O
GC	O
in	O
the	O
MDD	O
patients	O
,	O
if	O
present	O
,	O
probably	O
lies	O
beyond	O
the	O
initial	O
receptor	O
binding	O
.	O

On	O
the	O
other	O
hand	O
,	O
IL-10	B-protein
enhanced	O
the	O
degradation	O
of	O
IL-6	B-RNA
mRNA	I-RNA
in	O
a	O
mRNA	O
stability	O
assay	O
.	O

Furthermore	O
,	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
induced	O
24-hydroxylase	B-protein
mRNA	O
expression	O
and	O
metabolic	O
activity	O
in	O
both	O
U937	B-cell_line
cells	I-cell_line
and	O
lectin-activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
yet	O
failed	O
to	O
induce	O
24-hydroxylase	B-RNA
mRNA	I-RNA
or	O
its	O
metabolic	O
activity	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
increase	O
in	O
SCL	B-protein
protein	O
levels	O
in	O
early	O
erythroid	B-cell_type
precursors	I-cell_type
stimulated	O
with	O
Steel	B-protein
factor	I-protein
suggests	O
one	O
mechanism	O
through	O
which	O
Steel	B-protein
factor	I-protein
may	O
enhance	O
normal	O
erythroid	O
proliferation	O
.	O

The	O
same	O
agents	O
induce	O
transcription	O
from	O
the	O
interleukin-2	B-DNA
receptor	I-DNA
alpha-chain	I-DNA
and	I-DNA
interleukin-2	I-DNA
genes	I-DNA
,	O
depending	O
on	O
promoter	B-DNA
elements	I-DNA
that	O
bind	O
the	O
inducible	B-protein
transcription	I-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
(	O
or	O
an	O
NF-kappa	B-protein
B-like	I-protein
factor	I-protein
)	O
.	O

The	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
have	O
been	O
widely	O
used	O
to	O
prevent	O
and	O
treat	O
graft	O
rejection	O
after	O
human	O
organ	O
and	O
tissue	O
transplantations	O
.	O

The	O
development	O
of	O
ringed	B-cell_type
sideroblasts	I-cell_type
in	O
erythroid	B-cell_line
colonies	I-cell_line
by	O
iron	O
staining	O
and	O
their	O
X-inactivation	O
pattern	O
were	O
also	O
examined	O
.	O

Using	O
sequential	B-DNA
deletion	I-DNA
mutants	I-DNA
of	O
the	O
human	B-DNA
fas	I-DNA
promoter	I-DNA
in	O
transient	O
transfection	O
assays	O
,	O
we	O
identified	O
a	O
47-bp	B-DNA
sequence	I-DNA
(	O
positions	B-DNA
-306	I-DNA
to	I-DNA
-260	I-DNA
relative	O
to	O
the	O
ATG	O
)	O
required	O
for	O
activation-driven	O
fas	O
upregulation	O
.	O

These	O
results	O
demonstrate	O
that	O
one	O
of	O
the	O
first	O
biochemical	O
events	O
which	O
occurs	O
in	O
neutrophils	B-cell_type
following	O
G-CSF	B-protein
stimulation	O
,	O
activation	O
of	O
a	O
tyrosine	B-protein
kinase	I-protein
,	O
leads	O
directly	O
to	O
the	O
tyrosine	O
phosphorylation	O
of	O
p80c-rel	B-protein
.	O

We	O
identified	O
an	O
86-nucleotide	O
fragment	O
that	O
is	O
90	O
%	O
identical	O
to	O
the	O
recently	O
characterized	O
murine	B-DNA
IL-2-responsive	I-DNA
element	I-DNA
(	O
mIL-2rE	B-DNA
)	O
.	O

E2F-1	B-protein
activity	O
is	O
regulated	O
by	O
a	O
number	O
of	O
proteins	O
,	O
including	O
the	O
retinoblastoma	O
susceptibility	B-DNA
gene	I-DNA
product	O
,	O
cyclin-dependent	B-protein
kinases	I-protein
,	O
and	O
their	O
inhibitors	O
,	O
proteins	O
that	O
have	O
been	O
implicated	O
in	O
the	O
control	O
of	O
certain	O
developmental	O
processes	O
.	O

In	O
healthy	O
subjects	O
,	O
the	O
mean	O
GC-R	B-protein
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	B-cell_type
of	O
the	O
GC-sensitive	O
group	O
were	O
2.89	O
+/-	O
1.23	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
4.00	O
+/-	O
2.24	O
nM	O
,	O
respectively	O
.	O

The	O
ubiquitous	B-protein
octamer-binding	I-protein
protein	I-protein
(	O
s	O
)	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

Thus	O
,	O
Elf-1	B-protein
is	O
a	O
novel	B-protein
transcription	I-protein
factor	I-protein
that	O
appears	O
to	O
be	O
required	O
for	O
the	O
T-cell-receptor-mediated	O
trans	O
activation	O
of	O
HIV-2	O
gene	O
expression	O
.	O

Forced	O
expression	O
of	O
E2F1	B-protein
could	O
induce	O
expression	O
of	O
all	O
members	O
of	O
the	O
endogenous	B-DNA
MCM	I-DNA
genes	I-DNA
in	O
rat	B-cell_line
embryonal	I-cell_line
fibroblast	I-cell_line
REF52	I-cell_line
cells	I-cell_line
.	O

Dephosphorylation	O
by	O
in	O
vitro	O
treatment	O
with	O
calcineurin	B-protein
or	O
alkaline	B-protein
phosphatase	I-protein
restores	O
NFATp	B-protein
DNA	O
binding	O
activity	O
and	O
its	O
ability	O
to	O
reconstitute	O
an	O
NFAT	B-protein
complex	I-protein
with	O
Fos	B-protein
and	O
Jun	B-protein
proteins	O
.	O

Our	O
results	O
demonstrate	O
that	O
IL-10	B-protein
can	O
inhibit	O
the	O
induction	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
nuclear	O
activity	O
in	O
CD3-stimulated	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

The	O
data	O
further	O
indicate	O
that	O
the	O
IL-7R	B-protein
alpha	I-protein
chains	I-protein
are	O
directly	O
involved	O
in	O
the	O
activation	O
of	O
JAKs	B-protein
and	O
STATs	B-protein
and	O
have	O
a	O
major	O
role	O
in	O
proliferative	O
signaling	O
in	O
precursor	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Patients	O
with	O
HIV	O
infections	O
often	O
show	O
elevated	O
circulating	O
levels	O
of	O
cortisol	O
,	O
suggesting	O
some	O
misfunction	O
in	O
the	O
regulatory	O
systems	O
that	O
maintain	O
the	O
levels	O
of	O
this	O
critical	O
hormone	O
.	O

This	O
contrasts	O
with	O
findings	O
in	O
alpha-	O
and	O
beta-	O
herpesvirus	O
systems	O
(	O
herpes	O
simplex	O
,	O
cytomegalovirus	O
)	O
where	O
viral	O
interference	O
with	O
the	O
antigen-processing	O
pathway	O
during	O
lytic	O
infection	O
renders	O
immediate	B-protein
early	I-protein
and	I-protein
early	I-protein
proteins	I-protein
much	O
less	O
immunogenic	O
.	O

Transfection	O
of	O
cells	O
with	O
full	O
length	O
E2A	B-DNA
cDNA	I-DNA
leads	O
to	O
appearance	O
of	O
protein	O
co-migrating	O
with	O
the	O
73	B-protein
kDa	I-protein
protein	I-protein
on	O
SDS	O
gel	O
electrophoresis	O
and	O
co-migrating	O
with	O
LEF1/BCF1	B-protein
on	O
mobility	O
shift	O
analysis	O
.	O

Although	O
both	O
viruses	O
establish	O
latency	O
in	O
quiescent	O
human-peripheral-blood	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
the	O
asymptomatic	O
phase	O
of	O
HIV-2	O
infection	O
may	O
be	O
more	O
prolonged	O
than	O
that	O
of	O
HIV-1	O
.	O

Although	O
identical	O
in	O
composition	O
and	O
stoichiometry	O
to	O
TFIIHwt	B-protein
,	O
TFIIHmut	B-protein
shows	O
a	O
reduced	O
3	O
'	O
--	O
>	O
5	O
'	O
XPB	B-protein
helicase	O
activity	O
.	O

The	O
requirement	O
for	O
TNF	B-protein
is	O
further	O
confirmed	O
by	O
the	O
observation	O
that	O
the	O
inability	O
of	O
the	O
intermediate	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
to	O
replicate	O
the	O
virus	O
is	O
associated	O
with	O
a	O
defect	O
in	O
TNF	B-protein
production	O
during	O
their	O
interaction	O
with	O
TEC	B-cell_type
and	O
correlates	O
with	O
the	O
absence	O
of	O
nuclear	O
NF-kappaB	B-protein
activity	O
in	O
these	O
freshly	B-cell_type
isolated	I-cell_type
thymocytes	I-cell_type
.	O

The	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
independent	I-DNA
cis-acting	I-DNA
sequences	I-DNA
in	O
HIV-1	B-DNA
LTR	I-DNA
responsive	O
to	O
T-cell	O
activation	O
.	O

Alveolar	B-cell_type
macrophages	I-cell_type
and	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
are	O
activated	O
when	O
IgE/allergen	B-protein
immune	I-protein
complexes	I-protein
bind	O
to	O
the	O
CD23	B-protein
receptor	I-protein
,	O
which	O
leads	O
to	O
the	O
production	O
of	O
inflammatory	B-protein
cytokines	I-protein
.	O

NFAT	B-protein
regulates	O
transcription	O
of	O
a	O
number	O
of	O
cytokine	O
and	O
other	O
immunoregulatory	B-DNA
genes	I-DNA
.	O

The	O
Ikaros	B-DNA
gene	I-DNA
,	O
which	O
encodes	O
a	O
family	O
of	O
hemopoietic-specific	B-protein
zinc	I-protein
finger	I-protein
proteins	I-protein
,	O
is	O
described	O
as	O
a	O
central	O
regulator	O
of	O
lymphocyte	O
differentiation	O
.	O

Serial	O
sectioning	O
of	O
6	O
micrometer	O
was	O
performed	O
using	O
a	O
cryostat	O
,	O
and	O
samples	O
were	O
immunohistochemically	O
stained	O
using	O
the	O
streptoavidin	B-protein
-biotin	B-protein
peroxidase	I-protein
method	O
and	O
a	O
monoclonal	O
antibody	O
against	O
c-fos	O
.	O

Inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
sodium	O
salicylate	O
and	O
aspirin	O
[	O
see	O
comments	O
]	O

We	O
have	O
previously	O
shown	O
that	O
IL-6	B-protein
induces	O
activation	O
of	O
JAK1	B-protein
and	O
JAK2	B-protein
in	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

IL-2R	B-protein
alpha	I-protein
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	B-cell_type
cells	I-cell_type
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Protein	O
phosphorylation	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
these	O
two	O
factors	O
:	O
(	O
1	O
)	O
it	O
induces	O
the	O
transactivating	O
capacity	O
of	O
the	O
AP-1	B-protein
protein	I-protein
c-Jun	B-protein
;	O
and	O
(	O
2	O
)	O
it	O
is	O
involved	O
in	O
the	O
release	O
of	O
the	O
cytoplasmic	B-protein
inhibitor	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
from	O
NF-kappa	B-protein
B	I-protein
,	O
allowing	O
translocation	O
of	O
the	O
latter	O
into	O
the	O
nucleus	O
.	O

Role	O
of	O
EGR1	B-protein
in	O
regulation	O
of	O
stimulus-dependent	O
CD44	B-protein
transcription	O
in	O
B	O
lymphocytes	O
.	O

Two	O
families	O
of	O
transcription	B-protein
factors	I-protein
that	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
are	O
c-Myb	B-protein
and	O
Ets	B-protein
.	O

The	O
adult	O
male	O
progeny	O
(	O
3	O
mo	O
old	O
)	O
of	O
both	O
experimental	O
groups	O
showed	O
increased	O
basal	O
plasma	O
corticosterone	O
levels	O
.	O

We	O
then	O
analyzed	O
the	O
expression	O
of	O
the	O
master	B-DNA
GATA1	I-DNA
gene	I-DNA
,	O
which	O
encodes	O
a	O
finger	B-protein
transcription	I-protein
factor	I-protein
required	O
for	O
normal	O
erythroid	O
development	O
;	O
addition	O
of	O
RA	O
to	O
HPC	B-cell_type
stimulated	O
into	O
unilineage	O
erythropoietic	O
differentiation	O
in	O
liquid	O
culture	O
caused	O
a	O
virtually	O
complete	O
inhibition	O
of	O
GATA1	B-RNA
mRNA	I-RNA
induction	O
.	O

ALY	B-protein
,	O
a	O
context-dependent	B-protein
coactivator	I-protein
of	O
LEF-1	B-protein
and	O
AML-1	B-protein
,	O
is	O
required	O
for	O
TCRalpha	B-DNA
enhancer	I-DNA
function	O
.	O

We	O
show	O
that	O
in	O
S194	B-cell_line
plasma	I-cell_line
cells	I-cell_line
the	O
activity	O
of	O
each	O
element	O
correlates	O
well	O
with	O
the	O
relative	O
affinity	O
of	O
B-cell-derived	B-protein
NF-kappa	I-protein
B	I-protein
for	O
that	O
element	O
.	O

Circular	O
dichroism	O
analysis	O
reveals	O
that	O
NO	O
induces	O
a	O
profound	O
conformational	O
change	O
in	O
p21ras	B-DNA
in	O
association	O
with	O
GDP/GTP	O
exchange	O
.	O

The	O
antiviral	O
functions	O
of	O
infiltrating	B-cell_type
CD4-bearing	I-cell_type
T	I-cell_type
cells	I-cell_type
may	O
include	O
cytotoxicity	O
,	O
inhibition	O
of	O
viral	O
growth	O
,	O
lymphokine	B-protein
secretion	O
,	O
and	O
support	O
of	O
humoral	O
and	O
CD8	O
responses	O
.	O

Recently	O
we	O
have	O
reported	O
that	O
the	O
Pax5	B-DNA
gene	I-DNA
is	O
subject	O
to	O
allele	B-DNA
-specific	O
regulation	O
during	O
B	O
cell	O
development	O
.	O

Immature	O
thymocytes	B-cell_type
were	O
infected	O
by	O
EBV	O
,	O
as	O
determined	O
by	O
the	O
internalization	O
of	O
the	O
viral	B-DNA
genome	I-DNA
and	O
its	O
transcriptional	O
activity	O
.	O

These	O
findings	O
indicate	O
that	O
defective	O
transport	O
and	O
processing	O
of	O
class	B-protein
II	I-protein
molecules	I-protein
through	O
the	O
endosomal/lysosomal	O
system	O
is	O
responsible	O
for	O
diminished	O
cell	O
surface	O
expression	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
molecules	I-protein
in	O
cells	O
infected	O
with	O
M.	O
tuberculosis	O
.	O

IFN-gamma	B-protein
signaling	O
is	O
mediated	O
by	O
homodimeric	B-protein
STAT1	I-protein
protein	I-protein
.	O

These	O
data	O
indicate	O
that	O
tumor	B-cell_type
cells	I-cell_type
of	O
NLPHD	O
uniformly	O
display	O
a	O
GC	O
B-cell	O
phenotype	O
,	O
whereas	O
the	O
phenotype	O
of	O
tumor	B-cell_type
cells	I-cell_type
of	O
CHD	O
appears	O
to	O
be	O
modulated	O
by	O
the	O
surrounding	O
cellular	O
background	O
,	O
particularly	O
CD40L+	B-cell_type
reactive	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Activation	O
of	O
the	O
CD28	B-protein
surface	I-protein
receptor	I-protein
provides	O
a	O
major	O
costimulatory	O
signal	O
for	O
T	O
cell	O
activation	O
resulting	O
in	O
enhanced	O
production	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
and	O
cell	O
proliferation	O
.	O

Gel	O
mobility	O
shift	O
and	O
immunoprecipitation	O
analyses	O
revealed	O
that	O
in	O
addition	O
to	O
activating	O
STAT3	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription-3	I-protein
)	O
and	O
STAT5	B-protein
,	O
IL-2	B-protein
induced	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
STAT1	B-protein
alpha	I-protein
,	O
which	O
formed	O
IFN-gamma-activated	B-protein
sequence-binding	I-protein
complexes	I-protein
by	O
itself	O
and	O
with	O
STAT3	B-protein
.	O

In	O
the	O
present	O
study	O
,	O
we	O
cloned	O
and	O
characterized	O
the	O
human	B-DNA
LOX-1	I-DNA
gene	I-DNA
(	O
HGMW-approved	B-protein
symbol	I-protein
OLR1	I-protein
)	O
.	O

NF-kappaB	B-protein
activation	O
is	O
a	O
critical	O
regulator	O
of	O
human	O
granulocyte	O
apoptosis	O
in	O
vitro	O
.	O

The	O
effects	O
of	O
interleukin-13	B-protein
(	O
IL-13	B-protein
)	O
and	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
on	O
cellular	O
functions	O
were	O
shown	O
to	O
be	O
quite	O
similar	O
.	O

During	O
B	O
and	O
T	O
cell	O
differentiation	O
and	O
proliferation	O
many	O
genes	O
are	O
induced	O
or	O
repressed	O
while	O
certain	O
genes	O
are	O
constitutively	O
expressed	O
.	O

Dramatic	O
stimulation	O
of	O
actin	B-protein
assembly	O
is	O
linked	O
to	O
the	O
formation	O
of	O
a	O
ternary	O
IcsA-N-WASP-Arp2/3	B-protein
complex	I-protein
,	O
which	O
nucleates	O
actin	B-protein
polymerization	O
.	O

The	O
changes	O
in	O
gene	O
expression	O
brought	O
about	O
by	O
gamma	B-protein
interferon	I-protein
are	O
thought	O
to	O
involve	O
transient	O
increases	O
in	O
the	O
activities	O
of	O
cellular	B-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
,	O
including	O
the	O
Janus	B-protein
kinases	I-protein
Jak1	B-protein
and	O
Jak2	B-protein
,	O
leading	O
to	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcription	B-protein
factor	I-protein
Stat1	I-protein
.	O

Although	O
ICAM-1	B-protein
induction	O
was	O
unaffected	O
,	O
inhibitors	O
of	O
NADPH	B-protein
oxidase	I-protein
(	O
apocynin	O
)	O
or	O
cytochrome	B-protein
P-450	I-protein
(	O
SKF525a	O
)	O
suppressed	O
VCAM-1	B-protein
induction	O
by	O
TNF	O
,	O
revealing	O
that	O
several	O
radical-generating	O
systems	O
are	O
involved	O
in	O
its	O
regulation	O
.	O

Whereas	O
TPCK	B-protein
inhibits	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
and	O
,	O
consequently	O
,	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
it	O
markedly	O
enhances	O
the	O
activity	O
of	O
JNK	B-protein
,	O
the	O
MAP	B-protein
kinase-related	I-protein
kinase	I-protein
that	O
phosphorylates	O
the	O
transactivation	B-protein
domain	I-protein
of	O
c-Jun	B-protein
.	O

We	O
have	O
cloned	O
a	O
group	O
of	O
cDNAs	B-DNA
representing	O
mRNAs	B-RNA
that	O
are	O
rapidly	O
induced	O
following	O
adherence	O
of	O
human	B-cell_type
monocytes	I-cell_type
.	O

Ductal	B-cell_type
cells	I-cell_type
were	O
obtained	O
via	O
random	O
fine	O
needle	O
aspirations	O
and	O
cytologically	O
classified	O
.	O

HB24	B-DNA
is	O
likely	O
to	O
have	O
an	O
important	O
role	O
in	O
lymphocytes	B-cell_type
as	O
well	O
as	O
in	O
certain	O
developing	O
tissues	O
.	O

Furthermore	O
,	O
an	O
important	O
role	O
for	O
egr-1	B-DNA
in	O
determining	O
the	O
differentiation	O
pathway	O
of	O
myeloid	B-cell_type
cell	I-cell_type
precursors	I-cell_type
has	O
been	O
recently	O
elaborated	O
.	O

Transient	O
transfectants	O
of	O
the	O
porcine	B-cell_line
B-cell	I-cell_line
line	I-cell_line
L23	I-cell_line
with	O
the	O
mutated	O
CIITA	B-DNA
constructs	I-DNA
were	O
tested	O
for	O
the	O
suppression	O
of	O
constitutive	O
SLA-DR	O
and	O
SLA-DQ	O
expression	O
.	O

Chimeric	B-protein
oncoprotein	I-protein
E2a-Pbx1	B-protein
induces	O
apoptosis	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
by	O
a	O
p53	B-protein
-independent	O
mechanism	O
that	O
is	O
suppressed	O
by	O
Bcl-2	B-protein
.	O

CONCLUSIONS	O
:	O
(	O
1	O
)	O
GCs	O
of	O
AITL/GC	O
differed	O
from	O
those	O
of	O
other	O
reactive	O
follicular	O
hyperplasias	O
and	O
follicular	O
lymphomas	O
,	O
and	O
staining	O
for	O
Bcl-6	B-protein
was	O
useful	O
to	O
discern	O
them	O
.	O

Viral	O
transcription	O
,	O
as	O
measured	O
using	O
LTR	B-DNA
-CAT	B-protein
assays	O
,	O
was	O
only	O
slightly	O
enhanced	O
in	O
the	O
HIV-protease	B-cell_type
expressing	I-cell_type
cells	I-cell_type
,	O
while	O
secretion	O
of	O
IL-2	B-protein
and	O
expression	O
of	O
the	O
IL-2	B-protein
receptor	O
were	O
not	O
affected	O
.	O

Although	O
these	O
heterodimers	B-protein
do	O
not	O
recognize	O
a	O
classical	O
thyroid	B-DNA
hormone	I-DNA
response	I-DNA
element	I-DNA
(	O
TRE	B-DNA
)	O
characterized	O
by	O
direct	O
repeat	O
separated	O
by	O
four	O
nucleotides	O
(	O
DR+4	B-DNA
)	O
,	O
PPAR	B-protein
behaves	O
as	O
a	O
dominant	O
negative	O
regulator	O
of	O
thyroid	O
hormone	O
(	O
TH	O
)	O
action	O
.	O

This	O
suppressive	O
effect	O
was	O
also	O
seen	O
in	O
IL-2	B-protein
-driven	O
cell	O
growth	O
of	O
CD8-positive	B-cell_type
lymphocytes	I-cell_type
purified	O
from	O
7-day	B-cell_type
PHA-blasts	I-cell_type
,	O
indicating	O
that	O
CD4	B-protein
molecules	I-protein
were	O
not	O
required	O
for	O
the	O
suppression	O
.	O

Thus	O
,	O
CD45	B-protein
plays	O
an	O
active	O
role	O
in	O
the	O
physiology	O
of	O
T	B-cell_type
cells	I-cell_type
and	O
in	O
the	O
replication	O
of	O
HIV-1	O
.	O

Increased	O
mRNA	B-RNA
and	O
surface	O
expression	O
of	O
E-selectin	B-protein
,	O
ICAM-1	B-protein
,	O
and	O
VCAM-1	B-protein
were	O
noted	O
within	O
hours	O
.	O

These	O
findings	O
demonstrate	O
that	O
interaction	O
of	O
both	O
subunits	O
of	O
the	O
heterodimeric	B-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
with	O
DNA	O
is	O
required	O
for	O
DNA	O
binding	O
and	O
transcriptional	O
activation	O
and	O
suggest	O
that	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
individual	O
rel-related	B-protein
proteins	I-protein
will	O
differ	O
dramatically	O
,	O
depending	O
on	O
the	O
specific	O
kappa	O
B	O
motifs	O
present	O
.	O

Oligonucleotide	O
primers	O
based	O
on	O
the	O
murine	B-DNA
sequence	I-DNA
were	O
used	O
to	O
construct	O
a	O
quantitative	O
reverse	O
transcription-PCR	O
assay	O
for	O
gene	O
expression	O
.	O

T	O
cell	O
expression	O
of	O
interleukin	B-protein
3	I-protein
(	O
IL-3	B-protein
)	O
is	O
directed	O
by	O
positive	B-DNA
and	I-DNA
negative	I-DNA
cis-acting	I-DNA
DNA	I-DNA
elements	I-DNA
clustered	O
within	O
300	O
base	O
pairs	O
of	O
the	O
transcriptional	B-DNA
start	I-DNA
site	I-DNA
.	O

Differanisole	O
A	O
,	O
3	O
,	O
5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic	O
acid	O
,	O
inhibited	O
growth	O
of	O
human	B-cell_type
myeloid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

Inhibition	O
of	O
TF	B-protein
induction	O
in	O
the	O
presence	O
of	O
high	O
CsA	O
blood	O
concentrations	O
was	O
also	O
observed	O
when	O
stimulation	O
of	O
cells	O
was	O
performed	O
with	O
interferon-gamma	B-protein
or	O
interleukin-1beta	B-protein
.	O

Attenuated	O
function	O
of	O
a	O
variant	O
form	O
of	O
the	O
helix-loop-helix	B-protein
protein	I-protein
,	O
Id-3	B-protein
,	O
generated	O
by	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

Thus	O
,	O
the	O
DRA	B-DNA
promoter	I-DNA
discriminates	O
against	O
OTF-1	B-protein
activation	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
in	O
the	O
glioblastoma	B-cell_line
line	I-cell_line
.	O

The	O
human	B-DNA
interferon	I-DNA
beta	I-DNA
(	I-DNA
IFN-beta	I-DNA
)	I-DNA
regulatory	I-DNA
element	I-DNA
consists	O
of	O
multiple	O
enhanson	B-DNA
domains	I-DNA
which	O
are	O
targets	O
for	O
transcription	B-protein
factors	I-protein
involved	O
in	O
inducible	O
expression	O
of	O
the	O
promoter	B-DNA
.	O

A	O
series	O
of	O
uninfected	B-cell_line
parental	I-cell_line
HL-60	I-cell_line
subclones	I-cell_line
all	O
reduced	O
TR75	B-protein
surface	O
expression	O
in	O
response	O
to	O
TNF-alpha	B-protein
treatment	O
.	O

Using	O
the	O
wild-type	B-protein
or	I-protein
mutated	I-protein
human	I-protein
retinoic	I-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
as	O
a	O
model	O
,	O
kDa	O
values	O
determined	O
by	O
classical	O
competition	O
binding	O
assays	O
using	O
tritiated	O
ligands	O
are	O
in	O
agreement	O
with	O
those	O
measured	O
by	O
the	O
proteolytic	O
assay	O
.	O

In	O
transient	O
transfection	O
assays	O
,	O
both	O
multicopy	O
NFAT	B-protein
-and	O
IL-2	B-DNA
promoter-beta-galactosidase	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
could	O
be	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
/alpha-	O
CD28	B-protein
stimulation	O
,	O
and	O
this	O
activation	O
was	O
resistant	O
to	O
CsA	O
.	O

The	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
required	O
for	O
EBV-induced	O
immortalization	O
of	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
causes	O
tumorigenic	O
transformation	O
of	O
cell	B-cell_line
lines	I-cell_line
.	O

Analysis	O
of	O
RelA	B-RNA
(	I-RNA
p65	I-RNA
)	I-RNA
mRNA	I-RNA
revealed	O
that	O
the	O
stability	O
of	O
RelA	B-RNA
(	I-RNA
p65	I-RNA
)	I-RNA
mRNA	I-RNA
was	O
significantly	O
higher	O
in	O
MDMs	B-cell_type
,	O
compared	O
with	O
monocytes	B-cell_type
.	O

Since	O
TPA	O
activates	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
,	O
we	O
examined	O
translocation	O
of	O
PKC	B-protein
from	O
the	O
cytosol	O
to	O
the	O
membrane	O
fraction	O
.	O

NF-kappaB	B-protein
,	O
which	O
resides	O
in	O
an	O
inactive	O
,	O
cytoplasmic	B-protein
complex	I-protein
in	O
unstimulated	B-cell_line
cells	I-cell_line
,	O
is	O
activated	O
by	O
phosphorylation	O
and	O
degradation	O
of	O
its	O
inhibitory	B-protein
subunit	I-protein
,	O
IkappaB	B-protein
.	O

However	O
,	O
ILT-mat	B-cell_line
cells	I-cell_line
and	O
ATL16T	B-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
although	O
they	O
were	O
ATL	B-cell_line
cells	I-cell_line
,	O
showed	O
rather	O
low	O
surface	O
ICAM-1	B-protein
expression	O
and	O
ICAM-1	B-RNA
mRNA	I-RNA
expression	O
.	O

IL-10	B-protein
inhibited	O
translocation	O
of	O
NF-kappaB	B-protein
in	O
response	O
to	O
LPS	O
but	O
not	O
the	O
fungal	O
stimuli	O
.	O

The	O
inhibitory	O
effect	O
of	O
PDTC	O
was	O
also	O
observed	O
in	O
etoposide	O
-and	O
dexamethasone-induced	O
apoptosis	O
in	O
human	B-cell_type
thymocytes	I-cell_type
at	O
a	O
concentration	O
of	O
1-10	O
microM	O
.	O

Transient	O
transfection	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
ICAM-1	B-DNA
promoter	I-DNA
luciferase	I-DNA
reporter	I-DNA
gene	I-DNA
(	I-DNA
ICAM-1LUC	I-DNA
)	I-DNA
constructs	I-DNA
indicated	O
that	O
deletion	O
of	O
upstream	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
(	O
-533	B-DNA
bases	I-DNA
from	O
translation	B-DNA
start	I-DNA
site	I-DNA
)	O
had	O
no	O
effect	O
on	O
thrombin	B-protein
responsiveness	O
,	O
whereas	O
mutation/deletion	O
of	O
downstream	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
(	O
-223	B-DNA
bases	I-DNA
from	O
the	O
translation	B-DNA
start	I-DNA
site	I-DNA
)	O
prevented	O
the	O
activation	O
of	O
ICAM-1	B-DNA
promoter	I-DNA
,	O
indicating	O
that	O
the	O
downstream	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
is	O
critical	O
for	O
thrombin	B-protein
inducibility	O
.	O

Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
in	O
vitro	O
by	O
a	O
novel	O
combination	O
of	O
anti-Tat	B-protein
single-chain	I-protein
intrabodies	I-protein
and	O
NF-kappa	O
B	O
antagonists	O
.	O

A	O
low	O
temperature	O
(	O
26	O
degrees	O
C	O
)	O
increased	O
the	O
binding	O
both	O
in	O
HLA-A3	B-protein
and	O
HLA-Cw*0702	B-protein
,	O
while	O
FCS	O
reduced	O
it	O
.	O

5	O
'	O
deletion	O
constructs	O
which	O
lacked	O
the	O
Y	B-DNA
box	I-DNA
,	O
but	O
retained	O
the	O
``	B-DNA
octamer	I-DNA
''	I-DNA
motif	I-DNA
and	O
TATA	B-DNA
box	I-DNA
were	O
completely	O
inactive	O
,	O
and	O
internal	O
deletion	O
of	O
the	O
Y	B-DNA
box	I-DNA
reduced	O
transcription	O
by	O
95	O
%	O
.	O

The	O
present	O
study	O
demonstrates	O
the	O
existence	O
of	O
kappa	B-protein
B-specific	I-protein
binding	I-protein
factors	I-protein
present	O
in	O
human	B-cell_type
glial	I-cell_type
astrocytes	I-cell_type
that	O
differ	O
from	O
prototypical	O
NF-kappa	B-protein
B	I-protein
.	O

Recent	O
evidence	O
suggests	O
that	O
the	O
p53	B-protein
molecule	I-protein
appears	O
in	O
two	O
different	O
forms	O
:	O
the	O
mutant	B-protein
p53	I-protein
that	O
stimulates	O
tumor	O
progression	O
,	O
and	O
wild	B-protein
type	I-protein
p53	I-protein
that	O
inhibits	O
tumor	O
progression	O
.	O

RESULTS	O
:	O
Certain	O
aspects	O
of	O
TCR	B-protein
responses	O
such	O
as	O
the	O
induction	O
of	O
transcriptional	O
activity	O
of	O
AP1	B-protein
and	O
serum	B-protein
response	I-protein
factor	I-protein
were	O
not	O
affected	O
by	O
expression	O
of	O
the	O
mutant	O
forms	O
of	O
PI	B-protein
3-kinase	I-protein
.	O

The	O
authors	O
conclude	O
that	O
the	O
microscopic	O
examination	O
is	O
the	O
only	O
useful	O
tool	O
for	O
assessing	O
the	O
risk	O
of	O
local	O
failure	O
,	O
which	O
is	O
quite	O
low	O
for	O
the	O
majority	O
of	O
patients	O
treated	O
with	O
breast	O
conservation	O
.	O

Here	O
we	O
report	O
that	O
the	O
newly	O
synthesized	O
nuclear	B-protein
component	I-protein
of	O
NF-AT	B-protein
is	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
.	O

Lineage-	O
and	O
stage-specific	O
expression	O
of	O
runt	B-protein
box	I-protein
polypeptides	I-protein
in	O
primitive	O
and	O
definitive	O
hematopoiesis	O
.	O

Expression	O
of	O
Ah	B-protein
receptor	I-protein
(	O
TCDD	B-protein
receptor	I-protein
)	O
during	O
human	O
monocytic	O
differentiation	O
.	O

A	O
phosphorylated	O
form	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
increased	O
protein	O
turnover-degradation	O
correlate	O
with	O
increased	O
NF-kappa	B-protein
B	I-protein
nuclear	O
translocation	O
.	O

O-side	B-protein
chain-specific	I-protein
mAb	I-protein
concurrently	O
enhanced	O
complement-dependent	O
LPS	O
uptake	O
by	O
monocytes	O
through	O
complement	B-protein
receptor-1	I-protein
(	O
CR1	B-protein
)	O
and	O
uptake	O
by	O
CHO-CD14	B-cell_line
cells	I-cell_line
involving	O
another	O
heat-labile	B-protein
serum	I-protein
factor	I-protein
(	O
s	O
)	O
and	O
cell-associated	B-protein
recognition	I-protein
molecule	I-protein
(	O
s	O
)	O
.	O

Here	O
we	O
report	O
that	O
CsA	O
treatment	O
of	O
Raji	B-cell_line
B	I-cell_line
and	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
yields	O
a	O
phosphorylated	O
form	O
of	O
NFATp	B-protein
that	O
is	O
inhibited	O
in	O
DNA-binding	O
and	O
in	O
its	O
ability	O
to	O
form	O
an	O
NFAT	B-protein
complex	I-protein
with	O
Fos	B-protein
and	O
Jun	B-protein
.	O

However	O
,	O
in	O
contrast	O
to	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
IFN-gamma	B-protein
production	O
was	O
inhibited	O
and	O
IFN-gamma	B-RNA
mRNA	I-RNA
levels	O
were	O
unaffected	O
at	O
24	O
h	O
and	O
only	O
slightly	O
upregulated	O
at	O
48	O
and	O
72	O
h	O
of	O
culture	O
in	O
murine	B-cell_type
splenocytes	I-cell_type
incubated	O
with	O
cipro	O
(	O
20	O
micrograms/ml	O
)	O
.	O

These	O
findings	O
indicate	O
that	O
imbalanced	O
expression	O
of	O
the	O
GR	B-protein
isoforms	I-protein
may	O
be	O
a	O
mechanism	O
of	O
GC	O
resistance	O
,	O
and	O
may	O
have	O
implications	O
for	O
tumorigenesis	O
by	O
enhancing	O
cell	O
survival	O
.	O

Staphylococcal	B-protein
enterotoxins	I-protein
modulate	O
interleukin	B-protein
2	I-protein
receptor	I-protein
expression	O
and	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-protein
protein-tyrosine	I-protein
kinase	I-protein
3	I-protein
(	O
Jak3	B-protein
)	O
and	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
Stat	B-protein
proteins	I-protein
)	O
.	O

We	O
conclude	O
that	O
tyloxapol	O
is	O
potentially	O
useful	O
as	O
a	O
new	O
antiinflammatory	O
therapy	O
for	O
CF	O
lung	O
disease	O
,	O
and	O
could	O
possibly	O
promote	O
clearance	O
of	O
secretions	O
in	O
the	O
CF	O
airway	O
.	O

In	O
contrast	O
,	O
E1A-positive	B-cell_type
cells	I-cell_type
were	O
no	O
more	O
susceptible	O
to	O
injury-induced	O
necrosis	O
than	O
E1A-negative	B-cell_type
cells	I-cell_type
.	O

To	O
ascertain	O
whether	O
the	O
abnormal	O
NF-AT	B-protein
binding	O
activity	O
was	O
related	O
to	O
an	O
impaired	O
function	O
,	O
we	O
transfected	O
patient	O
and	O
control	O
T	B-cell_type
lymphocytes	I-cell_type
with	O
constructs	O
containing	O
the	O
reporter	O
gene	O
encoding	O
chloramphenicol	B-protein
acetyl	I-protein
transferase	I-protein
(	O
CAT	B-protein
)	O
under	O
the	O
control	O
of	O
the	O
entire	O
IL2	B-DNA
regulatory	I-DNA
region	I-DNA
or	O
of	O
multimers	O
of	O
individual	O
enhancer	B-DNA
sequences	I-DNA
.	O

We	O
hypothesized	O
that	O
adherence	O
itself	O
might	O
be	O
an	O
important	O
trigger	O
for	O
a	O
sequence	O
of	O
gene	O
activation	O
culminating	O
in	O
cells	O
with	O
increased	O
mRNA	B-RNA
encoding	O
profibrotic	O
growth	B-protein
factors	I-protein
such	O
as	O
platelet-derived	B-protein
growth	I-protein
factor	I-protein
B	I-protein
subunit	I-protein
(	O
PDGF	B-protein
[	I-protein
B	I-protein
]	I-protein
)	O
and	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
(	O
TGF-beta	B-protein
)	O
.	O

In	O
addition	O
,	O
we	O
provide	O
evidence	O
for	O
a	O
decrease	O
in	O
basal	O
transcription	O
activity	O
in	O
vitro	O
.	O

Thus	O
,	O
stable	O
expression	O
of	O
HB24	B-DNA
confers	O
an	O
activation	O
phenotype	O
on	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
implicating	O
this	O
gene	O
as	O
an	O
important	O
transcriptional	B-protein
factor	I-protein
during	O
T	O
cell	O
activation	O
and	O
growth	O
.	O

Possible	O
roles	O
of	O
ERK	B-protein
in	O
proliferation	O
of	O
transformed	B-cell_line
cells	I-cell_line
were	O
also	O
suggested	O
.	O

From	O
sequence	O
analysis	O
,	O
two	O
of	O
these	O
appear	O
to	O
be	O
novel	O
transcription	B-protein
factor	I-protein
binding	B-DNA
sites	I-DNA
,	O
whereas	O
the	O
third	O
was	O
identified	O
as	O
a	O
cyclic	B-DNA
AMP	I-DNA
response	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
.	O

Immunocytochemistry	O
identified	O
the	O
cells	O
in	O
the	O
infiltrate	O
as	O
cytotoxic	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

A	O
truncated	O
Tat	B-protein
protein	I-protein
(	O
Tat1-72	B-protein
)	O
,	O
known	O
to	O
transactivate	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
,	O
no	O
longer	O
affected	O
Mn-SOD	B-protein
expression	O
,	O
the	O
cellular	O
redox	O
state	O
or	O
TNF	B-protein
-mediated	O
cytotoxicity	O
.	O

We	O
conclude	O
that	O
contact	O
with	O
fibrinogen-derived	B-protein
proteins	I-protein
may	O
contribute	O
to	O
mononuclear	O
phagocyte	O
activation	O
by	O
signaling	O
through	O
CD11b/CD18	B-protein
,	O
resulting	O
in	O
selective	O
activation	O
of	O
transcriptional	B-protein
regulatory	I-protein
factors	I-protein
,	O
including	O
NF-kappa	B-protein
B	I-protein
.	O

Cells	O
of	O
monocyte	O
lineage	O
serve	O
as	O
effector	B-cell_type
cells	I-cell_type
in	O
the	O
cellular	O
immune	O
response	O
.	O

Currently	O
it	O
is	O
accepted	O
the	O
existence	O
of	O
a	O
cytoplasmic	B-protein
and/or	I-protein
nuclear	I-protein
receptor	I-protein
,	O
without	O
explaining	O
satisfactorily	O
how	O
the	O
hormones	O
come	O
to	O
the	O
nucleus	O
.	O

To	O
investigate	O
regulatory	O
networks	O
in	O
Legionella	O
pneumophila	O
,	O
the	O
gene	O
encoding	O
the	O
homolog	O
of	O
the	O
Escherichia	B-protein
coli	I-protein
stress	I-protein
and	I-protein
stationary-phase	I-protein
sigma	I-protein
factor	I-protein
RpoS	B-protein
was	O
identified	O
by	O
complementation	O
of	O
an	O
E.	O
coli	O
rpoS	B-DNA
mutation	O
.	O

Induction	O
of	O
phosphatidylinositol	O
turnover	O
and	O
EGR-1	B-RNA
mRNA	I-RNA
expression	O
by	O
crosslinking	O
of	O
surface	O
IgM	B-protein
and	O
IgD	B-protein
in	O
the	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
B104	I-cell_line
.	O

The	O
current	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
underlying	O
immunosenescence	O
is	O
still	O
fragmentary	O
.	O

We	O
used	O
cytokine	O
production	O
as	O
a	O
readout	O
for	O
monocyte	O
activation	O
and	O
found	O
that	O
CD15	O
cross-linking	O
induced	O
TNF-alpha	B-protein
release	O
from	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
cells	O
from	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
MM6	I-cell_line
.	O

The	O
enhancer	B-DNA
for	O
the	O
immunoglobulin	B-DNA
mu	I-DNA
heavy	I-DNA
chain	I-DNA
gene	I-DNA
(	O
IgH	B-protein
)	O
activates	O
a	O
heterologous	B-DNA
gene	I-DNA
at	O
the	O
pre-B	O
cell	O
stage	O
of	O
B	B-cell_type
lymphocyte	I-cell_type
differentiation	O
.	O

The	O
genes	O
and	O
mechanisms	O
that	O
control	O
programmed	O
cell	O
death	O
are	O
currently	O
the	O
subject	O
of	O
intense	O
study	O
.	O

Activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
kappaB	B-protein
-dependent	O
transcriptional	O
activity	O
was	O
enhanced	O
in	O
the	O
presence	O
of	O
activated	B-cell_type
platelets	I-cell_type
.	O

Here	O
we	O
show	O
that	O
when	O
added	O
exogenously	O
to	O
cells	O
,	O
Hsp70	B-protein
is	O
readily	O
imported	O
into	O
both	O
cytoplasmic	O
and	O
nuclear	O
compartments	O
in	O
a	O
cell-type-specific	O
fashion	O
.	O

Clinical	O
deterioration	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
is	O
associated	O
with	O
increased	O
levels	O
of	O
viral	O
replication	O
and	O
burden	O
in	O
the	O
peripheral	O
blood	O
and	O
lymphoid	O
organs	O
.	O

Eosinophils	B-cell_type
purified	O
from	O
a	O
female	O
patient	O
presenting	O
with	O
IHES	O
were	O
found	O
to	O
show	O
a	O
clonal	O
pattern	O
of	O
X-inactivation	O
.	O

When	O
tested	O
for	O
antiestrogenic	O
activity	O
,	O
the	O
industrial	O
compound	O
4-octylphenol	O
was	O
able	O
to	O
antagonize	O
the	O
response	O
to	O
E2	O
;	O
however	O
,	O
the	O
response	O
was	O
three	O
orders	O
of	O
magnitude	O
less	O
potent	O
than	O
H	O
1285	O
.	O

Similar	O
constructs	O
controlled	O
by	O
NF-kappa	B-protein
B	I-protein
or	O
the	O
entire	O
interleukin-2	B-DNA
enhancer	I-DNA
show	O
bimodal	O
expression	O
patterns	O
during	O
induction	O
,	O
suggesting	O
that	O
thresholds	O
set	O
by	O
the	O
concentration	O
of	O
transcription	B-protein
factors	I-protein
may	O
be	O
a	O
common	O
property	O
of	O
inducible	B-DNA
genes	I-DNA
.	O

Since	O
the	O
IRF-1	B-protein
gene	O
is	O
both	O
virus	O
and	O
IFN	B-protein
inducible	O
,	O
an	O
intriguing	O
issue	O
is	O
raised	O
as	O
to	O
whether	O
the	O
IRF-1	B-DNA
gene	I-DNA
is	O
functioning	O
in	O
IFN	B-protein
-mediated	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

These	O
results	O
suggest	O
that	O
the	O
IRE	B-RNA
motif	I-RNA
in	O
the	O
ALAS	B-RNA
mRNA	I-RNA
is	O
functional	O
and	O
imply	O
that	O
translation	O
of	O
the	O
mRNA	B-RNA
is	O
controlled	O
by	O
cellular	O
iron	O
availability	O
during	O
erythropoiesis	O
.	O

Twelve	O
amino	O
acid	O
peptides	O
encompassing	O
either	O
of	O
these	O
two	O
tyrosine	O
residues	O
in	O
phosphorylated	B-protein
form	I-protein
coprecipitated	O
Stat3	B-protein
but	O
not	O
Stat1	B-protein
and	O
blocked	O
IL-10	B-protein
-induced	O
Stat3	B-protein
phosphorylation	O
in	O
a	O
cell-free	O
system	O
.	O

In	O
conclusion	O
,	O
MDHM-stimulated	O
induction	O
of	O
cytokine	B-RNA
mRNA	I-RNA
expression	O
was	O
accompanied	O
by	O
different	O
proto-oncogene	B-DNA
responses	O
in	O
PBMo	B-cell_type
and	O
THP-1	B-cell_line
cells	I-cell_line
.	O

They	O
fail	O
to	O
induce	O
mRNA	B-RNA
of	O
TNF-alpha	B-protein
after	O
3	O
h	O
of	O
culture	O
.	O

Mutations	O
of	O
this	O
site	O
that	O
destroyed	O
potential	O
ets	B-DNA
transcription	I-DNA
factor	I-DNA
binding	I-DNA
sites	I-DNA
had	O
reduced	O
transcriptional	O
activity	O
.	O

We	O
now	O
report	O
that	O
dimers	O
consisting	O
of	O
p50	B-protein
NFkappaB1	I-protein
,	O
p65	B-protein
RelA	I-protein
,	O
and/or	O
c-Rel	B-protein
are	O
present	O
in	O
neutrophils	B-cell_type
and	O
that	O
the	O
greater	O
part	O
of	O
these	O
protein	B-protein
complexes	I-protein
is	O
physically	O
associated	O
with	O
cytoplasmic	B-protein
IkappaB-alpha	I-protein
in	O
resting	O
cells	O
.	O

Although	O
NFAT	B-protein
has	O
been	O
recently	O
shown	O
to	O
be	O
inducible	O
in	O
several	O
non-T	B-cell_type
immune	I-cell_type
cells	I-cell_type
,	O
the	O
NFAT	B-DNA
gene	I-DNA
family	I-DNA
members	I-DNA
characterized	O
to	O
date	O
have	O
been	O
isolated	O
only	O
from	O
T	B-cell_type
cells	I-cell_type
.	O

These	O
studies	O
identify	O
EGR1	B-protein
as	O
an	O
intermediary	O
linking	O
BCR	B-protein
-derived	O
signals	O
to	O
the	O
induction	O
of	O
CD44	B-protein
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
of	O
the	O
TCL1	B-DNA
genomic	I-DNA
locus	I-DNA
to	O
lymphocyte	O
metaphases	O
from	O
the	O
AT	O
patient	O
with	O
the	O
T-cell	O
clonal	O
expansion	O
showed	O
that	O
the	O
breakpoint	O
of	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
lies	O
within	O
the	O
TCL1	B-DNA
locus	I-DNA
and	O
is	O
accompanied	O
by	O
an	O
inverted	O
duplication	O
of	O
the	O
distal	B-DNA
part	I-DNA
of	O
chromosome	B-DNA
14	I-DNA
.	O

The	O
C-terminal	B-protein
domain	I-protein
of	O
the	O
precursor	O
is	O
rapidly	O
degraded	O
,	O
forming	O
the	O
mature	B-protein
p50	I-protein
subunit	I-protein
consisted	O
of	O
the	O
N-terminal	B-protein
region	I-protein
of	O
the	O
molecule	O
.	O

To	O
define	O
the	O
CD40	B-protein
signaling	O
components	O
upstream	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
the	O
functional	O
consequences	O
downstream	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
we	O
examined	O
mouse	B-cell_line
B	I-cell_line
cell	I-cell_line
transfectants	I-cell_line
expressing	O
wild-type	B-protein
or	I-protein
mutant	I-protein
human	I-protein
CD40	I-protein
.	O

Glucocorticoid	B-protein
receptors	I-protein
in	O
anorexia	O
nervosa	O
and	O
Cushing	O
's	O
disease	O
.	O

Transcriptional	O
activation	O
by	O
this	O
mutant	O
form	O
of	O
membrane-bound	B-protein
DeltaE	I-protein
was	O
approximately	O
equivalent	O
to	O
that	O
produced	O
by	O
intranuclear	B-protein
ICN	I-protein
.	O

Further	O
optimization	O
of	O
culture	O
conditions	O
,	O
type	O
of	O
Antigen	B-cell_type
Presenting	I-cell_type
Cells	I-cell_type
(	O
APC	B-cell_type
)	O
,	O
peptides	O
,	O
use	O
of	O
stabilizers	O
like	O
beta	B-protein
2-m	I-protein
are	O
still	O
needed	O
.	O

In	O
both	O
transformed	B-cell_type
and	I-cell_type
normal	I-cell_type
lymphocytes	I-cell_type
,	O
OKA	O
stimulation	O
induced	O
intense	O
phosphorylation	O
of	O
the	O
constitutively	O
expressed	O
Sp1	B-protein
protein	I-protein
in	O
the	O
nucleus	O
,	O
a	O
property	O
of	O
OKA	O
not	O
shared	O
by	O
TNF	B-protein
,	O
phorbol	O
ester	O
,	O
or	O
PHA	B-protein
and	O
interleukin	B-protein
2	I-protein
.	O

A	O
trace	O
element	O
preparation	O
(	O
Beres	O
Drops	O
Plus	O
,	O
BDP	O
)	O
elevates	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
gcR	B-protein
)	O
in	O
peripheral	B-cell_type
lymphocytes	I-cell_type
isolated	O
both	O
from	O
healthy	O
blood	O
donors	O
and	O
rheumatoid	O
arthritis	O
patients	O
.	O

Multiple	O
Oct2	B-protein
isoforms	I-protein
are	O
generated	O
by	O
alternative	O
splicing	O
.	O

This	O
complementary	B-DNA
DNA	I-DNA
encoded	O
a	O
protein	O
with	O
structural	O
similarities	O
to	O
the	O
c-jun	B-protein
proto-oncogene	I-protein
product	I-protein
,	O
and	O
its	O
target	O
sequence	O
was	O
closely	O
related	O
to	O
the	O
palindromic	B-DNA
target	I-DNA
sequence	I-DNA
of	O
c-jun	B-DNA
.	O

Moreover	O
,	O
induction	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
increased	O
events	O
distal	O
to	O
the	O
accumulation	O
of	O
cAMP	O
including	O
the	O
phosphorylation	O
of	O
the	O
transcription	O
factor	O
,	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
and	O
transcriptional	O
activation	O
of	O
cAMP-dependent	B-DNA
reporter	I-DNA
genes	I-DNA
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
exposure	O
of	O
cells	O
to	O
hypoxia	O
(	O
0.02	O
%	O
O2	O
)	O
results	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
,	O
increased	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
,	O
and	O
transactivation	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
construct	I-DNA
containing	O
two	O
NF-kappa	B-DNA
B	I-DNA
DNA	I-DNA
binding	I-DNA
sites	I-DNA
.	O

EBNA3C	B-protein
is	O
a	O
potent	O
repressor	O
of	O
transcription	O
when	O
bound	O
to	O
DNA	O
as	O
a	O
fusion	O
with	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
(	O
DBD	B-protein
)	O
of	O
GALA	O
.	O

The	O
AD1	B-protein
and	O
AD2	B-protein
transactivation	O
domains	O
of	O
E2A	B-protein
are	O
essential	O
for	O
the	O
antiapoptotic	O
activity	O
of	O
the	O
chimeric	B-protein
oncoprotein	I-protein
E2A-HLF	B-protein
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
NF-kappaB	B-protein
activation	O
by	O
LMP1	B-protein
or	O
by	O
each	O
of	O
its	O
effector	B-protein
sites	I-protein
is	O
mediated	O
by	O
a	O
pathway	O
that	O
includes	O
NIK	B-protein
,	O
IKKalpha	B-protein
,	O
and	O
IKKbeta	B-protein
.	O

It	O
is	O
clear	O
from	O
various	O
studies	O
that	O
the	O
activity	O
of	O
the	O
NADPH	B-protein
oxidase	I-protein
can	O
be	O
modulated	O
through	O
the	O
regulation	O
of	O
the	O
GTP-GDP	O
state	O
of	O
Rac	B-protein
.	O

Erythroid	O
differentiation	O
involves	O
the	O
activation	O
of	O
a	O
number	O
of	O
erythroid-specific	O
genes	O
,	O
most	O
of	O
which	O
,	O
including	O
the	O
globin	B-DNA
genes	I-DNA
and	O
the	O
erythropoietin	B-DNA
receptor	I-DNA
(	I-DNA
Epo-R	I-DNA
)	I-DNA
gene	I-DNA
,	O
are	O
,	O
at	O
least	O
in	O
part	O
,	O
regulated	O
by	O
the	O
transcription	B-protein
factor	I-protein
GATA-1	B-protein
.	O

Transcription	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type-1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
genome	I-DNA
is	O
regulated	O
in	O
part	O
by	O
cellular	B-protein
factors	I-protein
and	O
is	O
stimulated	O
by	O
activation	O
of	O
latently	B-cell_type
infected	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
STAT	O
serine	O
kinase	O
in	O
CLL	O
cells	O
has	O
not	O
been	O
identified	O
,	O
and	O
appears	O
to	O
be	O
neither	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
nor	O
pp70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
.	O

Dimerization	O
among	O
transcription	B-protein
factors	I-protein
has	O
become	O
a	O
recurrent	O
theme	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O

Furthermore	O
,	O
B	B-cell_type
cells	I-cell_type
transfected	O
with	O
a	O
chimeric	B-protein
CD8alpha/IL-4Ralpha	I-protein
receptor	I-protein
,	O
which	O
is	O
expressed	O
on	O
the	O
cell	O
surface	O
as	O
a	O
homodimer	B-protein
,	O
constitutively	O
expressed	O
Cepsilon	B-RNA
germline	I-RNA
transcripts	I-RNA
.	O

C/EBP	B-protein
activates	O
the	O
human	B-DNA
corticotropin-releasing	I-DNA
hormone	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

In	O
Rel-/-	B-cell_line
splenic	I-cell_line
T	I-cell_line
cell	I-cell_line
cultures	I-cell_line
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
,	O
the	O
levels	O
of	O
IL-3	O
,	O
IL-5	O
,	O
granulocyte-	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
and	O
gamma	B-protein
interferon	I-protein
(	O
IFN-gamma	B-protein
)	O
were	O
only	O
2-	O
to	O
3-fold	O
lower	O
compared	O
with	O
normal	O
T	O
cells	O
.	O

Consistent	O
with	O
the	O
ability	O
of	O
IL-4	B-protein
to	O
regulate	O
eosinophil	O
responses	O
,	O
IL-4	B-protein
signaling	I-protein
molecules	I-protein
are	O
present	O
in	O
human	B-cell_type
eosinophils	I-cell_type
.	O

Thus	O
,	O
our	O
experiments	O
demonstrate	O
that	O
the	O
C-terminal	B-protein
region	I-protein
of	O
HIV-1	B-protein
Tat	I-protein
is	O
required	O
to	O
suppress	O
Mn-SOD	B-protein
expression	O
and	O
to	O
induce	O
pro-oxidative	O
conditions	O
reflected	O
by	O
a	O
drop	O
in	O
reduced	O
glutathione	O
(	O
GSH	B-protein
)	O
and	O
the	O
GSH	O
:	O
oxidized	O
GSH	O
(	O
GSSG	O
)	O
ratio	O
.	O

Surprisingly	O
,	O
however	O
,	O
DMSO	O
has	O
no	O
effect	O
on	O
inducible	O
Rel	B-protein
A	I-protein
binding	O
.	O

These	O
data	O
are	O
well	O
in	O
line	O
with	O
the	O
long-standing	O
notion	O
that	O
interindividual	O
differences	O
in	O
platelet	B-protein
monoamine	I-protein
oxidase	I-protein
may	O
represent	O
differences	O
in	O
expression	O
of	O
the	O
enzyme	O
rather	O
than	O
genotypic	O
variation	O
.	O

Unicellular-unilineage	B-cell_line
erythropoietic	I-cell_line
cultures	I-cell_line
:	O
molecular	O
analysis	O
of	O
regulatory	O
gene	O
expression	O
at	O
sibling	O
cell	O
level	O
.	O

Erythropoietin	B-protein
(	O
Epo	B-protein
)	O
,	O
granulocyte/macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
and	O
interleukin	B-protein
3	I-protein
(	O
IL-3	B-protein
)	O
promoted	O
the	O
growth	O
of	O
NS-Meg	B-cell_line
cells	I-cell_line
.	O

To	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
RANTES	B-protein
expression	O
,	O
the	O
RANTES	B-DNA
promoter	I-DNA
region	I-DNA
was	O
analyzed	O
by	O
transient	O
expression	O
and	O
gel-mobility	O
shift	O
assays	O
.	O

METHODS	O
:	O
THP-1	B-cell_line
cells	I-cell_line
,	O
a	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
were	O
transfected	O
with	O
the	O
CMV	B-DNA
IE	I-DNA
genes	I-DNA
.	O

Both	O
of	O
these	O
events	O
were	O
blocked	O
by	O
preincubation	O
of	O
the	O
cells	O
with	O
FK506	O
,	O
a	O
calcineurin	B-protein
inhibitor	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
NFATp	B-protein
is	O
a	O
calcineurin	B-protein
substrate	O
in	O
cells	O
.	O

We	O
found	O
that	O
the	O
membrane	B-protein
proximal	I-protein
proline-rich	I-protein
domain	I-protein
and	O
adjacent	B-protein
16	I-protein
residues	I-protein
are	O
essential	O
for	O
both	O
hGM-CSF	B-protein
-dependent	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Monocytic	O
differentiation	O
of	O
HL-60	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
correlates	O
with	O
the	O
induction	O
of	O
Bcl-xL	B-protein
.	O

In	O
conclusion	O
,	O
AIDS	O
patients	O
with	O
hypercortisolism	O
and	O
clinical	O
features	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	O
are	O
characterized	O
by	O
abnormal	B-protein
glucocorticoid	I-protein
receptors	I-protein
on	O
lymphocytes	B-cell_type
.	O

However	O
,	O
p38	B-protein
MAPK	I-protein
is	O
activated	O
strongly	O
and	O
synergistically	O
by	O
either	O
CD3/CD28	B-protein
coligation	O
or	O
PMA/Ca2+	O
ionophore	O
stimulation	O
,	O
which	O
mimics	O
TCR	B-protein
-	O
CD3/CD28	B-protein
-mediated	O
signaling	O
.	O

A	O
1.2	O
kb	O
FasL	B-DNA
promoter	I-DNA
responded	O
to	O
DNA	O
damage	O
,	O
as	O
well	O
as	O
coexpression	O
with	O
p65	B-protein
Rel	I-protein
or	O
Fos/Jun	B-protein
.	O

A	O
second	O
peak	O
was	O
observed	O
at	O
a	O
later	O
time	O
point	O
following	O
LPS	O
stimulation	O
,	O
which	O
consisted	O
of	O
both	O
IKK-alpha	O
and	O
-beta	O
activity	O
.	O

DNA	O
methylation	O
changes	O
in	O
hematologic	O
malignancies	O
:	O
biologic	O
and	O
clinical	O
implications	O
.	O

Furthermore	O
,	O
these	O
oxidative	O
stresses	O
inhibited	O
activity	O
of	O
calcineurin	O
,	O
a	O
serine/	O
threonine	B-protein
phosphatase	I-protein
that	O
regulates	O
NFAT	B-protein
activation	O
.	O

The	O
malignant	B-cell_type
cells	I-cell_type
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
contain	O
a	O
reciprocal	O
chromosomal	O
translocation	O
that	O
fuses	O
the	O
promyelocytic	B-DNA
leukemia	I-DNA
gene	I-DNA
(	O
PML	O
)	O
with	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
(	O
RAR	B-protein
alpha	I-protein
)	O
.	O

IL-13	B-protein
activation	O
of	O
STAT6	B-protein
was	O
reduced	O
in	O
MDMac	B-cell_line
which	O
was	O
associated	O
with	O
diminished	O
IL-13	B-protein
-induced	O
expression	O
of	O
CD23	B-protein
and	O
MHC	B-protein
class	I-protein
II	I-protein
.	O

Calcium-dependent	O
immediate-early	B-DNA
gene	I-DNA
induction	O
in	O
lymphocytes	B-cell_type
is	O
negatively	O
regulated	O
by	O
p21Ha-ras	B-protein
.	O

Cloning	O
of	O
murine	B-protein
TCF-1	I-protein
,	O
a	O
T	O
cell-specific	O
transcription	B-protein
factor	I-protein
interacting	O
with	O
functional	B-DNA
motifs	I-DNA
in	O
the	O
CD3-epsilon	B-DNA
and	I-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
alpha	I-DNA
enhancers	I-DNA
.	O

Addition	O
of	O
ASA	O
to	O
an	O
in	O
vitro	O
T	O
helper	O
cell	O
differentiation	O
system	O
,	O
at	O
concentrations	O
compatible	O
with	O
plasma	O
levels	O
reached	O
during	O
anti-inflammatory	O
therapy	O
,	O
resulted	O
in	O
reduced	O
development	O
of	O
Th1	B-cell_type
cells	I-cell_type
.	O

Here	O
it	O
is	O
shown	O
that	O
microbial	B-protein
lipoproteins	I-protein
are	O
potent	O
stimulators	O
of	O
IL-12	B-protein
production	O
by	O
human	O
macrophages	B-cell_type
,	O
and	O
that	O
induction	O
is	O
mediated	O
by	O
Toll-like	B-protein
receptors	I-protein
(	O
TLRs	B-protein
)	O
.	O

Breast	O
tissue	O
biomarkers	O
which	O
accurately	O
predict	O
breast	O
cancer	O
development	O
within	O
a	O
10	O
year	O
period	O
in	O
high	O
risk	O
women	O
are	O
needed	O
but	O
currently	O
not	O
available	O
.	O

It	O
is	O
possible	O
that	O
the	O
normal	B-DNA
allele	I-DNA
may	O
be	O
functionally	O
inactivated	O
by	O
a	O
nonmutational	O
mechanism	O
.	O

The	O
c-Jun	B-protein
delta-domain	I-protein
inhibits	O
neuroendocrine	B-DNA
promoter	I-DNA
activity	O
in	O
a	O
DNA	O
sequence-	O
and	O
pituitary-specific	O
manner	O
.	O

Strikingly	O
,	O
deletion	O
of	O
346	B-protein
C-terminal	I-protein
residues	I-protein
augmented	O
this	O
activity	O
,	O
whereas	O
removal	O
of	O
20	O
additional	O
residues	O
abolished	O
it	O
.	O

Structural	O
and	O
functional	O
characterization	O
of	O
the	O
human	B-DNA
CD36	I-DNA
gene	I-DNA
promoter	I-DNA
:	O
identification	O
of	O
a	O
proximal	O
PEBP2/CBF	B-DNA
site	I-DNA
.	O

When	O
tested	O
in	O
cytotoxicity	O
assays	O
using	O
T-lymphocytes	B-cell_type
from	O
VZV	O
immune	O
human	O
donors	O
,	O
the	O
range	O
of	O
precursor	O
frequencies	O
for	O
T-lymphocytes	B-cell_type
that	O
recognized	O
VZV	B-protein
gE	I-protein
or	O
VZV	B-protein
IE62	I-protein
was	O
similar	O
whether	O
these	O
proteins	O
were	O
expressed	O
by	O
HSV-1	O
or	O
a	O
vaccinia	O
vector	O
.	O

However	O
,	O
in	O
contrast	O
to	O
GATA-1	B-protein
,	O
SCL	B-protein
is	O
expressed	O
in	O
the	O
developing	O
brain	O
.	O

Since	O
the	O
activation	O
of	O
NFAT	B-protein
is	O
MAPK	B-protein
-dependent	O
these	O
findings	O
suggested	O
that	O
the	O
activation	O
of	O
MAPK	B-protein
by	O
Tpl-2	B-protein
is	O
either	O
independent	O
or	O
only	O
partially	O
dependent	O
on	O
MEK1	B-protein
and	O
MEK2	B-protein
.	O

Ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
STATs	B-protein
promotes	O
their	O
homodimer	O
and	O
heterodimer	O
formation	O
and	O
subsequent	O
nuclear	O
translocation	O
.	O

Of	O
these	O
,	O
we	O
observed	O
that	O
another	O
transcription	B-protein
factor	I-protein
(	O
AP-1	B-protein
)	O
is	O
also	O
robustly	O
induced	O
at	O
the	O
DNA-binding	O
level	O
during	O
macrophage-like	O
HL-60	O
differentiation	O
,	O
but	O
not	O
during	O
granulocytic	O
differentiation	O
.	O

Transcriptional	O
inhibition	O
by	O
interleukin-6	B-protein
of	O
the	O
class	B-protein
A	I-protein
macrophage	I-protein
scavenger	I-protein
receptor	I-protein
in	O
macrophages	B-cell_type
derived	O
from	O
human	B-cell_type
peripheral	I-cell_type
monocytes	I-cell_type
and	O
the	O
THP-1	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

NAC	O
had	O
no	O
effect	O
on	O
the	O
half-life	O
of	O
E-selectin	B-RNA
or	I-RNA
VCAM-1	I-RNA
mRNA	I-RNA
.	O

Increased	O
CRH	B-protein
promoter	O
activity	O
following	O
phorbol	O
ester	O
treatment	O
was	O
inhibited	O
by	O
a	O
dominant	O
negative	O
NF-IL6	B-protein
mutant	I-protein
,	O
showing	O
that	O
the	O
effects	O
of	O
phorbol	O
ester	O
were	O
principally	O
mediated	O
by	O
C/EBP	B-protein
.	O

Therefore	O
,	O
we	O
examined	O
the	O
RB	B-protein
status	O
of	O
a	O
series	O
of	O
B-cell	O
mutants	O
that	O
are	O
defective	O
in	O
class	O
II	O
expression	O
,	O
generated	O
either	O
in	O
vitro	O
or	O
derived	O
from	O
Bare	O
Lymphocyte	O
Syndrome	O
(	O
BLS	O
)	O
patients	O
.	O

In	O
situ	O
immunolabelling	O
revealed	O
that	O
upregulation	O
of	O
protein	O
expression	O
by	O
IFN-alpha	B-protein
is	O
a	O
consequence	O
of	O
a	O
marked	O
increase	O
in	O
both	O
the	O
number	O
and	O
the	O
intensity	O
of	O
the	O
staining	O
of	O
so-called	O
PML	B-protein
nuclear	I-protein
bodies	I-protein
.	O

NK	O
cell	O
cytotoxicity	O
is	O
a	O
fast	O
and	O
efficient	O
mechanism	O
of	O
target	O
cell	O
lysis	O
.	O

E1A	B-DNA
's	O
inhibition	O
of	O
IFN	B-protein
-MCP	O
has	O
the	O
net	O
effect	O
of	O
promoting	O
the	O
selective	O
NK	O
cell-mediated	O
clearance	O
of	O
Ad-infected	O
or	O
Ad-transformed	B-cell_line
human	I-cell_line
cells	I-cell_line
.	O

Our	O
studies	O
reveal	O
that	O
inactivation	O
of	O
the	O
v-abl	B-protein
protein	I-protein
tyrosine	I-protein
kinase	I-protein
triggers	O
high-frequency	O
rearrangement	O
of	O
kappa	B-DNA
and	I-DNA
lambda	I-DNA
light-chain	I-DNA
genes	I-DNA
.	O

Expression	O
of	O
v-src	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
correlates	O
with	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Involvement	O
of	O
NF-chi	B-protein
B	I-protein
and	O
NF-IL6	B-protein
in	O
induction	O
of	O
IL-6	B-protein
transcription	O
by	O
monocytes	O
was	O
demonstrated	O
using	O
deleted	O
forms	O
of	O
the	O
IL-6	B-DNA
promoter	I-DNA
.	O

These	O
results	O
suggest	O
that	O
Nef	B-protein
downmodulates	O
LTR	B-DNA
activation	O
without	O
significantly	O
inhibiting	O
the	O
capacity	O
of	O
T	B-cell_type
cells	I-cell_type
to	O
respond	O
to	O
immunological	O
activations	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
types	O
I	O
(	O
HTLV-I	O
)	O
and	O
II	O
(	O
HTLV-II	O
)	O
have	O
two	O
nonstructural	B-DNA
trans-acting	I-DNA
regulatory	I-DNA
genes	I-DNA
,	O
tax	B-DNA
and	O
rex	B-DNA
,	O
located	O
in	O
the	O
3	B-DNA
'	I-DNA
region	I-DNA
of	O
the	O
viral	B-DNA
genome	I-DNA
.	O

In	O
addition	O
,	O
GST	B-protein
pull-down	O
experiments	O
demonstrated	O
a	O
physical	O
interaction	O
between	O
human	O
GATA-1	B-protein
and	O
C/EBPbeta	B-protein
.	O

Induction	O
of	O
monocytic	O
differentiation	O
and	O
NF-kappa	B-protein
B	I-protein
-like	O
activities	O
by	O
human	O
immunodeficiency	O
virus	O
1	O
infection	O
of	O
myelomonoblastic	B-cell_type
cells	I-cell_type
.	O

The	O
Duffy	O
blood	O
group	O
system	O
is	O
of	O
clinical	O
and	O
biological	O
significance	O
.	O

In	O
contrast	O
,	O
deletion	O
of	O
the	O
upstream	B-DNA
portion	I-DNA
of	O
the	O
delta	B-DNA
promoter	I-DNA
led	O
to	O
a	O
10	O
fold	O
decrease	O
in	O
expression	O
.	O

Nevertheless	O
,	O
we	O
show	O
that	O
H-7-sensitive	B-protein
kinases	I-protein
do	O
not	O
regulate	O
STAT3	B-protein
tyrosine	O
phosphorylation	O
or	O
phosphorylation	O
of	O
serine	O
727	O
.	O

These	O
observations	O
suggest	O
that	O
adherence	O
results	O
in	O
increases	O
of	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
EGR2	I-RNA
,	I-RNA
and	I-RNA
PDGF	I-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
.	O

Furthermore	O
,	O
PD98059	O
completely	O
blocked	O
the	O
TPA-induced	O
differentiation	O
of	O
ML-1	B-cell_line
cells	I-cell_line
,	O
as	O
assessed	O
by	O
a	O
number	O
of	O
features	O
associated	O
with	O
mononuclear	O
differentiation	O
including	O
changes	O
in	O
morphology	O
,	O
nonspecific	O
esterase	B-protein
activity	O
,	O
phagocytic	O
ability	O
,	O
NADPH	B-protein
oxidase	I-protein
activity	O
,	O
mitochondrial	O
respiration	O
,	O
and	O
c-jun	B-RNA
mRNA	I-RNA
inducibility	O
.	O

This	O
effect	O
was	O
paralleled	O
by	O
a	O
reduction	O
in	O
the	O
expression	O
of	O
MSR	B-protein
protein	O
and	O
mRNA	B-RNA
.	O

The	O
formation	O
of	O
this	O
complex	O
would	O
increase	O
,	O
independently	O
of	O
an	O
in	O
synergy	O
with	O
NF-kappa	B-protein
B	I-protein
,	O
the	O
low	O
basal	O
activity	O
of	O
the	O
HIV	B-DNA
LTR	I-DNA
observed	O
in	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Both	O
p105	B-protein
and	O
p98	B-protein
were	O
found	O
to	O
form	O
stable	O
complexes	O
with	O
other	O
Rel/NF-kappa	B-protein
B	I-protein
family	I-protein
members	I-protein
,	O
including	O
p65	B-protein
and	O
c-Rel	B-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Peroxisome	B-protein
proliferator-activated	I-protein
receptors	I-protein
(	O
PPARs	B-protein
)	O
,	O
members	O
of	O
the	O
nuclear	B-protein
receptor	I-protein
superfamily	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
are	O
activated	O
by	O
fatty	O
acid	O
metabolites	O
,	O
peroxisome	O
proliferators	O
,	O
and	O
thiazolidinediones	O
and	O
are	O
now	O
recognized	O
as	O
important	O
mediators	O
in	O
the	O
inflammatory	O
response	O
.	O

Capacitance	O
would	O
simply	O
involve	O
expression	O
of	O
IL-12R	B-protein
beta	I-protein
1	I-protein
and	I-protein
beta	I-protein
2	I-protein
subunits	I-protein
,	O
regulated	O
by	O
TCR	O
,	O
IL-4	B-protein
and	O
IFNs	B-protein
.	O

The	O
NFAT-controlled	B-DNA
luciferase	I-DNA
gene	I-DNA
system	I-DNA
distinguishes	O
CIF	B-protein
from	O
other	O
T	O
cell	O
inhibitory	O
activities	O
present	O
in	O
colostrum	O
,	O
in	O
particular	O
,	O
TGF	B-protein
beta	I-protein
1	I-protein
and	O
TGF	B-protein
beta	I-protein
2	I-protein
and	O
the	O
glucocorticoids	O
.	O

In	O
contrast	O
,	O
in	O
the	O
more	O
immature	O
,	O
multipotent	O
EML	B-cell_type
cells	I-cell_type
we	O
observed	O
that	O
this	O
RXR	B-protein
-specific	O
agonist	O
is	O
inactive	O
either	O
in	O
potentiating	O
IL-3	B-protein
-mediated	O
commitment	O
of	O
EML	B-cell_type
cells	I-cell_type
to	O
the	O
granulocyte	B-cell_type
lineage	I-cell_type
or	O
in	O
transactivating	O
RAR-RXR	B-DNA
response	I-DNA
elements	I-DNA
.	O

All	O
erythroid	B-cell_line
colonies	I-cell_line
consisted	O
of	O
ringed	B-cell_type
sideroblasts	I-cell_type
exclusively	O
showed	O
one	O
pattern	O
dominant	O
in	O
those	O
of	O
PMNCs	B-cell_type
.	O

Because	O
surfactant	B-protein
protein	I-protein
(	I-protein
SP	I-protein
)	I-protein
A	I-protein
is	O
involved	O
in	O
local	O
host	O
defense	O
in	O
the	O
lung	O
and	O
alters	O
immune	O
cell	O
function	O
by	O
modulating	O
the	O
expression	O
of	O
proinflammatory	B-protein
cytokines	I-protein
as	O
well	O
as	O
surface	B-protein
proteins	I-protein
involved	O
in	O
inflammation	O
,	O
we	O
hypothesized	O
that	O
SP-A	B-protein
exerts	O
its	O
action	O
,	O
at	O
least	O
in	O
part	O
,	O
via	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Eosinophils	B-cell_type
play	O
an	O
important	O
role	O
in	O
the	O
effector	O
phase	O
of	O
allergic	O
inflammation	O
.	O

BACKGROUND	O
:	O
Studies	O
from	O
our	O
laboratory	O
have	O
shown	O
that	O
the	O
earliest	O
stages	O
of	O
atherosclerosis	O
may	O
be	O
mediated	O
by	O
an	O
autoimmune	O
reaction	O
against	O
heat	B-protein
shock	I-protein
protein	I-protein
60	I-protein
(	O
Hsp60	B-protein
)	O
.	O

In	O
MDMs	B-cell_type
,	O
an	O
upregulation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
synthesis	O
as	O
well	O
as	O
the	O
appearance	O
of	O
a	O
novel	O
M	O
(	O
r	O
)	O
40	O
,	O
000	O
form	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
were	O
also	O
observed	O
.	O

Peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	B-protein
3H	I-protein
]	I-protein
calcitriol/VDR	I-protein
was	O
examined	O
after	O
exposure	O
of	O
whole	B-cell_type
cells	I-cell_type
to	O
10	O
(	O
-9	O
)	O
M/l	O
calcitriol	O
in	O
the	O
presence	O
and	O
absence	O
of	O
a	O
500-fold	O
excess	O
of	O
unlabeled	O
ligand	O
and	O
subsequent	O
isolation	O
of	O
nuclei	O
.	O

In	O
HIV-infected	O
cells	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
protein	O
levels	O
are	O
decreased	O
secondary	O
to	O
enhanced	O
protein	O
degradation	O
.	O

High	O
molecular	O
weight	O
dextran	O
sulfate	O
increases	O
the	O
activity	O
of	O
NF-kappaB-regulated	B-DNA
promoter	I-DNA
in	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
.	O

This	O
result	O
fits	O
well	O
into	O
the	O
general	O
observation	O
of	O
stress-induced	O
down-regulation	O
of	O
immune	O
responses	O
.	O

Selection	O
of	O
a	O
diverse	O
TCR	B-protein
repertoire	I-protein
in	O
response	O
to	O
an	O
Epstein-Barr	B-protein
virus-encoded	I-protein
transactivator	I-protein
protein	I-protein
BZLF1	B-protein
by	O
CD8+	B-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
during	O
primary	O
and	O
persistent	O
infection	O
.	O

This	O
liberates	O
NF-kappa	B-protein
B	I-protein
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
initiate	O
transcription	O
of	O
genes	B-DNA
important	O
for	O
the	O
defense	O
of	O
the	O
organism	O
.	O

Furthermore	O
,	O
expression	O
of	O
OBF-1	B-protein
in	O
HeLa	B-cell_line
cells	I-cell_line
selectively	O
stimulates	O
the	O
activity	O
of	O
a	O
natural	O
immunoglobulin	B-DNA
promoter	I-DNA
in	O
an	O
octamer	B-DNA
site	I-DNA
-dependent	O
manner	O
.	O

Results	O
were	O
expressed	O
as	O
a	O
median	O
(	O
interquartile	O
range	O
)	O
.	O

Detection	O
of	O
minimal	O
residual	O
disease	O
in	O
a	O
patient	O
with	O
acute	O
promyelocytic	O
leukemia	O
by	O
RT-PCR	O
:	O
necessity	O
of	O
chemotherapy	O
following	O
ATRA	O
therapy	O
.	O

Trifluoromethylketones	O
ameliorate	O
chronic	O
inflammation	O
in	O
vivo	O
.	O

Coexpression	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
and	O
Sp1	B-protein
transcription	B-protein
factors	I-protein
in	O
human	O
immunodeficiency	O
virus	O
1-induced	O
,	O
dendritic	O
cell-T-cell	O
syncytia	O
.	O

RB	B-protein
and	O
a	O
novel	O
E2F-1	B-protein
binding	I-protein
protein	I-protein
in	O
MHC	B-cell_line
class	I-cell_line
II	I-cell_line
deficient	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
and	O
normal	O
IFN-gamma	B-protein
induction	O
of	O
the	O
class	B-DNA
IL	I-DNA
transactivator	I-DNA
CIITA	B-DNA
in	O
class	B-cell_line
II	I-cell_line
non-inducible	I-cell_line
RB-defective	I-cell_line
tumor	I-cell_line
lines	I-cell_line
.	O

The	O
results	O
further	O
demonstrated	O
the	O
activation	O
of	O
S6	B-protein
kinase	I-protein
(	O
pp90rsk	B-protein
)	O
,	O
evidenced	O
by	O
phosphorylation	O
of	O
S6	B-protein
and	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
peptides	O
,	O
in	O
PWM	B-cell_line
treated	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O

However	O
,	O
we	O
show	O
that	O
JunB	B-protein
binds	O
directly	O
to	O
the	O
P1	B-DNA
site	I-DNA
and	O
synergizes	O
with	O
c-Maf	B-protein
to	O
activate	O
an	O
IL-4	B-DNA
luciferase	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

Cells	O
were	O
analyzed	O
by	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
.	O

Prolonged	O
corticosteroid	O
treatment	O
resulted	O
in	O
down-regulation	O
of	O
GcR	B-protein
,	O
while	O
the	O
mean	O
level	O
of	O
GcR	B-protein
in	O
Cushing	O
's	O
disease	O
was	O
normal	O
.	O

It	O
was	O
prominently	O
and	O
selectively	O
(	O
within	O
the	O
central	O
nervous	O
system	O
)	O
expressed	O
in	O
pyramidal	B-cell_type
cells	I-cell_type
of	O
the	O
cerebral	O
cortex	O
and	O
other	O
motor	B-cell_type
neurons	I-cell_type
,	O
e.g.	O
,	O
in	O
spinal	O
cord	O
and	O
brainstem	O
nuclei	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
Porphyromonas	O
gingivalis	O
LPS	O
(	O
P-LPS	O
)	O
also	O
is	O
able	O
to	O
induce	O
inflammatory	B-protein
cytokines	I-protein
in	O
human	B-cell_type
gingival	I-cell_type
fibroblasts	I-cell_type
.	O

CD14	B-protein
-mediated	O
translocation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
induced	O
by	O
lipopolysaccharide	O
does	O
not	O
require	O
tyrosine	B-protein
kinase	I-protein
activity	O
.	O

Erythropoietin	B-protein
-dependent	O
induction	O
of	O
hemoglobin	B-protein
synthesis	O
in	O
a	O
cytokine-dependent	B-cell_line
cell	I-cell_line
line	I-cell_line
M-TAT	B-cell_line
.	O

Several	O
studies	O
have	O
established	O
that	O
Tat	B-protein
releases	O
an	O
elongation	B-protein
block	I-protein
to	O
the	O
transcription	O
of	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
;	O
however	O
,	O
it	O
is	O
not	O
known	O
whether	O
this	O
mechanism	O
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
block	O
to	O
HIV	O
replication	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
when	O
Tat	B-protein
is	O
absent	O
.	O

Both	O
wild-type	B-protein
and	O
chimeric	B-protein
HLF	I-protein
proteins	I-protein
displayed	O
transcriptional	B-protein
activator	I-protein
properties	O
in	O
lymphoid	B-cell_type
and	I-cell_type
nonlymphoid	I-cell_type
cells	I-cell_type
on	O
reporter	B-DNA
genes	I-DNA
containing	O
HLF	B-DNA
or	I-DNA
C/EBP	I-DNA
consensus	I-DNA
binding	I-DNA
sites	I-DNA
.	O

The	O
involvement	O
of	O
p23	B-protein
,	O
hsp90	B-protein
,	O
and	O
immunophilins	B-protein
in	O
the	O
assembly	O
of	O
progesterone	B-protein
receptor	I-protein
complexes	I-protein
.	O

In	O
macrophages	B-cell_type
,	O
a	O
slight	O
enhancement	O
of	O
TNF-alpha	B-protein
production	O
was	O
seen	O
,	O
whereas	O
IL-1	B-protein
beta	I-protein
was	O
not	O
detected	O
.	O

The	O
best	O
characterized	O
are	O
the	O
B	B-protein
cell-specific	I-protein
OTF-2	I-protein
and	O
the	O
ubiquitous	O
OTF-1	B-protein
.	O

This	O
region	O
contains	O
two	O
DNA-binding	B-DNA
motifs	I-DNA
,	O
GM2	B-DNA
and	O
GC-box	B-DNA
.	O

The	O
mechanism	O
of	O
down-regulation	O
of	O
ICAM-I	B-protein
or	O
LFA-I	B-protein
in	O
4	B-cell_line
ATL	I-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
next	O
examined	O
.	O

We	O
studied	O
the	O
effects	O
of	O
TPA	O
on	O
the	O
regulation	O
of	O
c-jun	B-DNA
gene	O
expression	O
in	O
HL-60	B-cell_line
cells	I-cell_line
during	O
monocytic	O
differentiation	O
.	O

Furthermore	O
,	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
0.5	O
microM	O
)	O
,	O
a	O
structurally	O
distinct	O
agent	O
which	O
also	O
induces	O
HL-60	O
monocytic	O
differentiation	O
,	O
increased	O
c-jun	B-DNA
expression	O
.	O

OBJECTIVE	O
:	O
We	O
investigated	O
the	O
production	O
of	O
IL-5	B-protein
,	O
a	O
potent	O
growth	O
factor	O
and	O
chemotactic	O
factor	O
for	O
eosinophils	B-cell_type
,	O
by	O
CD4+	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
in	O
patients	O
with	O
asthma	O
.	O

The	O
link	O
between	O
cellular	O
production	O
of	O
such	O
important	O
mediators	O
of	O
inflammation	O
and	O
the	O
antioxidant	O
(	O
AO	O
)	O
thiols	O
,	O
cysteine	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
,	O
is	O
discussed	O
and	O
it	O
is	O
hypothesised	O
that	O
NF-kappa	B-protein
B	I-protein
antagonists	O
may	O
offer	O
important	O
therapeutic	O
benefits	O
.	O

These	O
results	O
confirm	O
at	O
a	O
molecular	O
level	O
the	O
ability	O
of	O
HIV-1	O
to	O
replicate	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
that	O
this	O
activity	O
is	O
strongly	O
associated	O
with	O
NF-kappaB	B-protein
.	O

Cross	O
competition	O
experiments	O
with	O
an	O
octamer	O
sequence	O
from	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
,	O
the	O
BAT	B-DNA
box	I-DNA
,	O
and	O
a	O
TA-rich	O
sequence	O
present	O
in	O
the	O
CD21	B-DNA
promoter	I-DNA
revealed	O
that	O
all	O
three	O
sequences	O
bound	O
the	O
same	O
nuclear	B-protein
proteins	I-protein
suggesting	O
that	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
were	O
Oct-1	B-protein
and	O
Oct-2	B-protein
.	O

T	B-cell_type
lymphocytes	I-cell_type
from	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
show	O
reduced	O
immune	O
function	O
and	O
impaired	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
NF-kappaB	B-protein
.	O

The	O
latter	O
issue	O
was	O
investigated	O
by	O
comparing	O
,	O
in	O
8	O
cases	O
,	O
constitutive	B-DNA
DNA	I-DNA
from	O
skin	B-cell_type
fibroblasts	I-cell_type
with	O
leukemic	B-DNA
DNA	I-DNA
.	O

It	O
is	O
also	O
expressed	O
in	O
transformed	B-cell_line
B-cells	I-cell_line
.	O

Steel	B-protein
factor	I-protein
affects	O
SCL	B-protein
expression	O
during	O
normal	O
erythroid	O
differentiation	O
.	O

Peripheral	O
blood	O
mononuclear	O
cell	O
GCR	B-protein
binding	O
affinities	O
for	O
dexamethasone	O
and	O
budesonide	O
were	O
also	O
determined	O
for	O
both	O
patient	O
groups	O
by	O
using	O
a	O
radioligand	O
binding	O
assay	O
and	O
Scatchard	O
analysis	O
.	O

RESULTS	O
:	O
Both	O
all-trans	O
and	O
9-cis	O
RA	O
inhibited	O
virus	O
replication	O
in	O
HIV-1	B-cell_line
IIIB-infected	I-cell_line
monocytoid	I-cell_line
cells	I-cell_line
,	O
in	O
the	O
presence	O
and	O
absence	O
of	O
the	O
co-stimulatory	O
agent	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

Finally	O
,	O
recovered	O
protein	O
was	O
identified	O
as	O
genuine	O
huGATA-3	B-protein
by	O
SDS-PAGE	O
,	O
Western	O
blotting	O
,	O
and	O
bandshift	O
assays	O
.	O

Induction	O
of	O
Cepsilon	B-RNA
germline	I-RNA
transcripts	I-RNA
by	O
IL-4	B-protein
in	O
B	B-cell_type
cells	I-cell_type
that	O
lack	O
the	O
gammac	B-protein
chain	I-protein
may	O
involve	O
signaling	O
via	O
the	O
IL-13R	B-protein
.	O

Regulation	O
of	O
the	O
Ets-related	B-protein
transcription	I-protein
factor	I-protein
Elf-1	B-protein
by	O
binding	O
to	O
the	O
retinoblastoma	B-protein
protein	I-protein
.	O

Our	O
data	O
suggest	O
that	O
stimulation	O
of	O
PML	B-DNA
expression	O
by	O
interferons	B-protein
and	O
IL-1	B-protein
may	O
account	O
for	O
upregulation	O
of	O
PML	B-protein
proteins	I-protein
observed	O
in	O
inflammatory	O
tissues	O
and	O
in	O
proliferative	O
states	O
.	O

Many	O
effects	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
on	O
gene	O
expression	O
,	O
including	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
,	O
in	O
monocytic	B-cell_type
cells	I-cell_type
are	O
mediated	O
by	O
activation	O
of	O
kappa	O
B	O
DNA-binding	O
proteins	O
.	O

T-lymphocytes	B-cell_type
from	O
individuals	O
with	O
filarial	O
inflammatory	O
disease	O
have	O
increased	O
transendothelial	O
migration	O
in	O
vitro	O
.	O

In	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
only	O
,	O
the	O
E	B-protein
(	I-protein
gre	I-protein
)	I-protein
-binding	I-protein
protein	I-protein
complexes	I-protein
included	O
ALF1	B-protein
or	O
HEB	B-protein
and	O
E2A	B-protein
basic	I-protein
helix-loop-helix	I-protein
proteins	I-protein
.	O

An	O
occasional	O
GC	O
with	O
an	O
ill-defined	O
border	O
was	O
invariably	O
surrounded	O
by	O
a	O
broad	O
mantle	O
zone	O
;	O
those	O
with	O
indistinct	O
mantle	O
zones	O
had	O
well-defined	O
,	O
regular	O
borders	O
.	O

When	O
co-transfected	O
with	O
a	O
construct	O
capable	O
of	O
overexpressing	O
the	O
tyrosine	B-protein
kinase	I-protein
p59fyn	B-protein
,	O
the	O
reporter	B-DNA
gene	I-DNA
was	O
activated	O
by	O
PMA	B-protein
alone	O
.	O

We	O
found	O
an	O
increase	O
in	O
Ca2+-dependent	B-protein
PKC	I-protein
isoforms	I-protein
in	O
monocytes	O
compared	O
with	O
alveolar	O
macrophages	O
.	O

Although	O
we	O
detected	O
no	O
IL-2	B-RNA
mRNA	I-RNA
in	O
ALD-treated	B-cell_line
cells	I-cell_line
,	O
the	O
nuclei	O
of	O
these	O
cells	O
contain	O
proteins	O
capable	O
of	O
binding	O
to	O
three	O
regulatory	B-DNA
sequences	I-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
region	I-DNA
:	O
NFAT	B-protein
,	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
AP-1	B-protein
.	O

Aspirin	O
inhibits	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
mobilization	O
and	O
monocyte	O
adhesion	O
in	O
stimulated	B-cell_line
human	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
.	O

Agonist-induced	O
monocytic	O
cell	O
adhesion	O
,	O
but	O
not	O
basal	O
adhesion	O
,	O
was	O
inhibited	O
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
by	O
alpha-tcp	O
.	O

Mutations	O
that	O
abolish	O
the	O
binding	O
of	O
each	O
factor	O
to	O
its	O
cognate	O
site	O
are	O
introduced	O
in	O
an	O
infectious	O
HIV-1	O
molecular	O
clone	O
to	O
study	O
their	O
effect	O
on	O
HIV-1	O
transcription	O
and	O
replication	O
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
are	O
produced	O
by	O
stimulation	O
with	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
leukemia	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
.	O

The	O
mechanisms	O
by	O
which	O
the	O
effects	O
of	O
IL-2	B-protein
are	O
propagated	O
within	O
cells	O
are	O
not	O
understood	O
.	O

Furthermore	O
,	O
a	O
truncated	O
form	O
of	O
NFAT1	B-protein
acts	O
as	O
a	O
dominant-negative	O
,	O
reducing	O
IL-4	B-DNA
promoter	I-DNA
activity	O
in	O
primed	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
confirming	O
the	O
importance	O
of	O
endogenous	B-protein
NFAT	I-protein
to	O
increased	O
IL-4	B-protein
gene	O
expression	O
by	O
effector	O
T	O
cells	O
.	O

[	O
Molecular-biologic	O
aspects	O
of	O
interaction	O
between	O
nervous	O
and	O
immune	O
systems	O
]	O

Oxidant-regulation	O
of	O
gene	O
expression	O
in	O
the	O
chronically	O
inflamed	O
intestine	O
.	O

The	O
myeloid	B-protein
integrin	I-protein
CD11b	I-protein
is	O
expressed	O
selectively	O
on	O
the	O
surface	O
of	O
mature	B-cell_type
macrophages	I-cell_type
,	O
monocytes	B-cell_type
,	O
neutrophils	B-cell_type
,	O
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

The	O
cellular	O
mechanism	O
governing	O
the	O
diminished	O
proliferative	O
response	O
of	O
neonatal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
to	O
anti-CD2	B-protein
may	O
therefore	O
be	O
due	O
to	O
decreased	O
NF	B-protein
kappa	I-protein
B	I-protein
induction	O
,	O
reduced	O
IL-2	B-RNA
mRNA	I-RNA
expression	O
and	O
deficient	O
IL-2	B-protein
production	O
.	O

Furthermore	O
,	O
cycloheximide	O
displayed	O
a	O
similar	O
capacity	O
to	O
enhance	O
TNF-alpha	B-protein
induced	O
neutrophil	O
apoptosis	O
even	O
at	O
time	O
points	O
when	O
cycloheximide	O
alone	O
had	O
no	O
pro-apoptotic	O
effect	O
,	O
suggesting	O
that	O
NF-kappaB	B-protein
may	O
regulate	O
the	O
production	O
of	O
protein	O
(	O
s	O
)	O
which	O
protect	O
neutrophils	B-cell_type
from	O
the	O
cytotoxic	O
effects	O
of	O
TNF-alpha	B-protein
.	O

In	O
addition	O
,	O
the	O
product	O
of	O
the	O
proto-oncogene	B-DNA
c-rel	I-DNA
can	O
bind	O
to	O
similar	O
DNA	O
motifs	O
by	O
itself	O
or	O
as	O
a	O
heterodimer	O
with	O
p50	B-protein
or	O
p65	B-protein
.	O

These	O
data	O
indicate	O
that	O
thrombin	B-protein
activates	O
endothelial	O
ICAM-1	B-protein
expression	O
and	O
polymorphonuclear	B-cell_type
leukocyte	I-cell_type
adhesion	O
by	O
NF-kappa	B-protein
Bp65	I-protein
binding	O
to	O
the	O
downstream	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
of	O
ICAM-1	B-DNA
promoter	I-DNA
after	O
proteolytically	O
activated	O
receptor-1	O
activation	O
.	O

Plasma	O
18-hydroxycorticosterone	O
was	O
also	O
significantly	O
(	O
P	O
less	O
than	O
0.025	O
)	O
lower	O
(	O
PIH	O
,	O
1071	O
+/-	O
149	O
pmol/L	O
;	O
controls	O
,	O
1907	O
+/-	O
318	O
pmol/L	O
)	O
.	O

LPS-Induced	O
NF-kappaB	B-protein
activation	O
and	O
TNF-alpha	B-protein
release	O
in	O
human	B-cell_type
monocytes	I-cell_type
are	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
dependent	O
and	O
protein	B-protein
kinase	I-protein
C	I-protein
independent	O
.	O

These	O
observations	O
suggest	O
that	O
reactivity	O
to	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
tightly	O
regulated	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
,	O
requiring	O
specific	O
signals	O
for	O
its	O
initiation	O
.	O

Unlike	O
other	O
class	B-DNA
II	I-DNA
promoters	I-DNA
,	O
the	O
HLA-DR	B-DNA
alpha	I-DNA
(	I-DNA
DRA	I-DNA
)	I-DNA
promoter	I-DNA
also	O
contains	O
one	O
element	O
identical	O
to	O
the	O
``	B-DNA
octamer	I-DNA
''	I-DNA
motif	I-DNA
of	O
immunoglobulin	B-DNA
variable	I-DNA
region	I-DNA
promoters	I-DNA
that	O
is	O
responsible	O
for	O
B	O
cell-specific	O
transcription	O
.	O

In	O
particular	O
,	O
staurosporine	O
achieved	O
approximately	O
90	O
%	O
inhibition	O
of	O
the	O
HIV-1	O
antigen	O
expression	O
in	O
heat	B-cell_line
shock-treated	I-cell_line
OM10.1	I-cell_line
at	O
a	O
non-toxic	O
concentration	O
.	O

These	O
are	O
known	O
to	O
bind	O
to	O
seven-transmembrane-domain	B-protein
containing	I-protein
receptors	I-protein
.	O

Herpesvirus	B-cell_line
saimiri	I-cell_line
immortalized	I-cell_line
gamma	I-cell_line
delta	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
activated	O
by	O
IL-12	B-protein
.	O

In	O
addition	O
,	O
IL-6	B-protein
and	O
IL-2	B-protein
synergistically	O
induce	O
homo-	O
and	O
heterodimerized	O
STAT1	B-protein
alpha	I-protein
and	O
STAT3	B-protein
in	O
both	O
NK	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
consistent	O
with	O
their	O
reported	O
synergism	O
in	O
modulating	O
perforin	B-DNA
gene	I-DNA
expression	O
.	O

Endothelial	B-cell_type
cells	I-cell_type
were	O
treated	O
with	O
TCP	O
,	O
alpha-tocopherol	O
acetate	O
(	O
TCP	O
acetate	O
)	O
,	O
or	O
alpha-tocopheryl	O
succinate	O
(	O
TCP	O
succinate	O
)	O
before	O
stimulation	O
with	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
;	O
10	O
U/ml	O
,	O
6	O
h	O
)	O
or	O
interleukin-1	B-protein
beta	I-protein
(	O
IL-1	B-protein
beta	I-protein
;	O
10	O
U/ml	O
,	O
6	O
h	O
)	O
.	O

NF-AT	B-protein
activation	O
induced	O
by	O
a	O
CAML	B-protein
-interacting	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
superfamily	I-protein
.	O

By	O
immunization	O
with	O
a	O
recombinant	B-protein
fusion	I-protein
protein	I-protein
,	O
we	O
show	O
that	O
TCF-1	B-protein
knock-out	O
mice	O
readily	O
yield	O
antiserum	O
titers	O
against	O
human	O
and	O
mouse	O
TCF-1	O
protein	O
.	O

We	O
have	O
investigated	O
whether	O
this	O
antigen	O
is	O
a	O
target	O
structure	O
for	O
human	B-cell_type
T-lymphocytes	I-cell_type
.	O

Inducible	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
regulated	O
by	O
a	O
cellular	O
transcription	B-protein
factor	I-protein
,	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

Further	O
results	O
,	O
in	O
which	O
beta-gal	B-protein
activity	O
is	O
correlated	O
with	O
NF-AT	B-protein
-binding	O
activity	O
,	O
indicate	O
that	O
the	O
concentration	O
of	O
NF-AT	B-protein
must	O
exceed	O
a	O
critical	O
threshold	O
before	O
transcription	O
initiates	O
.	O

Octamer	B-protein
transcription	I-protein
factors	I-protein
and	O
the	O
cell	B-DNA
type-specificity	I-DNA
of	I-DNA
immunoglobulin	I-DNA
gene	I-DNA
expression	O
.	O

CD45	B-protein
-dependent	O
events	O
such	O
as	O
tyrosine	B-protein
phosphorylation	I-protein
of	O
Shc	B-protein
,	O
activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
,	O
transcription	B-protein
factors	I-protein
,	O
and	O
stimulation	O
of	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
promoter	I-DNA
and	O
of	O
CD69	B-protein
and	O
CD25	B-protein
surface	O
expression	O
paralleled	O
activation	O
of	O
the	O
tyrosine	B-protein
kinases	I-protein
lck	B-protein
and	O
fyn	B-protein
.	O

STAT3	B-protein
expression	O
in	O
particular	O
has	O
been	O
associated	O
with	O
Abl	B-protein
,	O
Src	B-protein
,	O
and	O
HTLV-1	O
transformation	O
of	O
normal	B-cell_type
cells	I-cell_type
.	O

Moreover	O
,	O
IL-5	B-protein
induced	O
at	O
least	O
two	O
DNA-binding	B-protein
complexes	I-protein
,	O
using	O
nuclear	O
extracts	O
from	O
normal	O
human	B-cell_type
eosinophils	I-cell_type
and	O
the	O
IL-6/interferon-gamma	B-DNA
response	I-DNA
element	I-DNA
of	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
(	O
ICAM-1	B-DNA
pIRE	I-DNA
)	O
in	O
an	O
electromobility	O
shift	O
assay	O
.	O

Previous	O
reports	O
have	O
suggested	O
the	O
CD28	B-protein
stimulation	O
contributes	O
to	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
up-regulating	O
the	O
activity	O
of	O
several	O
transcription	B-protein
factors	I-protein
,	O
including	O
AP-1	B-protein
and	O
nuclear	B-protein
factor-kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
/Rel	I-protein
family	I-protein
members	I-protein
as	O
well	O
as	O
an	O
uncharacterized	B-protein
transcription	I-protein
factor	I-protein
called	O
CD28	B-protein
response	O
complex	O
.	O

Paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	B-protein
dynamics	O
kill	O
cells	O
in	O
a	O
Fas	B-protein
/Fas	B-protein
ligand	I-protein
(	O
FasL	B-protein
)	O
-dependent	O
manner	O
;	O
antibody	O
to	O
FasL	B-protein
inhibits	O
paclitaxel-induced	O
apoptosis	O
.	O

Three	O
aspects	O
of	O
the	O
involvement	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
pathogenesis	O
were	O
examined	O
.	O

[	O
Mechanism	O
of	O
action	O
of	O
steroid	O
hormones.	O
I.	O
Estrogens	O
]	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
the	O
involvement	O
of	O
the	O
Jak/Stat	B-protein
signal	O
pathway	O
in	O
MHC-I	B-protein
-induced	O
signal	O
transduction	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
have	O
mapped	O
the	O
inhibitory	O
activity	O
to	O
less	O
than	O
60	B-protein
residues	I-protein
,	O
containing	O
motifs	O
that	O
are	O
conserved	O
in	O
all	O
NFAT	B-protein
proteins	I-protein
.	O

This	O
is	O
the	O
third	O
patient	O
with	O
severe	O
FUra	O
toxicity	O
secondary	O
to	O
an	O
alteration	O
in	O
pyrimidine	O
catabolism	O
and	O
the	O
second	O
from	O
our	O
clinic	O
population	O
suggesting	O
that	O
the	O
frequency	O
of	O
this	O
genetic	O
defect	O
may	O
be	O
greater	O
than	O
previously	O
thought	O
.	O

In	O
this	O
model	O
system	O
,	O
the	O
activities	O
of	O
late	B-DNA
promoter-reporter	I-DNA
fusions	I-DNA
are	O
measured	O
following	O
transient	O
transfection	O
into	O
tissue	B-cell_line
culture	I-cell_line
cells	I-cell_line
expressing	O
EBV	O
during	O
different	O
stages	O
of	O
the	O
lytic	O
cycle	O
.	O

Biochemical	O
analysis	O
by	O
Western	O
blotting	O
of	O
fetal	B-cell_type
and	I-cell_type
adult	I-cell_type
hematopoietic	I-cell_type
populations	I-cell_type
shows	O
several	O
runt	B-protein
isoforms	I-protein
.	O

Concomitant	O
stimulation	O
by	O
VitD3	O
inhibited	O
the	O
RA-stimulated	O
formation	O
of	O
RAR	B-protein
beta/RXR	I-protein
heterodimers	I-protein
,	O
favoring	O
VDR	B-protein
/RXR	B-protein
binding	O
to	O
the	O
RARE	B-DNA
.	O

Here	O
,	O
we	O
studied	O
the	O
role	O
of	O
serine/threonine	B-protein
phosphatases	I-protein
in	O
STAT3	B-protein
signaling	O
in	O
human	B-cell_line
antigen-specific	I-cell_line
CD4	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
cutaneous	B-cell_line
T	I-cell_line
cell	I-cell_line
lymphoma	I-cell_line
lines	I-cell_line
,	O
expressing	O
a	O
constitutively	O
activated	O
STAT3	B-protein
.	O

We	O
show	O
that	O
JAK2	B-protein
kinase	I-protein
is	O
rapidly	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
IL-13	B-protein
.	O

Inhibition	O
of	O
the	O
gut	O
inflammatory	O
response	O
by	O
the	O
antisense	O
oligonucleotide	O
or	O
the	O
depletion	O
of	O
neutrophils	B-cell_type
from	O
SCID-HU-	O
INT	O
mice	O
blocked	O
the	O
increase	O
in	O
intestinal	O
permeability	O
observed	O
with	O
amebic	O
infection	O
.	O

These	O
homodimers	B-protein
and	O
heterodimers	B-protein
show	O
distinct	O
DNA-binding	O
specificities	O
and	O
affinities	O
for	O
various	O
kappa	B-DNA
B	I-DNA
motifs	I-DNA
.	O

Sequence	O
analysis	O
of	O
DD	B-protein
products	I-protein
revealed	O
two	O
cDNAs	B-DNA
with	O
identity	O
to	O
known	B-protein
gene	I-protein
products	I-protein
:	O
the	O
catalytic	B-protein
sub-unit	I-protein
of	I-protein
DNA-protein	I-protein
kinase	I-protein
(	O
DNA-PK	B-protein
(	I-protein
CS	I-protein
)	I-protein
)	O
,	O
and	O
the	O
peroxisomal	B-protein
enzyme	I-protein
17beta-hydroxysteroid	I-protein
dehydrogenase	I-protein
type	I-protein
IV	I-protein
(	O
17beta-HSD	B-protein
IV	I-protein
)	O
.	O

Our	O
previous	O
data	O
obtained	O
from	O
a	O
tax	B-protein
transgenic	O
mouse	O
model	O
revealed	O
that	O
tax	B-protein
transforms	O
mouse	B-cell_type
fibroblasts	I-cell_type
but	O
not	O
thymocytes	B-cell_type
,	O
despite	O
comparable	O
levels	O
of	O
tax	B-protein
expression	O
in	O
both	O
tissues	O
.	O

Proteins	O
in	O
the	O
second	O
group	O
carry	O
a	O
single	B-protein
HMG	I-protein
box	I-protein
with	O
affinity	O
for	O
the	O
minor	O
groove	O
of	O
the	O
heptamer	B-DNA
motif	I-DNA
AACAAAG	O
or	O
variations	O
thereof	O
.	O

I	B-protein
kappa	I-protein
B-alpha	I-protein
inhibits	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
by	O
retaining	O
it	O
in	O
the	O
cytoplasm	O
.	O

T	B-cell_type
cell	I-cell_type
activation	O
results	O
in	O
high	O
levels	O
of	O
HIV	O
replication	O
and	O
is	O
thought	O
to	O
be	O
one	O
mechanism	O
leading	O
to	O
the	O
conversion	O
from	O
latent	O
to	O
active	O
viral	O
infection	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

The	O
allele	B-DNA
-specific	O
regulation	O
of	O
Pax5	B-protein
raises	O
the	O
intriguing	O
possibility	O
that	O
monoallelic	O
expression	O
may	O
also	O
be	O
the	O
mechanism	O
causing	O
the	O
haploinsufficiency	O
of	O
other	O
Pax	B-DNA
genes	I-DNA
.	O

Transcriptional	O
activation	O
of	O
the	O
vascular	B-DNA
cell	I-DNA
adhesion	I-DNA
molecule-1	I-DNA
gene	I-DNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
expressing	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
protein	I-protein
.	O

NF-kappa	B-protein
B	I-protein
activation	O
,	O
minimal	O
in	O
unstimulated	B-cell_type
cells	I-cell_type
,	O
was	O
substantially	O
up-regulated	O
by	O
fibrinogen	B-protein
.	O

Non-steroidal	O
anti-inflammatory	O
drugs	O
inhibit	O
the	O
expression	O
of	O
cytokines	B-protein
and	O
induce	O
HSP70	B-protein
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

The	O
levels	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
of	O
the	O
patients	O
are	O
lower	O
than	O
in	O
normal	O
subjects	O
both	O
in	O
the	O
active	O
stage	O
of	O
the	O
disease	O
and	O
following	O
bilateral	O
total	O
adrenalectomy	O
.	O

Differential	O
effects	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
inhibitors	O
on	O
fibronectin	B-protein
-induced	O
interleukin-beta	B-DNA
gene	I-DNA
transcription	O
,	O
protein	O
synthesis	O
and	O
secretion	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

Several	O
cell	O
lines	O
of	O
hematopoietic	O
origin	O
including	O
the	O
leukemic	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
HPB.ALL	I-cell_line
and	O
the	O
erythroleukemic	B-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
were	O
responsive	O
to	O
thrombin	B-protein
,	O
whereas	O
others	O
such	O
as	O
THP1	B-cell_line
,	O
a	O
myelomonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
and	O
BL2	B-cell_line
,	I-cell_line
a	O
Burkitt	B-cell_line
lymphoma	I-cell_line
were	O
refractory	O
to	O
thrombin	B-protein
or	O
TRP	O
stimulation	O
.	O

The	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
I	I-protein
(	I-protein
HTLV-I	I-protein
)	I-protein
and	I-protein
HTLV-II	I-protein
Tax	I-protein
proteins	I-protein
are	O
potent	O
transactivators	B-protein
of	O
viral	O
and	O
cellular	O
gene	O
expression	O
.	O

In	O
mammalian	O
cells	O
the	O
MAPK	B-protein
p38	I-protein
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
responses	O
during	O
infection	O
through	O
its	O
effects	O
on	O
the	O
expression	O
of	O
proinflammatory	B-protein
molecules	I-protein
.	O

Furthermore	O
,	O
PDTC	O
differentially	O
targeted	O
both	O
NFATp	B-protein
and	I-protein
NFATc	I-protein
family	I-protein
members	I-protein
,	O
inhibiting	O
the	O
transactivation	O
functions	O
of	O
NFATp	B-protein
and	O
mRNA	O
induction	O
of	O
NFATc	B-protein
.	O

A	O
phosphoform	O
of	O
newly	O
synthesized	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
visible	O
when	O
degradation	O
by	O
the	O
proteasome	B-protein
is	O
inhibited	O
and	O
new	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
displays	O
the	O
same	O
properties	O
regarding	O
phosphorylation	O
and	O
degradation	O
in	O
response	O
to	O
a	O
second	O
inducer	O
.	O

A-myb	B-DNA
was	O
undetectable	O
in	O
4	O
prolymphocytic	O
leukemias	O
(	O
PLL	O
)	O
but	O
was	O
strongly	O
expressed	O
in	O
5/20	O
(	O
25	O
%	O
)	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
samples	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
by	O
western	O
blot	O
analysis	O
that	O
neutrophils	B-cell_type
express	O
an	O
alternatively	O
spliced	O
variant	O
of	O
the	O
pituitary	B-protein
transcription	I-protein
factor	I-protein
Pit-1	B-protein
,	O
designated	O
Pit-1b	B-protein
.	O

Finally	O
,	O
functional	O
activation	O
and	O
translocation	O
of	O
PKC	B-protein
were	O
investigated	O
with	O
a	O
selective	O
in	O
vitro	O
kinase	O
assay	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
a	O
construct	O
containing	O
the	O
IL-4	B-DNA
promoter	I-DNA
also	O
was	O
used	O
.	O

The	O
involvement	O
of	O
NFATp	B-protein
in	O
transcriptional	O
activation	O
of	O
both	O
the	O
interleukin-2	B-protein
and	O
TNF	B-DNA
alpha	I-DNA
genes	I-DNA
suggests	O
that	O
this	O
factor	O
plays	O
an	O
important	O
role	O
in	O
the	O
coordinate	O
induction	O
of	O
multiple	O
cytokine	B-DNA
genes	I-DNA
,	O
starting	O
at	O
the	O
earliest	O
stages	O
of	O
T	O
cell	O
activation	O
.	O

Both	O
signal	O
cascades	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
during	O
T-cell	O
activation	O
.	O

Systemic	O
hGR	B-protein
levels	O
in	O
patients	O
with	O
Crohn	O
's	O
disease	O
(	O
CD	O
)	O
treated	O
with	O
steroids	O
(	O
66.6	O
+/-	O
61.0	O
dpm	O
mg-1	O
cytosol	B-protein
protein	I-protein
)	O
were	O
not	O
different	O
from	O
those	O
in	O
patients	O
with	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
(	O
56.1	O
+/-	O
51.6	O
dpm	O
mg-1	O
cytosol	B-protein
protein	I-protein
)	O
.	O

In	O
smoking	O
menopausal	O
patients	O
,	O
lymphocyte	O
infiltration	O
was	O
found	O
to	O
be	O
higher	O
than	O
in	O
non-smokers	O
(	O
p	O
<	O
0.05	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
biologic	O
mediators	O
that	O
may	O
regulate	O
the	O
expression	O
of	O
TGF-alpha	B-protein
and	I-protein
-beta1	I-protein
by	O
eosinophils	B-cell_type
.	O

Glucocorticoids	O
are	O
known	O
to	O
have	O
a	O
lytic	O
effect	O
in	O
leukemic	B-cell_type
cells	I-cell_type
via	O
interactions	O
with	O
the	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
activation	O
of	O
CREB/ATF	B-protein
and	O
AP-1	B-protein
transcription	I-protein
factors	I-protein
by	O
PGN	O
or	O
by	O
any	O
other	O
component	O
of	O
Gram-positive	O
bacteria	O
.	O

In	O
this	O
report	O
,	O
we	O
address	O
the	O
possibility	O
of	O
rapid	O
mutational	O
analysis	O
of	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
for	O
initial	O
diagnosis	O
,	O
genetic	O
counseling	O
,	O
and	O
molecular	O
subclassification	O
of	O
affected	O
patients	O
and	O
their	O
families	O
.	O

These	O
heterozygous	O
mutant	O
mice	O
usually	O
developed	O
normally	O
,	O
but	O
they	O
began	O
to	O
die	O
after	O
5	O
months	O
.	O

We	O
show	O
here	O
that	O
soluble	O
TN	B-protein
inhibits	O
proliferation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
response	O
to	O
alpha	B-protein
CD3	I-protein
Ab	I-protein
co-immobilized	O
with	O
the	O
extracellular	B-protein
matrix	I-protein
protein	I-protein
fibronectin	B-protein
(	O
FN	B-protein
)	O
.	O

Three	O
of	O
these	O
peptides	O
designated	O
as	O
G75	O
:	O
AES1/2	O
(	O
128-135	B-protein
)	O
,	O
G60	O
:	O
AES1/2	O
(	O
127-137	B-protein
)	O
and	O
G61	O
:	O
AES1/2	O
(	O
125-133	B-protein
)	O
correspond	O
to	O
the	O
wildtype	B-DNA
AES	I-DNA
sequence	I-DNA
,	O
while	O
the	O
fourth	O
G76	O
:	O
GPLTPLPV	O
,	O
AES1/2	B-protein
(	I-protein
128-135	I-protein
)	I-protein
corresponds	O
to	O
a	O
variant	O
sequence	O
of	O
the	O
peptide	O
G75	O
with	O
the	O
N-terminal	O
Leu	O
substituted	O
to	O
glycine	O
.	O

Thus	O
,	O
CIITA	B-protein
not	O
only	O
activates	O
the	O
expression	O
of	O
class	B-DNA
II	I-DNA
genes	I-DNA
but	O
recruits	O
another	O
B	O
cell-specific	O
coactivator	O
to	O
increase	O
transcriptional	O
activity	O
of	O
class	B-DNA
II	I-DNA
promoters	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
.	O

Addition	O
of	O
ubiquitin	B-protein
protein	I-protein
ligase	I-protein
E3	I-protein
substantially	O
enhanced	O
the	O
E214K	B-protein
-mediated	O
ubiquitinylation	O
of	O
c-Jun	B-protein
and	O
c-Fos	B-protein
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
AECA	B-protein
may	O
directly	O
stimulate	O
EC	B-cell_type
in	O
Takayasu	O
arteritis	O
through	O
elevation	O
of	O
adhesion	B-protein
molecule	I-protein
expression	O
associated	O
with	O
NF-kappaB	B-protein
activation	O
and	O
adhesion	O
of	O
monocytes	B-cell_type
,	O
and	O
may	O
therefore	O
play	O
a	O
pathogenic	O
role	O
in	O
the	O
development	O
of	O
the	O
vasculopathy	O
in	O
Takayasu	O
arteritis	O
.	O

Suppression	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
and	O
CD18	B-protein
-mediated	O
leukocyte	O
adhesion	O
to	O
the	O
corneal	O
endothelium	O
by	O
dexamethasone	O
.	O

Egr-1	B-RNA
mRNA	I-RNA
expression	O
induced	O
by	O
sIgM-	O
and	O
sIgD-crosslinking	O
was	O
inhibited	O
by	O
H7	B-protein
,	O
erbstatin	O
and	O
genistein	O
,	O
but	O
not	O
by	O
HA1004	O
.	O

TSC2	B-RNA
messenger	I-RNA
RNA	I-RNA
was	O
widely	O
expressed	O
in	O
various	O
cell	O
types	O
throughout	O
the	O
body	O
,	O
including	O
epithelia	O
,	O
lymphocytes	B-cell_type
,	O
and	O
cells	O
with	O
endocrine	O
functions	O
,	O
e.g.	O
,	O
adrenal	O
cortex	O
and	O
anterior	O
pituitary	O
.	O

Phosphorylation	O
of	O
CREB	B-protein
occurred	O
through	O
a	O
herbimycin	O
A	O
and	O
Rp-cAMP-	O
sensitive	O
pathway	O
,	O
suggesting	O
phosphorylation	O
required	O
antecedent	O
activation	O
of	O
both	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
(	O
PTK	B-protein
)	O
and	O
protein	B-protein
kinase	I-protein
A	I-protein
(	O
PKA	B-protein
)	O
.	O

Effects	O
of	O
overexpression	O
of	O
IL-1	B-protein
receptor-associated	I-protein
kinase	I-protein
on	O
NFkappaB	B-protein
activation	O
,	O
IL-2	B-protein
production	O
and	O
stress-activated	O
protein	O
kinases	O
in	O
the	O
murine	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
EL4	I-cell_line
.	O

Interestingly	O
,	O
in	O
CIITA-transfected	B-cell_line
cell	I-cell_line
hybrids	I-cell_line
,	O
cell	O
surface	O
expression	O
of	O
the	O
human	B-protein
HLA-DQ	I-protein
heterodimer	I-protein
was	O
not	O
observed	O
.	O

To	O
detect	O
the	O
origin	O
of	O
the	O
cell	O
hybridized	O
with	O
a	O
c-myc	B-DNA
probe	I-DNA
,	O
a	O
combined	O
immunochemistry	O
in	O
situ	O
hybridization	O
histochemistry	O
technique	O
was	O
used	O
.	O

Induction	O
of	O
Bcl-x	B-protein
(	I-protein
L	I-protein
)	I-protein
expression	O
by	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
through	O
NF-kappaB	B-protein
in	O
apoptosis-resistant	B-cell_line
T-cell	I-cell_line
transfectants	I-cell_line
with	O
Tax	B-protein
.	O

This	O
locus	O
is	O
rearranged	O
by	O
chromosomal	O
translocations	O
in	O
human	O
myeloproliferative	O
disorders	O
and	O
leukemias	O
.	O

The	O
molecular	O
mechanism	O
for	O
this	O
steroid	O
resistance	O
is	O
unclear	O
.	O

Thus	O
,	O
PKC-zeta	B-protein
overexpression	O
stimulates	O
a	O
type	O
of	O
phenotypic	O
differentiation	O
that	O
differs	O
significantly	O
from	O
maturation	O
occurring	O
upon	O
activation	O
of	O
other	O
PKC	B-protein
subfamilies	I-protein
induced	O
by	O
phorbol	O
ester	O
treatment	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
IL-2	B-protein
production	O
,	O
cyclosporin	O
A	O
inhibited	O
the	O
induction	O
of	O
NF-MATp35	B-protein
.	O

When	O
transfected	O
into	O
K562	B-cell_line
cells	I-cell_line
,	O
which	O
express	O
zeta-globin	B-protein
,	O
comparable	O
amounts	O
of	O
activity	O
were	O
obtained	O
from	O
the	O
-557	B-DNA
and	I-DNA
-417	I-DNA
zeta-luciferase	I-DNA
constructs	I-DNA
and	O
the	O
alpha-luciferase	B-DNA
constructs	I-DNA
when	O
no	O
enhancers	B-DNA
or	O
the	O
alpha-globin	B-DNA
locus	I-DNA
enhancers	I-DNA
were	O
used	O
.	O

Few	O
known	O
genes	B-DNA
(	O
IL-2	B-protein
,	O
members	O
of	O
the	O
IL-8	B-DNA
family	I-DNA
,	O
interferon-gamma	B-DNA
)	O
are	O
induced	O
in	O
T	B-cell_type
cells	I-cell_type
only	O
through	O
the	O
combined	O
effect	O
of	O
phorbol	O
myristic	O
acetate	O
(	O
PMA	O
)	O
and	O
a	O
Ca	O
(	O
2+	O
)	O
-ionophore	O
,	O
and	O
expression	O
of	O
only	O
these	O
genes	B-DNA
can	O
be	O
fully	O
suppressed	O
by	O
Cyclosporin	O
A	O
(	O
CyA	O
)	O
.	O

The	O
results	O
reported	O
herein	O
indicate	O
that	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
CD28	B-protein
cosignaling	O
and	O
regulation	O
of	O
IL-2	B-protein
secretion	O
in	O
LP	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
unique	O
to	O
that	O
compartment	O
and	O
differ	O
from	O
those	O
seen	O
in	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Signaling	O
events	O
induced	O
by	O
lipopolysaccharide-activated	B-protein
toll-like	I-protein
receptor	I-protein
2	I-protein
.	O

These	O
cells	O
,	O
stimulated	O
by	O
an	O
agonistic	O
monoclonal	O
antibody	O
against	O
CD40	B-protein
or	O
by	O
transfection	O
with	O
a	O
CD40L	B-DNA
expression	I-DNA
vector	I-DNA
,	O
secreted	O
p40	B-protein
and	O
showed	O
enhanced	O
p40	B-RNA
mRNA	I-RNA
expression	O
.	O

In	O
an	O
effort	O
to	O
identify	O
this	O
factor	O
,	O
the	O
cellular	O
levels	O
of	O
components	O
of	O
the	O
GR	B-protein
heterocomplex	I-protein
in	O
SML	B-cell_type
and	O
human	B-cell_type
lymphocytes	I-cell_type
(	O
HL	B-cell_type
)	O
were	O
compared	O
.	O

By	O
biochemical	O
fractionation	O
and	O
reconstitution	O
,	O
we	O
showed	O
that	O
RanBP1	B-protein
restores	O
nuclear	O
export	O
after	O
the	O
RanQ69L	B-protein
preincubation	O
.	O

Pretreatment	O
of	O
HL-60	O
cells	O
or	O
thymocytes	B-cell_type
with	O
100-500	O
microM	O
OP	O
for	O
2	O
hr	O
,	O
but	O
not	O
10-60	O
mM	O
NAC	O
,	O
suppressed	O
subsequent	O
occurrence	O
of	O
apoptosis	O
induced	O
by	O
etoposide	O
.	O

When	O
transcriptionally	O
active	O
,	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
promoter	B-DNA
contains	O
a	O
nucleosome-free	O
region	O
encompassing	O
both	O
the	O
promoter/enhancer	B-DNA
region	I-DNA
and	O
a	O
large	O
region	O
(	O
255	B-DNA
nucleotides	I-DNA
[	O
nt	O
]	O
)	O
downstream	O
of	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
.	O

Deletion	O
of	O
this	O
region	O
significantly	O
impaired	O
IL-9	B-protein
-induced	O
cell	O
growth	O
,	O
activation	O
of	O
JAK	B-protein
kinases	I-protein
,	O
insulin	B-protein
receptor	I-protein
substrate-2	I-protein
,	O
and	O
STAT3	B-protein
and	O
expression	O
of	O
early	B-DNA
response	I-DNA
genes	I-DNA
.	O

Experimentally	O
B	B-cell_type
cell	I-cell_type
progenitors	I-cell_type
do	O
not	O
tolerate	O
constitutive	O
expression	O
of	O
E2a-Pbx1	B-protein
which	O
contrasts	O
with	O
transformation	O
of	O
several	O
other	O
cell	O
types	O
following	O
its	O
stable	O
expression	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
show	O
here	O
that	O
DTCs	O
inhibited	O
both	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
synthesis	O
and	O
membrane	O
expression	O
of	O
antigens	B-protein
which	O
are	O
induced	O
during	O
T-cell	O
activation	O
.	O

In	O
line	O
with	O
this	O
conclusion	O
,	O
we	O
show	O
that	O
the	O
cut/CDP	B-protein
protein	I-protein
,	O
a	O
transcriptional	O
repressor	O
that	O
inhibits	O
gpc91-phox	B-DNA
gene	I-DNA
expression	O
by	O
preventing	O
NF-Y	B-protein
binding	O
to	O
the	O
CAAT	B-DNA
box	I-DNA
,	O
is	O
absent	O
in	O
monocytes	B-cell_type
.	O

Five	O
T-cell	B-cell_line
clones	I-cell_line
specific	O
for	O
a	O
T-cell	B-protein
epitope	I-protein
located	O
at	O
the	O
carboxyterminal	B-protein
region	I-protein
of	O
HBxAg	B-protein
were	O
established	O
and	O
found	O
to	O
belong	O
to	O
the	O
CD2/CD4-positive	B-cell_line
,	I-cell_line
CD8-negative	I-cell_line
subtype	I-cell_line
.	O

IL-10	B-protein
arrested	O
cells	O
at	O
G0/G1	O
.	O

The	O
same	O
is	O
true	O
for	O
nuclear	O
extracts	O
taken	O
from	O
the	O
murine	B-cell_line
P388D1	I-cell_line
macrophage	I-cell_line
cell	I-cell_line
line	I-cell_line
when	O
tested	O
with	O
the	O
-516	B-DNA
motif	I-DNA
of	O
the	O
murine	B-DNA
TNF	I-DNA
promoter	I-DNA
(	O
GGGGGCTTTCCC	O
)	O
.	O

Moreover	O
,	O
anti-	O
STAT3	B-protein
antibodies	I-protein
specifically	O
precipitated	O
a	O
protein	O
of	O
92	B-protein
kDa	I-protein
that	O
becomes	O
phosphorylated	O
on	O
tyrosine	O
upon	O
lymphocyte	O
treatment	O
with	O
H2O2	O
.	O

Persistent	O
HIV	O
infection	O
of	O
U937	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
results	O
in	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

This	O
approach	O
uses	O
monoclonal	B-protein
antibodies	I-protein
that	O
distinguish	O
between	O
the	O
native	O
and	O
phosphorylated	O
forms	O
of	O
STAT-1	B-protein
.	O

Each	O
binding	B-DNA
site	I-DNA
contributes	O
to	O
the	O
overall	O
activity	O
of	O
the	O
enhancer	B-DNA
,	O
however	O
no	O
single	O
element	O
seems	O
absolutely	O
required	O
for	O
activity	O
.	O

The	O
kinetics	O
of	O
JNK	B-protein
activation	O
correlated	O
with	O
the	O
expression	O
of	O
c-jun	B-DNA
which	O
was	O
transient	O
after	O
stimulation	O
with	O
PMA	O
plus	O
ionophore	O
and	O
prolonged	O
in	O
response	O
to	O
PDTC	O
,	O
which	O
also	O
transiently	O
induced	O
c-fos	B-DNA
.	O

An	O
upstream	B-DNA
segment	I-DNA
contains	O
tandem	B-DNA
dinucleotide	I-DNA
repeats	I-DNA
(	B-DNA
CT	I-DNA
)	I-DNA
19/	I-DNA
(	I-DNA
CA	I-DNA
)	I-DNA
16	I-DNA
.	O

Distinct	O
signaling	O
properties	O
identify	O
functionally	O
different	O
CD4	B-protein
epitopes	I-protein
.	O

Myb-transformed	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
as	O
a	O
model	O
for	O
monocyte	O
differentiation	O
into	O
dendritic	B-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
.	O

Immunoprecipitation	O
analysis	O
revealed	O
that	O
unde3r	O
these	O
circumstances	O
,	O
Calphostin	O
C	O
inhibited	O
the	O
production	O
of	O
IL-1beta	B-protein
protein	I-protein
,	O
whereas	O
Staurosporine	O
allowed	O
protein	O
production	O
,	O
but	O
inhibited	O
its	O
secretion	O
.	O

This	O
pattern	O
of	O
EBNA	B-protein
expression	O
is	O
generated	O
by	O
usage	O
of	O
the	O
BamHI-Q	B-DNA
promoter	I-DNA
(	O
Qp	B-DNA
)	O
.	O

ZEBRA	B-protein
activation	O
can	O
be	O
replaced	O
by	O
a	O
heterologous	B-protein
acidic	I-protein
,	I-protein
proline-rich	I-protein
,	I-protein
or	I-protein
glutamine-rich	I-protein
activation	I-protein
domain	I-protein
.	O

The	O
interleukin	B-DNA
2	I-DNA
receptor	I-DNA
alpha-chain	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
is	O
a	O
key	O
regulator	O
of	O
lymphocyte	O
proliferation	O
.	O

The	O
activation	O
is	O
rapid	O
and	O
is	O
mediated	O
through	O
a	O
tyrosine	O
kinase-dependent	O
pathway	O
.	O

In	O
addition	O
,	O
IL-6	B-protein
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
bronchiolitis	O
obliterans	O
after	O
transplantation	O
.	O

Because	O
STAT6	B-protein
activation	O
plays	O
an	O
essential	O
role	O
in	O
IL-4	B-protein
/	O
IL-13	B-protein
-induced	O
gene	O
expression	O
,	O
the	O
ability	O
of	O
IFN-beta	B-protein
and	O
IFN-gamma	B-protein
to	O
inhibit	O
STAT6	B-protein
activity	O
provides	O
an	O
explanation	O
for	O
how	O
IFNs	B-protein
can	O
suppress	O
IL-4	B-protein
/	O
IL-13	B-protein
-inducible	O
gene	O
expression	O
.	O

An	O
acute	B-DNA
myeloid	I-DNA
leukemia	I-DNA
gene	I-DNA
,	O
AML1	B-DNA
,	O
regulates	O
transcriptional	O
activation	O
and	O
hemopoietic	O
myeloid	O
cell	O
differentiation	O
antagonistically	O
by	O
two	O
alternative	O
spliced	O
forms	O
.	O

Western	O
analysis	O
performed	O
on	O
cellular	O
fractions	O
of	O
resting	B-cell_type
cells	I-cell_type
and	O
of	O
TPA-activated	B-cell_type
cells	I-cell_type
revealed	O
abundant	O
expression	O
of	O
classical	B-protein
PKC-alpha	I-protein
(	O
cPKC-alpha	B-protein
)	O
,	O
cPKC-betaII	B-protein
,	O
and	O
atypical	B-protein
PKC-zeta	I-protein
isoforms	I-protein
and	O
identified	O
a	O
sustained	O
translocation	O
of	O
cPKC-alpha	B-protein
and	O
cPKC-betaII	B-protein
from	O
the	O
cytosolic	O
compartment	O
to	O
membranes	O
.	O

When	O
isolated	O
PBMC	B-cell_type
were	O
first	O
cultured	O
for	O
20	O
h	O
in	O
the	O
presence	O
of	O
IL-10	B-protein
on	O
Teflon	O
to	O
prevent	O
adherence	O
,	O
washed	O
to	O
remove	O
IL-10	B-protein
and	O
then	O
further	O
cultured	O
in	O
plastic	O
dishes	O
for	O
an	O
additional	O
20	O
h	O
in	O
the	O
presence	O
of	O
LPS	O
or	O
IL-1beta	B-protein
,	O
an	O
enhanced	O
release	O
of	O
TNF	B-protein
was	O
observed	O
.	O

GDSP	O
also	O
completely	O
inhibited	O
superoxide	O
formation	O
in	O
the	O
human	B-cell_type
neutrophils	I-cell_type
stimulated	O
by	O
N-formyl-methionine-leucine-phenyl-alanine	O
(	O
fMLP	O
)	O
or	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

To	O
clarify	O
the	O
underlying	O
mechanisms	O
,	O
we	O
examined	O
effects	O
of	O
Dex	O
on	O
the	O
binding	O
avidity	O
of	O
beta2	B-protein
integrin	I-protein
on	O
the	O
neutrophil	B-cell_type
surface	O
and	O
how	O
these	O
might	O
in	O
turn	O
affect	O
neutrophil	B-cell_type
-to-tumor	O
cell	O
binding	O
.	O

To	O
determine	O
whether	O
the	O
IL-10R	B-protein
has	O
signaling	O
functions	O
similar	O
to	O
IL-6R	B-protein
in	O
cells	O
normally	O
expressing	O
these	O
receptors	O
,	O
leukocytes	B-cell_type
of	O
the	O
B-	B-cell_type
,	I-cell_type
T-	I-cell_type
,	I-cell_type
and	I-cell_type
NK-cell	I-cell_type
lineages	I-cell_type
were	O
treated	O
with	O
either	O
cytokine	O
.	O

Nucleolin	B-protein
is	O
an	O
abundant	B-protein
nucleolar	I-protein
protein	I-protein
which	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
rDNA	B-DNA
transcription	O
or	O
organization	O
,	O
or	O
rRNA	B-RNA
processing	O
.	O

Upon	O
cellular	O
activation	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
phosphorylated	O
,	O
polyubiquitinated	O
,	O
and	O
degraded	O
in	O
the	O
proteasome	B-protein
.	O

We	O
conclude	O
from	O
these	O
results	O
that	O
the	O
functional	O
activity	O
of	O
members	O
of	O
the	O
rel	B-protein
family	I-protein
is	O
regulated	O
by	O
their	O
interaction	O
with	O
DNA	O
and	O
that	O
Rel	B-protein
can	O
be	O
a	O
potent	O
transcriptional	O
activator	O
on	O
specific	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
.	O

Thus	O
,	O
the	O
substitution	O
of	O
the	O
underlined	O
A	O
residue	O
to	O
a	O
C	O
within	O
the	O
GGGATTTCACC	B-DNA
motif	I-DNA
abolishes	O
its	O
T	O
cell-restricted	O
activity	O
and	O
leads	O
to	O
its	O
functioning	O
in	O
both	O
El4	B-cell_line
cells	I-cell_line
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O

These	O
data	O
demonstrate	O
that	O
the	O
transcriptional	O
competence	O
of	O
a	O
subfamily	O
of	O
Pax	B-protein
proteins	I-protein
is	O
determined	O
by	O
a	O
C-terminal	B-protein
regulatory	I-protein
module	I-protein
composed	O
of	O
activating	B-DNA
and	I-DNA
inhibitory	I-DNA
sequences	I-DNA
.	O

Transfectants	B-cell_line
grown	O
in	O
the	O
presence	O
of	O
tetracycline	O
contained	O
about	O
15	O
,	O
000	O
receptors/cell	O
,	O
a	O
value	O
approximately	O
equal	O
to	O
basal	O
level	O
GR	B-protein
expression	O
in	O
glucocorticoid-sensitive	B-cell_line
6TG1.1	I-cell_line
cells	I-cell_line
before	O
steroid	O
treatment	O
.	O

NFATp	B-protein
immunoprecipitated	O
from	O
32P-labeled	B-cell_line
HT-2	I-cell_line
cells	I-cell_line
migrated	O
as	O
an	O
approximately	O
120-kDa	O
protein	O
that	O
was	O
localized	O
to	O
the	O
cytosol	O
of	O
the	O
cells	O
.	O

For	O
this	O
purpose	O
,	O
human	B-protein
GATA-3	I-protein
,	O
either	O
recombinant	O
or	O
in	O
nuclear	O
extracts	O
,	O
and	O
three	O
natural	B-DNA
GATA	I-DNA
elements	I-DNA
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
sites	B-DNA
1	I-DNA
,	I-DNA
2	I-DNA
,	I-DNA
and	I-DNA
3	I-DNA
)	O
were	O
chosen	O
,	O
in	O
which	O
only	O
site	B-DNA
2	I-DNA
is	O
a	O
noncanonical	O
GATA	B-DNA
site	I-DNA
.	O

At	O
10	O
microM	O
,	O
both	O
compounds	O
inhibited	O
IL-2	O
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
NFAT-1-linked	B-cell_line
lac-Z	I-cell_line
transfectants	I-cell_line
,	O
and	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

These	O
studies	O
identify	O
RA	O
as	O
a	O
nuclear	O
signal	O
for	O
MCP-1	B-protein
induction	O
in	O
undifferentiated	B-cell_type
human	I-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

It	O
also	O
abolished	O
IL-4	B-protein
-induced	O
upregulation	O
of	O
CD40	B-protein
but	O
promoted	O
upregulation	O
of	O
CD23	O
.	O

The	O
multiple	O
biologic	O
activities	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
are	O
mediated	O
through	O
RAR	B-protein
and	O
retinoid	B-protein
X	I-protein
receptor	I-protein
(	I-protein
RXR	I-protein
)	I-protein
nuclear	I-protein
receptors	I-protein
that	O
interact	O
with	O
specific	O
DNA	B-DNA
target	I-DNA
sequences	I-DNA
as	O
heterodimers	B-protein
(	O
RXR-RAR	B-protein
)	O
or	O
homodimers	B-protein
(	O
RXR-RXR	B-protein
)	O
.	O

A	O
major	O
interest	O
of	O
this	O
project	O
is	O
the	O
predictive	O
value	O
of	O
perceived	O
social	O
support	O
,	O
as	O
a	O
potential	O
``	O
stress	O
''	O
buffer	O
,	O
related	O
to	O
NK	O
activity	O
.	O

Virus	O
production	O
occurred	O
with	O
slightly	O
delayed	O
kinetics	O
for	O
viruses	O
containing	O
combined	O
mutations	O
in	O
the	O
AP-1	B-DNA
(	I-DNA
III	I-DNA
)	I-DNA
,	O
AP3-L	B-DNA
,	O
and	O
DBF	B-DNA
sites	I-DNA
and	O
in	O
the	O
AP3-L	B-DNA
and	O
DBF-sites	B-DNA
,	O
whereas	O
viruses	O
mutated	O
in	O
the	O
AP-1	B-DNA
(	I-DNA
I	I-DNA
,	I-DNA
II	I-DNA
,	I-DNA
III	I-DNA
)	I-DNA
and	O
AP3-L	B-DNA
sites	I-DNA
and	O
in	O
the	O
AP-1	O
(	O
I	O
,	O
II	O
,	O
III	O
)	O
,	O
AP3-L	B-DNA
,	O
and	O
DBF	B-DNA
sites	I-DNA
exhibited	O
a	O
severely	O
defective	O
replicative	O
phenotype	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
level	O
of	O
CRE	B-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
was	O
the	O
same	O
in	O
all	O
cell	O
lines	O
and	O
that	O
the	O
putative	O
AR-CRE	B-protein
forms	O
specific	O
and	O
compatible	O
protein	O
interactions	O
with	O
CREB	B-protein
.	O

Adherence-dependent	O
increase	O
in	O
human	B-RNA
monocyte	I-RNA
PDGF	I-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
is	O
associated	O
with	O
increases	O
in	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
and	I-RNA
EGR2	I-RNA
mRNA	I-RNA
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
CREB	B-protein
inhibited	O
GAL4	B-protein
-p65	O
(	O
286-551	O
)	O
-mediated	O
transcription	O
.	O

As2O3	O
induced	O
PML	O
(	O
promyelocytic	O
leukemia	O
)	O
protein	O
degradation	O
but	O
did	O
not	O
modulate	O
expression	O
of	O
cell	B-protein
cycle-related	I-protein
proteins	I-protein
,	O
including	O
c-myc	B-protein
,	O
retinoblastoma	B-protein
protein	I-protein
,	O
cyclin-dependent	B-protein
kinase	I-protein
4	I-protein
,	O
cyclin	B-protein
D1	I-protein
,	O
and	O
p53	B-protein
,	O
or	O
expression	O
of	O
differentiation-related	B-protein
antigens	I-protein
.	O

In	O
addition	O
,	O
mutation	O
of	O
the	O
Y-box	B-DNA
element	I-DNA
alone	O
abrogated	O
Tax1	B-protein
-mediated	O
activation	O
.	O

K+	O
channel	O
blockade	O
by	O
progesterone	O
is	O
specific	O
;	O
other	O
steroid	O
hormones	O
had	O
little	O
or	O
no	O
effect	O
,	O
although	O
the	O
progesterone	O
antagonist	O
RU	O
486	O
also	O
blocked	O
KV	B-protein
and	O
KCa	B-protein
channels	O
.	O

The	O
p53	B-protein
paradox	O
in	O
the	O
pathogenesis	O
of	O
tumor	O
progression	O
.	O

Notably	O
,	O
the	O
lack	O
of	O
pRB	B-protein
in	O
these	O
U937-derived	B-cell_line
clones	I-cell_line
renders	O
these	O
p53-null	B-cell_line
cells	I-cell_line
highly	O
resistant	O
to	O
apoptosis	O
induced	O
by	O
serum	O
withdrawal	O
,	O
calphostin	O
C	O
,	O
and	O
ceramide	O
.	O

Furthermore	O
,	O
compared	O
with	O
wild-type	B-protein
Id3	I-protein
,	O
an	O
Id3	B-protein
Asp5	I-protein
mutant	I-protein
(	O
mimicking	O
phosphorylation	O
)	O
is	O
unable	O
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
in	O
transfected	B-cell_line
fibroblasts	I-cell_line
,	O
whereas	O
an	O
Id3	B-protein
Ala5	I-protein
mutant	I-protein
(	O
ablating	O
phosphorylation	O
)	O
displays	O
an	O
activity	O
significantly	O
greater	O
than	O
that	O
of	O
wild-type	B-protein
Id3	I-protein
protein	I-protein
.	O

Regulation	O
of	O
the	O
human	B-DNA
interleukin-2	I-DNA
gene	I-DNA
by	O
the	O
alpha	B-protein
and	I-protein
beta	I-protein
isoforms	I-protein
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

These	O
studies	O
suggest	O
that	O
the	O
specificities	O
of	O
some	O
of	O
the	O
known	O
biological	O
functions	O
of	O
ZEBRA	B-protein
are	O
not	O
dependent	O
upon	O
the	O
nature	O
of	O
the	O
activation	B-protein
domain	I-protein
present	I-protein
within	O
ZEBRA	B-protein
.	O

To	O
examine	O
the	O
hypothesis	O
that	O
interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
contributes	O
to	O
PMN	O
infiltration	O
and	O
lung	O
damage	O
in	O
HS	O
,	O
we	O
examined	O
the	O
lungs	O
of	O
rats	O
subjected	O
to	O
unresuscitated	O
and	O
resuscitated	O
HS	O
for	O
the	O
production	O
of	O
IL-6	B-protein
and	O
activation	O
of	O
Stat3	B-protein
.	O

CD16	B-protein
(	O
Fc	B-protein
gamma	I-protein
RIIIA	I-protein
)	O
-induced	O
expression	O
of	O
cytokine	B-RNA
mRNA	I-RNA
in	O
NK	B-cell_type
cells	I-cell_type
occurs	O
via	O
a	O
CsA-sensitive	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
mechanism	O
.	O

TCL1	B-protein
protein	O
expression	O
is	O
restricted	O
to	O
tumor	O
cells	O
in	O
AIDS	O
IBLP	O
tissue	O
samples	O
analyzed	O
with	O
immunohistochemical	O
staining	O
.	O

Moreover	O
,	O
mRNA	B-RNA
for	O
IL-2	B-protein
and	O
IFN-gamma	B-protein
could	O
not	O
be	O
detected	O
.	O

In	O
both	O
cell	O
types	O
the	O
cellular	O
levels	O
of	O
IkappaBalpha	B-RNA
mRNA	I-RNA
and	O
protein	O
were	O
evaluated	O
by	O
DEX	O
treatment	O
.	O

Major	O
STAT	B-protein
complexes	I-protein
activated	O
by	O
G-CSF-R/IL-7R	B-protein
alpha	I-protein
contained	O
STAT1	B-protein
or	O
STAT5	B-protein
,	O
while	O
some	O
formation	O
of	O
STAT3-containing	B-protein
complexes	I-protein
was	O
also	O
seen	O
.	O

The	O
human	O
C/EBP-epsilon	B-protein
protein	O
exhibited	O
strong	O
and	O
specific	O
binding	O
to	O
double-stranded	B-DNA
DNA	I-DNA
containing	I-DNA
consensus	I-DNA
C/EBP	I-DNA
sites	I-DNA
.	O

Studies	O
were	O
initiated	O
with	O
a	O
fragment	O
extending	O
2	O
,	O
738	O
nucleotides	O
5	O
'	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
and	O
lead	O
to	O
the	O
identification	O
of	O
253	O
nucleotides	O
retaining	O
full	O
promoter	O
activity	O
in	O
human	B-cell_type
erythroleukemia	I-cell_type
cells	I-cell_type
.	O

PURPOSE	O
:	O
Sex-related	O
influences	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
vernal	O
keratoconjunctivitis	O
(	O
VKC	O
)	O
,	O
an	O
allergic	O
eosinophilic	O
disease	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
CyA	O
,	O
aspirin	O
,	O
and	O
indomethacin	O
on	O
T	O
cell	O
proliferation	O
using	O
a	O
proliferation	O
assay	O
.	O

Transcriptional	O
regulation	O
of	O
T	O
lymphocyte	O
development	O
and	O
function	O
.	O

A	O
Rel-related	B-protein
,	I-protein
mitogen-inducible	I-protein
,	I-protein
kappa	I-protein
B-binding	I-protein
protein	I-protein
has	O
been	O
cloned	O
as	O
an	O
immediate-early	B-DNA
activation	I-DNA
gene	I-DNA
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
regulation	O
of	O
interleukin-2	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
(	O
IL-2R	B-protein
alpha	I-protein
)	O
expression	O
and	O
nuclear	B-protein
factor	I-protein
(	O
NF	O
)	O
activation	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
in	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
has	O
been	O
studied	O
.	O

These	O
results	O
suggest	O
that	O
M7	B-cell_type
blasts	I-cell_type
and	O
TMD	B-cell_type
blasts	I-cell_type
correspond	O
to	O
the	O
erythroid/megakaryocytic	B-cell_type
bipotential	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

We	O
overexpressed	O
in	O
the	O
Jurkat	B-cell_line
T-cell	I-cell_line
line	I-cell_line
ZAP-70	B-protein
mutated	O
on	O
Tyr-492	O
and	O
Tyr-493	O
in	O
the	O
putative	O
regulatory	O
loop	O
of	O
its	O
kinase	B-protein
domain	I-protein
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
is	O
a	O
pluripotent	O
activator	O
of	O
inflammation	O
by	O
inducing	O
a	O
proinflammatory	B-protein
cytokine	I-protein
cascade	O
.	O

This	O
resurgence	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
protein	O
acts	O
to	O
restore	O
an	O
equilibrium	O
in	O
which	O
NF-kappa	B-protein
B	I-protein
is	O
again	O
inhibited	O
.	O

The	O
effect	O
of	O
NAC	O
was	O
also	O
examined	O
on	O
deletional	O
switch	O
recombination	O
underlying	O
the	O
isotype	O
switch	O
to	O
IgE	B-protein
.	O

Overexpression	O
of	O
TRAMP	B-protein
leads	O
to	O
two	O
major	O
responses	O
,	O
NF-kappaB	B-protein
activation	O
and	O
apoptosis	O
.	O

They	O
are	O
particularly	O
abundant	O
in	O
lymphoid	O
tissues	O
and	O
are	O
thought	O
to	O
be	O
critical	O
for	O
the	O
transcription	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Gel	O
retardation	O
assays	O
with	O
STAT-binding	O
oligonucleotides	O
showed	O
that	O
IL-7	B-protein
induces	O
the	O
formation	O
of	O
two	O
major	O
STAT	B-protein
complexes	I-protein
in	O
BCP-ALL	B-cell_line
cells	I-cell_line
.	O

IL-5	B-protein
synthesis	O
was	O
not	O
only	O
induced	O
by	O
T-cell	O
receptor	O
stimulation	O
but	O
also	O
by	O
IL-2	B-protein
receptor	O
stimulation	O
.	O

Finally	O
,	O
these	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
molecular	O
pathogenesis	O
of	O
X-SCID	O
is	O
due	O
primarily	O
to	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
-mediated	O
defects	O
in	O
the	O
IL-7	B-protein
/IL-7R	B-protein
system	O

These	O
results	O
therefore	O
demonstrate	O
that	O
the	O
MHC	B-protein
class	I-protein
II	I-protein
gene	O
silencing	O
in	O
somatic	B-cell_line
cell	I-cell_line
hybrids	I-cell_line
is	O
due	O
to	O
an	O
active	O
suppression	O
of	O
one	O
of	O
the	O
promoters	B-DNA
of	O
the	O
CIITA	B-DNA
gene	I-DNA
,	O
mediated	O
by	O
the	O
epithelial	B-cell_type
cell	I-cell_type
fusion	I-cell_type
partner	I-cell_type
.	O

Finally	O
we	O
explored	O
the	O
possible	O
role	O
of	O
5-hydroxyeicosatetraenoic	O
acid	O
as	O
a	O
regulator	O
of	O
arachidonic	O
acid	O
liberation	O
demonstrating	O
that	O
endogenous	O
5-lipoxygenase	B-protein
activity	O
modulates	O
platelet-activating	B-protein
factor	I-protein
induced	O
arachidonic	O
acid	O
release	O
perhaps	O
acting	O
at	O
the	O
level	O
of	O
phospholipase	B-protein
A2	I-protein
.	O

Inhibition	O
of	O
the	O
transfer	O
of	O
tyrosine	O
phosphoryl	O
groups	O
onto	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
prevented	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
and	O
NF-kappa	B-protein
B	I-protein
binding	O
.	O

Putative	B-protein
steroid	I-protein
binding	I-protein
domain	I-protein
of	O
the	O
human	B-protein
mineralocorticoid	I-protein
receptor	I-protein
,	O
expressed	O
in	O
E.	O
coli	O
in	O
the	O
presence	O
of	O
heat	B-protein
shock	I-protein
proteins	I-protein
shows	O
typical	O
native	O
receptor	O
characteristics	O
.	O

The	O
CRE	B-DNA
and	I-DNA
kappaB3	I-DNA
sites	I-DNA
in	O
region	B-DNA
II	I-DNA
together	O
conferred	O
strong	O
LPS	O
responsiveness	O
to	O
a	O
heterologous	B-DNA
promoter	I-DNA
,	O
whereas	O
individually	O
they	O
failed	O
to	O
provide	O
transcriptional	O
activation	O
.	O

Although	O
CTCF	B-protein
has	O
been	O
characterized	O
in	O
some	O
detail	O
,	O
there	O
is	O
very	O
little	O
information	O
about	O
the	O
regulation	O
of	O
CTCF	B-protein
activity	O
.	O

To	O
examine	O
the	O
factors	O
controlling	O
vascular-specific	O
expression	O
of	O
PECAM-1	B-protein
,	O
we	O
cloned	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
PECAM-1	B-DNA
gene	I-DNA
and	O
analyzed	O
its	O
transcriptional	O
activity	O
.	O

Stimulation	O
of	O
CD40	B-protein
on	O
immunogenic	O
human	O
malignant	O
melanomas	O
augments	O
their	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocyte	I-cell_type
-mediated	O
lysis	O
and	O
induces	O
apoptosis	O
.	O

A	O
new	O
protein-DNA	O
interaction	O
has	O
been	O
identified	O
upstream	O
of	O
the	O
intron	B-DNA
enhancer	I-DNA
,	O
within	O
the	O
matrix-associated	B-DNA
region	I-DNA
of	O
the	O
J-C	B-DNA
intron	I-DNA
.	O

A	O
CpG	O
island	O
suggests	O
expression	O
in	O
the	O
germ	O
line	O
.	O

This	O
further	O
fraction	O
is	O
distinct	O
from	O
the	O
mediator	O
of	O
transcriptional	O
activation	O
described	O
previously	O
and	O
represents	O
a	O
second	O
component	O
in	O
addition	O
to	O
general	B-protein
initiation	I-protein
factors	I-protein
that	O
may	O
facilitate	O
a	O
response	O
to	O
acidic	B-protein
activators	I-protein
.	O

An	O
in	O
vitro	O
binding	O
site	O
selection	O
procedure	O
was	O
used	O
to	O
determine	O
DNA	O
sequences	O
preferentially	O
bound	O
by	O
wild-type	B-protein
HLF	I-protein
and	O
chimeric	B-protein
E2A-HLF	I-protein
proteins	O
isolated	O
from	O
various	O
t	B-cell_line
(	I-cell_line
17	I-cell_line
;	I-cell_line
19	I-cell_line
)	I-cell_line
-bearing	I-cell_line
leukemias	I-cell_line
.	O

An	O
unidentified	O
Ets	B-protein
family	I-protein
protein	I-protein
binds	O
to	O
the	O
EBS	B-DNA
overlapping	O
the	O
consensus	B-DNA
GAS	I-DNA
motif	I-DNA
and	O
appears	O
to	O
negatively	O
regulate	O
the	O
human	B-DNA
IL-2R	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O

In	O
this	O
paper	O
we	O
shall	O
advance	O
the	O
hypothesis	O
that	O
:	O
(	O
i	O
)	O
TNF-alpha	B-protein
indirectly	O
controls	O
immune	O
surveillance	O
;	O
and	O
(	O
ii	O
)	O
TNF-alpha	B-protein
controls	O
DNA	O
repair	O
and	O
tumor	O
suppression	O
through	O
the	O
regulation	O
of	O
wild	B-protein
type	I-protein
p53	I-protein
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
NF-kappa	B-protein
B	I-protein
activation	O
might	O
constitute	O
one	O
of	O
the	O
mechanisms	O
underlying	O
the	O
inducible	O
expression	O
of	O
kappa	B-DNA
B-dependent	I-DNA
genes	I-DNA
in	O
microglia	B-cell_type
stimulated	O
by	O
A	O
beta	O
peptides	O
and	O
IFN	B-protein
gamma	I-protein
,	O
or	O
by	O
LPS	O
.	O

Comparison	O
of	O
the	O
derived	O
protein	O
sequence	O
with	O
those	O
of	O
rodent	O
homologs	O
allows	O
classification	O
into	O
three	O
groups	O
.	O

Protein	O
synthesis	O
inhibitors	O
and	O
corticosteroids	O
,	O
which	O
suppress	O
arachidonate	O
release	O
and	O
the	O
synthesis	O
of	O
proinflammatory	B-protein
cytokines	I-protein
,	O
had	O
no	O
effect	O
on	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
CHO/	O
CD14	B-protein
or	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
demonstrating	O
that	O
NF-kappa	B-protein
B	I-protein
translocation	O
is	O
an	O
early	O
event	O
.	O

The	O
increased	O
T	O
cell	O
response	O
after	O
RAI	O
therapy	O
is	O
probably	O
epitope	O
specific	O
,	O
rather	O
than	O
a	O
response	O
to	O
the	O
whole	O
TSHR	B-protein
molecule	O
.	O

Activation	O
of	O
T	O
cells	O
results	O
in	O
the	O
rapid	O
calcineurin	B-protein
-dependent	O
translocation	O
of	O
NFAT	B-protein
transcription	B-protein
factors	I-protein
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
.	O

In	O
addition	O
,	O
NAC	O
blocks	O
the	O
suppression	O
of	O
T	O
cell	O
mitogenesis	O
and	O
cytokine	B-protein
production	O
by	O
protease	O
inhibitors	O
such	O
as	O
N-tosylphenylalanine	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
.	O

Our	O
previous	O
investigations	O
on	O
the	O
formation	O
of	O
LCR	B-DNA
HS4	I-DNA
demonstrated	O
that	O
NF-E2	B-DNA
and	I-DNA
tandem	I-DNA
,	I-DNA
inverted	I-DNA
GATA	I-DNA
binding	I-DNA
sites	I-DNA
are	O
required	O
for	O
the	O
formation	O
of	O
the	O
native	B-DNA
HS	I-DNA
.	O

Immunosuppressant	O
PG490	O
(	O
triptolide	O
)	O
inhibits	O
T-cell	B-protein
interleukin-2	I-protein
expression	O
at	O
the	O
level	O
of	O
purine-box/nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T-cells	I-cell_type
and	O
NF-kappaB	B-protein
transcriptional	O
activation	O
.	O

Nuclear	O
accumulation	O
of	O
NFAT4	B-protein
opposed	O
by	O
the	O
JNK	B-protein
signal	O
transduction	O
pathway	O
.	O

NF-kappa	B-protein
B	I-protein
is	O
a	O
nuclear	B-protein
protein	I-protein
of	O
the	O
rel	B-protein
oncogene	I-protein
family	I-protein
capable	O
of	O
enhancing	O
transcription	O
of	O
several	B-DNA
cellular	I-DNA
genes	I-DNA
,	O
including	O
IL-2	B-protein
and	O
the	O
IL-2	B-protein
receptor	I-protein
,	O
and	O
viral	B-DNA
genes	I-DNA
transcribed	O
from	O
the	O
HIV-1	B-DNA
LTR	I-DNA
.	O

Furthermore	O
,	O
Egr-1	B-protein
induction	O
was	O
required	O
for	O
endogenous	O
NF-kappa	B-DNA
B1	I-DNA
gene	O
expression	O
,	O
since	O
PMA/	O
PHA-stimulated	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
expressing	O
antisense	O
Egr-1	B-RNA
RNA	I-RNA
were	O
inhibited	O
in	O
their	O
ability	O
to	O
upregulate	O
NF-kappa	O
B1	O
transcription	O
.	O

In	O
keeping	O
with	O
this	O
finding	O
,	O
we	O
showed	O
that	O
apoptosis	O
of	O
U937	B-cell_line
cells	I-cell_line
is	O
characterized	O
by	O
the	O
rapid	O
disappearance	O
of	O
the	O
105	O
,	O
000-	O
to	O
110	O
,	O
000-molecular-weight	O
pRB	B-protein
forms	O
concomitantly	O
with	O
the	O
appearance	O
of	O
a	O
smear	O
of	O
immunoreactive	O
products	O
with	O
a	O
molecular	O
weight	O
of	O
greater	O
than	O
250	O
,	O
000	O
.	O

Quantitative	O
assays	O
demonstrated	O
a	O
direct	O
temporal	O
relationship	O
between	O
LMP-1	B-protein
protein	I-protein
levels	O
and	O
active	O
NF-kappaB	B-protein
during	O
the	O
time	O
course	O
of	O
infection	O
.	O

Here	O
we	O
demonstrate	O
that	O
fusion	O
of	O
HeLa	B-cell_line
cells	I-cell_line
with	O
either	O
diploid	B-cell_type
or	I-cell_type
tetraploid	I-cell_type
B	I-cell_type
cells	I-cell_type
(	O
Daudi	B-cell_line
)	O
results	O
in	O
widespread	O
extinction	O
of	O
several	O
other	O
B	B-DNA
cell-encoded	I-DNA
genes	I-DNA
that	O
are	O
expressed	O
in	O
a	O
B	O
cell-specific	O
manner	O
.	O

Previous	O
studies	O
found	O
that	O
P1	B-DNA
,	O
an	O
element	O
of	O
the	O
interleukin	B-DNA
4	I-DNA
(	I-DNA
IL-4	I-DNA
)	I-DNA
promoter	I-DNA
that	O
binds	O
AP-1	O
,	O
is	O
important	O
for	O
Th2-restricted	O
IL-4	B-protein
expression	O
.	O

Glucocorticoids	O
induced	O
down-regulation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
mRNA	O
expression	O
in	O
asthma	O
.	O

B-myb	B-protein
is	O
also	O
involved	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
,	O
but	O
,	O
unlike	O
c-myb	B-DNA
,	O
it	O
is	O
expressed	O
in	O
many	O
cell	O
types	O
.	O

We	O
hypothesize	O
that	O
an	O
unknown	O
gene	O
or	O
genes	O
in	O
linkage	O
with	O
the	O
polymorphisms	B-DNA
is	O
(	O
are	O
)	O
responsible	O
for	O
the	O
relationship	O
between	O
risk	O
of	O
prostate	O
cancer	O
and	O
VDR	B-protein
polymorphisms	B-DNA
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
can	O
establish	O
a	O
persistent	O
and	O
latent	O
infection	O
in	O
CD4+	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
(	O
W.C.Greene	O
,	O
N.Engl.J.	O
Med.324	O
:	O
308-317	O
,	O
1991	O
;	O
S.M.Schnittman	O
,	O
M.C.Psallidopoulos	O
,	O
H.C.	O
Lane	O
,	O
L.Thompson	O
,	O
M.Baseler	O
,	O
F.Massari	O
,	O
C.H.Fox	O
,	O
N.P.Salzman	O
,	O
and	O
A.S.Fauci	O
,	O
Science	O
245	O
:	O
305-308	O
,	O
1989	O
)	O
.	O

We	O
now	O
show	O
that	O
IL-2	B-protein
regulation	O
of	O
STAT3	B-protein
proteins	I-protein
in	O
T	B-cell_type
cells	I-cell_type
is	O
a	O
complex	O
response	O
involving	O
activation	O
of	O
two	O
forms	O
of	O
STAT3	B-protein
:	O
90-kDa	O
STAT3alpha	B-protein
and	O
an	O
83-kDa	B-protein
carboxyl-terminal	I-protein
truncated	I-protein
STAT3beta	I-protein
.	O

This	O
RFLP	B-DNA
pair	I-DNA
occurs	O
in	O
76	O
%	O
of	O
patients	O
with	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
precipitins	O
,	O
84	O
%	O
of	O
anti-	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
-positive	O
patients	O
lacking	O
La	B-protein
(	I-protein
SSB	I-protein
)	I-protein
precipitins	B-protein
,	O
but	O
only	O
41	O
%	O
of	O
the	O
patients	O
lacking	O
both	O
precipitins	B-protein
(	O
P	O
=	O
0.0004	O
)	O
.	O

This	O
process	O
requires	O
calcium-dependent	O
dephosphorylation	O
of	O
NFAT	B-protein
caused	O
by	O
the	O
phosphatase	B-protein
calcineurin	B-protein
.	O

We	O
show	O
that	O
depletion	O
of	O
Sp1	B-protein
(	O
A1	B-protein
)	O
from	O
nuclear	O
extracts	O
specifically	O
decreases	O
in	O
vitro	O
transcription	O
activity	O
on	O
GM-CSF	B-protein
templates	O
.	O

In	O
selenium-deprived	B-cell_line
Jurkat	I-cell_line
and	O
ESb-L	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
,	O
supplementation	O
of	O
selenium	O
led	O
to	O
a	O
substantial	O
increase	O
of	O
GPX	B-protein
activity	O
.	O

The	O
activating	O
and	O
inhibitory	O
domains	O
function	O
together	O
as	O
an	O
independent	O
regulatory	O
module	O
in	O
different	O
cell	O
types	O
as	O
shown	O
by	O
fusion	O
to	O
the	O
GAL4	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
.	O

Stimulation	O
of	O
the	O
cAMP	O
signal	O
transduction	O
pathway	O
,	O
which	O
skews	O
cytokine	B-protein
production	O
toward	O
a	O
Th2	O
pattern	O
,	O
resulted	O
in	O
the	O
preferential	O
suppression	O
of	O
Stat1	B-protein
activity	O
.	O

The	O
activation	O
of	O
JNK	B-protein
by	O
classical	O
T	O
cell	O
stimuli	O
was	O
transient	O
,	O
whereas	O
that	O
mediated	O
by	O
PDTC	O
and	O
butylated	O
hydroxyanisole	O
(	O
but	O
not	O
N-acetylcysteine	O
)	O
was	O
sustained	O
.	O

This	O
suggests	O
that	O
higher	O
intracellular	O
levels	O
of	O
STAT1	B-protein
,	O
STAT2	B-protein
,	O
and	O
p48	B-protein
protein	I-protein
may	O
result	O
in	O
enhanced	O
signal	O
transduction	O
for	O
cytokines	B-protein
utilizing	O
these	O
transcription	B-protein
factors	I-protein
.	O

Various	O
other	O
genes	O
,	O
for	O
example	O
interleukin-1	B-DNA
and	I-DNA
MHC	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
,	O
contain	O
an	O
octamer	B-DNA
sequence	I-DNA
in	O
the	O
promoter	B-DNA
and	O
are	O
expressed	O
in	O
cells	O
of	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

Flow	O
cytometric	O
and	O
morphological	O
analyses	O
demonstrated	O
that	O
the	O
addition	O
of	O
CD70	O
transfectants	O
to	O
B	B-cell_line
cell	I-cell_line
cultures	I-cell_line
remarkably	O
promoted	O
differentiation	O
into	O
plasma	B-cell_type
cells	I-cell_type
in	O
the	O
presence	O
of	O
IL-4	B-protein
and	O
CD40	B-protein
signaling	O
.	O

These	O
findings	O
suggest	O
either	O
low	O
level	O
of	O
activation	O
is	O
required	O
or	O
that	O
different	O
caspases	B-protein
are	O
involved	O
.	O

The	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
promoter	I-DNA
consists	O
of	O
several	O
independent	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
(	I-DNA
TcR	I-DNA
)	I-DNA
responsive	I-DNA
elements	I-DNA
.	O

LOX-1	B-protein
has	O
the	O
highest	O
homology	O
with	O
C-type	B-protein
lectin	I-protein
receptors	I-protein
expressed	O
on	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

Moreover	O
,	O
the	O
upregulation	O
of	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
is	O
regulated	O
by	O
the	O
triggering	O
of	O
selected	O
epitopes	B-protein
of	O
HLA-DR	B-protein
antigens	I-protein
.	O

Furthermore	O
overexpression	O
of	O
exogenous	B-protein
c-fos	I-protein
has	O
an	O
inhibitory	O
effect	O
on	O
GR	B-protein
-dependent	O
transcription	O
from	O
GRE	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Heat	O
shock	O
induces	O
HIV-1	O
replication	O
in	O
chronically	O
infected	O
promyelocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
OM10.1	I-cell_line
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
the	O
disparate	O
fates	O
of	O
HL-60	B-cell_line
cells	I-cell_line
treated	O
with	O
the	O
phorbol	O
ester	O
12	O
,	O
13-phorbol	O
dibutyric	O
acid	O
(	O
PDBu	O
)	O
or	O
DMSO	O
.	O

The	O
best	O
medium	O
of	O
those	O
tested	O
was	O
RPMI	O
1640	O
supplemented	O
with	O
5	O
micrograms/ml	O
each	O
transferrin	B-protein
and	O
insulin	B-protein
+	O
5	O
ng/ml	O
sodium	O
selenite	O
+/-	O
0.1	O
%	O
bovine	B-protein
serum	I-protein
albumin	I-protein
.	O

In	O
the	O
human	O
leukemic	O
cells	O
studied	O
here	O
,	O
the	O
ability	O
to	O
induce	O
CD8	B-protein
antigen	I-protein
expression	O
in	O
a	O
CD4+	B-cell_line
cells	I-cell_line
correlates	O
with	O
the	O
ability	O
to	O
induce	O
cell	O
lysis	O
in	O
a	O
glucocorticoid	B-cell_line
receptor	I-cell_line
positive	I-cell_line
cell	I-cell_line
population	I-cell_line
.	O

Here	O
we	O
show	O
that	O
both	O
a	O
FasL-	B-DNA
and	I-DNA
a	I-DNA
consensus	I-DNA
NF-kappaB-	I-DNA
reporter	I-DNA
construct	I-DNA
are	O
inefficiently	O
induced	O
in	O
these	O
cells	O
compared	O
to	O
wild-type	B-cell_type
cells	I-cell_type
.	O

We	O
previously	O
detected	O
a	O
tissue-specific	B-DNA
promoter	I-DNA
preceding	O
the	O
exon	O
encoding	O
the	O
N	B-protein
terminus	I-protein
of	O
the	O
pp52	B-protein
leukocyte	I-protein
protein	I-protein
.	O

Anti-immunoglobulin	B-protein
M	I-protein
activates	O
nuclear	B-protein
calcium/calmodulin-dependent	I-protein
protein	I-protein
kinase	I-protein
II	I-protein
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

Systemic	O
hGR	B-protein
levels	O
in	O
untreated	O
IBD	O
patients	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
in	O
control	O
subjects	O
.	O

Activation	O
of	O
E2F	B-protein
-mediated	O
transcription	O
by	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
I	I-protein
Tax	I-protein
protein	I-protein
in	O
a	O
p16	B-cell_line
(	I-cell_line
INK4A	I-cell_line
)	I-cell_line
-negative	I-cell_line
T-cell	I-cell_line
line	I-cell_line
.	O

This	O
compares	O
favourably	O
with	O
other	O
screening	O
methods	O
used	O
for	O
TSC2	B-DNA
,	O
notably	O
SSCP	O
,	O
and	O
since	O
PTT	O
involves	O
much	O
less	O
work	O
it	O
may	O
be	O
the	O
method	O
of	O
choice	O
.	O

These	O
results	O
indicate	O
that	O
the	O
functional	O
activity	O
of	O
ligands	O
built	O
from	O
the	O
binding	B-protein
site	I-protein
of	O
G28-5	B-protein
is	O
highly	O
dependent	O
upon	O
the	O
size	O
and	O
physical	O
properties	O
of	O
the	O
molecule	O
both	O
in	O
solution	O
and	O
on	O
the	O
cell	O
surfaces	O
.	O

When	O
immunoglobulin	B-cell_type
(	I-cell_type
Ig	I-cell_type
)	I-cell_type
expressing	I-cell_type
B	I-cell_type
cells	I-cell_type
are	O
fused	O
with	O
non-B	B-cell_type
cells	I-cell_type
,	O
Ig	O
expression	O
is	O
rapidly	O
suppressed	O
at	O
the	O
level	O
of	O
transcription	O
,	O
a	O
phenomenon	O
termed	O
extinction	O
.	O

However	O
,	O
all	O
these	O
cell	O
types	O
still	O
gave	O
strong	O
Ca2+	O
and	O
tyrosine	O
phosphorylation	O
responses	O
to	O
H2O2	O
.	O

However	O
,	O
CTLA-4	B-protein
ligation	O
did	O
not	O
appear	O
to	O
affect	O
the	O
CD28	B-protein
-mediated	O
stabilization	O
of	O
IL-2	B-RNA
mRNA	I-RNA
.	O

Although	O
the	O
assay	O
involves	O
the	O
dramatic	O
loss	O
of	O
red	O
cell	O
production	O
,	O
it	O
should	O
be	O
possible	O
to	O
define	O
important	O
regulatory	O
domains	O
that	O
can	O
then	O
be	O
assayed	O
using	O
less	O
stringent	O
systems	O
,	O
such	O
as	O
cell-free	O
extracts	O
for	O
in	O
vitro	O
transcription	O
.	O

In	O
contrast	O
to	O
wild-type	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
neither	O
of	O
the	O
class	B-cell_line
II	I-cell_line
mutant	I-cell_line
cell	I-cell_line
lines	I-cell_line
could	O
use	O
the	O
X	B-DNA
box	I-DNA
region	I-DNA
to	O
direct	O
the	O
expression	O
of	O
a	O
transiently	O
transfected	O
reporter	B-DNA
gene	I-DNA
,	O
indicating	O
that	O
the	O
X	O
box-dependent	O
transcriptional	O
pathway	O
is	O
defective	O
in	O
these	O
cells	O
.	O

Chronic	O
myelogenous	O
leukemia	O
evolves	O
in	O
two	O
clinically	O
distinct	O
stages	O
:	O
a	O
chronic	O
and	O
a	O
blast	O
crisis	O
phase	O
.	O

These	O
inhibitory	O
effects	O
of	O
c-Rel	B-protein
correlate	O
with	O
its	O
DNA-binding	O
activity	O
but	O
not	O
with	O
its	O
ability	O
to	O
heterodimerize	O
with	O
p50	B-protein
,	O
suggesting	O
that	O
c-Rel	B-protein
inhibition	O
involves	O
competition	O
with	O
p50/p65	B-protein
for	O
occupancy	O
of	O
the	O
kappa	O
B	O
enhancer	O
element	O
.	O

Interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
plays	O
a	O
central	O
role	O
in	O
numerous	O
inflammatory	O
and	O
immune	O
processes	O
.	O

constitutive	O
nuclear	O
translocation	O
and	O
DNA	O
binding	O
,	O
of	O
these	O
members	O
of	O
NF-AT	B-protein
,	O
NF-kB	B-protein
and	O
AP-1	B-protein
factor	I-protein
families	I-protein
.	O

Corticosteroid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
:	O
a	O
possible	O
marker	O
of	O
brain	O
involution	O
?	O

A	O
significant	O
increase	O
in	O
CD4	B-cell_type
thymocytes	I-cell_type
and	O
their	O
immediate	O
precursors	O
is	O
detected	O
,	O
and	O
because	O
these	O
cells	O
lack	O
markers	O
that	O
correlate	O
with	O
positive	O
selection	O
,	O
a	O
deregulation	O
in	O
their	O
maturation	O
process	O
is	O
suggested	O
.	O

A	O
new	O
member	O
of	O
the	O
leucine	B-protein
zipper	I-protein
class	I-protein
of	O
proteins	O
that	O
binds	O
to	O
the	O
HLA	B-DNA
DR	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O

In	O
the	O
TCR	B-cell_type
alpha	I-cell_type
beta	I-cell_type
lineage	I-cell_type
,	I-cell_type
however	O
,	O
the	O
final	O
gene	O
rearrangement	O
events	O
are	O
accompanied	O
by	O
rapid	O
proliferation	O
and	O
an	O
interruption	O
in	O
cellular	O
response	O
gene	O
inducibility	O
.	O

We	O
speculate	O
that	O
estrogens	O
exert	O
effects	O
on	O
erythropoiesis	O
by	O
modulating	O
GATA-1	B-protein
activity	O
through	O
protein-protein	O
interaction	O
with	O
the	O
ER	B-protein
.	O

Our	O
results	O
,	O
taken	O
together	O
,	O
indicate	O
that	O
META	B-DNA
(	I-DNA
D+	I-DNA
)	I-DNA
is	O
a	O
novel	O
transcriptional	B-DNA
enhancer	I-DNA
element	I-DNA
that	O
is	O
similar	O
in	O
its	O
cell-type	O
specificity	O
,	O
activation	O
dependence	O
,	O
and	O
CsA	O
sensitivity	O
to	O
the	O
NFAT	B-DNA
element	I-DNA
.	O

A	O
decrease	O
in	O
helicase	O
and	O
DNA-dependent	B-protein
ATPase	I-protein
activities	O
was	O
also	O
observed	O
with	O
the	O
mutated	O
recombinant	O
XPB	B-protein
protein	I-protein
.	O

TNFRI	B-protein
has	O
been	O
recently	O
shown	O
to	O
activate	O
NF-kappaB	B-protein
through	O
association	O
with	O
TRADD	B-protein
,	O
RIP	B-protein
,	O
and	O
TRAF2	B-protein
;	O
activation	O
of	O
the	O
NF-kappaB-inducing	B-protein
kinase	I-protein
(	O
NIK	B-protein
)	O
;	O
activation	O
of	O
the	O
IkappaB	B-protein
alpha	I-protein
kinases	I-protein
(	O
IKKalpha	B-protein
and	O
IKKbeta	B-protein
)	O
;	O
and	O
phosphorylation	O
of	O
IkappaB	B-protein
alpha	I-protein
.	O

The	O
mean	O
dissociation	O
constant	O
(	O
KD	O
)	O
was	O
similar	O
in	O
both	O
groups	O
of	O
patients	O
and	O
in	O
healthy	O
women	O
(	O
A-CRF	O
:	O
0.7	O
+/-	O
0.5	O
x	O
10	O
(	O
-10	O
)	O
M	O
;	O
M-CRF	O
:	O
1.1	O
+/-	O
0.9	O
x	O
10	O
(	O
-10	O
)	O
M	O
;	O
controls	O
:	O
1.0	O
+/-	O
0.6	O
x	O
10	O
(	O
-10	O
)	O
M	O
)	O
.	O

A	O
role	O
for	O
RanBP1	B-protein
in	O
the	O
release	O
of	O
CRM1	B-protein
from	O
the	O
nuclear	B-protein
pore	I-protein
complex	I-protein
in	O
a	O
terminal	O
step	O
of	O
nuclear	O
export	O
.	O

These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
both	O
CsA-sensitive	B-protein
transcription	I-protein
factors	I-protein
,	O
NFATp	B-protein
and	O
NFATc	B-protein
,	O
are	O
expressed	O
in	O
human	O
NK	B-cell_type
cells	I-cell_type
,	O
and	O
that	O
their	O
activation	O
and/or	O
expression	O
can	O
be	O
regulated	O
in	O
primary	O
cells	O
by	O
a	O
single	O
stimulus	O
,	O
that	O
,	O
in	O
the	O
case	O
of	O
CD16	O
in	O
NK	B-cell_type
cells	I-cell_type
,	O
results	O
in	O
early	O
activation	O
of	O
NFATp	B-protein
and	O
subsequently	O
induced	O
expression	O
of	O
NFATc	B-RNA
mRNA	I-RNA
.	O

In	O
particular	O
,	O
a	O
high-affinity	B-DNA
BSAP-binding	I-DNA
site	I-DNA
instead	O
of	O
a	O
TATA	B-DNA
sequence	I-DNA
is	O
located	O
in	O
the	O
-30	B-DNA
promoter	I-DNA
region	I-DNA
upstream	O
of	O
a	O
cluster	O
of	O
heterogeneous	O
transcription	O
start	O
sites	O
.	O

All	O
cell	O
lines	O
examined	O
in	O
this	O
group	O
also	O
expressed	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
.	O

The	O
nature	O
of	O
CD40	B-protein
-dependent	O
signals	O
in	O
proliferating	O
fresh	O
human	B-cell_line
Epstein-Barr	I-cell_line
virus-negative	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
is	O
currently	O
unknown	O
.	O

In	O
the	O
current	O
study	O
,	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
antioxidant	O
activity	O
,	O
has	O
been	O
used	O
to	O
further	O
investigate	O
the	O
role	O
of	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

To	O
propel	O
itself	O
in	O
infected	B-cell_type
cells	I-cell_type
,	O
the	O
pathogen	O
Shigella	O
flexneri	O
subverts	O
the	O
Cdc42	B-protein
-controlled	O
machinery	O
responsible	O
for	O
actin	B-protein
assembly	O
during	O
filopodia	O
formation	O
.	O

In	O
parallel	O
with	O
the	O
decreased	O
cytokine	B-protein
generation	O
,	O
each	O
cytokine	B-RNA
mRNA	I-RNA
was	O
less	O
expressed	O
in	O
the	O
presence	O
of	O
10	O
(	O
-5	O
)	O
M	O
Azeptin	O
.	O

We	O
also	O
showed	O
that	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
and	O
to	O
a	O
lesser	O
extent	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
,	O
secreted	O
within	O
the	O
coculture	O
,	O
induce	O
NF-kappaB	B-protein
activity	O
and	O
a	O
correlative	O
LTR	B-DNA
transactivation	O
.	O

SCL	B-protein
is	O
expressed	O
in	O
erythroid	B-cell_type
,	I-cell_type
megakaryocyte	I-cell_type
and	I-cell_type
mast	I-cell_type
cell	I-cell_type
populations	I-cell_type
(	O
the	O
same	O
cell	O
lineages	O
as	O
GATA-1	B-protein
,	O
a	O
zinc-finger	B-protein
transcription	I-protein
factor	I-protein
)	O
.	O

METHOD	O
:	O
They	O
measured	O
the	O
number	O
of	O
lymphocyte	B-protein
cytosolic	I-protein
glucocorticoid	I-protein
receptors	I-protein
and	O
plasma	O
cortisol	O
concentrations	O
in	O
15	O
consecutively	O
admitted	O
male	O
combat	O
Vietnam	O
veterans	O
with	O
PTSD	O
and	O
in	O
a	O
normal	O
comparison	O
group	O
of	O
11	O
subjects	O
.	O

Following	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
stimulation	O
,	O
SLP-76	B-protein
and	O
Vav	B-protein
both	O
undergo	O
tyrosine	O
phosphorylation	O
and	O
associate	O
with	O
each	O
other	O
via	O
the	O
SH2	O
domain	O
of	O
Vav	B-protein
and	O
phosphorylated	O
tyrosines	O
of	O
SLP-76	B-protein
.	O

In	O
contrast	O
,	O
the	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
is	O
not	O
required	O
for	O
activation-induced	O
FasL	B-protein
promoter	O
activity	O
.	O

Transcription	B-protein
factors	I-protein
USF1	B-protein
and	O
USF2	B-protein
up-regulate	O
gene	O
expression	O
(	O
i.e.	O
,	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeats	I-DNA
)	O
via	O
interaction	O
with	O
an	O
E	B-DNA
box	I-DNA
on	O
their	O
target	O
promoters	O
,	O
which	O
is	O
also	O
a	O
binding	B-DNA
site	I-DNA
for	O
c-Myc	B-protein
.	O

Recent	O
studies	O
have	O
identified	O
calcineurin	B-protein
as	O
a	O
key	O
enzyme	O
for	O
interleukin	O
(	O
IL	O
)	O
-2	O
and	O
IL-4	O
promoter	O
activation	O
.	O

Transcription	B-protein
factor	I-protein
binding	O
sites	O
downstream	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
are	O
important	O
for	O
virus	O
infectivity	O
.	O

In	O
contrast	O
,	O
it	O
was	O
found	O
to	O
be	O
TNF-alpha	B-protein
independent	O
in	O
the	O
early	O
time	O
point	O
.	O

Resorption	O
lacunae	O
can	O
be	O
observed	O
by	O
day	O
22	O
.	O

PPARgamma	B-protein
activation	O
induces	O
the	O
expression	O
of	O
the	O
adipocyte	B-DNA
fatty	I-DNA
acid	I-DNA
binding	I-DNA
protein	I-DNA
gene	I-DNA
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
several	O
of	O
these	O
agents	O
can	O
significantly	O
increase	O
HIV	O
replication	O
and	O
accelerate	O
CD4	B-protein
-positive	O
lymphocyte	O
cytotoxicity	O
in	O
vitro	O
.	O

The	O
transcription	B-protein
factors	I-protein
c-myb	B-protein
and	O
C/EBP	B-protein
alpha	I-protein
regulate	O
the	O
monocytic/myeloic	B-DNA
gene	I-DNA
MRP14	B-DNA
.	O

Analysis	O
of	O
the	O
chromatin	O
organization	O
of	O
the	O
integrated	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
genome	I-DNA
has	O
previously	O
revealed	O
a	O
major	B-DNA
constitutive	I-DNA
DNase	I-DNA
I-hypersensitive	I-DNA
site	I-DNA
associated	O
with	O
the	O
pol	B-DNA
gene	I-DNA
(	O
E.	O
Verdin	O
,	O
J.	O
Virol.	O
65	O
:	O
6790-6799	O
,	O
1991	O
)	O
.	O

It	O
was	O
proposed	O
that	O
the	O
mechanism	O
of	O
antiviral	O
action	O
of	O
S9a	O
was	O
on	O
the	O
host	O
cell	O
,	O
by	O
blocking	O
TNF-alpha	B-protein
transcription	O
via	O
a	O
Tat	B-protein
-induced	O
tar-independent	O
loop	O
,	O
which	O
decreases	O
downstream	O
NF-kappaB	B-protein
activation	O
of	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O

ER	O
content	O
in	O
lymphocytes	B-cell_type
of	O
peripheral	O
blood	O
from	O
27	O
SLE	O
patients	O
and	O
20	O
healthy	O
controls	O
were	O
determined	O
by	O
dextran-coated	O
charcoal	O
assay	O
.	O

Except	O
for	O
the	O
conserved	O
zinc-finger	B-protein
domains	I-protein
,	O
the	O
amino	B-protein
acid	I-protein
sequences	I-protein
of	O
the	O
three	O
proteins	O
are	O
distinct	O
.	O

Mechanism	O
of	O
antiandrogen	O
action	O
:	O
conformational	O
changes	O
of	O
the	O
receptor	O
.	O

Cellular	O
immune	O
and	O
cytokine	O
pathways	O
resulting	O
in	O
tissue	B-protein
factor	I-protein
expression	O
and	O
relevance	O
to	O
septic	O
shock	O
.	O

TCF-1	B-protein
alpha	I-protein
,	O
originally	O
identified	O
and	O
purified	O
through	O
its	O
binding	O
sites	O
on	O
the	O
HIV-1	B-DNA
promoter	I-DNA
,	O
was	O
found	O
to	O
bind	O
to	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
and	O
to	O
promoters	B-DNA
for	O
several	O
genes	B-DNA
expressed	O
at	O
significantly	O
earlier	O
stages	O
of	O
T-cell	O
development	O
than	O
the	O
TCR	B-DNA
alpha	I-DNA
gene	I-DNA
(	O
e.g.	O
,	O
p56lck	B-DNA
and	O
CD3	B-DNA
delta	I-DNA
)	O
.	O

Analysis	O
of	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
has	O
revealed	O
that	O
both	O
proteins	O
can	O
interact	O
with	O
related	O
DNA	O
sequences	O
through	O
either	O
homo-	O
or	O
heterodimer	O
formation	O
.	O

In	O
the	O
synovial	O
tissue	O
,	O
fully	O
differentiated	O
perivascular	B-cell_type
DC	I-cell_type
are	O
found	O
in	O
close	O
association	O
with	O
T	B-cell_type
cells	I-cell_type
and	O
with	O
B	B-cell_type
cell	I-cell_type
follicles	I-cell_type
,	O
sometimes	O
containing	O
follicular	B-cell_type
DC	I-cell_type
.	O

These	O
results	O
indicate	O
that	O
LTB4	O
may	O
regulate	O
the	O
production	O
of	O
different	O
cytokines	B-protein
by	O
modulating	O
the	O
yield	O
and/or	O
the	O
function	O
of	O
transcription	B-protein
factors	I-protein
such	O
as	O
AP-1	B-protein
-binding	O
proto-oncogene	B-protein
products	I-protein
.	O

Human	O
cytomegalovirus	O
induces	O
interleukin-8	B-protein
production	O
by	O
a	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
,	O
through	O
acting	O
concurrently	O
on	O
AP-1-	B-DNA
and	I-DNA
NF-kappaB-binding	I-DNA
sites	I-DNA
of	O
the	O
interleukin-8	B-DNA
gene	I-DNA
.	O

IL-4	B-protein
enhanced	O
CD11b	B-protein
,	O
but	O
inhibited	O
CD26	B-protein
expression	O
and	O
delayed	O
CD13	B-protein
loss	O
.	O

However	O
,	O
the	O
sensitivity	O
of	O
cells	O
to	O
these	O
agents	O
is	O
not	O
merely	O
governed	O
by	O
the	O
expression	O
of	O
their	O
receptors	O
and	O
the	O
availability	O
of	O
ligand	O
to	O
bind	O
them	O
.	O

Glucocorticoid	O
receptor	O
characteristics	O
were	O
examined	O
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
which	O
represents	O
an	O
index	O
of	O
DNA	O
synthesis	O
.	O

These	O
phenotypic	O
effects	O
are	O
specifically	O
attributable	O
to	O
the	O
action	O
of	O
ectopically	O
expressed	O
GATA-2/ER	B-protein
because	O
erythroblasts	O
expressing	O
exogenous	O
GATA-2	B-protein
are	O
constitutively	O
arrested	O
in	O
differentiation	O
and	O
because	O
erythroid	B-cell_line
progenitors	I-cell_line
expressing	O
either	O
Gal/ER	B-protein
or	O
GATA-3/ER	B-protein
do	O
not	O
display	O
a	O
hormone-responsive	O
block	O
in	O
differentiation	O
.	O

In	O
contrast	O
,	O
CsA	O
inhibited	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
the	O
NF-AT	B-DNA
,	O
but	O
not	O
the	O
AP-1	B-DNA
and	O
NF-kB	B-DNA
plasmids	I-DNA
.	O

Nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
regulates	O
transcription	O
of	O
a	O
number	O
of	O
cytokine	B-protein
genes	I-protein
,	O
and	O
NFAT	B-protein
DNA	O
binding	O
activity	O
is	O
stimulated	O
following	O
T	O
cell	O
activation	O
.	O

Addition	O
of	O
exogenous	O
TNF	B-protein
to	O
the	O
intermediate	B-cell_line
thymocyte	I-cell_line
cultures	I-cell_line
induces	O
NF-kappaB	B-protein
activity	O
and	O
is	O
sufficient	O
to	O
promote	O
HIV	O
replication	O
in	O
the	O
cocultures	O
with	O
TEC	B-cell_type
.	O

HIV-TF1	B-protein
had	O
a	O
molecular	O
weight	O
of	O
39	O
,	O
000	O
.	O

The	O
maximum	O
(	O
3H	O
)	O
-thymidine	O
incorporation	O
into	O
DNA	O
of	O
cord	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
all	O
preterms	O
,	O
with	O
or	O
without	O
NRDS	O
was	O
suppressed	O
when	O
compared	O
to	O
that	O
from	O
term	O
babies	O
or	O
adults	O
.	O

The	O
regulation	O
of	O
IL-6	B-protein
is	O
dependent	O
on	O
various	O
stimuli	O
that	O
include	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
viruses	O
,	O
and	O
other	O
cytokines	B-protein
.	O

For	O
cells	O
of	O
the	O
innate	O
immune	O
system	O
to	O
mount	O
a	O
host	O
defence	O
response	O
to	O
infection	O
,	O
they	O
must	O
recognize	O
products	O
of	O
microbial	O
pathogens	O
such	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
the	O
endotoxin	O
secreted	O
by	O
Gram-negative	O
bacteria	O
.	O

Such	O
proteasome	B-protein
activation	O
correlated	O
with	O
hypoxia-evoked	O
decreases	O
in	O
both	O
extracellular	O
and	O
intracellular	O
pH	O
.	O

The	O
mechanism	O
of	O
generation	O
of	O
p50	B-protein
is	O
not	O
known	O
.	O

Mutational	O
studies	O
of	O
the	O
-236	B-DNA
to	I-DNA
-96	I-DNA
sequence	I-DNA
indicated	O
that	O
the	O
presence	O
of	O
both	O
the	O
-130	B-DNA
AP-1-like	I-DNA
site	I-DNA
(	O
-187	B-DNA
to	I-DNA
-181	I-DNA
)	O
and	O
the	O
-150	B-DNA
proximal	I-DNA
AP-1	I-DNA
site	I-DNA
were	O
necessary	O
to	O
observe	O
anergy	O
.	O

An	O
element	O
termed	O
E1	B-DNA
located	O
at	O
-108	B-DNA
to	I-DNA
-95	I-DNA
nt	I-DNA
relative	O
to	O
the	O
major	O
transcription	O
start	O
site	O
was	O
found	O
to	O
be	O
critical	O
for	O
the	O
promoter	O
activity	O
.	O

In	O
some	O
donors	O
,	O
increased	O
IL-6	B-protein
and	O
TNF-alpha	B-protein
activity	O
also	O
was	O
detected	O
after	O
R24	B-protein
treatment	O
.	O

We	O
have	O
recently	O
characterised	O
a	O
new	O
factor	O
called	O
IK	B-protein
which	O
is	O
an	O
efficient	O
inhibitor	O
of	O
IFN-gamma	B-protein
induction	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
antigens	I-protein
expression	O
.	O

Whether	O
a	O
cortisol	O
resistance	O
or	O
a	O
reduced	O
availability	O
of	O
the	O
metabolic	O
substrates	O
necessary	O
to	O
develop	O
the	O
effect	O
of	O
glucocorticoids	O
is	O
responsible	O
for	O
this	O
has	O
not	O
been	O
established	O
.	O

NFAT1	B-protein
appears	O
to	O
be	O
the	O
major	O
NFAT	B-protein
family	I-protein
member	I-protein
responsible	O
for	O
the	O
initial	O
increased	O
expression	O
of	O
IL-4	B-protein
by	O
primed	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

musculin	B-DNA
:	O
a	O
murine	B-DNA
basic	I-DNA
helix-loop-helix	I-DNA
transcription	I-DNA
factor	I-DNA
gene	I-DNA
expressed	O
in	O
embryonic	O
skeletal	O
muscle	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
applied	O
these	O
two	O
markers	O
to	O
the	O
study	O
of	O
HIV-HD	O
histogenesis	O
and	O
correlated	O
their	O
expression	O
status	O
to	O
the	O
virologic	O
features	O
of	O
this	O
disease	O
.	O

These	O
activation	O
domains	O
restored	O
ZEBRA	B-protein
's	O
ability	O
to	O
induce	O
early	B-protein
antigen	I-protein
and	O
to	O
stimulate	O
origin	O
replication	O
to	O
levels	O
that	O
were	O
equal	O
to	O
or	O
greater	O
than	O
those	O
of	O
wild	O
type	O
.	O

In	O
this	O
study	O
,	O
we	O
characterize	O
an	O
essential	O
upstream	O
IL-2	B-DNA
response	I-DNA
element	I-DNA
that	O
contains	O
both	O
consensus	B-DNA
and	I-DNA
non-consensus	I-DNA
GAS	I-DNA
motifs	I-DNA
,	O
two	O
putative	O
Ets	B-DNA
binding	I-DNA
sites	I-DNA
(	O
EBS	B-DNA
)	O
,	O
one	O
of	O
which	O
overlaps	O
the	O
consensus	B-DNA
GAS	I-DNA
motif	I-DNA
,	O
and	O
a	O
GATA	B-DNA
motif	I-DNA
,	O
which	O
overlaps	O
the	O
non-consensus	B-DNA
GAS	I-DNA
motif	I-DNA
.	O

Efficient	O
transcription	O
and	O
replication	O
of	O
simian	O
immunodeficiency	O
virus	O
in	O
the	O
absence	O
of	O
NF-kappaB	B-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
elements	I-DNA
.	O

Programmed	O
cell	O
death	O
is	O
a	O
process	O
required	O
for	O
the	O
normal	O
development	O
of	O
an	O
organism	O
.	O

Following	O
integration	O
into	O
the	O
host	O
cell	O
genome	O
,	O
HTLV-I	O
replication	O
is	O
regulated	O
by	O
both	O
host	O
and	O
viral	O
mechanisms	O
that	O
control	O
transcription	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Exogenous	O
provision	O
of	O
NFkB	B-protein
rescued	O
IL2R	B-protein
alpha	O
expression	O
but	O
not	O
the	O
PTHrP	B-DNA
promoter	I-DNA
.	O

When	O
cells	O
were	O
treated	O
with	O
IL-4	B-protein
for	O
5	O
hours	O
before	O
LPS	O
activation	O
,	O
both	O
the	O
c-fos	O
and	O
the	O
c-jun	O
mRNA	O
expression	O
was	O
decreased	O
.	O

This	O
signal	O
transduction	O
is	O
dependent	O
on	O
the	O
cytoplasmic	B-protein
domain	I-protein
,	O
which	O
consists	O
of	O
213	O
amino	O
acids	O
.	O

Taken	O
together	O
,	O
ciprofloxacin	O
increased	O
the	O
levels	O
of	O
immediate-early	B-RNA
transcripts	I-RNA
,	O
enhanced	O
IL-2	B-protein
and	O
metallothionein	B-protein
promoter	O
induction	O
,	O
and	O
upregulated	O
AP-1	B-protein
concentrations	O
in	O
primary	B-cell_type
lymphocytes	I-cell_type
,	O
reflecting	O
a	O
program	O
commonly	O
observed	O
in	O
mammalian	O
stress	O
responses	O
.	O

Evaluation	O
of	O
the	O
role	O
of	O
ligand	O
and	O
thermal	O
activation	O
of	O
specific	O
DNA	O
binding	O
by	O
in	B-protein
vitro	I-protein
synthesized	I-protein
human	I-protein
glucocorticoid	I-protein
receptor	I-protein
.	O

In	O
vivo	O
expanded	O
CD4+CD28null	B-cell_line
and	I-cell_line
CD8+CD28null	I-cell_line
T	I-cell_line
cells	I-cell_line
uniformly	O
lack	O
alpha-	B-protein
and	I-protein
beta-	I-protein
bound	I-protein
complexes	I-protein
,	O
resembling	O
the	O
pattern	O
seen	O
in	O
chronically	B-cell_type
activated	I-cell_type
cells	I-cell_type
and	O
not	O
of	O
senescent	B-cell_type
cells	I-cell_type
.	O

Cyclosporin	O
A-resistant	O
transactivation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
requires	O
activity	O
of	O
okadaic	B-protein
acid-sensitive	I-protein
serine/threonine	I-protein
phosphatases	I-protein
.	O

Bcl-6	B-protein
expression	O
in	O
reactive	O
follicular	O
hyperplasia	O
,	O
follicular	O
lymphoma	O
,	O
and	O
angioimmunoblastic	O
T-cell	O
lymphoma	O
with	O
hyperplastic	O
germinal	O
centers	O
:	O
heterogeneity	O
of	O
intrafollicular	B-cell_type
T-cells	I-cell_type
and	O
their	O
altered	O
distribution	O
in	O
the	O
pathogenesis	O
of	O
angioimmunoblastic	O
T-cell	O
lymphoma	O
.	O

p27Kip1	B-DNA
directly	O
inhibits	O
the	O
catalytic	O
activity	O
of	O
cyclin/cdks	B-protein
(	I-protein
cyclin-dependent	I-protein
kinase	I-protein
)	I-protein
complexes	I-protein
and/or	O
interferes	O
physically	O
with	O
cyclin/cdks	B-protein
activation	O
by	O
CAK	B-protein
.	O

At	O
high	O
concentration	O
of	O
NE	O
,	O
all	O
of	O
the	O
TR	B-protein
bound	O
to	O
TREp	B-DNA
was	O
more	O
greatly	O
retarded	O
than	O
in	O
the	O
absence	O
of	O
NE	O
.	O

Substantial	O
decreases	O
of	O
IL-2	B-protein
production	O
were	O
observed	O
for	O
cell	O
cultures	O
from	O
7	O
of	O
12	O
elderly	O
individuals	O
in	O
response	O
to	O
the	O
different	O
stimuli	O
,	O
whereas	O
the	O
levels	O
of	O
IL-2	B-protein
produced	O
by	O
stimulated	O
T	B-cell_type
cells	I-cell_type
from	O
other	O
elderly	O
individuals	O
were	O
equivalent	O
to	O
those	O
observed	O
for	O
stimulated	O
T	O
cells	O
of	O
young	O
subjects	O
.	O

HLA-DO	B-protein
was	O
shown	O
to	O
block	O
HLA-DM	B-protein
function	O
.	O

Two	O
tyrosine	B-protein
phosphoproteins	I-protein
of	O
38	O
and	O
63	O
kD	O
bind	O
to	O
the	O
SH2	B-protein
domain	I-protein
of	O
Grb2	B-protein
following	O
Fc	B-protein
gamma	I-protein
RIIA	I-protein
stimulation	O
of	O
platelets	B-cell_type
.	O

Differential	O
monocyte	O
adhesion	O
and	O
adhesion	B-protein
molecule	I-protein
expression	O
in	O
venous	O
and	O
arterial	O
endothelial	O
cells	O
.	O

NF-kappaB	O
nuclear	O
translocation	O
is	O
secondary	O
to	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
the	O
NF-kappaB	B-protein
inhibitory	I-protein
molecule	I-protein
IkappaBalpha	B-protein
.	O

Neutrophils	B-cell_type
and	O
monocytes	B-cell_type
express	O
high	O
levels	O
of	O
PU.1	B-protein
(	O
Spi-1	B-protein
)	O
but	O
not	O
Spi-B	B-protein
.	O

In	O
both	O
types	O
of	O
donors	O
,	O
the	O
effect	O
of	O
IL-13	B-protein
on	O
IL-2	B-protein
-induced	O
IFN-gamma	B-protein
production	O
was	O
in	O
marked	O
contrast	O
to	O
the	O
strong	O
inhibition	O
seen	O
with	O
IL-4	B-protein
in	O
NK	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
the	O
TPA	O
responsiveness	O
of	O
both	O
CMV	B-DNA
elements	I-DNA
proved	O
to	O
involve	O
synergistic	O
interactions	O
between	O
the	O
core	O
SRF	B-DNA
binding	I-DNA
site	I-DNA
(	O
CCATATATGG	O
)	O
and	O
the	O
adjacent	O
inverted	O
ETS	B-DNA
binding	I-DNA
motifs	I-DNA
(	O
TTCC	O
)	O
,	O
which	O
correlated	O
directly	O
with	O
formation	O
of	O
a	O
bound	O
tripartite	B-protein
complex	I-protein
containing	O
both	O
the	O
cellular	O
SRF	B-protein
and	O
ELK-1	B-protein
proteins	I-protein
.	O

In	O
contrast	O
to	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
I	B-cell_line
kappa	I-cell_line
B	I-cell_line
alpha-/-	I-cell_line
embryonic	I-cell_line
fibroblasts	I-cell_line
show	O
minimal	O
constitutive	B-protein
NF-kappa	I-protein
B	I-protein
,	O
as	O
well	O
as	O
normal	O
signal-dependent	O
NF-kappa	B-protein
B	I-protein
activation	O
that	O
is	O
concomitant	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
degradation	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
C3a	B-protein
as	O
well	O
as	O
C3a	B-protein
(	I-protein
desArg	I-protein
)	I-protein
enhanced	O
LPS	O
-induced	B-RNA
mRNA	I-RNA
levels	O
for	O
IL-6	B-protein
.	O

Here	O
we	O
report	O
that	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	B-DNA
is	O
also	O
mediated	O
by	O
sequences	O
in	O
a	O
region	B-DNA
II	I-DNA
(	O
bp	O
-88	O
to	O
-	O
59	O
)	O
,	O
which	O
lies	O
10	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
PU.1-binding	B-DNA
site	I-DNA
.	O

The	O
association	O
of	O
20q	B-DNA
deletions	I-DNA
with	O
myeloid	O
``	O
stem	O
cell	O
''	O
disorders	O
suggests	O
that	O
the	O
deletions	O
mark	O
the	O
site	O
of	O
one	O
or	O
more	O
genes	O
,	O
loss	O
or	O
inactivation	O
of	O
which	O
plays	O
a	O
role	O
in	O
the	O
regulation	O
of	O
normal	B-cell_type
hematopoietic	I-cell_type
progenitors	I-cell_type
.	O

Glucocorticoid	B-protein
receptors	I-protein
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
Alzheimer	O
's	O
disease	O
.	O

Therefore	O
,	O
to	O
evaluate	O
the	O
mechanism	O
of	O
TPA	O
responsiveness	O
of	O
the	O
SNE	B-DNA
motifs	I-DNA
and	O
of	O
a	O
related	O
16-bp	O
SEE	B-DNA
(	O
SRF/ETS	B-DNA
element	I-DNA
)	O
motif	O
found	O
in	O
the	O
HCMV	B-DNA
and	I-DNA
chimpanzee	I-DNA
CMV	I-DNA
MIE	I-DNA
enhancers	I-DNA
,	O
we	O
have	O
examined	O
the	O
functional	O
responses	O
and	O
protein	O
binding	O
properties	O
of	O
multimerized	B-DNA
wild-type	I-DNA
and	I-DNA
mutant	I-DNA
elements	I-DNA
added	O
upstream	O
to	O
the	O
SCMV	B-DNA
MIE	I-DNA
or	O
simian	B-DNA
virus	I-DNA
40	I-DNA
minimal	I-DNA
promoter	I-DNA
regions	I-DNA
in	O
the	O
U-937	B-cell_line
,	O
K-562	B-cell_line
,	O
HL-60	B-cell_line
,	O
THP-1	B-cell_line
,	O
and	O
Jurkat	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Leukotriene	O
B4	O
produced	O
by	O
monocytes	B-cell_type
in	O
vitro	O
and	O
soluble	O
interleukin-2	B-protein
receptor	I-protein
released	O
by	O
lymphocytes	B-cell_type
in	O
vitro	O
and	O
cortisol	O
levels	O
in	O
plasma	O
were	O
determined	O
.	O

Using	O
this	O
system	O
,	O
we	O
observed	O
that	O
CD28	B-protein
stimulation	O
by	O
B7-transfected	B-cell_line
CHO	I-cell_line
cells	I-cell_line
induced	O
a	O
proliferative	O
response	O
in	O
T	B-cell_type
cells	I-cell_type
that	O
was	O
not	O
accompanied	O
by	O
measurable	O
IL-2	B-protein
production	O
.	O

Similar	O
effects	O
were	O
observed	O
after	O
pretreatment	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
cytochalasin	O
D	O
.	O

Peripheral	B-protein
blood	I-protein
mononuclear	I-protein
cell	I-protein
glucocorticoid	I-protein
receptors	I-protein
were	O
also	O
characterized	O
in	O
five	O
sensitive	O
and	O
seven	O
resistant	O
patients	O
.	O

Tissue	O
specific	O
regulation	O
of	O
gene	O
expression	O
by	O
transcription	B-protein
factors	I-protein
is	O
a	O
fascinating	O
new	O
field	O
in	O
molecular	O
immunology	O
.	O

We	O
used	O
reverse	B-protein
transcriptase	I-protein
-polymerase	O
chain	O
reaction	O
to	O
examine	O
both	O
fetal	O
and	O
term	O
neonatal	O
cord	O
bloods	O
for	O
mRNA	O
expression	O
of	O
three	O
transcription	B-protein
factors	I-protein
implicated	O
in	O
T-cell	O
activation	O
:	O
c-jun	B-protein
,	O
c-fos	B-protein
,	O
and	O
NF	B-protein
kappa	I-protein
B	I-protein
(	O
p50	B-protein
subunit	I-protein
)	O
.	O

Lymphocytic	O
levels	O
of	O
glucocorticoid	B-protein
receptors	I-protein
were	O
evaluated	O
in	O
114	O
patients	O
suffering	O
from	O
Icenko-Cushing	O
's	O
syndrome	O
.	O

Thus	O
enabled	O
to	O
perform	O
the	O
test	O
on	O
multiple	O
blood	B-cell_type
samples	I-cell_type
in	O
parallel	O
,	O
we	O
investigated	O
cardiac	O
infarction	O
patients	O
over	O
a	O
12-day	O
period	O
to	O
test	O
if	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
is	O
altered	O
in	O
this	O
'stressful	O
'	O
disease	O
.	O

HTLV-1-transformed	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
expressed	O
higher	O
amounts	O
of	O
STAT1	B-RNA
,	I-RNA
STAT3	I-RNA
and	I-RNA
STAT5	I-RNA
RNA	I-RNA
and	O
proteins	O
than	O
virus-negative	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
supernatant	O
from	O
activated	B-cell_type
T-lymphocytes	I-cell_type
is	O
able	O
to	O
induce	O
the	O
transcription	O
of	O
a	O
potent	O
cytokine	B-protein
,	O
TGF-beta	B-protein
2	I-protein
in	O
glial	B-cell_type
cells	I-cell_type
.	O

These	O
results	O
indicate	O
that	O
the	O
presence	O
of	O
the	O
codon-10-variant	B-DNA
type	I-DNA
is	O
not	O
a	O
characteristic	O
of	O
breast	O
cancer	O
.	O

LBF4	B-protein
is	O
B-	O
and	O
T-cell	O
specific	O
and	O
recognizes	O
the	O
PU.1	B-DNA
GGAA	I-DNA
core	I-DNA
sequence	I-DNA
as	O
shown	O
by	O
methylation	O
interference	O
.	O

Engagement	O
of	O
the	O
T-cell	B-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
-CD3	I-protein
complex	I-protein
induces	O
a	O
rapid	O
increase	O
in	O
the	O
activities	O
of	O
Src-family	B-protein
and	O
Syk/Zap-70-family	B-protein
kinases	I-protein
[	O
1	O
]	O
[	O
2	O
]	O
.	O

This	O
activity	O
is	O
further	O
inducible	O
in	O
activated	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
not	O
in	O
fibroblasts	B-cell_type
.	O

By	O
double-immunogold	O
labeling	O
of	O
PML	B-cell_type
and	O
LYSP100	B-DNA
,	O
some	O
LANDs	O
were	O
shown	O
to	O
contain	O
both	O
PML	B-cell_type
and	O
LYSP100	B-DNA
.	O

Surface	O
expression	O
of	O
ICAM-1	B-protein
,	O
P-selectin	B-protein
,	O
and	O
E-selectin	B-protein
on	O
HUVECs	B-cell_line
correlated	O
with	O
the	O
phase-1	O
and	O
-2	O
neutrophil	O
adhesion	O
responses	O
.	O

Finally	O
,	O
it	O
is	O
demonstrated	O
that	O
macrophages	B-cell_type
in	O
the	O
adrenal	O
gland	O
,	O
the	O
major	O
site	O
of	O
endogenous	O
GC	O
production	O
,	O
express	O
sialoadhesin	B-protein
.	O

The	O
synthesis	O
and	O
immunogenicity	O
of	O
varicella-zoster	B-protein
virus	I-protein
glycoprotein	I-protein
E	I-protein
and	O
immediate-early	B-protein
protein	I-protein
(	O
IE62	B-protein
)	O
expressed	O
in	O
recombinant	O
herpes	O
simplex	O
virus-1	O
.	O

In	O
parallel	O
,	O
the	O
inhibitory	O
effect	O
of	O
dexamethasone	O
on	O
3-O-methyl-D-glucose	O
uptake	O
was	O
assayed	O
in	O
the	O
corresponding	O
mononuclear	B-cell_type
leukocytes	I-cell_type
.	O

We	O
have	O
now	O
elucidated	O
the	O
mechanism	O
by	O
which	O
CNI-1493	O
inhibits	O
macrophage	O
TNF	B-protein
synthesis	O
and	O
show	O
here	O
that	O
it	O
acts	O
through	O
suppression	O
of	O
TNF	B-protein
translation	O
efficiency	O
.	O

SAC	O
consistently	O
exhibited	O
a	O
dose-dependent	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
induced	O
by	O
both	O
TNF-alpha	B-protein
and	O
H2O2	O
.	O

Cross-linking	O
of	O
MHC-I	B-protein
mediated	O
tyrosine	O
phosphorylation	O
of	O
Tyk2	B-protein
,	O
but	O
not	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Jak3	B-protein
.	O

Molecular	O
basis	O
of	O
a	O
multiple	O
lymphokine	B-protein
deficiency	O
in	O
a	O
patient	O
with	O
severe	O
combined	O
immunodeficiency	O
.	O

Our	O
results	O
suggest	O
that	O
overexpression	O
of	O
v-erbA	B-protein
is	O
required	O
for	O
its	O
function	O
as	O
an	O
oncoprotein	B-protein
.	O

These	O
results	O
suggest	O
that	O
blasts	B-cell_type
in	O
M7	O
and	O
TMD	O
may	O
correspond	O
to	O
progenitors	B-cell_type
of	O
both	O
erythroid	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineages	I-cell_type
.	O

The	O
demonstration	O
that	O
nucleolin	B-protein
is	O
a	O
component	O
of	O
a	O
B	B-protein
cell-specific	I-protein
complex	I-protein
that	O
binds	O
switch	O
region	O
sequences	O
suggests	O
that	O
the	O
G-rich	B-DNA
switch	I-DNA
regions	I-DNA
may	O
have	O
evolved	O
from	O
rDNA	B-DNA
.	O

As	O
a	O
step	O
toward	O
elucidating	O
the	O
pathophysiological	O
background	O
of	O
the	O
so-called	O
glucose	O
toxicity	O
to	O
pancreatic	B-cell_type
beta	I-cell_type
cells	I-cell_type
,	O
we	O
induced	O
glycation	O
in	O
HIT-T15	B-cell_type
cells	I-cell_type
using	O
a	O
sugar	O
with	O
strong	O
deoxidizing	O
activity	O
,	O
D-ribose	O
,	O
and	O
examined	O
the	O
effects	O
on	O
insulin	O
gene	O
transcription	O
.	O

Activation	O
of	O
T	B-cell_type
helper	I-cell_type
cells	I-cell_type
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	B-protein
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Adherence	O
to	O
either	O
fibronectin	O
or	O
collagen-coated	O
plastic	O
had	O
little	O
consistent	O
effect	O
on	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
accumulation	O
.	O

Finally	O
,	O
no	O
transcription	O
of	O
the	O
RAG-1	B-DNA
gene	I-DNA
could	O
be	O
detected	O
in	O
all	O
NK	B-cell_line
cell	I-cell_line
lines	I-cell_line
or	O
clones	O
analyzed	O
.	O

To	O
determine	O
the	O
mechanisms	O
responsible	O
for	O
these	O
differences	O
,	O
we	O
turned	O
to	O
human	B-cell_line
U937	I-cell_line
promonocytic	I-cell_line
cells	I-cell_line
.	O

The	O
effect	O
of	O
antioxidants	O
on	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
appeared	O
to	O
be	O
species	O
specific	O
,	O
with	O
no	O
effect	O
on	O
LPS-induced	O
tumor	O
necrosis	O
factor	O
in	O
murine	O
cells	O
,	O
but	O
with	O
inhibition	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

These	O
findings	O
suggest	O
that	O
high-level	O
IL-4	B-protein
production	O
in	O
atopic	B-cell_type
Th2	I-cell_type
cells	I-cell_type
is	O
associated	O
with	O
selective	O
reduction	O
of	O
suppressive	O
NFAT1	B-protein
activity	O
at	O
the	O
IL-4	B-DNA
P0	I-DNA
element	I-DNA
and	O
that	O
some	O
patients	O
with	O
this	O
multifactorial	O
disease	O
may	O
have	O
a	O
putative	O
systemic	O
disorder	O
at	O
this	O
level	O
.	O

In	O
this	O
paper	O
,	O
the	O
expression	O
of	O
this	O
gene	O
in	O
blood	B-cell_type
cells	I-cell_type
was	O
first	O
investigated	O
in	O
fractions	O
of	O
nucleated	B-cell_type
cells	I-cell_type
,	O
revealing	O
predominant	O
expression	O
of	O
the	O
Ah	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
the	O
monocyte	B-cell_type
fraction	I-cell_type
.	O

Mitogen	O
induction	O
of	O
the	O
electrophoretic	B-protein
mobility	I-protein
shift	I-protein
assay	I-protein
complexes	I-protein
is	O
not	O
accounted	O
for	O
by	O
protein	O
phosphorylation	O
or	O
by	O
induction	O
of	O
CREB	B-protein
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
binding	O
activity	O
of	O
IL-10-	B-protein
and	I-protein
IFN-gamma-activated	I-protein
STAT	I-protein
molecules	I-protein
to	O
two	O
kinds	O
of	O
GAS	B-DNA
-motif	O
sequences	O
.	O

An	O
additional	O
distinguishing	O
characteristic	O
of	O
HTLV-I	O
infection	O
is	O
the	O
profound	O
state	O
of	O
viral	O
latency	O
that	O
is	O
present	O
in	O
circulating	O
primary	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Here	O
,	O
we	O
show	O
that	O
v-erbA	B-protein
and	O
c-erbA	B-protein
bind	O
directly	O
to	O
sequences	O
within	O
the	O
promoter	B-DNA
of	O
the	O
erythrocyte-specific	B-protein
carbonic	I-protein
anhydrase	I-protein
II	I-protein
(	O
CAII	B-DNA
)	O
,	O
a	O
gene	O
whose	O
transcription	O
is	O
efficiently	O
suppressed	O
by	O
v-erbA	B-protein
.	O

The	O
specificity	O
of	O
HePTP	B-protein
correlated	O
with	O
its	O
physical	O
association	O
through	O
its	O
noncatalytic	O
N	B-protein
terminus	I-protein
with	O
Erk	B-protein
and	O
another	O
MAP	B-protein
kinase	I-protein
,	O
p38	B-protein
,	O
but	O
not	O
Jnk	B-protein
or	O
other	O
proteins	O
.	O

We	O
report	O
that	O
activation	O
of	O
the	O
two	O
transcription	O
factors	O
NF-kappa	O
B	O
and	O
AP-1	B-protein
is	O
crucially	O
involved	O
in	O
FasL	B-protein
expression	O
induced	O
by	O
etoposide	O
,	O
teniposide	O
,	O
and	O
UV	O
irradiation	O
.	O

The	O
expression	O
and	O
binding	O
activity	O
of	O
the	O
Nfil3	B-protein
protein	I-protein
(	O
also	O
called	O
E4bp4	B-protein
)	O
,	O
but	O
not	O
of	O
Hlf	B-protein
,	O
Dbp	B-protein
,	O
or	O
Tef	B-protein
,	O
was	O
found	O
to	O
be	O
regulated	O
by	O
IL-3	B-protein
in	O
mouse	B-cell_line
pro-B	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
Baf-3	B-cell_line
and	O
FL5.12	B-cell_line
)	O
.	O

YT-N17	B-cell_line
contained	O
11.8	O
fmol/mg	O
protein	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
mean	O
of	O
two	O
independent	O
assays	O
)	O
,	O
a	O
value	O
which	O
was	O
5-10-fold	O
higher	O
than	O
that	O
of	O
other	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
age-related	O
decline	O
in	O
induction	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
could	O
not	O
be	O
attributed	O
to	O
alteration	O
in	O
the	O
composition	O
of	O
subunits	O
,	O
p50	B-protein
and	O
p65	B-protein
were	O
found	O
to	O
be	O
the	O
predominant	O
subunits	O
of	O
induced	O
NF	B-protein
kappa	I-protein
B	I-protein
in	O
T	B-cell_type
cells	I-cell_type
from	O
young	O
as	O
well	O
as	O
elderly	O
donors	O
.	O

As	O
a	O
functional	O
correlate	O
of	O
this	O
finding	O
,	O
transient	O
co-transfection	O
of	O
HIV-1	B-DNA
LTR	I-DNA
reporter	I-DNA
constructs	I-DNA
in	O
a	O
different	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
demonstrated	O
that	O
v-src	B-DNA
activated	O
this	O
promoter	B-protein
in	O
a	O
kappa	O
B-dependent	O
manner	O
.	O

The	O
RpoN	O
mutant	O
,	O
lacking	O
pili	O
,	O
flagella	O
,	O
and	O
nonpilus	B-protein
adhesins	I-protein
,	O
bound	O
poorly	O
and	O
was	O
resistant	O
to	O
ingestion	O
by	O
both	O
macrophages	B-cell_type
and	O
neutrophils	B-cell_type
.	O

The	O
change	O
in	O
NF-kappaB	B-protein
components	I-protein
with	O
monocyte	O
differentiation	O
in	O
vivo	O
may	O
also	O
explain	O
the	O
different	O
transcriptional	O
activities	O
of	O
these	O
cell	O
populations	O
in	O
HIV-infected	O
individuals	O
.	O

The	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-dependent	I-protein
factor	I-protein
NF-ATp	B-protein
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
transcription	O
of	O
both	O
these	O
lymphokine	B-DNA
genes	I-DNA
.	O

The	O
presence	O
of	O
multiple	O
CREB	B-protein
isoforms	I-protein
with	O
identical	O
DNA-binding	O
specificities	O
but	O
differences	O
in	O
the	O
presumed	O
regulatory	B-protein
domain	I-protein
raises	O
the	O
possibility	O
that	O
CREB	B-protein
proteins	I-protein
may	O
be	O
able	O
to	O
integrate	O
distinct	O
regulatory	O
signals	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

The	O
transcriptional	O
response	O
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
to	O
stimulation	O
by	O
IL-1	B-protein
+	O
IL-2	B-protein
is	O
biphasic	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
N-acetyl-cysteine	O
reduced	O
the	O
accumulation	O
of	O
the	O
47-kD	B-protein
mature	I-protein
glycoprotein	I-protein
in	O
LPS-treated	B-cell_line
cells	I-cell_line
,	O
a	O
finding	O
consistent	O
with	O
the	O
results	O
of	O
the	O
immunofluorescence	O
studies	O
.	O

Binding	O
capacity	O
(	O
4978+/-391	O
versus	O
4131+/-321	O
sites/cell	O
)	O
,	O
Kd	O
values	O
for	O
dexamethasone	O
(	O
6.7+/-0.5	O
versus	O
5.7+/-0.3	O
nmol/L	O
)	O
,	O
and	O
IC50	O
values	O
for	O
dexamethasone	O
(	O
3.4+/-0.3	O
versus	O
3.1+/-0.2	O
nmol/L	O
)	O
and	O
cortisol	O
(	O
12.2+/-1.6	O
versus	O
9.5+/-0.3	O
nmol/L	O
)	O
were	O
not	O
significantly	O
different	O
.	O

Aberrant	O
splicing	O
of	O
the	O
TSG101	B-DNA
and	I-DNA
FHIT	I-DNA
genes	I-DNA
occurs	O
frequently	O
in	O
multiple	O
malignancies	O
and	O
in	O
normal	O
tissues	O
and	O
mimics	O
alterations	O
previously	O
described	O
in	O
tumours	O
.	O

Macrophage-differentiation	O
of	O
NB4	B-cell_line
reduced	O
levels	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
.	O

Activation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
by	O
lipopolysaccharide	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
is	O
prevented	O
by	O
inhibitors	O
of	O
cytosolic	B-protein
phospholipase	I-protein
A2	I-protein
.	O

The	O
functional	O
synergy	O
between	O
IL-12	B-protein
and	O
IL-2	B-protein
involves	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
and	O
is	O
associated	O
with	O
the	O
augmentation	O
of	O
STAT	O
serine	O
phosphorylation	O
.	O

In	O
humans	O
,	O
there	O
are	O
two	O
highly	O
homologous	B-DNA
genes	I-DNA
encoding	O
SCM-1alpha	B-protein
and	O
SCM-1beta	B-protein
.	O

We	O
observed	O
no	O
change	O
in	O
membrane	O
structural	O
order	O
with	O
RU	O
486	O
up	O
to	O
a	O
concentration	O
of	O
10	O
(	O
-4	O
)	O
M	O
.	O

Interestingly	O
,	O
an	O
enhanced	O
frequency	O
of	O
CD16	B-protein
and	O
CD68	O
(	O
+	O
)	O
cells	O
among	O
the	O
CD14	O
(	O
+	O
)	O
cells	O
was	O
observed	O
in	O
the	O
presence	O
of	O
IL-10	B-protein
,	O
independently	O
of	O
the	O
pre-culture	O
conditions	O
of	O
the	O
PBMC	B-cell_type
.	O

Conversely	O
,	O
inhibition	O
of	O
NF-kappaB	B-protein
confers	O
a	O
tenfold	O
increase	O
in	O
glucocorticoid	O
mediated	O
apoptosis	O
,	O
establishing	O
that	O
NF-kappaB	B-protein
also	O
functions	O
as	O
an	O
antiapoptotic	O
factor	O
.	O

In	O
addition	O
,	O
activation	O
of	O
c-raf	B-protein
kinase	I-protein
was	O
normal	O
.	O

In	O
astrocytes	B-cell_type
,	O
IFN-gamma	B-protein
treatment	O
induced	O
increased	O
occupancy	O
of	O
these	O
sites	O
.	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
controlling	O
CD19	B-protein
gene	O
expression	O
,	O
we	O
isolated	O
and	O
functionally	O
characterized	O
the	O
CD19	B-DNA
promoter	I-DNA
using	O
in	O
vivo	O
footprinting	O
,	O
gel	O
shift	O
assays	O
,	O
and	O
transfection	O
studies	O
.	O

Exposing	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVECs	B-cell_line
)	O
to	O
anoxia/reoxygenation	O
(	O
A/R	O
)	O
results	O
in	O
an	O
increase	O
in	O
polymorphonuclear	O
leukocyte	O
(	O
PMN	B-cell_type
)	O
adhesion	O
to	O
HUVECs	B-cell_line
.	O

Surprisingly	O
,	O
we	O
find	O
also	O
that	O
the	O
interaction	O
between	O
SLP-76	B-protein
and	O
Vav	B-protein
is	O
not	O
required	O
for	O
their	O
cooperation	O
in	O
augmenting	O
IL-2	B-DNA
promoter	I-DNA
activity	O
,	O
as	O
the	O
two	O
molecules	O
appear	O
to	O
function	O
in	O
different	O
signaling	O
pathways	O
upstream	O
of	O
IL-2	B-DNA
gene	I-DNA
expression	O
.	O

CD3	B-protein
-epsilon	O
gene	O
expression	O
is	O
confined	O
to	O
the	O
T	B-cell_line
cell	I-cell_line
lineage	I-cell_line
.	O

Analysis	O
of	O
the	O
inactive	B-DNA
X	I-DNA
specific	O
methylation	O
at	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
showed	O
unbalanced	O
inactivation	O
in	O
the	O
twins	O
'	O
fibroblasts	O
and	O
in	O
opposite	O
directions	O
.	O

Our	O
previous	O
results	O
show	O
that	O
recombinant	B-protein
gp41	I-protein
(	O
aa565-647	B-protein
)	O
,	O
the	O
extracellular	B-protein
domain	I-protein
of	O
HIV-1	B-protein
transmembrane	I-protein
glycoprotein	I-protein
,	O
stimulates	O
interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Expression	O
of	O
c-jun	B-DNA
,	I-DNA
jun	I-DNA
B	I-DNA
and	I-DNA
jun	I-DNA
D	I-DNA
proto-oncogenes	I-DNA
in	O
human	B-cell_type
peripheral-blood	I-cell_type
granulocytes	I-cell_type
.	O

The	O
c-Jun	B-protein
amino-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
phosphorylates	O
NFAT4	B-protein
on	O
two	O
sites	O
.	O

LNCaP	B-cell_line
cells	I-cell_line
treated	O
with	O
prostaglandin	O
E2	O
showed	O
neither	O
a	O
reduction	O
in	O
proliferation	O
nor	O
a	O
down-regulation	O
of	O
AR	B-protein
and	O
PSA	B-protein
levels	O
.	O

One	O
protein	O
,	O
NF-GM2	B-protein
is	O
similar	O
to	O
the	O
transcription	B-protein
factor	I-protein
NF-kB	B-protein
.	O

Thus	O
,	O
cosignaling	O
via	O
the	O
LT-beta	B-protein
and	I-protein
TNF-alpha	I-protein
receptors	I-protein
is	O
probably	O
involved	O
in	O
the	O
modulation	O
of	O
HIV-1	O
replication	O
and	O
the	O
subsequent	O
determination	O
of	O
HIV-1	O
viral	O
burden	O
in	O
monocytes	B-cell_type
.	O

Amplified	O
cDNA	B-DNA
were	O
sequenced	O
by	O
standard	O
methods	O
.	O

However	O
,	O
we	O
have	O
found	O
that	O
ICSAT	B-protein
has	O
a	O
different	O
repressive	O
effect	O
from	O
that	O
of	O
IRF-2	B-protein
or	O
ICSBP	B-protein
in	O
some	O
IFN-responsive	B-DNA
reporter	I-DNA
constructs	I-DNA
.	O

PML	B-protein
is	O
expressed	O
in	O
diverse	O
tissues	O
and	O
cell	O
lines	O
and	O
localized	O
in	O
the	O
nucleus	O
with	O
a	O
typical	O
speckled	O
pattern	O
.	O

Surprisingly	O
,	O
even	O
p65	B-protein
,	O
but	O
not	O
c-rel	B-protein
,	O
was	O
phosphorylated	O
after	O
induction	O
in	O
vivo	O
,	O
suggesting	O
that	O
TNF-alpha	B-protein
selectively	O
activates	O
only	O
specific	O
NF-kappa	B-protein
B	I-protein
heteromers	O
and	O
that	O
modifications	O
regulate	O
not	O
only	O
I	B-protein
kappa	I-protein
B	I-protein
molecules	I-protein
but	O
also	O
NF-kappa	B-protein
B	I-protein
molecules	O
.	O

We	O
have	O
previously	O
shown	O
that	O
NF-AT1	B-protein
is	O
constitutively	O
active	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
stably	O
transfected	O
with	O
the	O
Tax	B-DNA
cDNA	I-DNA
,	O
although	O
the	O
underlying	O
molecular	O
mechanism	O
and	O
physiological	O
relevance	O
of	O
this	O
finding	O
remain	O
unclear	O
.	O

Clonality	O
analysis	O
of	O
refractory	O
anemia	O
with	O
ring	B-cell_type
sideroblasts	I-cell_type
:	O
simultaneous	O
study	O
of	O
clonality	O
and	O
cytochemistry	O
of	O
bone	B-cell_type
marrow	I-cell_type
progenitors	I-cell_type
.	O

The	O
OCT-1-binding	O
genotype	O
,	O
found	O
in	O
approximately	O
5	O
%	O
of	O
Africans	O
,	O
is	O
associated	O
with	O
fourfold	O
increased	O
susceptibility	O
to	O
cerebral	O
malaria	O
in	O
large	O
case-control	O
studies	O
of	O
West	O
African	O
and	O
East	O
African	O
populations	O
,	O
after	O
correction	O
for	O
other	O
known	O
TNF	O
polymorphisms	O
and	O
linked	O
HLA	B-DNA
alleles	I-DNA
.	O

These	O
data	O
suggest	O
that	O
ERP	B-protein
might	O
play	O
a	O
role	O
in	O
B-cell	B-cell_type
development	O
and	O
in	O
IgH	B-DNA
gene	I-DNA
regulation	O
.	O

Recognition	O
of	O
NFATp/AP-1	B-DNA
composite	I-DNA
elements	I-DNA
within	O
genes	O
induced	O
upon	O
the	O
activation	O
of	O
immune	B-cell_type
cells	I-cell_type
.	O

Rather	O
,	O
the	O
data	O
indicate	O
that	O
mitogen	O
increases	O
the	O
levels	O
of	O
a	O
nuclear	O
factor	O
(	O
s	O
)	O
that	O
dimerizes	O
with	O
CREB	B-protein
.	O

Anaerobic	O
threshold	O
(	O
AT	O
)	O
was	O
determined	O
from	O
the	O
point	O
of	O
departure	O
of	O
the	O
ventilatory	O
response	O
from	O
linearity	O
and	O
from	O
the	O
sudden	O
increase	O
in	O
venous	O
blood	O
lactate	O
concentrations	O
during	O
MPE	O
.	O

Conversely	O
,	O
genistein	O
,	O
another	O
tyrosine	O
kinase	O
inhibitor	O
,	O
totally	O
abolished	O
the	O
expression	O
of	O
the	O
second	O
peak	O
of	O
junB	B-RNA
mRNA	I-RNA
whereas	O
it	O
did	O
not	O
affect	O
the	O
expression	O
of	O
the	O
first	O
peak	O
.	O

c-Maf	B-protein
induces	O
monocytic	O
differentiation	O
and	O
apoptosis	O
in	O
bipotent	B-cell_type
myeloid	I-cell_type
progenitors	I-cell_type
.	O

IFN-gamma	B-protein
decreased	O
basal	O
expression	O
as	O
well	O
as	O
the	O
induction	O
of	O
these	O
genes	O
by	O
IL-4	B-protein
and	O
IL-13	B-protein
.	O

The	O
thymic	O
cellularity	O
of	O
these	O
mice	O
was	O
significantly	O
decreased	O
.	O

Cell	O
cycle	O
analysis	O
showed	O
shifts	O
in	O
the	O
distribution	O
of	O
cells	O
from	O
G1	O
to	O
S	O
phase	O
,	O
which	O
were	O
more	O
pronounced	O
after	O
cadmium	O
treatment	O
.	O

Glucocorticoids	O
kill	O
certain	O
types	O
of	O
lymphoblasts	B-cell_type
,	O
but	O
the	O
mechanisms	O
are	O
unknown	O
.	O

In	O
contrast	O
,	O
PU.1	B-protein
is	O
expressed	O
at	O
high	O
levels	O
not	O
only	O
in	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
but	O
also	O
in	O
neutrophils	B-cell_type
,	O
indicating	O
that	O
PU.1	B-protein
can	O
activate	O
gene	O
expression	O
in	O
both	O
major	B-cell_type
myeloid	I-cell_type
lineages	I-cell_type
.	O

It	O
was	O
possible	O
that	O
one	O
of	O
the	O
clone	B-DNA
13	I-DNA
CIITA	I-DNA
alleles	I-DNA
bore	O
a	O
mutation	O
that	O
allowed	O
HLA-DQ	B-DNA
,	O
but	O
not	O
HLA-DR	O
or	O
-DP	O
transcription	O
.	O

STAT	B-protein
is	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
that	O
play	O
a	O
pivotal	O
role	O
in	O
cytokine-induced	O
functions	O
of	O
a	O
various	O
type	O
of	O
cells	O
.	O

Activated	B-cell_type
platelets	I-cell_type
induce	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
secretion	O
and	O
surface	O
expression	O
of	O
intercellular	B-cell_type
adhesion	I-cell_type
molecule-1	I-cell_type
on	O
endothelial	B-cell_type
cells	I-cell_type
[	O
see	O
comments	O
]	O

Accessing	O
Epstein-Barr	O
virus-specific	O
T-cell	O
memory	O
with	O
peptide-loaded	B-cell_line
dendritic	I-cell_line
cells	I-cell_line
.	O

Tal-1	B-protein
rearrangements	O
are	O
associated	O
with	O
nearly	O
30	O
%	O
of	O
human	O
T	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Co-stimulation	O
of	O
T-lymphocytes	B-cell_type
by	O
T-cell	B-protein
receptor	I-protein
(	O
TcR	B-protein
)	O
occupancy	O
and	O
activation	O
of	O
the	O
CD28	B-protein
surface	I-protein
molecule	I-protein
results	O
in	O
enhanced	O
proliferation	O
and	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
production	O
.	O

If	O
GATA-1	B-cell_line
-red	I-cell_line
cells	I-cell_line
were	O
available	O
,	O
the	O
analyses	O
would	O
involve	O
the	O
actual	O
transcription	O
of	O
or	O
chromatin	O
structure	O
surrounding	O
the	O
globin	B-DNA
genes	I-DNA
.	O

However	O
,	O
simultaneous	O
incubation	O
of	O
RU	O
486	O
with	O
dexamethasone	O
caused	O
a	O
distinct	O
interference	O
of	O
RU	O
486	O
with	O
dexamethasone	O
.	O

Messenger	B-RNA
RNA	I-RNA
(	O
mRNA	B-RNA
)	O
levels	O
for	O
the	O
granulocyte-colony	B-protein
stimulating	I-protein
factor	I-protein
(	I-protein
G-CSF	I-protein
)	I-protein
receptor	I-protein
,	O
granulocyte-macrophage	B-protein
(	I-protein
GM	I-protein
)	I-protein
-CSF	I-protein
receptor	I-protein
alpha	I-protein
subunit	I-protein
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
receptors	I-protein
I	I-protein
(	I-protein
p55	I-protein
)	I-protein
and	I-protein
II	I-protein
(	I-protein
p75	I-protein
)	I-protein
were	O
also	O
detected	O
in	O
this	O
subset	O
in	O
addition	O
to	O
c-kit	B-protein
and	O
flt-3	B-protein
,	O
receptors	O
known	O
to	O
be	O
expressed	O
on	O
progenitor	B-cell_type
cells	I-cell_type
.	O

T	O
lymphocytes	O
recognize	O
antigens	O
in	O
the	O
form	O
of	O
peptides	O
bound	O
to	O
HLA-molecules	B-protein
.	O

The	O
increased	O
sensitivity	O
of	O
CEM-C7	B-cell_line
cells	I-cell_line
and	O
its	O
subclones	O
to	O
dexamethasone	O
in	O
serum-free	O
medium	O
returned	O
to	O
previous	O
levels	O
when	O
these	O
cells	O
were	O
recultured	O
in	O
serum-containing	O
medium	O
.	O

Estrogen	O
decreases	O
TNF	B-protein
gene	O
expression	O
by	O
blocking	O
JNK	B-protein
activity	O
and	O
the	O
resulting	O
production	O
of	O
c-Jun	B-protein
and	O
JunD	B-protein
.	O

Furthermore	O
,	O
introduction	O
of	O
exogenous	O
GATA-1	B-protein
in	O
both	O
MEL	B-cell_line
cells	I-cell_line
and	O
Xenopus	O
embryos	O
and	O
explants	O
relieves	O
the	O
block	O
to	O
erythroid	O
differentiation	O
imposed	O
by	O
PU.1	B-protein
.	O

We	O
show	O
that	O
an	O
inhibitor	O
of	O
protein	B-protein
phosphatases	I-protein
(	O
PPs	B-protein
)	O
PP1/PP2A	B-protein
,	O
calyculin	B-protein
A	I-protein
,	O
induces	O
(	O
i	O
)	O
phosphorylation	O
of	O
STAT3	B-protein
on	O
serine	O
and	O
threonine	O
residues	O
,	O
(	O
ii	O
)	O
inhibition	O
of	O
STAT3	B-protein
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
,	O
and	O
(	O
iii	O
)	O
relocation	O
of	O
STAT3	B-protein
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

Cytokines	B-protein
,	O
the	O
peptide	B-protein
hormones	I-protein
which	O
control	O
the	O
homeostasis	O
of	O
the	O
immune	O
system	O
and	O
also	O
play	O
a	O
fundamental	O
role	O
in	O
inflammatory	O
and	O
immune	O
mediated	O
reactions	O
,	O
have	O
been	O
involved	O
at	O
multiple	O
levels	O
in	O
the	O
pathogenesis	O
of	O
the	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
.	O

Beta-catenin	O
is	O
the	O
vertebrate	O
homolog	O
of	O
the	O
Drosophila	B-DNA
segment	I-DNA
polarity	I-DNA
gene	I-DNA
Armadillo	B-DNA
and	O
plays	O
roles	O
in	O
both	O
cell-cell	O
adhesion	O
and	O
transduction	O
of	O
the	O
Wnt	O
signaling	O
cascade	O
.	O

U937	B-cell_line
cells	I-cell_line
differentiated	O
with	O
PMA	O
in	O
nonadherent	B-cell_line
culture	I-cell_line
were	O
shown	O
to	O
express	O
two	O
fibrinogen-binding	B-protein
integrins	I-protein
,	O
predominately	O
CD11b/CD18	B-protein
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
CD11c/CD18	B-protein
.	O

These	O
results	O
imply	O
that	O
membrane	O
potential	O
changes	O
secondary	O
to	O
the	O
ligand-dependent	O
opening	O
of	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-activated	I-protein
K+	I-protein
channels	I-protein
are	O
not	O
involved	O
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocyte	I-cell_type
activation	O
and	O
mitogenesis	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
regulating	O
this	O
early	O
inflammatory	O
response	O
.	O

Here	O
it	O
is	O
shown	O
that	O
the	O
HIV-1	O
viral	O
particle	O
contains	O
multiple	O
copies	O
of	O
the	O
vpr	B-protein
protein	I-protein
.	O

We	O
found	O
that	O
expression	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B-protein
could	O
substitute	O
for	O
Ca2+	O
ionophore	O
and	O
synergize	O
with	O
PMA	O
to	O
activate	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
and	O
conversely	O
that	O
mutant-activated	B-protein
Ras	I-protein
could	O
substitute	O
for	O
PMA	O
and	O
cooperate	O
with	O
Ca2+	O
ionophore	O
.	O

Furthermore	O
,	O
LMP1	B-protein
-induced	O
cell	O
size	O
increase	O
of	O
primary	B-cell_type
B	I-cell_type
cells	I-cell_type
was	O
unaffected	O
by	O
IkappaB	B-protein
expression	O
.	O

Further	O
,	O
in	O
consecutive	O
samples	O
of	O
fresh	O
blood	O
obtained	O
from	O
patients	O
with	O
B-CLL	B-cell_line
cells	I-cell_line
,	O
the	O
addition	O
of	O
IL-10	B-protein
inhibited	O
B-CLL	B-cell_line
proliferation	O
,	O
enhanced	O
B-CLL	B-cell_line
differentiation	O
,	O
but	O
did	O
not	O
induce	O
apoptosis	O
.	O

The	O
actions	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
suggest	O
a	O
novel	O
step	O
in	O
the	O
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Lysates	O
from	O
CD19	B-protein
cross-linked	O
1E8	B-cell_line
cells	I-cell_line
induced	O
robust	O
phosphorylation	O
of	O
an	O
Elk-1	B-protein
fusion	I-protein
protein	I-protein
in	O
vitro	O
,	O
whereas	O
no	O
phosphorylation	O
of	O
Elk-1	B-protein
fusion	I-protein
protein	I-protein
occurred	O
using	O
lysates	O
from	O
CD19	B-cell_line
cross-linked	I-cell_line
BLIN-1	I-cell_line
cells	I-cell_line
.	O

P-LPS-induced	O
expression	O
of	O
the	O
monocyte	B-DNA
chemoattractant	I-DNA
protein	I-DNA
1	I-DNA
(	I-DNA
MCP-1	I-DNA
)	I-DNA
gene	I-DNA
in	O
the	O
cells	O
was	O
inhibited	O
markedly	O
by	O
treatment	O
with	O
anti-human	O
CD14	B-protein
antibody	O
and	O
was	O
completely	O
inhibited	O
by	O
herbimycin	O
A	O
,	O
a	O
potent	O
inhibitor	O
of	O
tyrosine	B-protein
kinase	I-protein
.	O

In	O
summary	O
,	O
our	O
data	O
suggest	O
that	O
changes	O
in	O
the	O
composition	O
of	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
is	O
a	O
key	O
molecular	O
mechanism	O
for	O
increasing	O
IL-2	B-protein
transcription	O
and	O
may	O
underlie	O
the	O
phenomenon	O
of	O
costimulation	O
by	O
EC	B-cell_type
.	O

The	O
immunosuppressants	O
ciclosporin	O
and	O
FK506	O
block	O
the	O
Ca	O
(	O
2+	O
)	O
-dependent	O
signal-transduction	O
pathway	O
emanating	O
from	O
the	O
T-cell	B-protein
receptor	I-protein
,	O
thereby	O
inhibiting	O
the	O
activation	O
of	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
plays	O
a	O
major	O
role	O
in	O
this	O
process	O
by	O
promoting	O
the	O
differentiation	O
of	O
IL-4	B-protein
-secreting	O
Th2	O
cells	O
.	O

Inhibition	O
of	O
transcription	B-protein
factors	I-protein
belonging	O
to	O
the	O
rel/NF-kappa	B-protein
B	I-protein
family	I-protein
by	O
a	O
transdominant	B-protein
negative	I-protein
mutant	I-protein
.	O

For	O
this	O
purpose	O
,	O
mice	O
were	O
immunized	O
with	O
a	O
fusion	B-protein
protein	I-protein
including	O
the	O
sequence	O
Thr729-Lys984	B-protein
of	O
hMR	B-protein
.	O

We	O
suggested	O
that	O
negative	O
feedback	O
of	O
cortisol	O
could	O
be	O
deranged	O
.	O

Finally	O
,	O
we	O
did	O
genomic	O
footprinting	O
of	O
the	O
HS-40	B-DNA
enhancer	I-DNA
region	I-DNA
in	O
K562	B-cell_line
cells	I-cell_line
,	O
adult	B-cell_line
nucleated	I-cell_line
erythroblasts	I-cell_line
,	O
and	O
different	O
nonerythroid	B-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
there	O
was	O
little	O
effect	O
of	O
TPA	O
on	O
EGR-1	B-DNA
transcription	O
in	O
a	O
TPA-resistant	B-cell_line
U-937	I-cell_line
cell	I-cell_line
variant	I-cell_line
,	O
designated	O
TUR	B-cell_line
.	O

However	O
,	O
IL2	B-protein
does	O
not	O
reverse	O
CsA	O
inhibition	O
,	O
suggesting	O
that	O
at	O
least	O
one	O
other	O
NFAT-sensitive	B-DNA
gene	I-DNA
may	O
be	O
involved	O
.	O

During	O
the	O
treatment	O
with	O
As2O3	O
,	O
there	O
was	O
no	O
bone	O
marrow	O
depression	O
and	O
only	O
limited	O
side	O
effects	O
were	O
encountered	O
.	O

This	O
direct	O
inhibition	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
of	O
transcriptional	B-protein
activators	I-protein
of	O
the	O
IL-2	B-DNA
gene	I-DNA
may	O
provide	O
a	O
mechanistic	O
explanation	O
of	O
how	O
vitamin	O
derivatives	O
can	O
act	O
as	O
potent	O
immunosuppressive	O
agents	O
.	O

In	O
Jurkat	B-cell_line
cells	I-cell_line
that	O
are	O
not	O
sensitive	O
to	O
H2O2-induced	O
NF-kappaB	B-protein
activation	O
,	O
H2O2	O
potentiated	O
NF-kappaB	B-protein
activation	O
in	O
the	O
presence	O
of	O
sustained	O
high	O
[	O
Ca2+	O
]	O
i	O
following	O
thapsigargin	O
treatment	O
.	O

Of	O
the	O
GATA-binding	B-protein
proteins	I-protein
,	O
only	O
GATA-4	B-protein
selectively	O
regulates	O
the	O
human	B-DNA
IL-5	I-DNA
gene	I-DNA
promoter	I-DNA
in	O
IL-5	B-cell_type
producing	I-cell_type
cells	I-cell_type
which	O
express	O
multiple	B-protein
GATA-binding	I-protein
proteins	I-protein
.	O

COS-1	B-cell_line
cells	I-cell_line
,	O
co-expressing	O
the	O
human	O
IL-10R	B-protein
and	O
individual	O
STAT	B-protein
proteins	I-protein
,	O
confirmed	O
a	O
preference	O
of	O
the	O
IL-10R	B-protein
for	O
STAT3	B-protein
and	O
STAT1	B-protein
.	O

Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds-oligonucleotides	O
containing	O
the	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
or	O
activator	B-protein
protein-1	I-protein
cognate	B-DNA
DNA	I-DNA
sequences	I-DNA
significantly	O
attenuated	O
phase-2	O
response	O
,	O
suggesting	O
a	O
role	O
for	O
de	O
novo	O
macromolecule	O
synthesis	O
.	O

In	O
FL	O
,	O
follicles	O
were	O
densely	O
populated	O
,	O
and	O
their	O
borders	O
were	O
irregular	O
,	O
with	O
some	O
Bcl-6+	B-cell_type
cells	I-cell_type
in	O
the	O
interfollicular	O
zones	O
.	O

We	O
show	O
that	O
as	O
in	O
the	O
IL4R	B-protein
complex	I-protein
,	O
both	O
IL4R	B-protein
alpha	I-protein
and	O
IL2R	B-protein
gamma	I-protein
c	I-protein
are	O
components	O
of	O
the	O
IL13R	B-protein
and	O
that	O
both	O
cytokines	B-protein
induced	O
STAT6	B-protein
,	O
STAT3	B-protein
and	O
STAT5	B-protein
activation	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Studies	O
were	O
also	O
performed	O
with	O
an	O
HL-60/vinc	B-cell_line
revertant	I-cell_line
(	O
HL-60/vinc/R	B-cell_line
)	O
line	O
that	O
has	O
regained	O
partial	O
sensitivity	O
to	O
vincristine	O
.	O

This	O
difference	O
in	O
the	O
number	O
of	O
binding	O
sites	O
could	O
be	O
due	O
to	O
differences	O
in	O
cell	O
surface	O
(	O
UT-7	B-cell_line
cells	I-cell_line
are	O
20	O
%	O
smaller	O
than	O
the	O
parental	O
UT-7	B-cell_line
cells	I-cell_line
)	O
or	O
in	O
receptor	O
turnover	O
.	O

Messenger	B-RNA
RNA	I-RNA
production	O
coding	O
for	O
IL-8	B-protein
,	O
RANTES	B-protein
,	O
and	O
MCP-1	B-protein
showed	O
parallel	O
variations	O
to	O
the	O
production	O
of	O
the	O
correspondent	B-protein
proteins	I-protein
.	O

Our	O
results	O
suggest	O
that	O
the	O
target	O
of	O
PGE2	B-protein
action	O
is	O
a	O
component	O
in	O
the	O
signal	O
transduction	O
pathway	O
leading	O
to	O
the	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

Thus	O
,	O
it	O
is	O
not	O
unexpected	O
that	O
this	O
versatile	O
cellular	O
homeostatic	O
switch	O
would	O
be	O
affected	O
by	O
a	O
variety	O
of	O
viral	O
pathogens	O
,	O
which	O
have	O
evolved	O
mechanisms	O
to	O
utilize	O
various	O
aspects	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
activity	O
to	O
facilitate	O
their	O
replication	O
,	O
cell	O
survival	O
and	O
possibly	O
evasion	O
of	O
immune	O
responses	O
.	O

IL-6	B-protein
-induced	O
apoptosis	O
,	O
but	O
not	O
macrophage-differentiation	O
,	O
was	O
blocked	O
by	O
continuously	O
expressed	O
BCL2	B-protein
.	O

The	O
functions	O
of	O
NFAT	B-protein
proteins	I-protein
are	O
directly	O
controlled	O
by	O
the	O
calcium-	B-protein
and	I-protein
calmodulin-	I-protein
dependent	I-protein
phosphatase	I-protein
calcineurin	B-protein
.	O

Interaction	O
to	O
DNA	O
induces	O
changes	O
in	O
the	O
transcription	O
rate	O
,	O
leading	O
to	O
either	O
gene	O
induction	O
or	O
gene	O
repression	O
.	O

Formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
after	O
oxidative	O
stress	O
has	O
been	O
shown	O
to	O
be	O
an	O
activation	O
signal	O
for	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
e.g.	O
,	O
expression	O
of	O
IL-2	B-protein
and	O
its	O
receptor	B-protein
are	O
induced	O
.	O

This	O
protein	O
is	O
immunologically	O
distinct	O
from	O
IRF-1/ISGF2	B-protein
.	O

These	O
results	O
indicate	O
that	O
DNA	O
binding	O
by	O
VDR	B-protein
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
mediate	O
IL-2	B-protein
repression	O
.	O

Interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
and	O
interleukin-12	B-protein
(	O
IL-12	B-protein
)	O
control	O
the	O
differentiation	O
of	O
T-helper	B-cell_type
cells	I-cell_type
.	O

Hela	O
nuclear	O
extracts	O
contained	O
a	O
specific	B-protein
nuclear	I-protein
factor	I-protein
(	I-protein
s	I-protein
)	I-protein
binding	O
to	O
15-LO	B-DNA
promoter	I-DNA
DNA	I-DNA
which	O
are	O
distinct	O
from	O
those	O
derived	O
from	O
IL-13-treated	B-cell_line
human	I-cell_line
peripheral	I-cell_line
monocyte	I-cell_line
nuclear	O
extracts	O
.	O

Thus	O
,	O
phosphorylation	O
appears	O
to	O
be	O
a	O
general	O
mechanism	O
for	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
vivo	O
.	O

For	O
comparison	O
,	O
other	O
RBA	O
in	O
this	O
system	O
were	O
:	O
19-noraldosterone	O
,	O
20	O
%	O
;	O
18-deoxyaldosterone	O
,	O
5.8	O
%	O
;	O
18-deoxy-19-noraldosterone	O
,	O
4.7	O
%	O
;	O
18	O
,	O
21-anhydroaldosterone	O
,	O
0.37	O
%	O
;	O
17-isoaldosterone	O
,	O
7.6	O
%	O
and	O
apoaldosterone	O
,	O
4.3	O
%	O

This	O
activity	O
may	O
be	O
relevant	O
to	O
the	O
mechanisms	O
whereby	O
HTLV-I	O
which	O
does	O
not	O
contain	O
oncogenes	B-DNA
induces	O
neoplasia	O
.	O

In	O
contrast	O
,	O
CD19	B-protein
cross-linking	O
in	O
BLIN-1	B-cell_line
cells	I-cell_line
resulted	O
in	O
the	O
induction	O
of	O
NF-kappaB	B-protein
,	O
but	O
had	O
no	O
apparent	O
effect	O
on	O
AP-1	B-protein
-binding	O
activity	O
.	O

Ascorbic	O
acid	O
(	O
ascorbate	O
or	O
vitamin	O
C	O
)	O
has	O
been	O
shown	O
to	O
suppress	O
the	O
induction	O
of	O
HIV	O
in	O
latently	B-cell_type
infected	I-cell_type
T	I-cell_type
lymphocytic	I-cell_type
cells	I-cell_type
following	O
stimulation	O
with	O
a	O
tumor	O
promoter	O
(	O
PMA	O
)	O
and	O
inflammatory	B-protein
cytokine	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

Translocation	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q27	I-DNA
;	I-DNA
q11	I-DNA
)	I-DNA
:	O
a	O
new	O
variant	O
translocation	O
in	O
a	O
patient	O
with	O
non-Hodgkin	O
's	O
lymphoma	O
of	O
B-cell	O
type	O
with	O
BCL6	B-DNA
rearrangement	O
.	O

We	O
have	O
tried	O
to	O
find	O
out	O
whether	O
these	O
receptors	O
could	O
show	O
any	O
difference	O
in	O
sex	O
or	O
age	O
distribution	O
.	O

Some	O
of	O
these	O
complexes	O
were	O
demonstrated	O
to	O
contain	O
NF-IL6	B-protein
by	O
using	O
anti-C/EBP	B-protein
beta	I-protein
Abs	I-protein
.	O

The	O
transcription	B-protein
factors	I-protein
Sp1	B-protein
and	O
PU.1	B-protein
prime	I-protein
the	O
CD11b	B-DNA
promoter	I-DNA
,	O
but	O
the	O
nature	O
of	O
the	O
factors	O
responsible	O
for	O
its	O
inducible	O
expression	O
are	O
unknown	O
.	O

An	O
anti-IL-1	B-protein
beta	I-protein
antibody	I-protein
had	O
negligible	O
effects	O
on	O
HUVEC	B-protein
adhesion	I-protein
molecules	I-protein
,	O
PAI-1	B-protein
or	O
vWf	B-protein
production	O
.	O

The	O
integral	O
membrane	O
glycoprotein	B-protein
CD36	I-protein
appears	O
to	O
play	O
a	O
physiological	O
role	O
in	O
binding	O
and	O
uptake	O
of	O
Ox	O
LDL	O
by	O
monocyte-macrophages	B-cell_type
,	O
although	O
the	O
molecular	O
events	O
associated	O
with	O
CD36	B-protein
-Ox	O
LDL	O
interaction	O
are	O
unknown	O
.	O

Monochloramine	O
inhibits	O
phorbol	O
ester-inducible	O
neutrophil	O
respiratory	O
burst	O
activation	O
and	O
T	O
cell	O
interleukin-2	B-protein
receptor	O
expression	O
by	O
inhibiting	O
inducible	O
protein	B-protein
kinase	I-protein
C	I-protein
activity	O
.	O

IL-4	B-protein
conducts	O
its	O
biological	O
activities	O
through	O
binding	O
to	O
the	O
IL-4	B-protein
receptor	I-protein
(	O
IL-4R	B-protein
)	O
on	O
the	O
surface	O
of	O
target	B-cell_type
cells	I-cell_type
.	O

Although	O
IL-4	B-protein
activated	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
6	I-protein
in	O
addition	O
to	O
NF-kappaB	B-protein
,	O
NAC	O
treatment	O
or	O
the	O
transfection	O
of	O
decoy	O
oligodeoxynucleotides	O
for	O
NF-kappaB	B-protein
or	O
STAT6	B-protein
only	O
partly	O
blocked	O
IL-4	B-protein
-induced	O
germline	B-DNA
Cepsilon	O
transcription	O
.	O

The	O
mechanism	O
of	O
activation	O
is	O
due	O
to	O
S-nitrosylation	O
of	O
a	O
critical	O
cysteine	O
residue	O
which	O
stimulates	O
guanine	O
nucleotide	O
exchange	O
.	O

Translocation	B-DNA
breakpoints	I-DNA
in	O
three	O
patients	O
with	O
campomelic	O
dysplasia	O
and	O
autosomal	O
sex	O
reversal	O
map	O
more	O
than	O
130	O
kb	O
from	O
SOX9	B-DNA
.	O

Deletion	O
of	O
the	O
glucocorticoid	O
response	O
elements	O
located	O
at	O
ca.	B-DNA
bp	I-DNA
-850	I-DNA
upstream	O
of	O
Cp	B-DNA
did	O
not	O
result	O
in	O
a	O
significant	O
loss	O
in	O
activity	O
.	O

Recent	O
evidence	O
indicates	O
that	O
the	O
rate	O
of	O
progression	O
of	O
the	O
HIV-1	O
disease	O
is	O
significantly	O
reduced	O
in	O
thalassaemia	O
major	O
patients	O
upon	O
treatment	O
with	O
high	O
doses	O
of	O
desferrioxamine	O
(	O
DFX	O
)	O
.	O

Transcription	B-protein
factors	I-protein
of	O
the	O
NFAT	B-protein
family	I-protein
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	B-DNA
genes	I-DNA
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O

B	B-cell_type
cells	I-cell_type
were	O
prestimulated	O
with	O
SAC	O
for	O
48	O
hrs	O
.	O

Previous	O
studies	O
established	O
a	O
potential	O
role	O
for	O
the	O
Src-family	B-protein
kinase	I-protein
Lck	B-protein
in	O
JAK	B-protein
-STAT	B-protein
signaling	O
.	O

Here	O
we	O
map	O
the	O
cis-acting	B-DNA
elements	I-DNA
that	O
mediate	O
interleukin	O
responsiveness	O
of	O
the	O
mouse	B-DNA
IL-2R	I-DNA
alpha	I-DNA
gene	I-DNA
using	O
a	O
thymic	B-cell_line
lymphoma-derived	I-cell_line
hybridoma	I-cell_line
(	O
PC60	B-cell_line
)	O
.	O

The	O
OTF	O
interactions	O
we	O
observed	O
extended	O
over	O
the	O
heptamer	B-DNA
element	I-DNA
5'-CTCAGGA-3	O
'	O
,	O
and	O
it	O
seems	O
likely	O
that	O
the	O
binding	O
of	O
the	O
purified	B-protein
factors	I-protein
involves	O
cooperation	O
between	O
octamer	B-DNA
and	I-DNA
heptamer	I-DNA
sites	I-DNA
in	O
this	O
promoter	B-DNA
.	O

Relative	O
expressions	O
of	O
SERCA	B-protein
2	O
and	O
3	O
isoforms	O
and	O
Ras-related	B-protein
protein	I-protein
(	I-protein
Rap	I-protein
)	I-protein
1	I-protein
in	O
platelet	O
membranes	O
were	O
determined	O
by	O
Western	O
immunoblots	O
.	O

Those	O
results	O
indicate	O
that	O
,	O
in	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
PKC	B-protein
activation	O
has	O
only	O
a	O
triggering	O
role	O
,	O
whereas	O
the	O
endogenously	O
secreted	O
TNF	B-protein
alpha	I-protein
plays	O
an	O
essential	O
role	O
in	O
the	O
quantitative	O
control	O
of	O
the	O
expression	O
of	O
IL-2R	B-protein
alpha	I-protein
chain	O
or	O
NF.kappa	B-protein
B	I-protein
activation	O
.	O

Upregulation	O
of	O
c-Fos	B-protein
in	O
activated	B-cell_type
T	I-cell_type
lymphoid	I-cell_type
and	I-cell_type
monocytic	I-cell_type
cells	I-cell_type
by	O
human	B-protein
immunodeficiency	I-protein
virus-1	I-protein
Tat	I-protein
protein	I-protein
.	O

Now	O
we	O
report	O
that	O
sublytic	O
TCC	B-protein
induced	O
Ras	B-protein
,	O
Raf-1	B-protein
,	O
and	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	I-protein
ERK	I-protein
)	I-protein
1	I-protein
activation	O
in	O
JY25	O
B	O
cell	O
line	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infects	O
B	B-cell_type
cells	I-cell_type
,	O
resulting	O
in	O
the	O
outgrowth	O
of	O
immortalised	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
LCLs	B-cell_line
)	O
.	O

These	O
findings	O
thus	O
reveal	O
the	O
presence	O
of	O
a	O
second	O
inducible	O
autoregulated	O
inhibitory	O
pathway	O
that	O
helps	O
ensure	O
the	O
rapid	O
but	O
transient	O
action	O
of	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
.	O

Two	O
such	O
clusters	O
were	O
found	O
to	O
have	O
patterns	O
that	O
correlated	O
with	O
variation	O
in	O
cell	O
proliferation	O
rates	O
and	O
with	O
activation	O
of	O
the	O
IFN	B-protein
-regulated	O
signal	O
transduction	O
pathway	O
,	O
respectively	O
.	O

The	O
two	O
mutations	O
R217A	O
and	O
R294A	O
caused	O
an	O
increased	O
binding	O
efficiency	O
for	O
antagonists	O
but	O
no	O
change	O
in	O
agonist	O
binding	O
.	O

The	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
was	O
63	O
%	O
greater	O
in	O
the	O
morning	O
and	O
26	O
%	O
greater	O
in	O
the	O
afternoon	O
in	O
the	O
patients	O
with	O
PTSD	O
than	O
in	O
the	O
normal	O
subjects	O
.	O

The	O
smaller	O
of	O
the	O
two	O
proteins	O
(	O
50	B-protein
kDa	I-protein
)	O
was	O
indistinguishable	O
from	O
the	O
classical	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
and	O
,	O
similar	O
to	O
the	O
classical	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
,	O
was	O
upregulated	O
in	O
a	O
dose-dependent	O
fashion	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

RFX-B	B-DNA
complements	O
the	O
predominant	O
BLS	B-protein
complementation	I-protein
group	I-protein
(	O
group	B-protein
B	I-protein
)	O
and	O
was	O
found	O
to	O
be	O
mutant	O
in	O
cell	B-cell_line
lines	I-cell_line
from	O
this	O
BLS	O
group	O
.	O

The	O
Epstein-Barr	B-DNA
virus	I-DNA
latency	I-DNA
BamHI-Q	I-DNA
promoter	I-DNA
is	O
positively	O
regulated	O
by	O
STATs	B-protein
and	O
Zta	B-protein
interference	O
with	O
JAK	B-protein
/STAT	B-protein
activation	O
leads	O
to	O
loss	O
of	O
BamHI-Q	B-DNA
promoter	I-DNA
activity	O
.	O

Purified	B-cell_line
human	I-cell_line
peripheral	I-cell_line
T	I-cell_line
cells	I-cell_line
or	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
were	O
stimulated	O
with	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
expressing	O
either	O
human	B-protein
CD80	I-protein
(	O
CHO-CD80	B-protein
)	O
or	O
human	B-protein
CD86	I-protein
(	O
CHO-CD86	B-protein
)	O
or	O
with	O
anti-CD28	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	O
)	O
.	O

Furthermore	O
,	O
Elf-1	B-protein
interacts	O
specifically	O
with	O
the	O
E74	B-DNA
target	I-DNA
sequence	I-DNA
and	O
can	O
stimulate	O
transcription	O
driven	O
by	O
the	O
E74	B-DNA
site	I-DNA
independent	O
of	O
mitogenic	O
signaling	O
.	O

Differential	O
expression	O
was	O
confirmed	O
subsequently	O
by	O
Northern	O
blot	O
analysis	O
.	O

She	O
was	O
treated	O
with	O
6	O
g	O
of	O
salt	O
daily	O
to	O
prevent	O
dehydration	O
,	O
which	O
she	O
stopped	O
herself	O
because	O
of	O
reduced	O
fecal	O
losses	O
.	O

TGFs	B-protein
play	O
important	O
roles	O
in	O
wound	O
healing	O
and	O
carcinogenesis	O
.	O

By	O
contrast	O
,	O
glucocorticoids	O
failed	O
to	O
inhibit	O
IFNalpha	B-protein
production	O
from	O
AIDS-GR	B-cell_type
monocytes	I-cell_type
(	O
approximately	O
20	O
%	O
inhibition	O
)	O
.	O

For	O
comparison	O
,	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
were	O
determined	O
in	O
lymphocytes	B-cell_type
and	O
normal	O
thyroid	O
tissue	O
of	O
euthyroid	O
patients	O
.	O

Transcription	B-protein
factors	I-protein
of	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
--	O
basic	O
research	O
and	O
clinical	O
perspectives	O
for	O
gastroenterology	O
.	O

The	O
carboxyl-terminal	B-protein
cytoplasmic	I-protein
domain	I-protein
of	O
CD36	B-protein
is	O
required	O
for	O
oxidized	O
low-density	O
lipoprotein	O
modulation	O
of	O
NF-kappaB	B-protein
activity	O
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
.	O

One	O
contains	O
hsp90	B-protein
bound	O
to	O
hsp70	B-protein
and	O
p60	B-protein
and	O
this	O
complex	O
forms	O
spontaneously	O
in	O
the	O
absence	O
of	O
ATP	O
.	O

Although	O
it	O
has	O
been	O
reported	O
that	O
there	O
are	O
some	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
produce	O
IFN-gamma	B-protein
in	O
response	O
to	O
IL-2	O
and	O
IL-12	O
stimulation	O
,	O
there	O
has	O
as	O
yet	O
been	O
no	O
report	O
of	O
a	O
natural	B-cell_line
killer	I-cell_line
(	I-cell_line
NK	I-cell_line
)	I-cell_line
cell	I-cell_line
line	I-cell_line
that	O
responds	O
in	O
a	O
similar	O
manner	O
.	O

However	O
,	O
these	O
studies	O
have	O
used	O
a	O
limited	O
number	O
of	O
known	O
kappa	O
B	O
DNA	O
motifs	O
,	O
and	O
the	O
question	O
of	O
the	O
optimal	O
DNA	O
sequences	O
preferred	O
by	O
each	O
homodimer	O
has	O
not	O
been	O
addressed	O
.	O

Molecular	O
mechanisms	O
leading	O
to	O
restricted	O
HIV-1	O
replication	O
may	O
differ	O
between	O
certain	O
cell	O
types	O
.	O

The	O
decreased	O
T	O
cell	O
reactivity	O
to	O
thyroid	B-protein
antigens	I-protein
after	O
thyroidectomy	O
could	O
be	O
the	O
result	O
of	O
removal	O
of	O
a	O
major	O
part	O
of	O
the	O
thyroid	O
gland	O
or	O
redistribution	O
of	O
suppressor-inducer	O
T	B-cell_type
cells	I-cell_type
.	O

Depletion	O
of	O
CD8+	B-cell_line
cells	I-cell_line
was	O
accompanied	O
by	O
62	O
+/-	O
18	O
%	O
loss	O
of	O
progesterone	B-cell_line
receptor-bearing	I-cell_line
cells	I-cell_line
,	O
while	O
depletion	O
of	O
CD4+	B-cell_line
cells	I-cell_line
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
number	O
of	O
positively	O
staining	O
lymphocytes	B-cell_line
.	O

The	O
magnitude	O
of	O
responsiveness	O
is	O
cell	O
type	O
dependent	O
.	O

After	O
the	O
recent	O
discovery	O
that	O
the	O
cyclosporin	B-protein
A-binding	I-protein
protein	I-protein
cyclophilin	B-protein
is	O
identical	O
to	O
peptidylprolyl	B-protein
cis-trans	I-protein
isomerase	I-protein
,	O
a	O
cellular	B-protein
binding	I-protein
protein	I-protein
for	O
FK506	O
was	O
found	O
to	O
be	O
distinct	O
from	O
cyclophilin	B-protein
but	O
to	O
have	O
the	O
same	O
enzymatic	O
activity	O
.	O

In	O
our	O
attempt	O
to	O
identify	O
chemokine	B-protein
receptors	I-protein
that	O
are	O
related	O
to	O
Burkitt	B-protein
's	I-protein
lymphoma	I-protein
receptor	I-protein
1	I-protein
(	O
BLR1	B-protein
)	O
and	O
are	O
expressed	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
we	O
used	O
RT-PCR	O
resulting	O
in	O
the	O
isolation	O
of	O
a	O
cDNA	O
encoding	O
a	O
seven	B-protein
transmembrane	I-protein
receptor	I-protein
termed	O
BLR2	B-protein
.	O

IkappaBalpha	B-protein
phosphorylation	O
and	O
degradation	O
was	O
analyzed	O
by	O
Western	O
blot	O
.	O

In	O
this	O
study	O
,	O
we	O
propose	O
a	O
novel	O
function	O
for	O
CD44	O
.	O

However	O
,	O
the	O
phenotypic	O
analysis	O
of	O
NF-AT	B-protein
-deficient	O
mice	O
supports	O
the	O
idea	O
that	O
there	O
are	O
tissue-	O
and	O
gene-	O
specific	O
functions	O
as	O
well	O
.	O

Furthermore	O
,	O
the	O
same	O
cell	B-cell_line
lines	I-cell_line
were	O
resistant	O
to	O
cytolytic	O
action	O
of	O
other	O
cytotoxic	B-protein
proteins	I-protein
secreted	O
by	O
LAK	B-cell_line
cells	I-cell_line
.	O

Negative	O
transcriptional	O
regulation	O
of	O
human	B-DNA
interleukin	I-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
by	O
glucocorticoids	O
through	O
interference	O
with	O
nuclear	B-protein
transcription	I-protein
factors	I-protein
AP-1	B-protein
and	O
NF-AT	B-protein
.	O

The	O
c-jun	B-DNA
gene	I-DNA
expression	O
was	O
very	O
transient	O
and	O
was	O
not	O
detectable	O
by	O
60	O
min	O
after	O
M-CSF	B-protein
addition	O
.	O

DR3	B-protein
signal	O
transduction	O
is	O
mediated	O
by	O
a	O
complex	O
of	O
intracellular	B-protein
signaling	I-protein
molecules	I-protein
including	O
TRADD	B-protein
,	O
TRAF2	B-protein
,	O
FADD	B-protein
,	O
and	O
FLICE	B-protein
.	O

Lack	O
of	O
full	O
activation	O
of	O
NF-AT	B-protein
could	O
be	O
correlated	O
to	O
a	O
dramatically	O
reduced	O
capacity	O
to	O
induce	O
calcium	O
flux	O
and	O
could	O
be	O
complemented	O
with	O
a	O
calcium	O
ionophore	O
.	O

Double	O
staining	O
revealed	O
that	O
these	O
interfollicular	B-cell_type
Bcl-6+	I-cell_type
cells	I-cell_type
in	O
AITL/GC	O
were	O
Bcl6+/CD3+/CD20-/CD57-	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
1.955-kb	B-DNA
viral	I-DNA
segment	I-DNA
includes	O
a	O
dyad	O
symmetry	O
region	O
located	O
between	O
two	O
small	B-DNA
nuclear	I-DNA
RNA	I-DNA
genes	I-DNA
and	O
is	O
located	O
upstream	O
of	O
the	O
dihydrofolate	B-DNA
reductase	I-DNA
gene	I-DNA
homolog	I-DNA
.	O

The	O
inhibition	O
in	O
protein	O
synthesis	O
correlates	O
with	O
specific	O
regulation	O
of	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
4E-BP1	B-protein
and	O
4E-BP2	B-protein
.	O

Furthermore	O
,	O
maximal	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
could	O
be	O
enhanced	O
by	O
co-stimulation	O
with	O
LPS	O
or	O
MDP	O
,	O
suggesting	O
that	O
different	O
receptors	O
and/or	O
transduction	O
pathways	O
were	O
involved	O
.	O

In	O
the	O
cell	O
types	O
tested	O
,	O
the	O
LS	O
mutations	O
indicated	O
an	O
apparent	O
requirement	O
not	O
only	O
for	O
the	O
intact	O
NF-kappa	B-protein
B	I-protein
and	O
SP1-binding	B-DNA
sites	I-DNA
but	O
also	O
for	O
several	O
regions	O
between	O
-201	B-DNA
and	I-DNA
-130	I-DNA
not	O
previously	O
associated	O
with	O
viral	O
infectivity	O
.	O

A	O
signal	O
transduction	O
pathway	O
activated	O
by	O
many	O
cytokines	B-protein
has	O
recently	O
been	O
elaborated	O
.	O

All-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
is	O
an	O
important	O
morphogen	O
in	O
vertebrate	O
development	O
,	O
a	O
normal	O
constituent	O
in	O
human	O
adult	O
blood	O
and	O
is	O
also	O
involved	O
in	O
the	O
control	O
of	O
cell	O
growth	O
and	O
differentiation	O
in	O
acute	O
promyelocytic	O
leukemia	O
.	O

The	O
HB9	B-DNA
homeodomain	I-DNA
is	O
most	O
similar	O
to	O
that	O
of	O
the	O
Drosophila	B-DNA
melanogaster	I-DNA
homeobox	I-DNA
gene	I-DNA
proboscipedia	B-DNA
.	O

IFN-gamma	B-protein
priming	O
of	O
monocytes	B-cell_type
enhances	O
LPS-induced	O
TNF	B-protein
production	O
by	O
augmenting	O
both	O
transcription	O
and	O
MRNA	O
stability	O
.	O

Cross-linking	O
CD19	B-protein
on	O
early	O
human	B-cell_type
B	I-cell_type
lineage	I-cell_type
cells	I-cell_type
induces	O
the	O
formation	O
of	O
a	O
CD19/Vav/phosphatidylinositol-3	B-protein
kinase	I-protein
complex	I-protein
,	O
tyrosine	O
phosphorylation	O
of	O
CD19	B-protein
and	O
Vav	B-protein
,	O
and	O
activation	O
of	O
the	O
Ras	B-protein
pathway	O
.	O

The	O
different	O
patterns	O
of	O
p50	B-protein
,	O
p52	B-protein
and	O
RelB	B-protein
protein	O
nuclear	O
localization	O
may	O
provide	O
insight	O
into	O
their	O
different	O
roles	O
during	O
the	O
immune	O
response	O
in	O
vivo	O
.	O

The	O
ets	B-DNA
proto-oncogene	I-DNA
family	I-DNA
is	O
a	O
group	O
of	O
sequence-related	B-DNA
genes	I-DNA
whose	O
normal	O
cellular	O
function	O
is	O
unknown	O
.	O

Severe	O
combined	O
immunodeficiency	O
due	O
to	O
defective	O
binding	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
of	O
two	O
male	O
siblings	O
.	O

In	O
summary	O
,	O
we	O
have	O
discovered	O
that	O
expression	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
is	O
markedly	O
enhanced	O
as	O
the	O
NB4	B-cell_line
promyelocytes	I-cell_line
are	O
induced	O
by	O
retinoids	O
to	O
differentiate	O
towards	O
granulocytes	B-cell_type
.	O

The	O
control	O
group	O
consisted	O
of	O
24	O
healthy	O
laboratory	O
employees	O
.	O

HIV	B-protein
glycoprotein	I-protein
120	I-protein
enhances	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
gene	O
expression	O
in	O
glial	B-cell_type
cells	I-cell_type
.	O

These	O
synthetic	O
ligands	O
specifically	O
inhibit	O
DNA-binding	O
of	O
each	O
transcription	B-protein
factor	I-protein
and	O
HIV	O
type	O
1	O
transcription	O
in	O
cell-free	O
assays	O
.	O

This	O
may	O
imply	O
a	O
role	O
for	O
ets	B-protein
transcription	I-protein
factors	I-protein
in	O
the	O
production	O
of	O
TNF-alpha	B-protein
.	O

The	O
human	B-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
alpha	I-DNA
(	I-DNA
TNF-alpha	I-DNA
)	I-DNA
gene	I-DNA
is	O
one	O
of	O
the	O
earliest	O
genes	O
transcribed	O
after	O
the	O
stimulation	O
of	O
a	O
B	B-cell_type
cell	I-cell_type
through	O
its	O
antigen	B-protein
receptor	I-protein
or	O
via	O
the	O
CD-40	O
pathway	O
.	O

These	O
results	O
emphasize	O
the	O
structural	O
versatility	O
of	O
the	O
Oct-1	B-protein
POU	I-protein
domain	I-protein
in	O
its	O
interaction	O
with	O
coregulators	O
.	O

Several	O
DNA-binding	B-protein
proteins	I-protein
are	O
known	O
to	O
bind	O
this	O
sequence	O
.	O

Human	B-protein
Toll-like	I-protein
receptor	I-protein
2	I-protein
(	I-protein
TLR2	I-protein
)	I-protein
is	O
a	O
signaling	B-protein
receptor	I-protein
that	O
responds	O
to	O
LPS	O
and	O
activates	O
NF-kappaB	B-protein
.	O

Thrombin	B-protein
generation	O
by	O
apoptotic	B-cell_type
vascular	I-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
.	O

In	O
T	B-cell_type
cells	I-cell_type
,	O
IL-13	B-protein
inhibits	O
anti-CD3	O
mAb/IL-2-	O
or	O
PHA-mediated	O
IFN-gamma	O
production	O
and	O
enhances	O
cytolytic	O
potential	O
.	O

Various	O
cellular	O
stimuli	O
relieve	O
this	O
inhibition	O
by	O
mechanisms	O
largely	O
unknown	O
,	O
leading	O
to	O
NF-kappa	B-protein
B	I-protein
nuclear	O
localization	O
and	O
transactivation	O
of	O
its	O
target	O
genes	O
.	O

p53	B-protein
and	O
p21/Cip1	B-protein
,	O
respectively	O
,	O
inhibit	O
the	O
expression	O
and	O
activation	O
of	O
PCNA	B-protein
,	O
whereas	O
p130	B-protein
and	O
pRb	B-protein
,	O
respectively	O
,	O
inhibit	O
the	O
expression	O
and	O
activation	O
of	O
E2F1	B-protein
.	O

The	O
mechanism	O
by	O
which	O
progesterone	O
causes	O
localized	O
suppression	O
of	O
the	O
immune	O
response	O
during	O
pregnancy	O
has	O
remained	O
elusive	O
.	O

These	O
data	O
suggest	O
that	O
the	O
regulation	O
of	O
IL-2	B-DNA
gene	I-DNA
expression	O
is	O
a	O
complex	O
process	O
and	O
multiple	O
cis-acting	B-DNA
regulatory	I-DNA
sites	I-DNA
interact	O
to	O
exert	O
different	O
effects	O
in	O
T	B-cell_type
cells	I-cell_type
representative	O
of	O
alternative	O
stages	O
of	O
differentiation	O
.	O

It	O
can	O
be	O
deduced	O
that	O
the	O
erythroid	B-protein
ALAS	I-protein
precursor	I-protein
protein	I-protein
has	O
a	O
molecular	O
weight	O
of	O
64.6	O
kd	O
,	O
and	O
is	O
similar	O
in	O
size	O
to	O
the	O
previously	O
isolated	O
human	B-protein
housekeeping	I-protein
ALAS	I-protein
precursor	I-protein
of	O
molecular	O
weight	O
70.6	O
kd	O
.	O

Mice	O
lacking	O
Rel	B-protein
are	O
defective	O
in	O
mitogenic	O
activation	O
of	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
display	O
impaired	O
humoral	O
immunity	O
.	O

Heat-shock	O
for	O
2	O
hours	O
at	O
42	O
degrees	O
C	O
,	O
or	O
the	O
administration	O
for	O
3	O
hours	O
of	O
100	O
or	O
150	O
microM	O
cadmium	O
chloride	O
,	O
inhibited	O
the	O
subsequent	B-cell_line
proliferation	I-cell_line
activity	I-cell_line
,	O
induced	O
the	O
expression	O
of	O
functional	O
differentiation	B-protein
markers	I-protein
,	O
and	O
caused	O
an	O
increase	O
in	O
the	O
amount	O
of	O
the	O
stress-responsive	B-protein
HSP70	I-protein
protein	I-protein
in	O
U-937	B-cell_line
human	I-cell_line
promonocytic	I-cell_line
cells	I-cell_line
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
determine	O
the	O
in	O
vivo	O
modulation	O
of	O
GR	B-RNA
mRNA	I-RNA
expression	O
by	O
fluticasone	O
propionate	O
(	O
FP	O
)	O
in	O
subjects	O
with	O
mild	O
asthma	O
.	O

Conversely	O
,	O
the	O
murine	B-DNA
kappa	I-DNA
light	I-DNA
chain	I-DNA
enhancer	I-DNA
motif	I-DNA
(	O
GGGGACTTTCCG	O
)	O
does	O
not	O
efficiently	O
bind	O
the	O
nuclear	O
p50p50	B-protein
from	O
tolerant	B-cell_line
murine	I-cell_line
P388	I-cell_line
macrophages	I-cell_line
.	O

Tat	B-protein
transactivation	O
mediated	O
by	O
the	O
kappa	B-DNA
B	I-DNA
domain	I-DNA
is	O
sufficient	O
to	O
allow	O
replication	O
of	O
TAR	B-DNA
-deleted	O
mutant	O
HIV-1	O
in	O
astrocytes	B-cell_type
.	O

Freshly	O
isolated	O
monocytes	O
constitutively	O
expressed	O
high	O
levels	O
of	O
transcriptionally	B-protein
inactive	I-protein
p50	I-protein
homodimer	I-protein
which	O
decreased	O
with	O
time	O
in	O
culture	O
in	O
favor	O
of	O
the	O
transcriptionally	O
active	O
p50/p65	B-protein
and	I-protein
p50/RelB	I-protein
heterodimers	I-protein
.	O

The	O
mechanism	O
of	O
action	O
of	O
DM	O
on	O
IL-2R	B-protein
alpha	I-protein
transcription	O
was	O
examined	O
by	O
determining	O
the	O
mRNA	O
levels	O
of	O
the	O
p50	O
subunit	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
that	O
stimulates	O
IL-2R	B-protein
alpha	I-protein
gene	O
expression	O
.	O

Both	O
C1	B-protein
and	O
C2	B-protein
proteins	I-protein
also	O
bind	O
to	O
a	O
similar	O
sequence	O
found	O
in	O
the	O
interleukin-2-receptor	B-DNA
alpha-subunit	I-DNA
enhancer	I-DNA
.	O

The	O
minimal	B-DNA
EBNA-2-responsive	I-DNA
LMP-1	I-DNA
promoter	I-DNA
includes	O
one	O
J	B-DNA
kappa-binding	I-DNA
site	I-DNA
,	O
and	O
we	O
now	O
show	O
that	O
mutation	O
of	O
that	O
site	O
,	O
such	O
that	O
J	B-protein
kappa	I-protein
can	O
not	O
bind	O
,	O
reduces	O
EBNA-2	B-protein
responsiveness	O
by	O
60	O
%	O
.	O

Transient	O
transfection	O
assays	O
with	O
EGR-1	B-DNA
promoter	I-DNA
fragments	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
demonstrated	O
that	O
PWM	B-protein
induced	O
EGR-1	B-DNA
transcription	O
is	O
conferred	O
by	O
the	O
CArG	B-DNA
motif	I-DNA
(	O
C	B-DNA
C	I-DNA
[	I-DNA
AT	I-DNA
]	I-DNA
6GG	I-DNA
)	O
in	O
the	O
EGR-1	B-DNA
promoter	I-DNA
.	O

We	O
demonstrate	O
evidence	O
suggesting	O
that	O
redox	O
regulation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
by	O
Trx	B-protein
might	O
be	O
exerted	O
at	O
a	O
step	O
after	O
dissociation	O
of	O
the	O
inhibitory	O
molecule	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
a	O
cytosolic-anchoring	B-protein
protein	I-protein
for	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O

All	O
the	O
tumors	O
exhibited	O
very	O
low	O
proliferative	O
activity	O
,	O
fewer	O
than	O
10	O
%	O
of	O
the	O
tumor	O
cell	O
nuclei	O
being	O
stained	O
by	O
the	O
antibody	B-protein
MIB-1	I-protein
(	O
Ki-67	B-protein
antigen	I-protein
)	O
.	O

A	O
15-base	O
oligonucleotide	O
,	O
GM3	O
,	O
was	O
targeted	O
to	O
a	O
purine-rich	B-DNA
region	I-DNA
in	O
the	O
GM-CSF	B-DNA
proximal	I-DNA
promoter	I-DNA
,	O
which	O
overlaps	O
the	O
kappaB	B-DNA
element	I-DNA
.	O

Structurally	O
related	O
divalent	O
cations	O
like	O
cobalt	O
,	O
nickel	O
,	O
and	O
mercury	O
also	O
partially	O
increase	O
monokine	O
secretion	O
but	O
to	O
a	O
much	O
lower	O
and	O
thus	O
insignificant	O
extent	O
.	O

Rel/NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
and	O
the	O
control	O
of	O
apoptosis	O
.	O

A	O
full-length	O
PML/RARalpha	B-DNA
cDNA	I-DNA
driven	O
by	O
the	O
CD11b	B-DNA
promoter	I-DNA
was	O
expressed	O
in	O
transgenic	O
mice	O
.	O

These	O
results	O
indicate	O
that	O
both	O
a	O
decrease	O
and	O
an	O
increase	O
of	O
human	O
motor	O
activity	O
resulted	O
in	O
significant	O
changes	O
of	O
specific	O
glucocorticoid	O
binding	O
which	O
were	O
not	O
influenced	O
by	O
changes	O
of	O
circulating	O
hormone	O
concentrations	O
in	O
blood	O
but	O
by	O
some	O
other	O
factors	O
affected	O
by	O
physical	O
activity	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
regulating	O
this	O
activation	O
remains	O
unknown	O
.	O

There	O
is	O
no	O
detectable	O
NF-AT	B-protein
protein	O
expression	O
in	O
the	O
nuclei	O
of	O
resting	B-cell_type
eosinophils	I-cell_type
.	O

Activation	O
of	O
the	O
Jak	B-protein
-Stat	B-protein
pathway	O
correlates	O
with	O
proliferative	O
signaling	O
by	O
the	O
G-CSFR	B-protein
and	O
requires	O
the	O
membrane-proximal	B-protein
box	I-protein
1	I-protein
PXP	I-protein
motif	I-protein
,	O
which	O
is	O
conserved	O
in	O
members	O
of	O
the	O
cytokine	B-protein
receptor	I-protein
superfamily	I-protein
.	O

To	O
determine	O
whether	O
the	O
substitutions	O
per	O
se	O
were	O
responsible	O
for	O
decreased	O
affinity	O
,	O
squirrel	O
monkey	O
and	O
human	B-protein
glucocorticoid	I-protein
receptors	I-protein
were	O
expressed	O
in	O
the	O
TNT	O
Coupled	O
Reticulocyte	O
Lysate	O
System	O
.	O

Here	O
we	O
examine	O
the	O
biochemical	O
basis	O
for	O
the	O
transcriptional	O
regulation	O
of	O
HIV	O
by	O
NFKB2	B-protein
.	O

Estrogen	B-protein
receptor	I-protein
diminishes	O
DNA-binding	O
activities	O
of	O
chicken	B-protein
GATA-1	I-protein
and	O
CACCC-binding	B-protein
proteins	I-protein
.	O

To	O
identify	O
such	O
target	B-DNA
genes	I-DNA
,	O
we	O
established	O
Egr-1-overexpressing	B-cell_line
transfectants	I-cell_line
from	O
the	O
murine	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
K46	I-cell_line
and	O
from	O
human	B-cell_line
Ramos	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Our	O
results	O
point	O
to	O
an	O
important	O
difference	O
between	O
antiandrogens	O
and	O
antagonists	O
of	O
other	O
steroid	B-protein
hormone	I-protein
receptors	I-protein
.	O

Hirsutism	O
,	O
graded	O
by	O
the	O
modified	O
Ferriman-Gallwey	O
score	O
,	O
and	O
hormonal	O
parameters	O
were	O
evaluated	O
basally	O
and	O
at	O
4-month	O
intervals	O
during	O
treatment	O
.	O

Among	O
these	O
properties	O
are	O
NF-kappa	B-protein
B	I-protein
's	O
rapid	O
posttranslational	O
activation	O
in	O
response	O
to	O
many	O
pathogenic	O
signals	O
,	O
its	O
direct	O
participation	O
in	O
cytoplasmic/nuclear	O
signaling	O
,	O
and	O
its	O
potency	O
to	O
activate	O
transcription	O
of	O
a	O
great	O
variety	O
of	O
genes	O
encoding	O
immunologically	B-protein
relevant	I-protein
proteins	I-protein
.	O

Macrophages	B-cell_type
and	O
granulocytes	B-cell_type
,	O
which	O
are	O
developed	O
from	O
a	O
common	O
progenitor	O
cell	O
,	O
are	O
the	O
cellular	O
components	O
of	O
the	O
specific	O
and	O
non-specific	O
immunoreaction	O
.	O

HTLV-I	O
is	O
the	O
etiologic	O
agent	O
of	O
adult	O
T-cell	O
leukemia/lymphoma	O
and	O
is	O
associated	O
with	O
tropical	O
spastic	O
paraparesis/HTLV-I-associated	O
myelopathy	O
.	O

Analysis	O
of	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
-driven	O
secreted	O
alkaline	B-protein
phosphatase	I-protein
activity	O
in	O
transient	O
assays	O
showed	O
that	O
,	O
unlike	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
the	O
SIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
possesses	O
an	O
enhancer	B-DNA
region	I-DNA
just	O
upstream	O
of	O
the	O
NF-kappaB	B-DNA
element	I-DNA
which	O
maintains	O
significant	O
levels	O
of	O
basal	O
transcription	O
in	O
the	O
absence	O
of	O
NF-kappaB	B-DNA
and	I-DNA
Sp1	I-DNA
sites	I-DNA
.	O

Our	O
findings	O
suggest	O
that	O
constitutive	O
expression	O
of	O
Bcl-x	B-protein
(	I-protein
L	I-protein
)	I-protein
induced	O
by	O
Tax	B-protein
through	O
the	O
NF-kappaB	B-protein
pathway	O
contributes	O
to	O
the	O
inhibition	O
of	O
apoptosis	O
in	O
CTLL-2	B-cell_line
cells	I-cell_line
after	O
IL-2	B-protein
deprivation	O
.	O

However	O
,	O
the	O
transcription	O
and	O
synthesis	O
of	O
interleukin	B-protein
2	I-protein
and	O
other	O
delayed	O
early	O
cytokines	B-protein
were	O
markedly	O
attenuated	O
by	O
BCL-2	B-protein
.	O

However	O
,	O
examination	O
of	O
proteasome	B-protein
activity	O
in	O
these	O
T	B-cell_type
cells	I-cell_type
using	O
fluorogenic	O
peptide	O
assays	O
revealed	O
a	O
significant	O
age-related	O
decline	O
in	O
chymotryptic	O
activity	O
.	O

The	O
results	O
suggest	O
that	O
M.	O
tuberculosis	O
can	O
upregulate	O
HIV-1	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
could	O
thus	O
have	O
the	O
potential	O
to	O
influence	O
the	O
pathogenesis	O
of	O
HIV-1	O
infection	O
.	O

Using	O
semiquantitative	O
RT-PCR	O
,	O
we	O
found	O
a	O
striking	O
increase	O
in	O
IL-6	B-RNA
mRNA	I-RNA
levels	O
only	O
in	O
resuscitated	O
HS	O
,	O
with	O
peak	O
levels	O
observed	O
1	O
h	O
after	O
initiation	O
of	O
resuscitation	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
p21	B-protein
(	I-protein
WAF1/CIP1	I-protein
)	I-protein
and	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	I-protein
transcripts	O
were	O
induced	O
after	O
6	O
hours	O
'	O
exposure	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
then	O
decreased	O
to	O
basal	O
levels	O
over	O
48	O
hours	O
.	O

We	O
provide	O
evidence	O
that	O
several	O
NF-kappaB	B-protein
complexes	I-protein
are	O
constitutively	O
found	O
in	O
the	O
nuclei	O
of	O
thymocytes	B-cell_type
either	O
freshly	O
isolated	O
from	O
the	O
thymus	O
or	O
maintained	O
in	O
coculture	O
with	O
autologous	O
or	O
heterologous	O
TEC	B-cell_type
.	O

Therefore	O
,	O
Tax	B-protein
appears	O
to	O
inhibit	O
the	O
interaction	O
of	O
Sp	B-protein
family	I-protein
members	I-protein
with	O
the	O
pp	B-DNA
repeat	I-DNA
.	O

Treatment	O
with	O
PMA	O
plus	O
ionomycin	O
(	O
P/I	O
)	O
results	O
in	O
the	O
upregulation	O
of	O
Fas	B-protein
Ligand	I-protein
(	O
FasL	B-protein
)	O
and	O
induction	O
of	O
apoptosis	O
.	O

We	O
studied	O
their	O
activity	O
after	O
transfection	O
into	O
K562	B-cell_line
cells	I-cell_line
,	O
an	O
erythroleukemia	B-cell_line
cell	I-cell_line
line	I-cell_line
with	O
an	O
embryonic-fetal	O
phenotype	O
.	O

Here	O
we	O
show	O
that	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
Tpl-2	B-protein
is	O
inhibited	O
by	O
mutant	B-protein
signaling	I-protein
molecules	I-protein
that	O
inhibit	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
or	O
the	O
calcineurin	B-protein
/NFAT	B-protein
pathways	O
and	O
is	O
promoted	O
by	O
combinations	O
of	O
signaling	B-protein
molecules	I-protein
that	O
activate	O
these	O
pathways	O
.	O

Pretreatment	O
(	O
or	O
up	O
to	O
15	O
minutes	O
posttreatment	O
)	O
relative	O
to	O
TNFalpha	B-protein
with	O
the	O
antioxidant	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
(	O
2	O
%	O
[	O
vol/vol	O
]	O
)	O
blocks	O
80	O
%	O
of	O
NF-kappaB	B-protein
-dependent	O
transcription	O
.	O

Molecular	O
characterization	O
and	O
pattern	O
of	O
tissue	O
expression	O
of	O
the	O
gene	O
for	O
neutrophil	B-protein
gelatinase-associated	I-protein
lipocalin	I-protein
from	O
humans	O
.	O

A	O
thiol	O
antioxidant	O
regulates	O
IgE	B-protein
isotype	I-protein
switching	O
by	O
inhibiting	O
activation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
.	O

However	O
,	O
the	O
role	O
of	O
CaM-K	B-protein
II	I-protein
remains	O
unknown	O
.	O

BCL-6	B-RNA
mRNA	I-RNA
levels	O
began	O
to	O
decrease	O
8	O
to	O
16	O
hours	O
after	O
stimulation	O
,	O
before	O
cells	O
entered	O
S	O
phase	O
.	O

BACKGROUND	O
:	O
Glucocorticoids	O
are	O
important	O
medications	O
used	O
to	O
control	O
the	O
airway	O
inflammation	O
associated	O
with	O
asthma	O
.	O

Separate	O
epitopes	B-protein
in	O
VP22	B-protein
were	O
defined	O
for	O
T-cell	B-cell_line
clones	I-cell_line
from	O
each	O
of	O
three	O
patients	O
.	O

These	O
results	O
establish	O
EKLF	B-protein
as	O
a	O
tissue-specific	B-protein
transcription	I-protein
factor	I-protein
that	O
undergoes	O
post-translational	O
acetylation	O
and	O
suggest	O
a	O
mechanism	O
by	O
which	O
EKLF	B-protein
is	O
able	O
to	O
alter	O
chromatin	B-DNA
structure	O
and	O
induce	O
beta-globin	B-protein
expression	O
within	O
the	O
beta-like	B-DNA
globin	I-DNA
cluster	I-DNA
.	O

Mildly	O
oxLDLs	B-protein
(	O
50	O
and	O
100	O
microgram/ml	O
)	O
decreased	O
the	O
number	O
of	O
lymphoblasts	B-cell_type
and	O
the	O
level	O
of	O
IL-2	O
concentration	O
in	O
the	O
culture	O
supernatants	O
after	O
activation	O
of	O
lymphocytes	B-cell_type
by	O
phytohaemagglutinin	B-protein
and	O
PMA+ionomycin	O
.	O

When	O
expressed	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
recombinant	O
NFAT1	B-protein
is	O
regulated	O
,	O
as	O
expected	O
,	O
by	O
the	O
calmodulin-dependent	B-protein
phosphatase	I-protein
calcineurin	B-protein
,	O
and	O
its	O
function	O
is	O
inhibited	O
by	O
the	O
immunosuppressive	O
agent	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

We	O
show	O
that	O
IL-6	B-protein
signaling	O
leads	O
to	O
marked	O
increases	O
in	O
the	O
synthesis	O
and	O
secretion	O
of	O
Ig	B-protein
in	O
clonal	B-cell_line
human	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
newly	O
isolated	B-cell_type
polyclonal	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
in	O
vitro	O
.	O

An	O
NF-kappa	B-protein
B	I-protein
binding	O
site	O
is	O
an	O
essential	O
component	O
of	O
the	O
element	O
but	O
alone	O
is	O
not	O
sufficient	O
to	O
account	O
for	O
the	O
activity	O
or	O
the	O
specificity	O
of	O
the	O
element	O
.	O

Twenty-seven	O
patients	O
with	O
tumors	O
of	O
the	O
oral	O
cavity	O
,	O
oropharynx	O
,	O
and	O
maxillary	O
sinus	O
were	O
examined	O
,	O
all	O
of	O
which	O
were	O
confirmed	O
as	O
squamous	O
cell	O
carcinomas	O
.	O

Moreover	O
,	O
the	O
mechanism	O
of	O
action	O
of	O
BHRF1	B-protein
resembled	O
that	O
of	O
Bcl-2	B-protein
and	O
Bcl-xL	B-protein
as	O
it	O
inhibited	O
TNF-	O
and	O
anti-Fas-induced	O
activation	O
of	O
two	O
enzymes	O
participating	O
in	O
the	O
apoptosis	O
pathway	O
,	O
cytosolic	B-protein
phospholipase	I-protein
A2	I-protein
and	O
caspase-3/CPP32	B-protein
,	O
but	O
did	O
not	O
interfere	O
with	O
the	O
activation	O
of	O
NF-kappaB-like	B-protein
transcription	I-protein
factors	I-protein
.	O

Synthetic	O
glucocorticoids	O
vary	O
in	O
their	O
binding	O
affinity	O
for	O
the	O
glucocorticoid	O
receptor	O
(	O
GCR	O
)	O
.	O

Lung	O
instillation	O
of	O
TNF-alpha	B-protein
in	O
alveolar	O
macrophage-depleted	O
rats	O
restored	O
the	O
NF-kappaB	B-protein
activation	O
response	O
in	O
whole	O
lung	O
.	O

While	O
the	O
binding	O
of	O
IL-2	B-protein
to	O
its	O
receptor	O
was	O
recently	O
shown	O
to	O
lead	O
to	O
the	O
activation	O
of	O
two	O
kinases	B-protein
,	O
Jak-1	B-protein
and	O
Jak-3	B-protein
,	O
subsequent	O
steps	O
in	O
the	O
signaling	O
pathway	O
to	O
the	O
nucleus	O
that	O
lead	O
to	O
the	O
activation	O
of	O
specific	O
genes	O
had	O
not	O
been	O
characterized	O
.	O

Here	O
,	O
we	O
characterize	O
the	O
putative	B-protein
human	I-protein
homolog	I-protein
of	O
NRL	B-protein
,	O
neutrophil	B-protein
gelatinase-associated	I-protein
lipocalin	I-protein
(	O
NGAL	B-protein
)	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
T	B-cell_type
lymphocytes	I-cell_type
of	O
a	O
child	O
with	O
severe	O
combined	O
immunodeficiency	O
are	O
defective	O
in	O
the	O
transcription	O
of	O
several	O
lymphokine	B-DNA
genes	I-DNA
that	O
include	O
IL2	B-DNA
,	O
IL3	B-DNA
,	O
IL4	B-DNA
,	O
and	O
IL5	B-DNA
,	O
which	O
encode	O
interleukins	B-protein
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
(	O
IL-2	B-protein
,	O
-3	B-protein
,	O
-4	B-protein
,	O
and	O
-5	B-protein
)	O
.	O

Three	O
binding	B-DNA
sites	I-DNA
for	O
the	O
Ets	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
are	O
found	O
in	O
this	O
region	O
:	O
two	O
adjacent	O
sites	O
at	O
positions	O
-50	B-DNA
and	I-DNA
-54	I-DNA
bp	I-DNA
and	O
a	O
more	O
5	B-DNA
'	I-DNA
site	I-DNA
at	O
position	O
-67	B-DNA
bp	I-DNA
.	O

While	O
this	O
expectation	O
may	O
be	O
realized	O
in	O
some	O
cases	O
,	O
we	O
have	O
not	O
found	O
evidence	O
for	O
it	O
.	O

Furthermore	O
,	O
the	O
potentiated	O
aggregation	O
was	O
shown	O
to	O
result	O
from	O
an	O
increased	O
capacity	O
of	O
platelets	O
to	O
bind	O
fibrinogen	O
.	O

The	O
activation	O
of	O
STAT	B-protein
nuclear	I-protein
factors	I-protein
was	O
studied	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
gamma	B-DNA
activation	I-DNA
site	I-DNA
(	O
GAS	B-DNA
)	O
probe	O
.	O

In	O
a	O
series	O
of	O
electrophoretic	O
mobility	O
shift	O
assays	O
with	O
protein	O
extracts	O
of	O
highly	B-cell_line
polarized	I-cell_line
Th2	I-cell_line
clones	I-cell_line
from	O
atopics	O
and	O
Th1	B-cell_line
clones	I-cell_line
from	O
controls	O
we	O
compared	O
DNA-binding	O
activities	O
at	O
the	O
two	O
NFAT-binding	B-DNA
elements	I-DNA
P0	B-DNA
and	O
P1	B-DNA
of	O
the	O
crucial	O
proximal	O
human	O
IL-4	B-DNA
promoter	I-DNA
.	O

METHODS	O
.	O

We	O
conclude	O
that	O
FMS	O
patients	O
have	O
a	O
mild	O
hypocortisolemia	O
,	O
increased	O
cortisol	O
feedback	O
resistance	O
in	O
combination	O
probably	O
with	O
a	O
reduced	O
CRH	O
synthesis	O
or	O
release	O
in	O
the	O
hypothalamus	O
.	O

DESIGN	O
:	O
Retrospective	O
study	O
based	O
on	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
to	O
detect	O
EBV	O
replicative	O
gene	O
products	O
in	O
tissue	O
samples	O
from	O
patients	O
affected	O
by	O
ARNHL	O
and	O
correlation	O
with	O
CD4+	B-protein
cell	O
counts	O
and	O
results	O
of	O
EBV	O
serology	O
(	O
including	O
anti-	O
ZEBRA	B-protein
activity	O
)	O
in	O
sera	O
from	O
the	O
same	O
patients	O
.	O

When	O
analyzed	O
by	O
DNase	B-protein
footprinting	O
,	O
region	B-DNA
II	I-DNA
was	O
protected	O
preferentially	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Priming	O
with	O
IFN-gamma	B-protein
followed	O
by	O
LPS	O
stimulation	O
resulted	O
in	O
a	O
further	O
increase	O
in	O
the	O
expression	O
of	O
p65	B-RNA
mRNA	I-RNA
.	O

Expression	O
of	O
EBNA2	B-protein
led	O
to	O
the	O
transcriptional	O
activation	O
of	O
both	O
endogenous	O
or	O
transfected	O
IFN-stimulated	B-DNA
genes	I-DNA
(	O
ISGs	B-DNA
)	O
,	O
genes	O
which	O
contain	O
within	O
their	O
promoters	B-DNA
either	O
the	O
interferon-stimulated	B-DNA
response	I-DNA
element	I-DNA
(	O
ISRE	B-DNA
)	O
or	O
the	O
gamma	B-DNA
interferon	I-DNA
activation	I-DNA
site	I-DNA
(	O
GAS	B-DNA
)	O
.	O

Costimulation	O
with	O
anti-CD28	B-protein
MoAb	I-protein
greatly	O
enhanced	O
the	O
proliferative	O
response	O
of	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
levels	O
equivalent	O
to	O
those	O
of	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
whereas	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
showed	O
only	O
slight	O
increases	O
.	O

U1	B-cell_line
lines	I-cell_line
overexpressing	O
C/EBP	B-protein
activator	I-protein
NF-IL-6	B-protein
produced	O
more	O
viral	B-RNA
mRNA	I-RNA
and	O
virus	O
particles	O
following	O
cellular	O
activation	O
than	O
control	B-cell_line
lines	I-cell_line
,	O
demonstrating	O
that	O
C/EBP	B-protein
proteins	I-protein
are	O
limiting	O
for	O
virus	O
transcription	O
.	O

Immunostained	B-cell_type
tumor	I-cell_type
cells	I-cell_type
were	O
more	O
frequently	O
distributed	O
in	O
the	O
area	O
where	O
tumor	O
cell	O
infiltration	O
was	O
more	O
invasive	O
.	O

In	O
contrast	O
,	O
it	O
is	O
also	O
becoming	O
clear	O
that	O
the	O
dysregulated	O
expression	O
of	O
proteins	O
that	O
are	O
not	O
genetically	O
altered	O
can	O
also	O
contribute	O
to	O
the	O
progression	O
of	O
lymphoid	O
malignancies	O
.	O

Abnormal	O
NFkappaB	B-protein
activation	O
after	O
stimulation	O
with	O
phorbol	O
myristate	O
acetate/ionomycin	O
and/or	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	I-protein
was	O
found	O
in	O
59	O
%	O
of	O
patients	O
(	O
17	O
of	O
28	O
)	O
and	O
was	O
not	O
accounted	O
for	O
by	O
the	O
advanced	O
age	O
of	O
the	O
study	O
cohort	O
.	O

G	O
(	O
Anh	O
)	O
MTetra	O
was	O
found	O
to	O
strongly	O
induce	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
beta	I-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
after	O
2	O
h	O
and	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-protein
protein	I-protein
secretion	O
after	O
48	O
h	O
of	O
activation	O
.	O

Activation	O
of	O
NF-kappaB	B-protein
is	O
thought	O
to	O
be	O
required	O
for	O
cytokine	O
release	O
from	O
LPS-responsive	B-cell_type
cells	I-cell_type
,	O
a	O
critical	O
step	O
for	O
endotoxic	O
effects	O
.	O

Furthermore	O
,	O
using	O
DNA	B-DNA
templates	I-DNA
containing	O
two	O
copies	O
of	O
the	O
PRDII	B-DNA
domain	I-DNA
linked	O
to	O
the	O
rabbit	B-DNA
beta	I-DNA
globin	I-DNA
gene	I-DNA
,	O
the	O
purified	O
polypeptides	O
specifically	O
stimulated	O
NF-kappa	B-protein
B	I-protein
dependent	O
transcription	O
in	O
an	O
in	O
vitro	O
reconstitution	O
assay	O
as	O
heterodimers	O
but	O
not	O
as	O
p50	B-protein
homodimers	I-protein
.	O

Sequence	O
analyses	O
of	O
pCD41	B-DNA
indicate	O
that	O
there	O
are	O
two	O
potential	O
open	B-DNA
reading	I-DNA
frames	I-DNA
(	O
ORFs	B-DNA
)	O
,	O
A	B-DNA
and	O
B	B-DNA
,	O
which	O
are	O
homologous	O
to	O
the	O
ORFs	B-DNA
found	O
in	O
the	O
genomic	O
clone	O
pGD41	B-DNA
.	O

To	O
study	O
this	O
element	O
and	O
its	O
role	O
in	O
class	B-DNA
II	I-DNA
gene	I-DNA
regulation	O
further	O
,	O
a	O
cDNA	B-DNA
library	I-DNA
was	O
screened	O
with	O
oligonucleotide	O
probes	O
containing	O
both	O
the	O
S	B-DNA
element	I-DNA
and	O
the	O
nearby	O
J	B-DNA
element	I-DNA
of	O
the	O
human	B-DNA
DPA	I-DNA
gene	I-DNA
.	O

Promoter	O
deletion	O
constructs	O
demonstrated	O
the	O
potential	O
role	O
of	O
distal	B-DNA
promoter	I-DNA
sequences	I-DNA
in	O
regulating	O
collagenase-1	B-protein
transcription	O
.	O

A	O
region	O
upstream	O
to	O
the	O
first	O
exon	O
,	O
and	O
highly	O
conserved	O
between	O
mouse	O
and	O
man	O
,	O
acts	O
as	O
an	O
erythroid	O
specific	O
enhancer	O
in	O
transient	O
assays	O
,	O
if	O
linked	O
to	O
the	O
GATA-1	B-protein
or	O
to	O
the	O
SV40	O
promoter	O
.	O

Further	O
,	O
we	O
show	O
that	O
inhibitory	O
NLS	B-protein
peptide	O
interacts	O
in	O
vitro	O
with	O
a	O
cytoplasmic	B-protein
NLS	I-protein
receptor	I-protein
complex	I-protein
comprised	O
of	O
the	O
Rch1/importin	B-protein
(	I-protein
karyopherin	I-protein
)	I-protein
-beta	I-protein
heterodimer	I-protein
expressed	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

After	O
exposure	O
to	O
137Cs	O
gamma	O
rays	O
at	O
a	O
dose	O
rate	O
of	O
1.17	O
Gy/min	O
,	O
a	O
maximum	O
in	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
seen	O
at	O
8	O
h	O
after	O
a	O
0.5-Gy	O
exposure	O
.	O

When	O
both	O
mutants	O
were	O
used	O
in	O
combination	O
,	O
gamma	B-protein
B*CaM-K	I-protein
inhibited	O
the	O
induction	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
delta	B-protein
CaM-AI	I-protein
.	O

The	O
interactions	O
of	O
Hsp60-specific	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
arterial	O
endothelial	B-cell_type
cells	I-cell_type
(	O
EC	B-cell_type
)	O
require	O
expression	O
of	O
both	O
Hsp60	B-protein
and	O
certain	O
adhesion	B-protein
molecules	I-protein
shown	O
to	O
be	O
induced	O
simultaneously	O
in	O
EC	B-cell_type
by	O
mechanical	O
and	O
other	O
types	O
of	O
stress	O
.	O

The	O
mature	O
mitochondrial	O
forms	O
of	O
the	O
erythroid	O
and	O
housekeeping	B-protein
ALAS	I-protein
isozymes	I-protein
are	O
predicted	O
to	O
have	O
molecular	O
weights	O
of	O
59.5	O
kd	O
and	O
64.6	O
kd	O
,	O
respectively	O
.	O

In	O
this	O
study	O
,	O
therefore	O
,	O
the	O
human	B-cell_line
monoblastic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
has	O
been	O
used	O
as	O
a	O
model	O
system	O
to	O
investigate	O
the	O
role	O
of	O
one	O
of	O
the	O
RXRs	B-protein
,	O
RXR-alpha	B-protein
,	O
in	O
monoblast	O
differentiation	O
.	O

Using	O
in	O
vivo	O
footprinting	O
we	O
identified	O
two	O
sites	O
in	O
the	O
promoter	O
at	O
-45	B-DNA
and	I-DNA
-160	I-DNA
that	O
were	O
occupied	O
only	O
in	O
CD20	B-protein
+	O
B	O
cells	O
.	O

There	O
is	O
a	O
single	O
methionine	B-DNA
codon-initiated	I-DNA
open	I-DNA
reading	I-DNA
frame	I-DNA
of	O
1	O
,	O
458	O
nt	O
in	O
frame	O
with	O
a	O
homeobox	B-DNA
and	O
a	O
CAX	B-DNA
repeat	I-DNA
,	O
and	O
the	O
open	B-DNA
reading	I-DNA
frame	I-DNA
is	O
predicted	O
to	O
encode	O
a	O
protein	O
of	O
51	O
,	O
659	O
daltons	O
.	O

Malignant	O
transformation	O
usually	O
inhibits	O
terminal	O
cell	O
differentiation	O
but	O
the	O
precise	O
mechanisms	O
involved	O
are	O
not	O
understood	O
.	O

The	O
clinical	O
course	O
and	O
the	O
laboratory	O
data	O
suggest	O
that	O
the	O
tachycardia	O
crises	O
are	O
the	O
consequence	O
of	O
a	O
hypersensitivity	O
of	O
the	O
heart	O
to	O
thyroid	O
hormones	O
,	O
associated	O
with	O
an	O
increased	O
number	O
of	O
T3	B-protein
nuclear	I-protein
receptor	I-protein
sites	O
in	O
lymphocytes	B-cell_type
.	O

The	O
addition	O
of	O
mifepristone	O
or	O
caspase-3	O
inhibitor	O
could	O
partially	O
abrogate	O
GC-induced	O
apoptosis	O
as	O
well	O
as	O
GC-induced	O
inhibition	O
of	O
IL-1beta	B-protein
.	O

The	O
first	O
was	O
to	O
abruptly	O
terminate	O
tumor	O
necrosis	O
factor-induced	O
NF-kappaB	B-protein
binding	O
to	O
the	O
enhancer	O
sequences	O
in	O
U1	O
monocytic	O
cells	O
,	O
using	O
a	O
short	O
pulse	O
of	O
exogenous	B-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
.	O

Neither	O
Kd	O
nor	O
Nmax	O
were	O
significantly	O
correlated	O
with	O
age	O
.	O

These	O
results	O
show	O
that	O
AM580	O
is	O
more	O
powerful	O
than	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
differentiation	O
antigens	O
only	O
in	O
cells	O
in	O
which	O
PML-RAR	B-protein
is	O
present	O
.	O

And	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
NDP	B-protein
kinase	I-protein
expression	O
between	O
SCC	O
with	O
metastasis	O
and	O
SCC	O
without	O
metastasis	O
.	O

These	O
results	O
identify	O
a	O
potential	O
role	O
for	O
IL-7	B-protein
signaling	O
pathways	O
in	O
transformation	O
by	O
v-Abl	B-protein
while	O
demonstrating	O
that	O
a	O
combination	O
of	O
IL-4	B-protein
and	O
IL-7	B-protein
signaling	O
can	O
not	O
substitute	O
for	O
an	O
active	O
v-Abl	B-protein
kinase	O
in	O
transformed	B-cell_type
pre-B	I-cell_type
cells	I-cell_type
.	O

MZF-1	B-DNA
expression	O
vectors	O
were	O
cotransfected	O
with	O
the	O
luciferase	B-DNA
reporter	I-DNA
plasmids	I-DNA
regulated	O
by	O
the	O
CD34	B-DNA
promoter	I-DNA
into	O
both	O
nonhematopoietic	B-cell_line
and	I-cell_line
hematopoietic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
mechanism	O
by	O
which	O
TGF-beta	B-protein
inhibits	O
Ig	O
chain	O
synthesis	O
is	O
unclear	O
although	O
it	O
does	O
not	O
involve	O
inhibition	O
of	O
the	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
or	O
Oct-2	B-protein
to	O
their	O
respective	O
target	O
sequences	O
.	O

Both	O
these	O
signals	O
were	O
necessary	O
for	O
expression	O
of	O
the	O
reporter	B-DNA
gene	I-DNA
.	O

This	O
sequence	B-DNA
motif	I-DNA
is	O
a	O
binding	O
site	O
for	O
nuclear	B-protein
proteins	I-protein
,	O
the	O
so-called	O
octamer	B-protein
transcription	I-protein
factors	I-protein
(	O
Oct	B-protein
or	O
OTF	B-protein
factors	I-protein
)	O
.	O

These	O
foci	O
,	O
which	O
were	O
preferentially	O
found	O
adjacent	O
to	O
nucleoli	O
or	O
at	O
the	O
nuclear	O
periphery	O
,	O
did	O
not	O
represent	O
sites	O
of	O
active	O
transcription	O
or	O
binding	O
of	O
GATA-1	B-protein
to	O
consensus	B-DNA
sites	I-DNA
in	O
the	O
beta-globin	B-DNA
loci	I-DNA
.	O

HS	B-DNA
I	I-DNA
directs	O
high-level	O
expression	O
of	O
reporter	O
GATA-1/lacZ	B-DNA
genes	I-DNA
to	O
primitive	B-cell_type
and	I-cell_type
definitive	I-cell_type
erythroid	I-cell_type
cells	I-cell_type
and	O
megakaryocytes	B-cell_type
in	O
transgenic	O
mice	O
.	O

Plasma	O
cortisol	O
concentration	O
and	O
blood	O
leukocyte	O
content	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GCR	B-protein
)	O
were	O
assayed	O
in	O
20	O
patients	O
with	O
deficiency	O
syndromes	O
,	O
10	O
cold	O
in	O
property	O
(	O
deficiency-cold	O
)	O
,	O
the	O
other	O
10	O
hot	O
in	O
property	O
(	O
deficiency-heat	O
)	O
,	O
and	O
also	O
in	O
10	O
healthy	O
individuals	O
as	O
normal	O
control	O
for	O
the	O
purpose	O
of	O
investigating	O
the	O
nature	O
of	O
cold	O
and	O
heat	O
syndromes	O
.	O

We	O
took	O
advantage	O
of	O
our	O
monoclonal	O
model	O
of	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cell	I-cell_type
differentiation	O
,	O
IgM+	B-cell_line
IgD+	I-cell_line
CL-01	I-cell_line
cells	I-cell_line
,	O
to	O
define	O
the	O
role	O
of	O
the	O
I	B-protein
gamma	I-protein
3	I-protein
evolutionarily	B-DNA
conserved	I-DNA
sequence	I-DNA
(	O
ECS	B-DNA
)	O
in	O
the	O
germline	B-DNA
transcriptional	O
activation	O
of	O
the	O
human	B-DNA
C	I-DNA
gamma	I-DNA
3	I-DNA
gene	I-DNA
.	O

The	O
sequence	O
shows	O
high	O
homology	O
with	O
the	O
murine	B-DNA
FOSB	I-DNA
gene	I-DNA
,	O
which	O
encodes	O
a	O
component	O
of	O
the	O
AP1	B-protein
transcriptional	I-protein
regulator	I-protein
.	O

Hypoxic	O
endothelia	O
showed	O
a	O
>	O
10-fold	O
increase	O
in	O
sensitivity	O
to	O
inhibitors	O
of	O
proteasome	B-protein
activation	O
,	O
and	O
combinations	O
of	O
hypoxia	O
and	O
LPS	O
enhanced	O
proteasome	B-protein
-dependent	O
cytoplasmic-to-nuclear	O
localization	O
of	O
the	O
nuclear	B-protein
transcription	I-protein
factor-kappa	I-protein
B	I-protein
p65	I-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
subunit	I-protein
.	O

Quantification	O
of	O
vitamin	B-RNA
D	I-RNA
receptor	I-RNA
mRNA	I-RNA
by	O
competitive	O
polymerase	O
chain	O
reaction	O
in	O
PBMC	B-cell_type
:	O
lack	O
of	O
correspondence	O
with	O
common	B-DNA
allelic	I-DNA
variants	I-DNA
.	O

An	O
early	O
biochemical	O
event	O
associated	O
with	O
T	O
cell	O
activation	O
through	O
the	O
interleukin-2	B-protein
receptor	I-protein
(	O
IL-2R	B-protein
)	O
is	O
tyrosine	O
phosphorylation	O
of	O
several	O
intracellular	O
substrates	O
.	O

Compared	O
with	O
its	O
wild-type	O
counterpart	O
,	O
this	O
mutated	O
provirus	O
showed	O
a	O
profoundly	O
decreased	O
,	O
Z-LLL-H-insensitive	O
transcriptional	O
and	O
replicative	O
activity	O
in	O
U937	B-cell_line
monocytes	I-cell_line
.	O

JunB	B-protein
-control	O
of	O
IL-4	B-protein
expression	O
is	O
mediated	O
by	O
the	O
phosphorylation	O
of	O
JunB	B-protein
at	O
Thr102	O
and-	O
104	O
by	O
JNK	B-protein
MAP	I-protein
kinase	I-protein
.	O

DNA-protein	O
crosslinking	O
studies	O
have	O
revealed	O
that	O
the	O
more	O
rapidly	O
migrating	O
B2	B-protein
complex	I-protein
contains	O
both	O
p50	B-protein
and	O
p55	B-protein
while	O
the	O
more	O
slowly	O
migrating	O
B1	B-protein
complex	I-protein
is	O
composed	O
of	O
p50	B-protein
,	O
p55	B-protein
,	O
p75	B-protein
,	O
and	O
p85	B-protein
.	O

EBNA2	B-protein
is	O
thus	O
required	O
not	O
only	O
for	O
initiation	O
but	O
also	O
for	O
maintenance	O
of	O
transformation	O
.	O

Taken	O
together	O
,	O
the	O
findings	O
of	O
the	O
present	O
study	O
are	O
consistent	O
with	O
a	O
role	O
for	O
NF-kappaB	B-protein
in	O
the	O
development	O
of	O
A/R	O
tolerance	O
(	O
with	O
respect	O
to	O
PMN	B-cell_type
adhesion	O
)	O
,	O
perhaps	O
by	O
transcriptional	O
regulation	O
of	O
GTP-cyclohydrolase	B-protein
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
determine	O
the	O
structure	O
and	O
organization	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
and	O
demonstrate	O
that	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
expression	O
can	O
be	O
regulated	O
by	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
via	O
induction	O
of	O
an	O
AP-2-like	B-protein
nuclear	I-protein
factor	I-protein
binding	O
to	O
upstream	B-DNA
promoter	I-DNA
elements	I-DNA
.	O

The	O
subjects	O
were	O
exposed	O
to	O
cold	O
air	O
(	O
4	O
degrees	O
C	O
)	O
twice/d	O
,	O
30	O
min/exposure	O
,	O
for	O
a	O
total	O
of	O
80	O
exposures	O
.	O

Using	O
ATL-16T	B-cell_line
cells	I-cell_line
which	O
express	O
IL-5	B-RNA
mRNA	I-RNA
,	O
we	O
have	O
identified	O
a	O
region	O
,	O
within	O
the	O
human	B-DNA
IL-5	I-DNA
gene	I-DNA
promoter	I-DNA
,	O
that	O
regulates	O
IL-5	B-DNA
gene	I-DNA
transcription	O
.	O

DRA	B-DNA
promoter	I-DNA
occupancy	O
in	O
other	O
class	B-cell_line
II-negative	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
derived	O
from	O
patients	O
with	O
bare	O
lymphocyte	O
syndrome	O
,	O
is	O
drastically	O
different	O
from	O
the	O
one	O
observed	O
in	O
RJ	B-cell_line
2.2.5	I-cell_line
and	O
Raji	B-cell_line
cells	I-cell_line
.	O

GR	B-protein
binding	O
capacity	O
was	O
higher	O
in	O
younger	O
subjects	O
than	O
in	O
older	O
ones	O
,	O
and	O
lower	O
in	O
the	O
group	O
of	O
athletes	O
than	O
in	O
the	O
younger	O
and	O
older	O
sedentary	O
subjects	O
.	O

We	O
distinguish	O
the	O
stimuli-specific	O
pathways	O
by	O
showing	O
that	O
the	O
oxidative	O
stimuli	O
trigger	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
only	O
one	O
of	O
two	O
human	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
(	O
Wurzburg	B-cell_line
but	O
not	O
Jurkat	B-cell_line
)	O
,	O
whereas	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
readily	O
stimulate	O
in	O
both	O
lines	O
.	O

A	O
Y341	O
--	O
>	O
F	B-protein
mutant	I-protein
of	O
Syk	B-protein
,	O
which	O
is	O
deficient	O
in	O
its	O
interaction	O
with	O
phospholipase	B-protein
Cy1	I-protein
and	O
Vav	B-protein
,	O
was	O
less	O
efficient	O
than	O
wild-type	B-protein
Syk	I-protein
.	O

Addition	O
of	O
r-hTBP-1	B-protein
to	O
U1	B-cell_line
cells	I-cell_line
during	O
the	O
last	O
4	O
h	O
of	O
a	O
24	O
h	O
incubation	O
with	O
PMA	O
still	O
inhibited	O
p24	B-protein
antigen	I-protein
production	O
by	O
15	O
%	O
.	O

Similarly	O
,	O
the	O
p105	B-protein
precursor	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
p50	B-protein
subunit	I-protein
is	O
also	O
post-translationally	O
processed	O
in	O
the	O
proteasome	B-protein
.	O

Now	O
we	O
have	O
examined	O
whether	O
naive	B-cell_type
and	I-cell_type
memory	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
differ	O
in	O
their	O
sensitivity	O
to	O
ROI-mediated	O
signals	O
.	O

Site-directed	O
mutagenesis	O
of	O
the	O
wild-type	B-DNA
IL-2R	I-DNA
alpha	I-DNA
kappa	I-DNA
B	I-DNA
enhancer	I-DNA
(	O
GGGGAATCTCCC	O
)	O
has	O
revealed	O
that	O
the	O
binding	O
of	O
p50	O
and	O
p55	B-protein
(	O
B2	B-protein
complex	I-protein
)	O
is	O
particularly	O
sensitive	O
to	O
alteration	O
of	O
the	O
5	B-DNA
'	I-DNA
triplet	I-DNA
of	O
deoxyguanosine	O
residues	O
.	O

The	O
results	O
showed	O
that	O
GCR	B-protein
was	O
significantly	O
lower	O
in	O
the	O
aged	O
persons	O
or	O
rats	O
than	O
that	O
in	O
the	O
young	O
while	O
the	O
plasma	O
cortisol	O
level	O
did	O
n't	O
change	O
with	O
aging	O
.	O

Stably	O
transfected	O
Jurkat	O
cells	O
behaved	O
similarly	O
to	O
the	O
transiently	O
transfected	O
ones	O
with	O
respect	O
to	O
inhibition	O
by	O
CIF	B-protein
and	O
cyclosporine	O
.	O

Exposure	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
to	O
VD3	O
also	O
inhibited	O
proliferation	O
and	O
DNA	O
synthesis	O
with	O
a	O
50	O
%	O
effective	O
dose	O
of	O
3.5-10	O
nM	O
within	O
72	O
h	O
;	O
in	O
addition	O
,	O
protein	O
and	O
RNA	O
synthesis	O
were	O
inhibited	O
by	O
VD3	O
treatment	O
.	O

IL-4	B-protein
also	O
induced	O
Stat6	B-protein
DNA	O
binding	O
activity	O
from	O
lysates	O
of	O
1D4	B-cell_line
but	O
not	O
E1C3	B-cell_line
cells	I-cell_line
utilizing	O
a	O
radiolabeled	B-DNA
immunoglobulin	I-DNA
heavy	I-DNA
chain	I-DNA
germline	I-DNA
epsilon	I-DNA
promotor	I-DNA
sequence	I-DNA
(	O
Iepsilon	B-DNA
)	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Acute	O
megakaryoblastic	O
leukemia	O
(	O
AML-M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	B-cell_type
blast	I-cell_type
cells	I-cell_type
which	O
express	O
megakaryocytic	B-protein
markers	I-protein
.	O

Transcription	B-protein
factor	I-protein
IID	I-protein
(	O
TFIID	B-protein
)	O
binds	O
to	O
the	O
TATA	B-DNA
box	I-DNA
promoter	I-DNA
element	I-DNA
and	O
regulates	O
the	O
expression	O
of	O
most	O
eukaryotic	B-DNA
genes	I-DNA
transcribed	O
by	O
RNA	B-protein
polymerase	I-protein
II	I-protein
.	O

The	O
expression	O
of	O
the	O
gene	O
encoding	O
the	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
is	O
induced	O
upon	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
phytohemagglutinin	B-protein
and	O
active	O
phorbolester	O
and	O
upon	O
expression	O
of	O
tax1	B-protein
,	O
a	O
transactivating	B-protein
protein	I-protein
of	O
the	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
.	O

The	O
function	O
of	O
a	O
putative	B-DNA
NFAT-1	I-DNA
site	I-DNA
in	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
enhancer	I-DNA
has	O
been	O
analyzed	O
.	O

A	O
proportion	O
of	O
HIV-infected	O
individuals	O
experience	O
episodes	O
of	O
localized	O
or	O
systemic	O
bacterial	O
infections	O
caused	O
by	O
Gram-negative	O
bacteria	O
.	O

Our	O
studies	O
suggest	O
that	O
this	O
form	O
of	O
acute	O
leukemia	O
may	O
arise	O
from	O
transformation	O
of	O
a	O
precursor	O
cell	O
common	O
to	O
both	O
the	O
myeloid	B-cell_type
and	I-cell_type
NK	I-cell_type
cell	I-cell_type
lineages	I-cell_type
;	O
thus	O
we	O
propose	O
the	O
designation	O
myeloid/NK	O
acute	O
leukemia	O
.	O

The	O
mean	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
both	O
sexes	O
(	O
1.35	O
+/-	O
0.70	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
males	O
,	O
1.13	O
+/-	O
0.66	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
females	O
)	O
,	O
but	O
the	O
concentration	O
of	O
binding	O
sites	O
(	O
Nmax	O
)	O
was	O
significantly	O
lower	O
in	O
females	O
(	O
2.32	O
+/-	O
0.92	O
fmol/10	O
(	O
7	O
)	O
PBMC	B-cell_type
vs	O
4.43	O
+/-	O
1.38	O
fmol/10	O
(	O
7	O
)	O
PBMC	B-cell_type
in	O
males	O
;	O
p	O
=	O
0.0001	O
)	O
.	O

The	O
immunosuppressant	O
drug	O
cyclosporin	O
A	O
blocks	O
a	O
calcium-dependent	O
signal	O
from	O
the	O
T-cell	B-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
that	O
normally	O
leads	O
to	O
T-cell	O
activation	O
.	O

Progesterone	O
had	O
little	O
or	O
no	O
effect	O
on	O
a	O
cloned	B-protein
voltage-gated	I-protein
Na+	I-protein
channel	I-protein
,	O
an	O
inward	O
rectifier	O
K+	B-protein
channel	I-protein
,	O
or	O
on	O
lymphocyte	B-protein
Ca2+	I-protein
and	I-protein
Cl-	I-protein
channels	I-protein
.	O

Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
EBNA2	B-protein
)	O
,	O
a	O
protein	O
involved	O
in	O
cell	O
transformation	O
,	O
interferes	O
with	O
the	O
cellular	O
response	O
to	O
type	B-protein
I	I-protein
interferons	I-protein
(	O
IFN-alpha/beta	B-protein
)	O
.	O

Characterization	O
and	O
purification	O
of	O
a	O
protein	B-protein
kinase	I-protein
C	I-protein
substrate	I-protein
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Prostaglandin	O
E2	O
Up-regulates	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
-driven	O
gene	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
via	O
NF-kappaB-dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O

The	O
stimulatory	O
effect	O
of	O
gp160	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
is	O
protein	O
synthesis	O
independent	O
,	O
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
,	O
and	O
abrogated	O
by	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

Activation	O
of	O
T	B-cell_type
cells	I-cell_type
is	O
initiated	O
by	O
the	O
recognition	O
of	O
antigen	O
on	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
to	O
exert	O
the	O
effector	O
functions	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Values	O
were	O
compared	O
with	O
those	O
of	O
patients	O
with	O
benign	O
tumors	O
(	O
n	O
=	O
4	O
)	O
,	O
or	O
undergoing	O
a	O
mammary	O
reduction	O
(	O
n	O
=	O
7	O
)	O
.	O

Analyses	O
of	O
nuclear	O
translocation	O
of	O
individual	O
members	O
of	O
Rel	B-protein
proteins	I-protein
after	O
CD40	B-protein
induction	O
of	O
primary	B-cell_type
B	I-cell_type
cells	I-cell_type
showed	O
a	O
strong	O
and	O
long-lasting	O
accumulation	O
of	O
RelB	B-protein
and	O
,	O
less	O
pronounced	O
,	O
of	O
c-Rel	B-protein
.	O

Gel	O
shift	O
analyses	O
demonstrate	O
that	O
NF-kappa	B-protein
B	I-protein
nuclear	O
translocation	O
is	O
stimulated	O
primarily	O
by	O
IL-1	B-protein
rather	O
than	O
by	O
antigen	B-protein
receptor	I-protein
signals	O
.	O

Furthermore	O
,	O
nuclear	O
extracts	O
from	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
display	O
high	O
levels	O
of	O
a	O
novel	O
specific	O
binding	O
activity	O
at	O
the	O
NF-AT	B-DNA
site	I-DNA
,	O
which	O
is	O
present	O
at	O
much	O
lower	O
levels	O
in	O
freshly	O
isolated	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Binding	O
of	O
RBP	O
to	O
this	O
site	O
could	O
be	O
inhibited	O
by	O
addition	O
of	O
EBV	B-protein
nuclear	I-protein
proteins	I-protein
3	I-protein
and	I-protein
6	I-protein
,	O
suggesting	O
that	O
these	O
proteins	O
displace	O
RBP	B-protein
from	O
its	O
recognition	B-DNA
sequence	I-DNA
,	O
removing	O
transcriptional	O
repression	O
and	O
allowing	O
gene	O
transcription	O
to	O
occur	O
.	O

The	O
severe	O
phenotype	O
of	O
females	O
with	O
tiny	B-DNA
ring	I-DNA
X	I-DNA
chromosomes	I-DNA
is	O
associated	O
with	O
inability	O
of	O
these	O
chromosomes	B-DNA
to	O
undergo	O
X	O
inactivation	O
.	O

The	O
combination	O
of	O
the	O
immune	B-protein
costimulatory	I-protein
molecule	I-protein
B7.1	B-protein
and	O
IL-12	B-protein
has	O
been	O
shown	O
to	O
be	O
synergistic	O
for	O
T	O
cell	O
activation	O
.	O

Elf-1	B-protein
contains	O
a	O
DNA	B-protein
binding	I-protein
domain	I-protein
that	O
is	O
nearly	O
identical	O
to	O
that	O
of	O
E74	B-protein
,	O
the	O
ecdysone-inducible	B-protein
Drosophila	I-protein
transcription	I-protein
factor	I-protein
required	O
for	O
metamorphosis	O
(	O
hence	O
the	O
name	O
Elf-1	B-protein
,	O
for	O
E74-like	B-protein
factor	I-protein
1	I-protein
)	O
.	O

p38	B-protein
and	O
p63	B-protein
may	O
provide	O
a	O
docking	O
site	O
for	O
Grb2	B-protein
,	O
thereby	O
linking	O
Grb2	B-protein
SH3-binding	I-protein
proteins	I-protein
SOS1	B-protein
,	O
SLP-76	B-protein
,	O
and	O
p120	B-protein
to	O
downstream	O
signalling	O
events	O
.	O

In	O
contrast	O
,	O
neither	O
the	O
RA-stimulated	O
,	O
RARE	B-DNA
-mediated	O
transcription	O
nor	O
the	O
induced	O
RAR-beta	B-protein
expression	O
was	O
suppressed	O
by	O
VitD3	O
,	O
suggesting	O
that	O
VitD3	O
selectively	O
inhibited	O
the	O
retinoid-induced	O
differentiation	O
program	O
but	O
not	O
the	O
RARE	B-DNA
-mediated	O
signal	O
.	O

Access	O
to	O
this	O
site	O
is	O
blocked	O
in	O
the	O
normal	B-DNA
silent	I-DNA
c-myc	I-DNA
allele	I-DNA
;	O
these	O
data	O
suggest	O
that	O
the	O
Nm23H2	B-protein
protein	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
translocated	O
c-myc	B-DNA
allele	I-DNA
in	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
.	O

All	O
cases	O
of	O
follicular	O
,	O
mixed	O
small	O
and	O
large	O
cell	O
lymphomas	O
showed	O
LAZ3/BCL6	B-protein
expression	O
confined	O
to	O
the	O
neoplastic	O
follicles	O
.	O

An	O
AP-1	O
site	O
at	O
-146	O
to	O
-140	O
was	O
shown	O
to	O
be	O
involved	O
in	O
the	O
expression	O
of	O
the	O
IL-9	B-DNA
gene	I-DNA
.	O

This	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-induced	O
G1	O
arrest	O
is	O
enhanced	O
by	O
all-trans	O
RA	O
.	O

After	O
its	O
associated	O
proteins	O
,	O
especially	O
the	O
heat-shock	B-protein
protein	I-protein
hsp90	I-protein
,	O
had	O
been	O
cross-linked	O
with	O
the	O
hMR	B-protein
by	O
dimethylpimelimidate	O
,	O
18C7	B-protein
was	O
still	O
able	O
to	O
react	O
with	O
the	O
receptor	O
.	O

The	O
data	O
presented	O
below	O
indicate	O
that	O
Notch-1	B-protein
expression	O
provides	O
significant	O
protection	O
to	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
from	O
TCR	B-protein
-mediated	O
apoptosis	O
.	O

Methylation	O
studies	O
indicated	O
that	O
the	O
tal-15	B-DNA
'	I-DNA
GC-rich	I-DNA
region	I-DNA
behaves	O
like	O
a	O
CpG	B-DNA
island	I-DNA
,	O
hypomethylated	O
in	O
normal	B-cell_type
cells	I-cell_type
,	O
and	O
methylated	O
de	O
novo	O
on	O
transcriptionally	B-DNA
inactive	I-DNA
alleles	I-DNA
in	O
established	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Numerous	O
cellular	O
and	O
biochemical	O
abnormalities	O
in	O
immune	O
regulation	O
have	O
been	O
described	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
including	O
surface	O
Ag	B-protein
receptor	I-protein
-initiated	O
signaling	O
events	O
and	O
lymphokine	B-protein
production	O
.	O

Productive	O
infection	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
typically	O
requires	O
that	O
the	O
T	B-cell_type
cells	I-cell_type
be	O
stimulated	O
with	O
antigens	O
or	O
mitogens	O
.	O

CD27	B-protein
/CD70	O
interaction	O
enhanced	O
B	B-cell_type
cell	I-cell_type
proliferation	O
in	O
the	O
presence	O
of	O
IL-4	B-protein
or	O
IL-4	B-protein
plus	O
anti-CD40	B-protein
.	O

These	O
results	O
indicate	O
that	O
,	O
although	O
purified	O
peptide/glycoprotein	B-protein
96	I-protein
complexes	I-protein
are	O
potent	O
immunogens	O
,	O
the	O
mechanism	O
of	O
CTL	O
cross-priming	O
in	O
vivo	O
does	O
not	O
depend	O
upon	O
antigenic	O
peptides	O
in	O
the	O
ER	O
of	O
immunizing	B-cell_type
cells	I-cell_type
.	O

Additionally	O
,	O
virus	O
reactivation	O
in	O
resting	B-cell_type
PBMCs	I-cell_type
infected	O
in	O
vitro	O
with	O
HIV-1	O
was	O
found	O
to	O
be	O
specifically	O
induced	O
by	O
ligands	O
of	O
the	O
CDR2-loop	B-protein
in	O
domain	B-protein
1	I-protein
(	O
D1	B-protein
)	O
of	O
CD4	B-protein
(	O
virus	B-protein
envelope	I-protein
and	I-protein
anti-CD4	I-protein
monoclonal	I-protein
antibodies	I-protein
)	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
took	O
advantage	O
of	O
a	O
panel	O
of	O
CD8+	B-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
from	O
the	O
joint	O
of	O
a	O
rheumatoid	O
arthritis	O
patient	O
and	O
selected	O
for	O
their	O
reactivity	O
against	O
a	O
single	B-protein
MHC/peptide	I-protein
complex	I-protein
.	O

Irrespective	O
of	O
the	O
etiology	O
,	O
many	O
kidney	O
diseases	O
result	O
in	O
inflammation	O
and	O
fibrosis	O
of	O
the	O
tubulointerstitium	O
,	O
with	O
the	O
subsequent	O
loss	O
of	O
renal	O
function	O
.	O

This	O
suggests	O
that	O
mutated	B-protein
Ras	I-protein
activates	O
mechanisms	O
,	O
which	O
favor	O
tumor	O
growth	O
,	O
enhance	O
the	O
metastatic	O
capacity	O
of	O
tumors	O
or	O
modulate	O
tumor-specific	O
immune	O
responses	O
.	O

Activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
requires	O
the	O
combined	O
signaling	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
and	O
costimulatory	B-protein
molecules	I-protein
such	O
as	O
CD28	B-protein
.	O

EBV-encoded	B-protein
nuclear	I-protein
antigen	I-protein
(	I-protein
EBNA	I-protein
)	I-protein
-1	I-protein
is	O
expressed	O
,	O
whereas	O
the	O
immunogenic	O
and	O
proliferative	O
EBNAs	B-protein
are	O
not	O
.	O

Int-2	B-DNA
was	O
amplified	O
in	O
13.1	O
%	O
and	O
c-myc	B-DNA
was	O
amplified	O
in	O
10.3	O
%	O
.	O

Four	O
P-like	B-DNA
elements	I-DNA
are	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
mouse	B-DNA
IL-4	I-DNA
gene	I-DNA
:	O
involvement	O
of	O
a	O
distinct	O
set	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
and	O
activator	B-protein
protein-1	I-protein
family	I-protein
proteins	I-protein
.	O

In	O
all	O
three	O
cases	O
,	O
we	O
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
stability	O
.	O

4.	O
Fluorescence	O
HPLC	O
showed	O
that	O
SMX-NHOH	O
and	O
SMX-NO	O
depleted	O
CYS	O
and	O
GSH	O
in	O
buffer	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
in	O
cells	O
and	O
plasma	O
.	O

Both	O
methods	O
demonstrated	O
that	O
the	O
tal-1	B-protein
gene	O
is	O
expressed	O
in	O
megakaryocytes	O
and	O
erythroblasts	O
as	O
well	O
as	O
in	O
basophilic	B-cell_type
granulocytes	I-cell_type
.	O

Erythroid	B-protein
Kruppel-like	I-protein
factor	I-protein
(	O
EKLF	B-protein
)	O
,	O
which	O
binds	O
to	O
the	O
CACCC	O
box	O
in	O
the	O
beta-globin	B-DNA
promoter	I-DNA
,	O
is	O
required	O
for	O
the	O
expression	O
of	O
the	O
beta-globin	B-DNA
gene	I-DNA
in	O
adult	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O

Inhibition	O
of	O
endogenous	B-protein
C/EBP	I-protein
proteins	I-protein
,	O
using	O
either	O
an	O
excess	O
of	O
C/EBP	B-DNA
binding	I-DNA
sites	I-DNA
or	O
a	O
trans-	B-DNA
dominant	I-DNA
negative	I-DNA
inhibitor	I-DNA
,	O
demonstrated	O
that	O
C/EBP	B-protein
proteins	I-protein
are	O
required	O
for	O
basal	O
and	O
activated	O
levels	O
of	O
HIV-1	B-DNA
LTR	I-DNA
transcription	O
in	O
the	O
promonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
.	O

This	O
was	O
not	O
observed	O
when	O
the	O
NFAT-1	B-DNA
mutant	I-DNA
LTR	I-DNA
was	O
activated	O
by	O
mitogen	B-protein
.	O

Galectin-3	B-protein
is	O
widely	O
distributed	O
in	O
various	O
tissues	O
and	O
cell	O
types	O
and	O
is	O
expressed	O
in	O
many	O
leukocytes	B-cell_type
,	O
with	O
the	O
notable	O
exception	O
of	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Activation	O
of	O
the	O
signal	O
transducer	O
and	O
transcription	O
(	O
STAT	B-protein
)	O
signaling	O
pathway	O
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O

This	O
result	O
suggests	O
that	O
the	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
,	O
CREB	B-protein
,	O
is	O
involved	O
in	O
the	O
protein-TRE-DNA	B-protein
complex	I-protein
and	O
in	O
mediating	O
the	O
Tax	B-protein
response	O
.	O

Transcriptional	O
activation	O
of	O
the	O
macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
by	O
IL-2	B-protein
is	O
associated	O
with	O
secretion	O
of	O
bioactive	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
protein	I-protein
by	O
monocytes	B-cell_type
and	O
involves	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
.	O

Higher	O
concentrations	O
of	O
A	O
beta	O
(	O
25-35	O
)	O
were	O
effective	O
by	O
themselves	O
in	O
inducing	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
both	O
in	O
the	O
N9	B-cell_line
microglial	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
in	O
rat	B-cell_line
primary	I-cell_line
microglia	I-cell_line
,	O
as	O
well	O
as	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Thus	O
,	O
overall	O
,	O
our	O
results	O
demonstrate	O
that	O
a	O
PTPase	B-protein
is	O
involved	O
either	O
directly	O
or	O
indirectly	O
in	O
the	O
pathway	O
leading	O
to	O
the	O
induction	O
of	O
endothelial	B-protein
cell	I-protein
adhesion	I-protein
molecules	I-protein
by	O
TNF	B-protein
.	O

To	O
approach	O
this	O
,	O
we	O
generated	O
a	O
luciferase	B-DNA
reporter	I-DNA
construct	I-DNA
containing	O
elements	O
of	O
the	O
CD95	B-protein
ligand	I-protein
promoter	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
C/EBP	B-protein
alpha	I-protein
can	O
also	O
active	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
in	O
nonmyeloid	B-cell_type
cells	I-cell_type
.	O

Part	O
of	O
this	O
process	O
involves	O
the	O
prevention	O
of	O
the	O
development	O
of	O
Th1	B-cell_type
cells	I-cell_type
,	O
which	O
are	O
a	O
primary	O
source	O
of	O
interferon	B-protein
gamma	I-protein
(	O
IFNgamma	B-protein
)	O
,	O
a	O
potent	O
activator	O
of	O
monocytes	B-cell_type
and	O
an	O
inhibitor	O
of	O
Th2	O
proliferation	O
.	O

In	O
addition	O
to	O
increasing	O
our	O
understanding	O
of	O
the	O
molecular	O
pathways	O
that	O
regulate	O
T	O
cell	O
development	O
and	O
function	O
,	O
these	O
results	O
have	O
suggested	O
novel	O
targets	O
for	O
genetic	O
and	O
pharmacological	O
manipulation	O
of	O
T	O
cell	O
immunity	O
.	O

Homozygotes	O
for	O
a	O
polymorphism	O
at	O
codon	B-DNA
352	I-DNA
(	O
genotype	O
tt	O
)	O
were	O
significantly	O
underrepresented	O
among	O
those	O
with	O
tuberculosis	O
(	O
chi2=6.22	O
,	O
1	O
df	O
,	O
P=.01	O
)	O
and	O
persistent	O
hepatitis	O
B	O
infection	O
(	O
chi2=6.25	O
,	O
1	O
df	O
,	O
P=.01	O
)	O
but	O
not	O
in	O
subjects	O
with	O
clinical	O
malaria	O
compared	O
with	O
the	O
other	O
genotypes	O
.	O

Down-regulation	O
of	O
immunogenic	B-protein
proteins	I-protein
(	O
EBNA2-EBNA6	B-protein
)	O
in	O
nasal	O
lymphoma	O
may	O
enable	O
tumour	B-cell_type
cells	I-cell_type
to	O
evade	O
host	O
cytotoxic	O
T-cell	O
surveillance	O
.	O

The	O
gene	O
has	O
41	B-DNA
small	I-DNA
exons	I-DNA
spanning	O
45	B-DNA
kb	I-DNA
of	O
genomic	B-DNA
DNA	I-DNA
and	O
encoding	O
a	O
5.5	B-RNA
kb	I-RNA
mRNA	I-RNA
.	O

E3	B-protein
transcripts	I-protein
were	O
RA-inducible	O
in	O
HL60	B-cell_line
cells	I-cell_line
,	O
but	O
not	O
in	O
an	O
RA-resistant	B-cell_line
subclone	I-cell_line
,	O
HL60R	B-cell_line
,	O
that	O
harbors	O
a	O
mutated	O
RAR	B-DNA
alpha	I-DNA
gene	I-DNA
.	O

To	O
explore	O
the	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
,	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
,	O
and	O
Hsp60	B-protein
in	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
HUVECs	B-cell_type
)	O
,	O
Northern	O
blot	O
analyses	O
were	O
used	O
.	O

Enhancing	O
effect	O
of	O
17	O
beta-estradiol	O
on	O
human	O
NK	O
cell	O
activity	O
.	O

In	O
2	O
complex	O
translocations	O
,	O
none	O
of	O
the	O
three	O
genes	O
was	O
rearranged	O
.	O

It	O
appears	O
that	O
a	O
basal	O
redox	O
equilibrium	O
tending	O
toward	O
oxidation	O
is	O
a	O
prerequisite	O
for	O
full	O
activation	O
of	O
transduction	O
pathways	O
regulating	O
the	O
activity	O
of	O
NF-kappa	B-DNA
B-dependent	I-DNA
genes	I-DNA
.	O

gamma	B-protein
B*CaM-K	I-protein
also	O
downregulated	O
the	O
activation	O
of	O
AP-1	B-protein
in	O
response	O
to	O
transfection	O
with	O
a	O
constitutively	O
active	O
mutant	O
of	O
PKC	B-protein
or	O
stimulation	O
with	O
PMA	O
.	O

Similar	O
inhibition	O
of	O
NFAT	B-protein
-1-mediated	O
gene	O
expression	O
was	O
observed	O
in	O
a	O
second	O
cell	B-cell_line
line	I-cell_line
,	O
which	O
is	O
stably	O
transfected	O
with	O
NFAT-1	B-DNA
regulatory	I-DNA
elements	I-DNA
linked	O
to	O
the	O
reporter	B-DNA
gene	I-DNA
for	I-DNA
sCD8	I-DNA
.	O

We	O
found	O
that	O
resistance	O
to	O
defensin	O
requires	O
the	O
function	O
of	O
both	O
components	O
of	O
this	O
regulatory	O
system	O
,	O
because	O
strains	O
expressing	O
PhoQ	B-protein
without	O
PhoP	B-protein
were	O
still	O
markedly	O
sensitive	O
to	O
defensins	B-protein
.	O

In	O
view	O
of	O
the	O
increasing	O
use	O
of	O
antiestrogens	O
in	O
cancer	O
therapy	O
and	O
prevention	O
,	O
there	O
is	O
obvious	O
merit	O
in	O
long-term	O
in	O
vivo	O
studies	O
to	O
be	O
conducted	O
.	O

However	O
,	O
only	O
64.1	B-protein
induced	O
NF-AT	B-protein
in	O
the	O
nucleus	O
,	O
correlating	O
with	O
its	O
ability	O
to	O
activate	O
T	B-cell_type
cells	I-cell_type
.	O

Pb-induced	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
is	O
blocked	O
by	O
antibodies	B-protein
for	O
p65	B-protein
and	O
p50	B-protein
subunits	O
but	O
not	O
cRel	B-protein
,	O
indicating	O
that	O
the	O
p65	B-protein
:	I-protein
p50	I-protein
heterodimer	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
involved	O
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
induces	O
immediate	O
effects	O
in	O
monocytes	O
by	O
activation	O
of	O
the	O
Janus	B-protein
kinase	I-protein
(	O
JAK2	B-protein
)	O
and	O
STAT	B-protein
transcription	I-protein
factor	I-protein
(	O
STAT5	B-protein
)	O
pathway	O
.	O

Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds-oligonucleotides	O
that	O
contained	O
nuclear	B-protein
factor-kappaB	I-protein
or	O
activator	B-protein
protein-1	I-protein
cognate	O
DNA	O
sequences	O
significantly	O
attenuated	O
the	O
phase	O
2	O
response	O
,	O
which	O
implicated	O
a	O
role	O
for	O
de	O
novo	O
protein	O
synthesis	O
.	O

Inhibition	O
of	O
NF-kappaB	B-protein
activity	O
inhibits	O
the	O
P/I	O
mediated	O
induction	O
of	O
FasL	B-RNA
mRNA	I-RNA
and	O
decreases	O
the	O
level	O
of	O
apoptosis	O
in	O
these	O
cultures	O
,	O
thus	O
establishing	O
NF-kappaB	B-protein
as	O
a	O
proapoptotic	B-protein
factor	I-protein
in	O
this	O
context	O
.	O

A	O
lymphoid	B-protein
cell-specific	I-protein
nuclear	I-protein
factor	I-protein
containing	O
c-Rel-like	B-protein
proteins	I-protein
preferentially	O
interacts	O
with	O
interleukin-6	B-DNA
kappa	I-DNA
B-related	I-DNA
motifs	I-DNA
whose	O
activities	O
are	O
repressed	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

The	O
regulatory	O
effect	O
of	O
insulin	B-protein
on	O
the	O
specific	O
binding	O
power	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
of	O
human	B-cell_type
leukocytes	I-cell_type
was	O
assessed	O
by	O
the	O
unoccupied	B-protein
receptor	I-protein
sites	I-protein
capable	O
of	O
combining	O
with	O
[	O
3H	O
]	O
labelled	O
dexamethasone	O
measured	O
at	O
3	O
and	O
24	O
h	O
after	O
incubation	O
with	O
various	O
concentrations	O
of	O
insulin	B-protein
added	O
to	O
the	O
medium	O
.	O

Moreover	O
,	O
platelet-activating	B-protein
factor	I-protein
was	O
capable	O
of	O
inducing	O
transcription	O
of	O
the	O
nuclear	B-DNA
proto-oncogenes	I-DNA
c-fos	B-DNA
and	O
c-jun	B-DNA
.	O

Human	B-protein
T	I-protein
cell	I-protein
transcription	I-protein
factor	I-protein
GATA-3	B-protein
stimulates	O
HIV-1	O
expression	O
.	O

These	O
results	O
suggests	O
that	O
both	O
proximal	O
steps	O
in	O
CD8+	O
T-cell	O
activation	O
as	O
well	O
as	O
the	O
later	O
phases	O
are	O
unresponsive	O
to	O
A6H	B-protein
ligation	O
.	O

Cell	O
type-	O
and	O
stage-specific	O
expression	O
of	O
the	O
CD20/B1	B-protein
antigen	I-protein
correlates	O
with	O
the	O
activity	O
of	O
a	O
diverged	O
octamer	O
DNA	O
motif	O
present	O
in	O
its	O
promoter	B-DNA
.	O

In	O
addition	O
,	O
this	O
proliferative	O
parameter	O
maintained	O
its	O
prognostic	O
significance	O
when	O
the	O
patients	O
were	O
stratified	O
according	O
to	O
lymph	O
node	O
involvement	O
,	O
menopausal	O
status	O
,	O
and	O
nuclear	B-protein
estrogen	I-protein
receptor	I-protein
content	O
.	O

The	O
level	O
of	O
constitutive	O
NF-kappa	B-protein
B	I-protein
in	O
these	O
cells	O
is	O
variable	O
and	O
is	O
frequently	O
found	O
to	O
be	O
lower	O
in	O
the	O
more	O
mature	B-cell_type
macrophages	I-cell_type
.	O

In	O
fact	O
,	O
the	O
offspring	O
of	O
alcoholics	O
have	O
higher	O
levels	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
in	O
certain	O
tissues	O
compared	O
with	O
the	O
offspring	O
of	O
nonalcoholics	O
.	O

Plasma	B-protein
renin	I-protein
activity	O
and	O
aldosterone	O
were	O
not	O
correlated	O
with	O
the	O
electrolyte	O
response	O
and	O
were	O
within	O
the	O
normal	O
limits	O
.	O

Cyclosporin	O
A	O
impaired	O
not	O
only	O
early	O
and	O
late	O
,	O
but	O
also	O
immediate	O
events	O
;	O
however	O
,	O
addition	O
of	O
TNF-alpha	B-protein
prevented	O
all	O
inhibition	O
.	O

Nuclear	O
appearance	O
of	O
a	O
factor	O
that	O
binds	O
the	O
CD28	B-DNA
response	I-DNA
element	I-DNA
within	O
the	O
interleukin-2	B-DNA
enhancer	I-DNA
correlates	O
with	O
interleukin-2	B-protein
production	O
.	O

High	O
levels	O
of	O
the	O
DNA-binding	O
activity	O
of	O
E2F	B-protein
in	O
adult	O
T-cell	O
leukemia	O
and	O
human	B-cell_type
T-cell	I-cell_type
leukemia	I-cell_type
virus	I-cell_type
type	I-cell_type
I-infected	I-cell_type
cells	I-cell_type
:	O
possible	O
enhancement	O
of	O
DNA-binding	O
of	O
E2F	B-protein
by	O
the	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
I	I-protein
transactivating	I-protein
protein	I-protein
,	O
Tax	B-protein
.	O

The	O
KBF1/p50	B-protein
factor	I-protein
binds	O
as	O
a	O
homodimer	B-protein
but	O
can	O
also	O
form	O
heterodimers	B-protein
with	O
the	O
products	O
of	O
other	O
members	O
of	O
the	O
same	O
family	O
,	O
like	O
the	O
c-rel	B-DNA
and	I-DNA
v-rel	I-DNA
(	I-DNA
proto	I-DNA
)	I-DNA
oncogenes	I-DNA
.	O

Rapid	O
tyrosine	O
phosphorylation	O
of	O
key	O
cellular	O
proteins	O
is	O
a	O
crucial	O
event	O
in	O
the	O
transduction	O
of	O
activation	O
signals	O
to	O
T-lymphocytes	B-cell_type
.	O

Furthermore	O
,	O
sublethal	O
levels	O
of	O
H2O2	O
actively	O
suppressed	O
the	O
transcriptional	O
activation	O
of	O
NF-AT	B-protein
and	O
IL-2	B-DNA
reporters	I-DNA
as	O
well	O
as	O
the	O
expression	O
of	O
IL-2	B-RNA
mRNA	I-RNA
in	O
cells	O
stimulated	O
with	O
PHA/PMA	O
.	O

Thus	O
,	O
intact	O
microtubules	B-protein
are	O
essential	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-dependent	O
modulation	O
of	O
gene	O
transcription	O
.	O

RARs	B-protein
are	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
receptor	I-protein
superfamily	I-protein
and	O
exhibit	O
a	O
molecular	O
structure	O
that	O
possess	O
discrete	O
DNA-binding	O
and	O
RA	B-protein
(	I-protein
ligand	I-protein
)	I-protein
-binding	I-protein
domains	I-protein
.	O

Bcl6	O
mutation	O
was	O
found	O
in	O
13	O
of	O
24	O
(	O
54	O
%	O
)	O
clones	O
from	O
the	O
germinal	O
centre	O
but	O
only	O
in	O
1	O
of	O
24	O
(	O
4	O
%	O
)	O
clones	O
from	O
the	O
naive	B-cell_type
B	I-cell_type
cells	I-cell_type
of	O
the	O
mantle	O
zone	O
.	O

In	O
humans	O
,	O
mutation	O
of	O
the	O
XPB	B-DNA
or	I-DNA
XPD	I-DNA
gene	I-DNA
impairs	O
NER	O
,	O
resulting	O
in	O
hyper-sensitivity	O
to	O
sunlight	O
and	O
greatly	O
increased	O
skin	O
tumor	O
formation	O
.	O

The	O
poly	B-protein
(	I-protein
I	I-protein
)	I-protein
-poly	I-protein
(	I-protein
C	I-protein
)	I-protein
-induced	I-protein
IFN	I-protein
alpha	I-protein
production	O
by	O
monocytes	B-cell_type
was	O
inhibited	O
by	O
glucocorticoids	O
in	O
the	O
C	O
and	O
AIDS-C	O
groups	O
(	O
approximately	O
80	O
%	O
inhibition	O
in	O
both	O
groups	O
)	O
;	O
the	O
effect	O
was	O
reversed	O
by	O
the	O
receptor	O
antagonist	O
RU-38486	O
.	O

The	O
sophisticated	O
control	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
activity	O
is	O
not	O
surprising	O
since	O
this	O
transcription	B-protein
factor	I-protein
is	O
involved	O
in	O
a	O
wide	O
array	O
of	O
cellular	O
responses	O
to	O
extracellular	O
cues	O
,	O
associated	O
with	O
growth	O
,	O
development	O
,	O
apoptosis	O
,	O
and	O
pathogen	O
invasion	O
.	O

Regulation	O
of	O
inosine-5'-monophosphate	B-protein
dehydrogenase	I-protein
type	I-protein
II	I-protein
gene	O
expression	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Direct	O
sequencing	O
of	O
the	O
viral	B-DNA
genomes	I-DNA
and	O
reinfection	O
kinetics	O
showed	O
no	O
evidence	O
of	O
wild-type	O
reversion	O
even	O
after	O
prolonged	O
infection	O
with	O
the	O
Tat	B-protein
-virus	O
.	O

Our	O
data	O
strengthen	O
the	O
idea	O
of	O
a	O
close	O
association	O
between	O
the	O
erythrocytic	B-cell_line
and	I-cell_line
the	I-cell_line
megakaryocytic	I-cell_line
lineages	I-cell_line
and	O
could	O
also	O
explain	O
the	O
expression	O
of	O
markers	O
specific	O
to	O
the	O
erythrocytic	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineages	I-cell_type
in	O
most	O
erythroblastic	B-cell_line
and	I-cell_line
megakaryoblastic	I-cell_line
permanent	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

[	O
The	O
inhibitory	O
effect	O
of	O
hydrocortisone	O
on	O
the	O
chemotactic	O
migration	O
of	O
human	B-cell_type
leukocytes	I-cell_type
]	O

The	O
PEBP2betaMYH11	B-protein
fusion	O
created	O
by	O
Inv	B-DNA
(	I-DNA
16	I-DNA
)	I-DNA
(	I-DNA
p13	I-DNA
;	I-DNA
q22	I-DNA
)	I-DNA
in	O
myeloid	O
leukemia	O
impairs	O
neutrophil	O
maturation	O
and	O
contributes	O
to	O
granulocytic	O
dysplasia	O
.	O

The	O
role	O
of	O
platelets	O
for	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
secretion	O
and	O
surface	O
expression	O
of	O
intercellular	B-cell_type
adhesion	I-cell_type
molecule-1	I-cell_type
(	O
ICAM-1	B-protein
)	O
on	O
endothelial	B-cell_type
cells	I-cell_type
has	O
been	O
assessed	O
.	O

Identification	O
and	O
purification	O
of	O
human	B-protein
Stat	I-protein
proteins	I-protein
activated	O
in	O
response	O
to	O
interleukin-2	B-protein
.	O

In	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
activated	O
by	O
phorbol-12-myristate-13-acetate	O
and	O
phytohemagglutinin	B-protein
,	O
CCK-8	O
induced	O
IL-2	O
expression	O
.	O

We	O
have	O
measured	O
both	O
lymphocyte	B-protein
GR	I-protein
receptor	O
binding	O
parameters	O
and	O
plasma	O
sialyltransferase	B-protein
activity	O
,	O
as	O
a	O
biochemical	O
marker	O
of	O
GR	B-protein
function	O
,	O
in	O
two	O
groups	O
of	O
patients	O
suffering	O
from	O
depression	O
or	O
schizophrenia	O
and	O
in	O
a	O
group	O
of	O
age-	O
and	O
sex-matched	O
controls	O
.	O

Studies	O
on	O
the	O
biological	O
activity	O
of	O
triiodothyronine	O
sulfate	O
.	O

We	O
also	O
show	O
that	O
expression	O
of	O
the	O
B1	B-RNA
transcript	I-RNA
from	O
a	O
second	O
gene	O
,	O
MTCP1	B-DNA
,	O
occurred	O
at	O
a	O
relatively	O
high	O
level	O
only	O
in	O
two	O
T-PLL	O
tumours	O
from	O
A-T	O
patients	O
with	O
t	O
(	O
X	O
;	O
14	O
)	O
translocations	O
whereas	O
the	O
MTCP1/A1	B-RNA
transcript	I-RNA
is	O
much	O
more	O
widely	O
expressed	O
in	O
both	O
tumour	B-cell_type
and	I-cell_type
non	I-cell_type
tumour	I-cell_type
cells	I-cell_type
of	O
A-T	O
and	O
non-A-T	O
individuals	O
.	O

There	O
were	O
12	O
independent	O
mutation	O
events	O
at	O
a	O
single	B-DNA
mutation	I-DNA
site	I-DNA
,	O
defining	O
a	O
small	B-DNA
deletion	I-DNA
hotspot	I-DNA
.	O

Expression	O
of	O
E2A-HLF	B-protein
chimeric	I-protein
protein	I-protein
induced	O
T-cell	O
apoptosis	O
,	O
B-cell	O
maturation	O
arrest	O
,	O
and	O
development	O
of	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Interferon-gamma	O
(	O
IFN-gamma	B-protein
)	O
,	O
also	O
known	O
as	O
type	B-protein
II	I-protein
interferon	I-protein
,	O
is	O
an	O
important	O
immunoregulatory	O
gene	O
that	O
has	O
multiple	O
effects	O
on	O
the	O
development	O
,	O
maturation	O
,	O
and	O
function	O
of	O
the	O
immune	O
system	O
.	O

Here	O
we	O
provide	O
evidence	O
showing	O
that	O
15	O
amino	O
acids	O
in	O
the	O
carboxyl-terminal	B-protein
end	I-protein
of	O
NFATx1	B-protein
are	O
required	O
for	O
its	O
maximum	O
transactivation	O
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Core	B-protein
binding	I-protein
factor	I-protein
(	O
CBF	B-protein
)	O
,	O
also	O
known	O
as	O
polyomavirus	B-protein
enhancer-binding	I-protein
protein	I-protein
2	I-protein
and	O
SL3	B-protein
enhancer	I-protein
factor	I-protein
1	I-protein
,	O
is	O
a	O
mammalian	B-protein
transcription	I-protein
factor	I-protein
that	O
binds	O
to	O
an	O
element	O
termed	O
the	O
core	O
within	O
the	O
enhancers	B-DNA
of	O
the	O
murine	O
leukemia	O
virus	O
family	O
of	O
retroviruses	O
.	O

Tamoxifen	O
was	O
also	O
found	O
to	O
compete	O
with	O
17	O
beta-estradiol	O
for	O
type	B-protein
II	I-protein
EBS	I-protein
in	O
PBMC	B-cell_type
,	O
although	O
to	O
a	O
lesser	O
extent	O
than	O
diethylstilbestrol	O
.	O

The	O
hierarchy	O
of	O
transcriptional	O
control	O
in	O
B-cell	O
development	O
has	O
recently	O
been	O
analyzed	O
by	O
targeted	O
gene	O
inactivation	O
in	O
the	O
mouse	O
.	O

This	O
event	O
is	O
associated	O
with	O
induction	O
of	O
the	O
c-jun	B-DNA
early	I-DNA
response	I-DNA
gene	I-DNA
and	O
appearance	O
of	O
a	O
monocytic	O
phenotype	O
.	O

In	O
this	O
study	O
multiple	O
NF-kappa	B-protein
B	I-protein
related	I-protein
polypeptides	I-protein
ranging	O
from	O
85	O
to	O
45	O
kDa	O
were	O
examined	O
for	O
their	O
capacity	O
to	O
interact	O
with	O
the	O
PRDII	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
interferon	B-DNA
beta	I-DNA
and	O
were	O
shown	O
to	O
possess	O
distinct	O
intrinsic	O
DNA	O
binding	O
affinities	O
for	O
this	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
and	O
form	O
multiple	B-protein
DNA	I-protein
binding	I-protein
homo-	I-protein
and	I-protein
heterodimer	I-protein
complexes	I-protein
in	O
co-renaturation	O
experiments	O
.	O

In	O
contrast	O
,	O
BA-induced	O
cell	O
growth	O
inhibition	O
was	O
not	O
affected	O
.	O

Intimate	O
interactions	O
between	O
multipotential	O
hemopoietic	B-cell_type
stem	I-cell_type
cells	I-cell_type
and	O
their	O
microenvironment	O
work	O
towards	O
redefining	O
the	O
identity	O
and	O
the	O
differentiative	O
fate	O
of	O
these	O
primitive	B-cell_type
cells	I-cell_type
.	O

NAD	B-protein
(	I-protein
P	I-protein
)	I-protein
H	I-protein
:	I-protein
quinone	I-protein
reductase	I-protein
(	O
QR	B-protein
)	O
is	O
known	O
to	O
protect	O
against	O
BQ	O
toxicity	O
.	O

This	O
prompted	O
us	O
to	O
analyze	O
the	O
octamer-binding	B-protein
proteins	I-protein
in	O
the	O
latter	O
cells	O
.	O

Use	O
of	O
new	O
biologic	O
markers	O
in	O
the	O
ovulation	O
induction	O
.	O

This	O
makes	O
the	O
identification	O
of	O
genetic	O
targets	O
for	O
this	O
transcription	B-protein
factor	I-protein
pertinent	O
for	O
the	O
understanding	O
of	O
early	O
B-cell	O
development	O
.	O

The	O
NR2	B-cell_line
hybrid	I-cell_line
allowed	O
us	O
to	O
exclude	O
three	O
candidate	B-DNA
genes	I-DNA
for	O
AGS	O
:	O
hepatic	B-DNA
nuclear	I-DNA
factor	I-DNA
3	I-DNA
beta	I-DNA
(	O
HNF3	B-DNA
beta	I-DNA
)	O
,	O
paired	B-DNA
box	I-DNA
1	I-DNA
(	O
PAX1	B-DNA
)	O
,	O
and	O
cystatin	B-DNA
C	I-DNA
(	O
CST3	B-DNA
)	O
as	O
shown	O
by	O
their	O
localization	O
outside	O
of	O
the	O
deletion	O
.	O

In	O
addition	O
,	O
these	O
promoters	O
respond	O
only	O
indirectly	O
to	O
the	O
viral	B-DNA
immediate-early	I-DNA
transactivator	I-DNA
,	O
ZEBRA	B-DNA
.	O

[	O
Molecular	O
mechanism	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
in	O
Th1	B-cell_line
and	O
Th2	B-cell_line
]	O

We	O
have	O
identified	O
and	O
separated	O
four	O
nuclear	B-protein
proteins	I-protein
from	O
C81-66-45	O
cells	O
,	O
an	O
HTLV-I	B-cell_line
immortalized	I-cell_line
Tax-expressing	I-cell_line
human	I-cell_line
T-lymphocyte	I-cell_line
line	I-cell_line
(	O
Salahuddin	O
et	O
al.	O
,	O
1983	O
)	O
,	O
that	O
interact	O
with	O
the	O
TRE-DNA	B-DNA
,	O
none	O
of	O
which	O
are	O
identical	O
with	O
the	O
Tax-protein	B-protein
.	O

Transcriptional	O
analysis	O
of	O
Epstein-Barr	O
virus	O
gene	O
expression	O
in	O
EBV-positive	O
gastric	O
carcinoma	O
:	O
unique	O
viral	O
latency	O
in	O
the	O
tumour	B-cell_type
cells	I-cell_type
.	O

The	O
present	O
data	O
,	O
along	O
with	O
other	O
findings	O
of	O
HPA	O
abnormalities	O
in	O
PTSD	O
,	O
support	O
the	O
possibility	O
of	O
a	O
greater	O
negative	O
feedback	O
sensitivity	O
at	O
one	O
or	O
more	O
levels	O
of	O
the	O
HPA	O
axis	O
.	O

Triplex	O
formation	O
by	O
GM3	O
blocked	O
recombinant	B-protein
and	I-protein
nuclear	I-protein
NF-kappaB	I-protein
proteins	I-protein
binding	O
to	O
the	O
GM-CSF	B-DNA
element	I-DNA
.	O

We	O
demonstrate	O
that	O
a	O
fusion	O
protein	O
composed	O
of	O
a	O
C-terminal	O
Hsp70	B-protein
peptide	O
and	O
the	O
p50	B-protein
subunit	I-protein
of	O
NF-kappaB	B-protein
was	O
directed	O
into	O
the	O
nucleus	O
of	O
cells	O
,	O
could	O
bind	O
DNA	O
specifically	O
,	O
and	O
activated	O
Igkappa	B-protein
expression	O
and	O
TNFalpha	B-protein
production	O
.	O

We	O
report	O
here	O
the	O
cleavage	O
of	O
the	O
transcription	B-protein
factor	I-protein
SP1	B-protein
in	O
the	O
human	B-cell_line
Burkitt	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
BL60	I-cell_line
during	O
anti-IgM	B-protein
-induced	O
apoptosis	O
.	O

Furthermore	O
,	O
our	O
studies	O
showed	O
association	O
of	O
the	O
IKK-alpha/beta	B-protein
heterodimer	I-protein
with	O
NIK	B-protein
,	O
IkappaB-alpha	B-protein
and	O
-epsilon	B-protein
in	O
unstimulated	B-cell_type
cells	I-cell_type
.	O

Resolution	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
in	O
gel	O
shift	O
analysis	O
shows	O
that	O
the	O
binding	B-protein
protein	I-protein
,	O
mobilized	O
in	O
naive	B-cell_line
Mono	I-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
,	O
consists	O
mainly	O
of	O
p50-p65	B-protein
heterodimers	I-protein
,	O
while	O
in	O
tolerant	B-cell_line
cells	I-cell_line
,	O
the	O
p50	B-protein
homodimer	I-protein
is	O
predominant	O
.	O

Beyond	O
this	O
nonspecific	O
increase	O
in	O
gene	O
expression	O
,	O
hemin	B-protein
induction	O
acts	O
to	O
increase	O
the	O
activity	O
of	O
the	O
lineage	B-protein
limited	I-protein
transcription	I-protein
factor	I-protein
NF-E2	O
.	O

Intracellular	O
ILs	B-protein
were	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

NK	B-cell_type
cell	I-cell_type
activity	O
did	O
not	O
increase	O
in	O
patients	O
with	O
HER-2/neu	B-protein
overexpression	O
.	O

However	O
,	O
the	O
signaling	O
events	O
responsible	O
for	O
these	O
effects	O
remain	O
unclear	O
.	O

As	O
detected	O
by	O
in	O
vivo	O
footprinting	O
,	O
priming	O
markedly	O
increases	O
the	O
activation-dependent	O
engagement	O
of	O
the	O
P0	B-DNA
and	O
P1	B-DNA
NFAT-binding	B-DNA
elements	I-DNA
of	O
the	O
IL-4	B-DNA
promoter	I-DNA
.	O

The	O
response	O
to	O
antigen	O
proceeds	O
at	O
the	O
T	B-cell_type
helper	I-cell_type
cell	I-cell_type
level	O
through	O
two	O
independent	O
forms	O
of	O
cellular	O
collaboration	O
,	O
contact	O
and	O
lymphokine	B-protein
.	O

Nuclear	O
and	O
post-nuclear	O
extracts	O
were	O
prepared	O
from	O
two	O
B-lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
known	O
to	O
be	O
representative	O
of	O
the	O
vitamin	B-cell_line
D-resistant	I-cell_line
and	O
wild	B-cell_line
type	I-cell_line
phenotypes	I-cell_line
,	O
respectively	O
.	O

We	O
hypothesized	O
that	O
IL-10	B-protein
prevents	O
human	O
monocyte	O
NF-kappaB	B-protein
activation	O
and	O
resultant	O
TNF-alpha	B-protein
production	O
by	O
stabilization	O
of	O
IkappaB-alpha	B-protein
.	O

These	O
binding	O
activities	O
are	O
expressed	O
only	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

We	O
have	O
investigated	O
whether	O
a	O
palmitate	B-protein
conjugate	I-protein
of	O
a	O
human	B-protein
monoclonal	I-protein
antibody	I-protein
specific	O
for	O
thyroglobulin	B-protein
(	O
TG	B-protein
)	O
could	O
function	O
as	O
a	O
surrogate	B-protein
TG	I-protein
receptor	I-protein
on	O
blood	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
separated	O
into	O
fractions	O
enriched	O
for	O
T	B-cell_type
cells	I-cell_type
or	O
depleted	O
of	O
T	B-cell_type
cells	I-cell_type
(	O
non-T	B-cell_type
cells	I-cell_type
)	O
.	O

Lavage	O
T-lymphocytes	O
from	O
patients	O
with	O
tuberculosis	O
or	O
with	O
sarcoidosis	O
,	O
but	O
not	O
those	O
from	O
normal	O
control	O
subjects	O
,	O
expressed	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
as	O
demonstrated	O
by	O
binding	O
of	O
[	O
3H	O
]	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
which	O
was	O
inhibited	O
by	O
the	O
presence	O
of	O
excess	O
unlabeled	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
not	O
by	O
the	O
presence	O
of	O
unlabeled	O
25	O
(	O
OH	O
)	O
D3	O
(	O
receptor-positive	B-cell_type
lymphocytes	I-cell_type
:	O
sarcoidosis	O
,	O
20	O
+/-	O
12	O
%	O
;	O
tuberculosis	O
,	O
31	O
+/-	O
17	O
%	O
)	O
.	O

The	O
authors	O
revealed	O
alterations	O
in	O
the	O
functional	O
activity	O
of	O
the	O
indicated	O
endocrine	O
glands	O
depending	O
on	O
the	O
intensity	O
of	O
bronchial	O
patency	O
disorders	O
and	O
the	O
nature	O
of	O
the	O
therapeutic	O
measures	O
carried	O
out	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
C.	O
pneumoniae-mediated	O
activation	O
of	O
endothelial	B-cell_type
cells	I-cell_type
and	O
demonstrated	O
an	O
enhanced	O
expression	O
of	O
endothelial	B-protein
adhesion	I-protein
molecules	I-protein
followed	O
by	O
subsequent	O
rolling	O
,	O
adhesion	O
,	O
and	O
transmigration	O
of	O
leukocytes	B-cell_type
(	O
monocytes	B-cell_type
,	O
granulocytes	B-cell_type
)	O
.	O

Moreover	O
,	O
impaired	O
activation	O
of	O
NFkappaB	B-protein
does	O
not	O
appear	O
linked	O
to	O
a	O
reduction	O
of	O
TCRzeta	B-protein
expression	O
,	O
because	O
in	O
five	O
patients	O
,	O
normal	O
TCRzeta	B-protein
levels	O
were	O
present	O
although	O
kappaB	B-protein
binding	O
was	O
not	O
inducible	O
.	O

[	O
Glucocorticoid	B-protein
receptors	I-protein
on	O
human	B-cell_type
peripheral	I-cell_type
mononuclear	I-cell_type
and	I-cell_type
polymorphonuclear	I-cell_type
leucocytes	I-cell_type
:	O
changes	O
in	O
patients	O
with	O
yang-deficiency	O
]	O

The	O
two	B-protein
nuclear	I-protein
proteins	I-protein
NF-kappa	B-protein
B	I-protein
(	O
consisting	O
of	O
subunits	O
p50	B-protein
an	O
dp65	B-protein
)	O
and	O
the	O
DNA-binding	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
(	O
p50	B-protein
)	O
by	O
itself	O
,	O
also	O
called	O
KBF1	B-protein
,	O
are	O
constitutively	O
expressed	O
and	O
localized	O
in	O
the	O
nucleus	O
of	O
the	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
IARC	B-cell_line
301.5	I-cell_line
.	O

In	O
order	O
to	O
delineate	O
the	O
tissue-specific	O
mechanisms	O
governing	O
the	O
control	O
of	O
nonpituitary	O
PRL	B-DNA
gene	I-DNA
expression	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
3	B-DNA
kb	I-DNA
5'-flanking	I-DNA
DNA	I-DNA
of	O
the	O
upstream	O
decidual/lymphoid	B-DNA
(	I-DNA
dPRL	I-DNA
)	I-DNA
promoter	I-DNA
.	O

Conversion	O
of	O
E2	O
to	O
E1	O
was	O
upregulated	O
within	O
24	O
hours	O
when	O
HL60	B-cell_line
cells	I-cell_line
were	O
treated	O
with	O
either	O
all-trans	O
retinoic	O
acid	O
or	O
D3	O
at	O
doses	O
that	O
induce	O
their	O
differentiation	O
toward	O
neutrophils	B-cell_type
or	O
monocytes	B-cell_type
,	O
respectively	O
.	O

The	O
intermediate	O
complex	O
appeared	O
to	O
react	O
with	O
both	O
anti-STAT	B-protein
6	I-protein
and	O
anti-STAT	B-protein
1	I-protein
.	O

In	O
addition	O
,	O
the	O
macrophage	O
transcription	B-protein
factor	I-protein
PU.1	O
binds	O
the	O
CD11b	B-DNA
promoter	I-DNA
in	O
vitro	O
and	O
in	O
vivo	O
close	O
to	O
the	O
Sp1	B-DNA
site	I-DNA
.	O

These	O
alternative	O
polyadenylation	O
events	O
ensure	O
the	O
rapid	O
accumulation	O
of	O
high	O
concentrations	O
of	O
NF-ATc	B-protein
necessary	O
to	O
exceed	O
critical	O
threshold	O
levels	O
of	O
NF-ATc	B-protein
for	O
gene	O
induction	O
in	O
effector	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
multiple	O
biological	O
activities	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
are	O
mediated	O
by	O
two	O
distinct	O
cell	B-protein
surface	I-protein
receptors	I-protein
of	O
55	B-protein
kd	I-protein
(	O
TNFRp55	B-protein
)	O
and	O
75	B-protein
kd	I-protein
(	O
TNFRp75	B-protein
)	O
.	O

Using	O
a	O
radiolabeled	O
chemical	O
probe	O
,	O
we	O
here	O
purified	O
a	O
target	O
of	O
SR	O
31747A	O
and	O
called	O
it	O
SR	B-protein
31747A-binding	I-protein
protein	I-protein
(	O
SR-BP	B-protein
)	O
.	O

To	O
clarify	O
the	O
presence	O
of	O
histamine	B-protein
receptor	I-protein
and	O
its	O
transmembrane	O
mechanism	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
we	O
investigated	O
the	O
effects	O
of	O
agonists	O
or	O
antagonists	O
of	O
histamine	B-protein
receptor	I-protein
subtypes	O
and	O
bacterial	O
toxins	O
on	O
intracellular	O
concentration	O
of	O
Ca2+	O
[	O
Ca2+	O
]	O
i	O
)	O
,	O
[	O
3H	O
]	O
pyrilamine	O
binding	O
and	O
c-fos	B-RNA
mRNA	I-RNA
expression	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
cloned	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

An	O
increase	O
in	O
TR75	B-protein
expression	O
was	O
also	O
evident	O
during	O
the	O
peak	O
of	O
an	O
acute	O
HIV-1	O
infection	O
of	O
HL-60	B-cell_line
promyelocytes	I-cell_line
.	O

We	O
failed	O
to	O
find	O
any	O
correlation	O
between	O
age	O
and	O
X-	B-DNA
chromosome	I-DNA
inactivation	O
pattern	O
(	O
r	O
=	O
0.17	O
)	O
,	O
even	O
subdividing	O
the	O
subjects	O
in	O
different	O
age	O
groups	O
according	O
to	O
the	O
criteria	O
used	O
by	O
other	O
researchers	O
,	O
and	O
therefore	O
reaffirm	O
that	O
,	O
when	O
tested	O
for	O
with	O
well-standardized	O
and	O
accurate	O
criteria	O
,	O
extremely	O
unbalanced	O
inactivation	O
of	O
the	O
X	B-DNA
chromosome	I-DNA
is	O
a	O
truly	O
uncommon	O
phenomenon	O
in	O
normal	O
women	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
Rb	B-protein
expression	O
on	O
the	O
activation	O
of	O
the	O
promoter	O
for	O
HLA-DRA	B-DNA
,	O
the	O
prototype	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
.	O

Additionally	O
,	O
this	O
signaling	O
pathway	O
also	O
leads	O
to	O
activation-induced	O
apoptosis	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
that	O
is	O
dependent	O
on	O
FasL	O
transcription	O
and	O
expression	O
.	O

The	O
Legionella	O
pneumophila	O
rpoS	B-DNA
gene	I-DNA
is	O
required	O
for	O
growth	O
within	O
Acanthamoeba	O
castellanii	O
.	O

Our	O
results	O
demonstrate	O
that	O
in	O
resting	O
and	O
PMA-activated	B-cell_type
human	I-cell_type
PBL	I-cell_type
,	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
is	O
present	O
in	O
the	O
nucleus	O
in	O
an	O
apparently	O
inactive	O
form	O
unable	O
to	O
disrupt	O
NF-kappaB	B-protein
binding	O
from	O
DNA	O
.	O

The	O
presence	O
of	O
both	O
p65	B-protein
and	O
p50	B-protein
NF-kappa	B-protein
B	I-protein
components	I-protein
in	O
LPS-activated	O
THP-1	B-cell_line
cells	I-cell_line
was	O
confirmed	O
by	O
specific	O
antibody	O
induction	O
of	O
supershifts	O
in	O
mobility	O
assays	O
.	O

To	O
further	O
define	O
the	O
effects	O
of	O
dexamethasone	O
at	O
the	O
molecular	O
level	O
,	O
we	O
prepared	O
a	O
series	O
of	O
deleted	O
c-jun	B-DNA
promoter	I-DNA
fragments	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
.	O

We	O
demonstrated	O
that	O
CMV	O
infection	O
increased	O
both	O
IL-6	B-protein
protein	I-protein
and	O
mRNA	B-RNA
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Thus	O
,	O
the	O
novel	O
enhancer	O
element	O
identified	O
in	O
this	O
study	O
is	O
probably	O
a	O
target	O
site	O
for	O
both	O
positive	B-protein
and	I-protein
negative	I-protein
factors	I-protein
.	O

The	O
I	B-protein
gamma	I-protein
3	I-protein
ECS	B-DNA
lies	O
upstream	O
of	O
the	O
major	B-DNA
I	I-DNA
gamma	I-DNA
3	I-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
and	O
displays	O
more	O
than	O
90	O
%	O
identity	O
with	O
the	O
corresponding	O
human	B-DNA
I	I-DNA
gamma	I-DNA
1	I-DNA
,	O
I	B-DNA
gamma	I-DNA
2	I-DNA
,	O
and	O
I	B-DNA
gamma	I-DNA
4	I-DNA
regions	O
.	O

NF-ATc	B-protein
isoforms	I-protein
are	O
differentially	O
expressed	O
and	O
regulated	O
in	O
murine	B-cell_type
T	I-cell_type
and	I-cell_type
mast	I-cell_type
cells	I-cell_type
.	O

The	O
fluoroquinolone	O
antibiotic	O
ciprofloxacin	O
has	O
recently	O
been	O
reported	O
to	O
upregulate	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
gene	O
induction	O
.	O

Interferon-gamma	O
(	O
IFN-gamma	B-protein
)	O
is	O
a	O
key	O
cytokine	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
with	O
major	O
regulatory	O
functions	O
in	O
the	O
immune	O
system	O
.	O

We	O
determined	O
that	O
an	O
initiator-like	B-DNA
sequence	I-DNA
present	O
at	O
the	O
cap	B-DNA
site	I-DNA
and	O
an	O
Ets	B-DNA
consensus	I-DNA
sequence	I-DNA
are	O
required	O
for	O
full	O
promoter	B-DNA
function	O
.	O

Our	O
results	O
demonstrate	O
the	O
regulation	O
of	O
STAT	B-protein
activity	O
by	O
a	O
signaling	O
pathway	O
that	O
regulates	O
the	O
T	O
cell	O
functional	O
phenotype	O
and	O
is	O
distinct	O
from	O
the	O
cytokine	B-protein
-activated	O
Janus	B-protein
kinase	I-protein
-STAT	B-protein
signaling	O
pathway	O
.	O

The	O
protein	O
expressed	O
by	O
the	O
v-erb	B-DNA
A	I-DNA
oncogene	I-DNA
binds	O
to	O
DNA	O
and	O
acts	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
of	O
both	O
the	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
and	O
the	O
closely	O
related	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
.	O

Here	O
we	O
show	O
that	O
the	O
lymphoid	B-protein
lineage-determining	I-protein
factors	I-protein
Ikaros	B-protein
and	O
Aiolos	B-protein
can	O
function	O
as	O
strong	B-protein
transcriptional	I-protein
repressors	I-protein
.	O

Combined	O
treatment	O
of	O
HPCs	B-cell_type
with	O
alpha-PML	B-protein
and	O
alpha-Rb	O
oligomers	O
inhibited	O
both	O
PML	O
and	O
Rb	O
protein	O
expression	O
and	O
completely	O
blocked	O
erythroid	O
colony	O
development	O
.	O

Finally	O
,	O
addition	O
of	O
REF-1	B-protein
from	O
activated	B-cell_type
monocytes	I-cell_type
to	O
alveolar	O
macrophage	O
nuclear	O
proteins	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
AP-1	B-protein
DNA	O
binding	O
.	O

PEBP2	B-protein
alpha	I-protein
A1	I-protein
,	O
alpha	B-protein
B1	I-protein
,	O
and	O
alpha	B-protein
B2	I-protein
proteins	I-protein
bound	O
the	O
PEBP2	B-DNA
site	I-DNA
within	O
the	O
mouse	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
differences	O
in	O
patterns	O
of	O
expression	O
between	O
Spi-B	B-protein
and	O
PU.1	B-protein
distinguish	O
the	O
function	O
of	O
each	O
protein	O
during	O
development	O
of	O
the	O
immune	O
system	O
.	O

Furthermore	O
,	O
the	O
VitD3	O
-and	O
the	O
PMA-induced	O
CD14	B-protein
expression	O
was	O
inhibited	O
as	O
a	O
temporal	O
consequence	O
of	O
the	O
RA-induced	O
differentiation	O
.	O

The	O
EGR1	B-DNA
binding	I-DNA
motif	I-DNA
was	O
shown	O
to	O
be	O
necessary	O
for	O
stimulus-induced	O
expression	O
of	O
a	O
CD44	B-protein
promoter-chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
construct	I-DNA
in	O
nontransformed	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
and	O
was	O
required	O
for	O
transactivation	O
by	O
an	O
EGR1	B-DNA
expression	I-DNA
vector	I-DNA
in	O
a	O
B-cell	B-cell_line
line	I-cell_line
.	O

This	O
pattern	O
was	O
in	O
contrast	O
to	O
cultures	O
derived	O
from	O
normal	O
adult	O
peripheral	O
blood	O
,	O
in	O
which	O
both	O
GATA-1	B-protein
and	O
SP1	B-protein
activities	O
were	O
high	O
.	O

Although	O
specific	O
binding	O
sites	O
have	O
been	O
difficult	O
to	O
localize	O
by	O
chemical	O
or	O
enzymatic	O
footprinting	O
procedures	O
,	O
NF-muNR	B-protein
binding	O
sites	O
are	O
critical	O
for	O
efficient	O
MAR-BP1	B-protein
binding	O
.	O

TNFalpha	B-protein
treatment	O
induces	O
a	O
rapid	O
translocation	O
of	O
the	O
65	B-protein
kD	I-protein
transcriptional	I-protein
activator	I-protein
NF-kappaB	B-protein
subunit	I-protein
,	O
Rel	B-protein
A	I-protein
,	O
whose	O
binding	O
in	O
the	O
nucleus	O
occurs	O
before	O
changes	O
in	O
intracellular	O
ROS	O
.	O

The	O
activity	O
was	O
tested	O
by	O
quantitating	O
the	O
nuclear	B-protein
proteins	I-protein
binding	O
to	O
an	O
oligonucleotide	O
containing	O
the	O
consensus	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
sequence	I-DNA
(	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
.	O

Following	O
PCr	O
administration	O
we	O
observed	O
lower	O
blood	O
lactate	O
concentrations	O
and	O
different	O
patterns	O
of	O
some	O
enzyme	O
activities	O
,	O
less	O
pronounced	O
changes	O
in	O
plasma	B-protein
ACTH	I-protein
and	O
cortisol	O
concentrations	O
and	O
in	O
glucocorticoid	O
binding	O
in	O
lymphocytes	B-cell_type
,	O
but	O
no	O
changes	O
in	O
plasma	O
growth	O
hormone	O
concentrations	O
compared	O
to	O
the	O
placebo	O
.	O

Furthermore	O
,	O
the	O
binding	O
of	O
both	O
forms	O
of	O
NFATp	B-protein
to	O
calcineurin	B-protein
was	O
inhibited	O
by	O
pretreatment	O
of	O
calcineurin	B-protein
with	O
a	O
complex	O
of	O
FK506	O
and	O
its	O
ligand	O
FKBP12	O
.	O

During	O
T	O
cell	O
differentiation	O
,	O
expression	O
peaked	O
in	O
the	O
actively	B-cell_type
dividing	I-cell_type
immature	I-cell_type
single	I-cell_type
positive	I-cell_type
cells	I-cell_type
.	O

It	O
is	O
very	O
likely	O
that	O
these	O
domains	O
bind	O
megakaryocyte-specific	B-protein
nuclear	I-protein
proteins	I-protein
acting	O
as	O
positive	B-protein
transcription	I-protein
factors	I-protein
.	O

Selective	O
expression	O
of	O
an	O
interleukin-12	B-protein
receptor	I-protein
component	I-protein
by	O
human	B-cell_type
T	I-cell_type
helper	I-cell_type
1	I-cell_type
cells	I-cell_type
.	O

We	O
have	O
previously	O
described	O
a	O
mutant	B-cell_line
B	I-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Clone-13	B-cell_line
,	I-cell_line
that	O
expresses	O
HLA-DQ	B-protein
in	O
the	O
absence	O
of	O
HLA-DR	B-protein
and	I-protein
-DP	I-protein
.	O

We	O
have	O
developed	O
a	O
reporter	O
assay	O
to	O
begin	O
characterizing	O
the	O
mechanisms	O
that	O
regulate	O
late	O
gene	O
expression	O
in	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O

Thus	O
,	O
while	O
IL-10	B-protein
has	O
deactivating	O
effects	O
on	O
PBMC	B-cell_type
responses	O
to	O
all	O
three	O
stimuli	O
,	O
disparate	O
stimulus-	O
and	O
response-specific	O
patterns	O
of	O
deactivation	O
are	O
seen	O
.	O

The	O
kinetics	O
of	O
activation	O
of	O
kinase	O
activity	O
in	O
monocytic	B-cell_type
cells	I-cell_type
are	O
relatively	O
slow	O
with	O
maximal	O
activity	O
observed	O
at	O
60	O
min	O
,	O
which	O
coincides	O
with	O
the	O
degradation	O
of	O
IkappaBs	B-protein
and	O
the	O
nuclear	O
translocation	O
of	O
NF-kappaB	B-protein
.	O

1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
inhibited	O
CD23	B-protein
expression	O
in	O
U937	B-cell_line
cells	I-cell_line
,	O
yet	O
failed	O
to	O
modulate	O
CD23	B-protein
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

This	O
finding	O
,	O
taken	O
together	O
with	O
other	O
evidence	O
that	O
this	O
social	O
variable	O
is	O
associated	O
with	O
longer	O
survival	O
in	O
breast	O
cancer	O
populations	O
,	O
underscores	O
the	O
potential	O
importance	O
of	O
this	O
social	O
support	O
variable	O
.	O

The	O
effect	O
was	O
greatly	O
potentiated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
at	O
a	O
concentration	O
where	O
neither	O
phorbol	O
ester	O
nor	O
ciprofibrate	O
alone	O
had	O
any	O
effect	O
on	O
these	O
cells	O
.	O

The	O
v-src-induced	B-protein
complex	I-protein
comprised	O
the	O
p50	B-protein
and	O
p65	B-protein
components	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
as	O
determined	O
by	O
supershift	O
and	O
immunoblot	O
analysis	O
.	O

Analysis	O
of	O
the	O
binding	O
proteins	O
employing	O
the	O
-605	O
motif	O
of	O
the	O
human	B-DNA
TNF	I-DNA
promoter	I-DNA
(	O
GGGGCTGTCCC	O
)	O
revealed	O
that	O
in	O
tolerant	O
cells	O
of	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
there	O
is	O
a	O
predominance	O
of	O
p50p50	B-protein
of	O
NF-kappa	B-protein
B	I-protein
.	O

By	O
fusing	O
lymphoblastoid	B-cell_type
cells	I-cell_type
of	O
an	O
AGS	O
patient	O
that	O
exhibited	O
a	O
microdeletion	O
in	O
the	O
short	B-DNA
arm	I-DNA
of	I-DNA
Chr	I-DNA
20	I-DNA
encompassing	O
bands	O
p11.23	B-DNA
to	I-DNA
p12.3	I-DNA
with	O
rodent	B-cell_line
thermosensitive	I-cell_line
mutant	I-cell_line
cells	I-cell_line
(	O
CHOtsH1-1	B-cell_line
)	O
deficient	O
in-leucyl-tRNA	B-protein
synthetase	I-protein
,	O
we	O
isolated	O
a	O
somatic	B-cell_line
cell	I-cell_line
hybrid	I-cell_line
segregating	O
the	O
deleted	O
human	O
Chr	B-DNA
20	I-DNA
.	O

Presence	O
of	O
a	O
variant	O
form	O
of	O
the	O
estrogen	B-protein
receptor	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
normal	O
individuals	O
and	O
lupus	O
patients	O
.	O

Basophils	B-cell_type
express	O
GATA-2	B-protein
and	O
GATA-3	B-protein
.	O

Both	O
TCDD	O
and	O
estradiol	O
induce	O
extrathymic	O
T-cell	O
differentiation	O
in	O
the	O
liver	O
.	O

It	O
encodes	O
a	O
protein	O
predicted	O
to	O
contain	O
688	O
amino	O
acid	O
residues	O
,	O
including	O
11	O
zinc	B-protein
finger	I-protein
motifs	I-protein
of	O
the	O
C2H2	B-protein
type	I-protein
in	O
the	O
C-terminal	B-protein
region	I-protein
,	O
that	O
are	O
Kruppel-like	O
in	O
the	O
conservation	O
of	O
the	O
H/C	B-protein
link	I-protein
sequence	I-protein
connecting	O
them	O
.	O

The	O
three	O
jun	B-DNA
genes	I-DNA
showed	O
a	O
similar	O
time	O
course	O
in	O
their	O
induction	O
by	O
PMA	O
,	O
maximal	O
mRNA	O
levels	O
being	O
reached	O
after	O
60	O
min	O
of	O
induction	O
.	O

We	O
have	O
generated	O
a	O
monoclonal	B-protein
antibody	I-protein
,	O
BZ1	B-protein
,	O
to	O
BZLF1	B-protein
which	O
reacts	O
in	O
immunohistology	O
,	O
immunoblotting	O
,	O
and	O
immunoprecipitation	O
and	O
which	O
recognizes	O
both	O
the	O
active	B-protein
,	I-protein
dimeric	I-protein
form	I-protein
and	O
the	O
inactive	B-protein
,	I-protein
monomeric	I-protein
form	I-protein
of	O
the	O
protein	O
.	O

These	O
results	O
indicate	O
that	O
the	O
adhesion	O
of	O
RA	B-cell_type
synovial	I-cell_type
cells	I-cell_type
to	O
matrices	O
such	O
as	O
hyaluronic	O
acid	O
through	O
CD44	B-protein
could	O
up-regulate	O
VCAM-1	B-protein
expression	O
and	O
VCAM-1	B-protein
-mediated	O
adhesion	O
to	O
T	B-cell_type
cells	I-cell_type
,	O
which	O
might	O
in	O
turn	O
cause	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
and	O
synovial	B-cell_type
cells	I-cell_type
in	O
RA	O
synovitis	O
.	O

The	O
MNDA	B-RNA
mRNA	I-RNA
level	O
in	O
the	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
also	O
unaffected	O
by	O
the	O
latter	O
four	O
agents	O
.	O

This	O
induction	O
of	O
CAT	B-protein
activity	O
was	O
sensitive	O
to	O
dexamethasone	O
.	O

By	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
this	O
increase	O
in	O
mRNA	B-RNA
was	O
associated	O
with	O
a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
STAT1-containing	B-protein
DNA-binding	I-protein
complex	I-protein
that	O
binds	O
to	O
Fc	B-DNA
gammaRI	I-DNA
promoter	I-DNA
elements	I-DNA
.	O

On	O
the	O
basis	O
of	O
cross-linking	O
results	O
with	O
21	O
different	O
EMCV	B-DNA
IRES	I-DNA
fragments	I-DNA
and	O
cytoplasmic	O
HeLa	O
extract	O
or	O
rabbit	O
reticulocyte	O
lysate	O
as	O
the	O
source	O
of	O
polypeptides	O
,	O
consensus	B-DNA
binding	I-DNA
sites	I-DNA
for	O
p52	B-protein
,	O
p57	B-protein
,	O
p70	B-protein
,	O
and	O
p100	B-protein
are	O
proposed	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
Southwestern	O
blotting	O
experiments	O
were	O
used	O
to	O
detect	O
the	O
binding	O
of	O
cellular	B-protein
transactivation	I-protein
factor	I-protein
NF-KB	B-protein
to	O
the	O
double	B-DNA
repeat-KB	I-DNA
enhancer	I-DNA
sequence	I-DNA
located	O
in	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
.	O

Dexamethasone	O
treatment	O
of	O
a	O
human	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
clone	I-cell_line
CEM	I-cell_line
C7	I-cell_line
caused	O
an	O
increase	O
in	O
a	O
subset	O
of	O
cells	O
expressing	O
the	O
surface	B-protein
antigen	I-protein
CD8	I-protein
,	O
which	O
is	O
present	O
on	O
suppressor	O
and	O
cytotoxic	B-cell_type
T-lymphocytes	I-cell_type
.	O

B	B-cell_type
lymphocytes	I-cell_type
in	O
the	O
peripheral	O
circulation	O
are	O
maintained	O
in	O
a	O
non-proliferative	O
state	O
.	O

Only	O
the	O
catalytic	O
,	O
but	O
not	O
the	O
NH2	B-protein
regulatory	O
,	O
domain	O
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
was	O
able	O
to	O
induce	O
NF-AT	B-protein
region	O
transactivation	O
on	O
its	O
own	O
and	O
to	O
cooperate	O
with	O
other	O
intracellular	O
signals	O
to	O
trigger	O
this	O
response	O
.	O

We	O
show	O
here	O
that	O
estrogens	O
also	O
reduce	O
the	O
number	O
of	O
erythroid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
in	O
primary	B-cell_line
human	I-cell_line
bone	I-cell_line
marrow	I-cell_line
cultures	I-cell_line
.	O

Oct-2	B-RNA
mRNA	I-RNA
induction	O
during	O
antigen-driven	O
T-cell	B-cell_type
activation	O
was	O
blocked	O
by	O
cyclosporin	O
A	O
,	O
as	O
well	O
as	O
by	O
protein	O
synthesis	O
inhibitors	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
lipoproteins	B-protein
of	O
Treponema	O
pallidum	O
and	O
Borrelia	O
burgdorferi	O
are	O
key	O
inflammatory	O
mediators	O
during	O
syphilis	O
and	O
Lyme	O
disease	O
.	O

Rather	O
,	O
EBV	O
remains	O
in	O
a	O
linear	O
configuration	O
from	O
which	O
replicative	B-DNA
genes	I-DNA
are	O
transcribed	O
.	O

CONCLUSIONS	O
:	O
Sexual	O
hormones	O
,	O
through	O
their	O
receptors	B-protein
,	O
may	O
influence	O
the	O
activity	O
of	O
eosinophils	B-cell_type
in	O
patients	O
with	O
VKC	O
.	O

When	O
submitted	O
to	O
an	O
in	O
vitro	O
CD4	B-protein
cross-linking	O
by	O
iHIV-1	O
,	O
PBMCs	B-cell_type
from	O
HIV-1-infected	O
patients	O
were	O
found	O
to	O
produce	O
virus	O
.	O

Activation	O
of	O
the	O
NF-kappaB	B-protein
pathway	O
by	O
inflammatory	O
stimuli	O
in	O
human	B-cell_type
neutrophils	I-cell_type
.	O

LR1	B-protein
also	O
binds	O
Ig	B-protein
heavy	I-protein
chain	I-protein
switch	O
region	O
sequences	O
and	O
may	O
function	O
in	O
class	O
switch	O
recombination	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
how	O
this	O
viral	B-protein
protein	I-protein
induces	O
a	O
persistent	O
rather	O
than	O
transient	O
NF-kappaB	B-protein
response	O
.	O

Transcriptional	O
activation	O
and	O
repression	O
,	O
two	O
properties	O
of	O
the	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
Oct-2a	B-protein
.	O

These	O
results	O
indicate	O
selective	O
functions	O
for	O
different	O
PKC	B-protein
isotypes	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

Transient	O
transfection	O
experiments	O
with	O
expression	O
vectors	O
for	O
two	O
of	O
the	O
isoforms	O
demonstrated	O
that	O
the	O
32.2-kDa	B-protein
protein	I-protein
is	O
an	O
activator	O
of	O
transcription	O
of	O
granulocyte	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
receptor	I-DNA
promoter	I-DNA
,	O
while	O
the	O
14.3-kDa	B-protein
protein	I-protein
is	O
not	O
.	O

After	O
T-cell	B-protein
receptor	I-protein
stimulation	O
,	O
ZAP-70	B-protein
associates	O
with	O
the	O
receptor	O
and	O
is	O
phosphorylated	O
on	O
many	O
tyrosines	O
,	O
including	O
Y292	O
,	O
Y315	O
,	O
and	O
Y319	O
within	O
interdomain	O
B	O
.	O

The	O
erythroid	O
differentiation	O
of	O
HEL	B-cell_line
cells	I-cell_line
was	O
inhibited	O
by	O
recombinant	B-protein
human	I-protein
nm23-H1	I-protein
,	I-protein
-H2	I-protein
,	I-protein
mouse	I-protein
nm23-M1	I-protein
,	I-protein
and	I-protein
-M2	I-protein
proteins	I-protein
.	O

Previous	O
work	O
has	O
shown	O
that	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
a	O
set	O
of	O
widely	O
expressed	O
transcription	B-protein
factors	I-protein
(	O
the	O
ICK-1	B-protein
family	I-protein
)	O
affect	O
the	O
GOS19	B-DNA
promoter	I-DNA
.	O

Inhibition	O
of	O
sequence-specific	B-protein
DNA-binding	I-protein
proteins	I-protein
was	O
achieved	O
with	O
double-stranded	O
(	O
ds	O
)	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
octamer	B-DNA
or	I-DNA
kappa	I-DNA
B	I-DNA
consensus	I-DNA
sequences	I-DNA
.	O

Treatment	O
of	O
human	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
phorbol	O
esters	O
strongly	O
induced	O
the	O
expression	O
of	O
IL-2R	B-protein
alpha	I-protein
and	O
the	O
activation	O
of	O
NF.kappa	B-protein
B	I-protein
.	O

The	O
range	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
produced	O
was	O
found	O
to	O
mimic	O
a	O
physiologically	O
relevant	O
spectrum	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
in	O
membranes	O
derived	O
from	O
human	O
tissues	O
and	O
rat	O
brain	O
.	O

Then	O
the	O
expression	O
levels	O
of	O
AhR	B-RNA
mRNA	I-RNA
in	O
various	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
examined	O
together	O
with	O
those	O
of	O
Arnt	B-protein
and	O
P450IA1	B-protein
.	O

DN	O
constructs	O
of	O
myeloid	B-protein
differentiation	I-protein
protein	I-protein
,	O
IRAK	B-protein
,	O
TNF	B-protein
receptor-associated	I-protein
factor	I-protein
6	I-protein
,	O
and	O
NF-kappaB-inducing	B-protein
kinase	I-protein
,	O
when	O
coexpressed	O
with	O
TLR2	B-protein
,	O
abrogate	O
TLR2	B-protein
-mediated	O
NF-kappaB	B-protein
activation	O
.	O

In	O
B	B-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
it	O
is	O
constitutively	O
present	O
in	O
cell	O
nuclei	O
,	O
whereas	O
in	O
many	O
other	O
cell	O
types	O
,	O
NF-kappa	B-protein
B	I-protein
translocates	O
from	O
cytosol	O
to	O
nucleus	O
as	O
a	O
result	O
of	O
transduction	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
,	O
phorbol	O
ester	O
,	O
and	O
other	O
polyclonal	O
signals	O
.	O

Additionally	O
,	O
it	O
inhibited	O
the	O
production	O
of	O
LTB4	B-protein
(	O
IC50	O
=	O
0.5	O
microM	O
)	O
and	O
the	O
cytokines	B-protein
IL-2	B-protein
,	O
IL-6	B-protein
and	O
TNF	B-protein
alpha	I-protein
(	O
IC50	O
=	O
10-12	O
microM	O
)	O
.	O

The	O
nuclear	O
extracts	O
from	O
resting	O
and	O
induced	B-cell_line
ML-1	I-cell_line
cells	I-cell_line
contain	O
proteins	O
binding	O
specifically	O
to	O
the	O
AP-1	B-DNA
,	I-DNA
AP-2	I-DNA
,	I-DNA
and	I-DNA
NF	I-DNA
kappa	I-DNA
B	I-DNA
sequence	I-DNA
located	O
within	O
the	O
TNF	B-DNA
promoter	I-DNA
.	O

By	O
combining	O
partially	B-protein
purified	I-protein
proteins	I-protein
in	O
vitro	O
,	O
we	O
observed	O
the	O
loss	O
of	O
the	O
bound	O
NFATp/AP-1-DNA	B-protein
complex	I-protein
upon	O
inclusion	O
of	O
VDR	B-protein
or	O
VDR-retinoid	B-protein
X	I-protein
receptor	I-protein
.	O

These	O
studies	O
show	O
that	O
the	O
differential	O
expression	O
of	O
PKC	B-protein
isoforms	I-protein
in	O
alveolar	B-cell_type
macrophages	I-cell_type
and	O
blood	B-cell_type
monocytes	I-cell_type
is	O
associated	O
with	O
important	O
functional	O
alterations	O
in	O
the	O
cells	O
.	O

Analysis	O
of	O
10	O
matched	O
pairs	O
of	O
high	O
grade	O
malignant	O
astrocytomas	O
and	O
their	O
subsequent	O
recurrences	O
identified	O
three	O
distinct	O
groups	O
.	O

To	O
further	O
clarify	O
the	O
complex	O
transcriptional	O
regulation	O
of	O
the	O
human	B-DNA
GM-CSF	I-DNA
gene	I-DNA
,	O
which	O
was	O
extensively	O
investigated	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
we	O
have	O
studied	O
the	O
role	O
of	O
an	O
upstream	O
NF-kappaB	B-DNA
like	I-DNA
site	I-DNA
in	O
the	O
5637	B-cell_line
non-lymphoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
derives	O
from	O
a	O
bladder	O
carcinoma	O
and	O
constitutively	O
produces	O
GM-CSF	B-protein
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
stimulates	O
JAK2	B-protein
signaling	O
pathway	O
and	O
rapidly	O
activates	O
p93fes	B-protein
,	O
STAT1	B-protein
p91	I-protein
,	O
and	O
STAT3	B-protein
p92	I-protein
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
human	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
and	I-DNA
enhancer	I-DNA
also	O
encompass	O
binding	O
sites	O
for	O
core-binding	B-protein
factor	I-protein
(	O
CBF	B-protein
)	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
beta-casein	B-DNA
gene	I-DNA
by	O
cytokines	B-protein
:	O
cross-talk	O
between	O
STAT5	B-protein
and	O
other	O
signaling	B-protein
molecules	I-protein
.	O

Ionizing	O
radiation	O
triggers	O
a	O
signal	O
in	O
human	B-cell_type
B-lymphocyte	I-cell_type
precursors	I-cell_type
that	O
is	O
intimately	O
linked	O
to	O
an	O
active	O
protein-tyrosine	B-protein
kinase	I-protein
regulatory	O
pathway	O
.	O

We	O
investigated	O
the	O
role	O
of	O
this	O
G	B-DNA
+	I-DNA
C-rich	I-DNA
region	I-DNA
in	O
augmenting	O
alpha-globin	B-DNA
promoter	I-DNA
activity	O
in	O
the	O
presence	O
of	O
the	O
far-upstream	B-DNA
alpha-globin	I-DNA
enhancer	I-DNA
,	O
HS-40	B-DNA
.	O

A	O
loss-of-function	O
mutation	O
in	O
Cbl-b	B-protein
disrupted	O
the	O
interaction	O
between	O
Cbl-b	B-protein
and	O
Zap-70	B-protein
and	O
nearly	O
completely	O
abrogated	O
the	O
Cbl-b	B-protein
-mediated	O
activation	O
of	O
NFAT	B-protein
.	O

Our	O
data	O
suggest	O
that	O
the	O
inflammatory	O
effects	O
of	O
gamma-IFN	B-protein
signaling	O
could	O
play	O
a	O
role	O
in	O
foam	O
cell	O
formation	O
and	O
xanthomatosis	O
.	O

These	O
results	O
suggest	O
a	O
potential	O
role	O
of	O
PAF	B-protein
in	O
HB-EGF	B-protein
expression	O
and	O
provide	O
evidence	O
that	O
this	O
stimulation	O
may	O
occur	O
through	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

Inhibition	O
of	O
rat	B-cell_type
splenocyte	I-cell_type
proliferation	O
with	O
methylprednisolone	O
:	O
in	O
vivo	O
effect	O
of	O
liposomal	O
formulation	O
.	O

This	O
finding	O
may	O
provide	O
a	O
tool	O
to	O
improve	O
current	O
protocols	O
of	O
immunotherapy	O
and	O
insights	O
to	O
how	O
tumor	B-cell_type
cells	I-cell_type
are	O
or	O
are	O
not	O
killed	O
by	O
LAK	B-cell_line
cells	I-cell_line
.	O

Maximal	O
induction	O
of	O
TNF	B-RNA
alpha	I-RNA
mRNA	I-RNA
can	O
be	O
induced	O
by	O
treatment	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
calcium	O
ionophores	O
alone	O
,	O
via	O
a	O
calcineurin	B-protein
-dependent	O
process	O
that	O
is	O
blocked	O
by	O
cyclosporin	O
A	O
.	O

The	O
complementary	B-DNA
DNAs	I-DNA
are	O
the	O
products	O
of	O
distinct	O
genes	O
,	O
yet	O
both	O
ITF-1	B-protein
and	O
ITF-2	B-protein
are	O
structurally	O
and	O
functionally	O
similar	O
.	O

The	O
importance	O
of	O
NF-kappaB	B-protein
complexes	I-protein
in	O
viral	O
functions	O
has	O
been	O
established	O
comparing	O
the	O
level	O
of	O
NF-kappaB	O
DNA-binding	O
complexes	O
with	O
syncytia-forming	O
activity	O
of	O
8e51	B-cell_line
cells	I-cell_line
.	O

We	O
therefore	O
speculate	O
that	O
N-Oct-3	B-protein
and	O
other	O
N-Oct	B-protein
factors	I-protein
have	O
a	O
specific	O
role	O
in	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
nervous	O
system	O
.	O

Positive	O
regulators	O
of	O
the	O
lineage-specific	O
transcription	B-protein
factor	I-protein
GATA-1	B-protein
in	O
differentiating	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O

In	O
late	O
stages	O
of	O
erythroid	O
maturation	O
,	O
GPA	B-protein
was	O
upregulated	O
,	O
whereas	O
CD34	B-protein
,	O
c-kit	B-protein
,	O
PU.1	B-protein
,	O
and	O
GATA-2	B-protein
were	O
barely	O
or	O
not	O
detected	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
EBF	B-protein
represents	O
a	O
novel	O
regulator	O
of	O
B	O
lymphocyte-specific	O
gene	O
expression	O
.	O

In	O
addition	O
,	O
JNK	B-protein
activation	O
by	O
PMA	O
plus	O
ionophore	O
was	O
sensitive	O
to	O
inhibitors	O
of	O
signaling	O
pathways	O
involving	O
Ca2+	O
,	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
and	O
tyrosine	O
phosphorylation	O
,	O
which	O
failed	O
to	O
inhibit	O
the	O
activation	O
mediated	O
by	O
PDTC	O
.	O

In	O
contrast	O
mRNA	O
representing	O
pAT	O
591/EGR2	B-protein
was	O
not	O
expressed	O
in	O
these	O
cells	O
.	O

The	O
onset	O
of	O
apoptosis	O
in	O
both	O
cell	O
types	O
can	O
be	O
delayed	O
by	O
hemopoietins	B-protein
and	O
inflammatory	B-protein
mediators	I-protein
.	O

Even	O
a	O
moderate	O
increase	O
in	O
the	O
cellular	O
cysteine	O
supply	O
elevates	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
and	O
glutathione	O
disulfide	O
(	O
GSSG	O
)	O
levels	O
and	O
potentiates	O
immunological	O
functions	O
of	O
lymphocytes	B-cell_type
in	O
vitro	O
.	O

Following	O
stimulation	O
,	O
TNF-alpha	B-protein
was	O
measured	O
in	O
cell	O
supernatants	O
by	O
ELISA	O
,	O
NF-kappaB	B-protein
activity	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
and	O
IkappaB-alpha	B-protein
levels	O
by	O
Western	O
blot	O
.	O

Differential	O
interaction	O
of	O
nuclear	O
factors	O
with	O
the	O
PRE-I	B-DNA
enhancer	I-DNA
element	I-DNA
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
in	O
different	O
T	B-cell_type
cell	I-cell_type
subsets	I-cell_type
.	O

The	O
5'-UTR	B-DNA
contains	O
binding	B-DNA
sites	I-DNA
for	O
the	O
transcription	B-protein
factors	I-protein
AP-1	O
,	O
NF-kappaB	B-protein
,	O
NF-AT	B-protein
,	O
IRF	B-protein
,	O
and	O
Sp1	B-protein
.	O

Similarities	O
between	O
the	O
effects	O
of	O
dexamethasone	O
and	O
RU486	O
suggest	O
that	O
the	O
antiglucocorticoid	O
properties	O
of	O
RU486	O
do	O
not	O
occur	O
at	O
the	O
level	O
of	O
specific	O
DNA	O
binding	O
.	O

Our	O
studies	O
demonstrate	O
that	O
incubation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
low	O
concentrations	O
(	O
approximately	O
1-5	O
nM	O
)	O
of	O
calyculin	O
A	O
or	O
okadaic	O
acid	O
,	O
potent	O
inhibitors	O
of	O
protein	B-protein
phosphatase	I-protein
type	I-protein
1	I-protein
(	I-protein
PP-1	I-protein
)	I-protein
and	I-protein
type	I-protein
2A	I-protein
(	O
PP-2A	B-protein
)	O
,	O
induces	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
even	O
in	O
the	O
absence	O
of	O
any	O
cellular	O
stimulus	O
.	O

These	O
results	O
indicate	O
that	O
the	O
function	O
of	O
adrenal	O
cortex	O
may	O
be	O
improved	O
by	O
the	O
compensation	O
mechanism	O
of	O
the	O
patients	O
,	O
but	O
the	O
lower	O
GCR	B-protein
number	O
was	O
the	O
result	O
of	O
lacking	O
of	O
oxygen	O
in	O
the	O
patients	O
.	O

These	O
studies	O
,	O
the	O
first	O
to	O
demonstrate	O
induction	O
of	O
LT	B-DNA
promoter	I-DNA
activity	O
over	O
basal	O
levels	O
,	O
indicate	O
that	O
HTLV-I	B-protein
tax	I-protein
causes	O
low-level	O
activation	O
of	O
both	O
endogenous	O
LT	B-protein
and	O
the	O
LT	B-DNA
promoter	I-DNA
,	O
at	O
least	O
in	O
part	O
through	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

To	O
identify	O
the	O
requisite	O
bacterial	O
ligands	O
,	O
studies	O
with	O
isogenic	O
mutants	O
of	O
P.	O
aeruginosa	O
PAK	O
lacking	O
pili	O
,	O
flagella	O
,	O
and	O
the	O
RpoN	B-protein
sigma	I-protein
factor	I-protein
were	O
undertaken	O
.	O

Our	O
results	O
indicate	O
that	O
I	O
kappa	O
b	O
beta	O
,	O
but	O
not	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
is	O
required	O
for	O
the	O
signal-dependent	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
fibroblasts	B-cell_type
.	O

Thus	O
,	O
Oct-2A	B-protein
and	O
HMG	B-protein
I/Y	I-protein
may	O
synergize	O
to	O
activate	O
HLA-DRA	B-DNA
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

By	O
using	O
a	O
nucleosome	B-protein
-assembly	O
system	O
derived	O
from	O
Drosophila	O
embryos	O
,	O
we	O
find	O
that	O
the	O
packaging	O
of	O
DNA	O
into	O
chromatin	B-DNA
in	O
vitro	O
strongly	O
represses	O
HIV-1	O
transcription	O
and	O
that	O
repression	O
can	O
be	O
counteracted	O
efficiently	O
by	O
preincubation	O
of	O
the	O
DNA	O
with	O
LEF-1	B-protein
(	O
or	O
LEF-1	B-protein
and	O
Ets-1	B-protein
)	O
supplemented	O
with	O
fractions	O
containing	O
the	O
promoter-binding	B-protein
protein	I-protein
,	O
Sp1	B-protein
.	O

Cells	O
from	O
TNFRp55-/-mutant	O
mice	O
lack	O
expression	O
of	O
TNFRp55	B-protein
but	O
display	O
normal	O
numbers	O
of	O
high	B-protein
affinity	I-protein
TNFRp75	I-protein
molecules	I-protein
.	O

These	O
results	O
indicate	O
that	O
LPS	O
induction	O
of	O
kappaB-dependent	O
gene	O
expression	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
requires	O
activation	O
of	O
IKK2	B-protein
.	O

IL-10	B-protein
inhibition	O
of	O
IFN-gamma	B-protein
-induced	O
ICAM-1	B-protein
expression	O
was	O
apparent	O
as	O
early	O
as	O
3	O
hours	O
and	O
was	O
blocked	O
by	O
an	O
anti-IL-10	B-protein
antibody	I-protein
but	O
not	O
by	O
an	O
isotype-matched	B-protein
control	I-protein
antibody	I-protein
.	O

A	O
further	O
decrease	O
in	O
the	O
T	O
cell	O
reactivity	O
to	O
TSHR	B-protein
peptides	O
was	O
observed	O
3-6	O
months	O
after	O
surgery	O
.	O

Similar	O
to	O
the	O
E2	O
response	O
,	O
the	O
slope	O
factors	O
for	O
alpha-zearalenol	O
,	O
zearalenone	O
,	O
and	O
genistein	O
were	O
close	O
to	O
3.0	O
,	O
suggesting	O
positive	O
cooperativity	O
in	O
the	O
estrogenic	O
response	O
.	O

The	O
second	O
was	O
to	O
suppress	O
the	O
permanent	O
NF-kappaB	B-protein
translocation	O
induced	O
by	O
HIV-1	O
replication	O
itself	O
in	O
chronically	B-cell_line
infected	I-cell_line
U937	I-cell_line
cells	I-cell_line
,	O
using	O
a	O
specific	O
proteasome	O
inhibitor	O
(	O
Z-LLL-H	O
)	O
.	O

We	O
propose	O
that	O
ets-1	B-protein
functions	O
as	O
a	O
transcriptional	O
activator	O
of	O
mammalian	O
type-C	O
retroviruses	O
and	O
speculate	O
that	O
ets-related	B-DNA
genes	I-DNA
constitute	O
a	O
new	O
group	O
of	O
eukaryotic	B-protein
DNA-binding	I-protein
proteins	I-protein
.	O

In	O
order	O
to	O
analyse	O
the	O
immune	O
function	O
data	O
effectively	O
,	O
low	O
responders	O
were	O
identified	O
with	O
stringent	O
cut-off	O
values	O
.	O

The	O
promoters	B-DNA
and	O
enhancers	B-DNA
of	O
cell	O
type-specific	O
genes	O
are	O
often	O
conserved	O
in	O
evolution	O
,	O
and	O
hence	O
one	O
might	O
expect	O
that	O
a	O
given	O
enhancer	B-DNA
has	O
evolved	O
to	O
work	O
best	O
with	O
its	O
own	O
promoter	B-DNA
.	O

Although	O
the	O
mRNA	O
level	O
in	O
liver	O
was	O
only	O
fourfold	O
higher	O
than	O
that	O
in	O
keratinocytes	B-cell_type
and	O
fibroblasts	B-cell_type
,	O
the	O
hepatic	B-protein
PCD/DCoH	I-protein
protein	I-protein
level	O
was	O
20-fold	O
higher	O
than	O
that	O
in	O
normal	B-cell_type
human	I-cell_type
epidermal	I-cell_type
keratinocytes	I-cell_type
and	O
dermal	B-cell_type
fibroblasts	I-cell_type
.	O

We	O
report	O
that	O
removal	O
of	O
the	O
N-terminal	B-protein
151	I-protein
amino	I-protein
acids	I-protein
,	O
encompassing	O
all	O
of	O
the	O
acidic	B-protein
domain	I-protein
but	O
leaving	O
intact	O
the	O
proline/serine/threonine-rich	B-protein
domain	I-protein
,	O
results	O
in	O
a	O
mutant	O
protein	O
with	O
potent	O
suppressive	O
properties	O
for	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
.	O

Activation	O
of	O
human	B-cell_type
macrophages	I-cell_type
by	O
mechanical	O
ventilation	O
in	O
vitro	O
.	O

Anti-	O
HLA-DR	B-protein
abrogated	O
proliferation	O
to	O
SSB	B-protein
and	O
tetanus	O
toxoid	O
.	O

All	O
conserved	O
cysteine	O
and	O
arginine	O
residues	O
in	O
this	O
domain	O
were	O
mutated	O
by	O
site-directed	O
mutagenesis	O
,	O
and	O
the	O
mutant	B-protein
proteins	I-protein
were	O
characterized	O
by	O
blocking	O
reactions	O
,	O
ligand-binding	O
experiments	O
,	O
transactivation	O
assays	O
,	O
and	O
protease	B-protein
mapping	O
.	O

We	O
now	O
report	O
the	O
characterization	O
of	O
a	O
second	O
essential	B-DNA
positive	I-DNA
regulatory	I-DNA
element	I-DNA
located	O
between	O
nucleotides	B-DNA
-137	I-DNA
and	I-DNA
-64	I-DNA
that	O
binds	O
Elf-1	B-protein
and	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
.	O

Spi-1/PU.1	B-protein
is	O
a	O
myeloid-	B-protein
and	I-protein
B-cell	I-protein
specific	I-protein
transcription	I-protein
factor	I-protein
which	O
is	O
also	O
involved	O
in	O
Friend	O
virus-induced	O
murine	O
erythroleukemia	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Formalin-fixed	O
paraffin	O
sections	O
were	O
used	O
for	O
immunostaining	O
of	O
Bcl-6	B-protein
.	O

Our	O
analyses	O
of	O
the	O
induction	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NFkappaB	B-protein
)	O
in	O
activated	O
memory	B-cell_type
(	I-cell_type
CD45RO+	I-cell_type
)	I-cell_type
and	I-cell_type
naive	I-cell_type
(	I-cell_type
CD45RA+	I-cell_type
)	I-cell_type
T	I-cell_type
cell	I-cell_type
subsets	I-cell_type
from	O
young	O
and	O
elderly	O
donors	O
has	O
demonstrated	O
that	O
,	O
regardless	O
of	O
donor	O
age	O
,	O
memory	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
not	O
significantly	O
altered	O
in	O
their	O
responsiveness	O
to	O
TNF-alpha	B-protein
-mediated	O
induction	O
of	O
NFkappaB	B-protein
.	O

The	O
BAT	B-DNA
box	I-DNA
and	O
Oct-2	B-protein
were	O
also	O
implicated	O
in	O
the	O
induction	O
of	O
CD20	B-protein
in	O
the	O
pre-B	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
PB-697	B-cell_line
,	O
via	O
phorbol	O
esters	O
.	O

In	O
contrast	O
,	O
several	O
mutant	O
p85	B-protein
alleles	O
had	O
dramatic	O
effects	O
on	O
NFAT	B-protein
activation	O
.	O

Viral	B-DNA
DNA	I-DNA
fragments	I-DNA
that	O
potentially	O
contain	O
oriP	B-DNA
were	O
cloned	O
into	O
a	O
plasmid	B-DNA
that	O
contains	O
the	O
hygromycin	B-DNA
resistance	I-DNA
gene	I-DNA
.	O

The	O
tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
mediates	O
the	O
transactivation	O
of	O
the	O
c-sis/platelet-derived	B-DNA
growth	I-DNA
factor-B	I-DNA
promoter	I-DNA
through	O
interactions	O
with	O
the	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
Sp1	B-protein
and	O
NGFI-A/Egr-1	B-protein
.	O

In	O
contrast	O
,	O
lipopolysaccharide	O
stimulation	O
primarily	O
induced	O
the	O
p65/p50	B-protein
heterodimer	I-protein
that	O
has	O
been	O
shown	O
to	O
result	O
in	O
gene	O
activation	O
.	O

The	O
human	B-DNA
CD19	I-DNA
gene	I-DNA
has	O
been	O
cloned	O
,	O
and	O
several	O
BSAP-binding	B-DNA
sites	I-DNA
have	O
been	O
mapped	O
by	O
in	O
vitro	O
protein-DNA	O
binding	O
studies	O
.	O

In	O
this	O
report	O
we	O
begin	O
to	O
uncover	O
the	O
influence	O
of	O
platelet-activating	B-protein
factor	I-protein
on	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

Furthermore	O
,	O
multimerized	B-DNA
region	I-DNA
II	I-DNA
sequence	I-DNA
elements	I-DNA
enhanced	O
the	O
activity	O
of	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
in	O
monocytic	B-cell_type
cells	I-cell_type
but	O
not	O
other	O
cell	O
types	O
tested	O
.	O

Our	O
data	O
constitute	O
a	O
starting	O
point	O
for	O
studies	O
to	O
elucidate	O
the	O
molecular	O
mechanism	O
by	O
which	O
TGF-beta	B-protein
regulates	O
IgA	B-protein
production	O
.	O

The	O
triptolide-induced	O
apoptosis	O
is	O
accompanied	O
by	O
increase	O
of	O
DEVD-cleavable	O
caspases	B-protein
activity	O
and	O
degradation	O
of	O
caspase	B-protein
substrate	I-protein
poly	I-protein
(	I-protein
ADP-ribose	I-protein
)	I-protein
polymerase	I-protein
(	O
PARP	B-protein
)	O
.	O

Furthermore	O
,	O
GCRbeta	B-protein
expression	O
in	O
GC-insensitive	O
asthma	O
was	O
particularly	O
high	O
in	O
airway	O
T	B-cell_type
cells	I-cell_type
,	O
which	O
are	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
.	O

Thus	O
,	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
not	O
required	O
for	O
neuroblastoma	B-cell_type
cell	O
differentiation	O
.	O

Interleukin-1	B-protein
stimulated	O
U-937	B-cell_line
cell	I-cell_line
adhesion	O
to	O
and	O
VCAM-1	B-protein
surface	O
expression	O
in	O
both	O
HUVECs	B-cell_type
and	O
HUAECs	B-cell_type
.	O

The	O
isoleucine	O
for	O
valine	O
substitution	O
at	O
amino	O
acid	O
729	O
impairs	O
the	O
function	O
of	O
the	O
hGR	B-protein
and	O
is	O
the	O
likely	O
cause	O
of	O
primary	O
cortisol	O
resistance	O
in	O
this	O
subject	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
protects	O
infected	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
apoptosis	O
.	O

The	O
genes	O
KOX	B-DNA
4	I-DNA
and	O
KOX	B-DNA
9	I-DNA
,	O
mapped	O
on	O
chromosome	B-DNA
8q24	I-DNA
,	O
were	O
found	O
to	O
be	O
located	O
within	O
a	O
DNA	B-DNA
fragment	I-DNA
of	O
450	O
kb	O
.	O

The	O
75-kD	B-protein
protein	I-protein
is	O
recognized	O
by	O
antibodies	O
to	O
SLP-76	B-protein
,	O
which	O
has	O
recently	O
been	O
isolated	O
from	O
T	B-cell_type
cells	I-cell_type
and	O
sequenced	O
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
DNA	I-DNA
of	O
the	O
15-lox	B-DNA
gene	I-DNA
contains	O
sequences	O
which	O
down-regulate	O
its	O
activity	O
in	O
a	O
variety	O
of	O
non-erythroid	B-cell_line
cell	I-cell_line
lines	I-cell_line
but	O
not	O
in	O
two	O
erythroid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
controls	O
the	O
induction	O
of	O
numerous	O
cytokine	B-DNA
promoters	I-DNA
during	O
the	O
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Signals	O
transduced	O
through	O
the	O
CD4	B-protein
molecule	I-protein
on	O
T	B-cell_type
lymphocytes	I-cell_type
activate	O
NF-kappa	B-protein
B	I-protein
.	O

These	O
findings	O
suggest	O
that	O
expression	O
of	O
the	O
1	B-protein
,	I-protein
25-	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
in	O
lymphocytes	B-cell_type
is	O
triggered	O
by	O
distinct	O
and	O
contingent	O
signals	O
,	O
and	O
that	O
the	O
protein	O
and	O
the	O
mRNA	B-RNA
encoding	O
it	O
are	O
identical	O
to	O
the	O
classical	B-protein
vitamin	I-protein
D	I-protein
receptor	I-protein
.	O

PMLRAR	O
alpha	O
transgenic	O
mice	O
exhibited	O
impaired	O
neutrophil	O
maturation	O
early	O
in	O
life	O
,	O
which	O
progressed	O
at	O
a	O
low	O
frequency	O
over	O
the	O
course	O
of	O
several	O
months	O
to	O
overt	O
APL	O
.	O

Finally	O
,	O
we	O
found	O
that	O
the	O
addition	O
of	O
NAC	O
to	O
MLR	O
between	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
allogeneic	O
DC	B-cell_type
resulted	O
in	O
a	O
profound	O
inhibition	O
of	O
alloreactive	O
responses	O
,	O
which	O
could	O
be	O
attributed	O
to	O
a	O
defect	O
of	O
DC	B-cell_type
as	O
APC-independent	O
T	O
cell	O
responses	O
were	O
not	O
inhibited	O
by	O
NAC	O
.	O

Only	O
stably	O
transfected	B-cell_line
target	I-cell_line
cells	I-cell_line
exhibited	O
cytolytic	O
susceptibility	O
,	O
despite	O
expression	O
of	O
equivalent	O
levels	O
of	O
E1A	B-protein
proteins	I-protein
in	O
Ad-infected	B-cell_line
targets	I-cell_line
.	O

Interleukin-7	B-protein
signaling	O
in	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
precursor	I-cell_line
acute	I-cell_line
lymphoblastic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
and	O
murine	B-cell_line
BAF3	I-cell_line
cells	I-cell_line
involves	O
activation	O
of	O
STAT1	B-protein
and	O
STAT5	B-protein
mediated	O
via	O
the	O
interleukin-7	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
.	O

Our	O
data	O
showed	O
that	O
TNF	B-protein
resistance	O
in	O
vitro	O
correlates	O
with	O
the	O
increased	O
level	O
of	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O

ANG	B-protein
II	I-protein
,	O
like	O
TNFalpha	B-protein
,	O
caused	O
rapid	O
activation	O
of	O
NF-kappaB	B-protein
in	O
human	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
isolated	O
from	O
peripheral	O
blood	O
by	O
Ficoll	O
density	O
gradient	O
.	O

However	O
,	O
a	O
minority	O
of	O
LYSP100	B-DNA
nuclear	O
dots	O
exactly	O
colocalized	O
with	O
PML	B-cell_type
and	O
SP100	B-protein
.	O

There	O
was	O
no	O
difference	O
in	O
glucocorticoid	B-protein
receptor	I-protein
number	O
or	O
affinity	O
between	O
depressed	O
patients	O
and	O
recovered	O
or	O
control	O
subjects	O
.	O

In	O
circulating	O
T	B-cell_type
cells	I-cell_type
from	O
a	O
subset	O
of	O
patients	O
with	O
RCCs	O
,	O
the	O
suppression	O
of	O
NFkappaB	B-protein
binding	O
activity	O
is	O
downstream	O
from	O
the	O
stimulus-induced	O
degradation	O
of	O
the	O
cytoplasmic	B-protein
factor	I-protein
IkappaBalpha	B-protein
.	O

Isoforms	O
Pax-5b	B-protein
and	O
Pax-5e	B-protein
have	O
spliced	O
out	O
their	O
second	O
exon	O
,	O
resulting	O
in	O
proteins	O
with	O
only	O
a	O
partial	O
DNA-binding	B-protein
domain	I-protein
.	O

Since	O
the	O
adenovirus	B-DNA
E2	I-DNA
promoter	I-DNA
has	O
been	O
well	O
characterized	O
and	O
is	O
known	O
to	O
be	O
regulated	O
by	O
transactivators	B-protein
encoded	O
by	O
many	O
viruses	O
,	O
the	O
activity	O
of	O
this	O
promoter	O
in	O
specific	O
cell	O
types	O
is	O
discussed	O
in	O
reference	O
to	O
both	O
the	O
biology	O
of	O
the	O
cell	O
and	O
the	O
possible	O
presence	O
of	O
as	O
yet	O
undetected	O
viral	B-protein
gene	I-protein
products	I-protein
.	O

Phosphorylation	O
of	O
the	O
retinoblastoma	B-protein
protein	I-protein
by	O
cyclin-dependent	B-protein
kinases	I-protein
4	I-protein
and	I-protein
6	I-protein
prevents	O
its	O
interaction	O
with	O
the	O
transcription	B-protein
factor	I-protein
E2F	B-protein
,	O
which	O
subsequently	O
promotes	O
the	O
expression	O
of	O
S	B-DNA
phase	I-DNA
regulated	I-DNA
genes	I-DNA
,	O
such	O
as	O
thymidine	B-protein
kinase	I-protein
.	O

Fragmentation	O
was	O
not	O
observed	O
in	O
ICR27TK.3	B-cell_line
cells	I-cell_line
containing	O
mutant	B-protein
glucocorticoid	I-protein
receptors	I-protein
(	O
L753F	B-cell_line
)	O
that	O
are	O
activation-deficient	O
but	O
retain	O
the	O
ability	O
to	O
repress	O
AP-1	B-protein
activity	O
.	O

Tyrphostin	O
AG-490	O
inhibits	O
cytokine-mediated	O
JAK3	B-protein
/STAT5a/b	B-protein
signal	O
transduction	O
and	O
cellular	O
proliferation	O
of	O
antigen-activated	O
human	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
only	O
a	O
subset	O
of	O
the	O
NSAIDs	O
induced	O
HSP70	B-RNA
mRNA	I-RNA
species	I-RNA
.	O

This	O
may	O
occur	O
through	O
the	O
ability	O
of	O
IL-10	B-protein
to	O
induce	O
expression	O
of	O
the	O
gene	O
,	O
suppressor	O
of	O
cytokine	B-protein
signaling	I-protein
3	I-protein
(	O
SOCS3	B-protein
)	O
.	O

They	O
also	O
indicate	O
that	O
abundant	O
TCL1	B-protein
expression	O
in	O
quiescent	B-cell_type
mantle	I-cell_type
zone	I-cell_type
B	I-cell_type
cells	I-cell_type
is	O
down-regulated	O
in	O
activated	O
germinal	B-cell_type
center	I-cell_type
follicular	I-cell_type
B	I-cell_type
cells	I-cell_type
in	O
parallel	O
to	O
the	O
known	O
expression	O
pattern	O
of	O
BCL-2	B-protein
.	O

Prior	O
to	O
in	O
vivo	O
IL-2	B-protein
administration	O
,	O
the	O
typical	O
binding	O
pattern	O
of	O
transcription	B-protein
factors	I-protein
in	O
PBMC	B-cell_type
from	O
patients	O
resembled	O
that	O
seen	O
in	O
fresh	O
PBMC	B-cell_type
from	O
healthy	O
individuals	O
.	O

Human	B-cell_line
U-937	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
differentiate	O
along	O
the	O
monocytic	B-cell_type
lineage	I-cell_type
following	O
3-day	O
exposures	O
to	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

These	O
results	O
do	O
not	O
lend	O
support	O
to	O
previous	O
reports	O
suggesting	O
that	O
GC	O
resistance	O
in	O
MDD	O
results	O
from	O
a	O
GC	O
receptor-binding	O
abnormality	O
,	O
and	O
they	O
emphasize	O
the	O
importance	O
of	O
considering	O
receptor	O
studies	O
in	O
the	O
context	O
of	O
GC-mediated	O
cell	O
processes	O
in	O
order	O
to	O
identify	O
the	O
exact	O
cellular	O
defect	O
(	O
s	O
)	O
leading	O
to	O
GC	O
resistance	O
.	O

Compared	O
with	O
IL-2	B-protein
,	O
CD3	B-protein
ligation	O
induces	O
a	O
delayed	O
Stat3	B-protein
binding	O
to	O
oligonucleotide	O
probes	O
from	O
the	O
ICAM-1	B-protein
and	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
.	O

The	O
system	O
is	O
based	O
on	O
the	O
use	O
of	O
an	O
oligomerized	O
NFAT-1	B-protein
binding	O
motif	O
that	O
directs	O
transcription	B-protein
of	I-protein
SV40	I-protein
T-antigen	I-protein
in	O
transgenic	O
mice	O
.	O

Using	O
limiting-dilution	O
analysis	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
,	O
a	O
high	O
RAKFKQLLQ-specific	O
CTL	O
precursor	O
frequency	O
was	O
demonstrated	O
after	O
specific	O
peptide	O
or	O
autologous	O
lymphoblastoid	O
cell	O
line	O
stimulation	O
in	O
both	O
type	O
A	O
and	O
type	O
B	O
EBV	O
carriers	O
.	O

The	O
functional	O
synergy	O
between	O
IL-2	B-protein
and	O
IL-12	B-protein
is	O
also	O
associated	O
with	O
a	O
prominent	O
increase	O
in	O
STAT1	B-protein
and	O
STAT3	B-protein
serine	O
phosphorylation	O
over	O
that	O
observed	O
with	O
IL-12	B-protein
or	O
IL-2	B-protein
alone	O
.	O

Gel	O
supershift	O
assays	O
demonstrated	O
that	O
thrombin	B-protein
induced	O
binding	O
of	O
NF-kappa	B-protein
Bp65	I-protein
(	O
Rel	B-protein
A	I-protein
)	O
to	O
downstream	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
of	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
.	O

Although	O
the	O
-20	O
GATA	B-DNA
binding	I-DNA
site	I-DNA
(	O
AGATAA	O
)	O
is	O
also	O
a	O
potential	O
TFIID	B-DNA
binding	I-DNA
site	I-DNA
,	O
it	O
does	O
not	O
bind	O
TFIID	B-protein
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
glucocorticoid	O
hormones	O
on	O
neutrophil	B-cell_type
-mediated	O
tumor	O
cell	O
cytostasis	O
and	O
found	O
that	O
hydrocortisone	O
and	O
a	O
synthetic	O
hormone	O
,	O
dexamethasone	O
(	O
Dex	O
)	O
,	O
inhibited	O
cytostasis	O
in	O
the	O
presence	O
or	O
absence	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
.	O

The	O
two	O
5'-most	B-DNA
distal	I-DNA
CArG	I-DNA
sequences	I-DNA
conferred	O
TPA	O
inducibility	O
.	O

This	O
result	O
suggests	O
that	O
expression	O
of	O
Aldh1	B-protein
protein	I-protein
is	O
negatively	O
regulated	O
by	O
Hox11	B-protein
and	O
that	O
abnormal	O
expression	O
of	O
Aldh1	B-protein
in	O
Hox11	B-protein
null	O
mice	O
may	O
cause	O
loss	O
of	O
splenic	B-cell_type
precursor	I-cell_type
cells	I-cell_type
by	O
aberrant	O
retinoic	O
acid	O
metabolism	O

After	O
corticosteroid	O
suppression	O
of	O
her	O
blood	O
eosinophilia	O
,	O
a	O
clonal	O
population	O
of	O
eosinophils	B-cell_type
could	O
no	O
longer	O
be	O
detected	O
in	O
purified	B-cell_type
eosinophils	I-cell_type
.	O

Correlations	O
were	O
found	O
between	O
plasma	B-protein
IFN	I-protein
alpha	I-protein
and	O
receptor	O
Kd	O
on	O
monocytes	B-cell_type
of	O
AIDS-GR	O
(	O
r	O
=	O
0.77	O
)	O
and	O
between	O
IFN	B-protein
alpha	I-protein
and	O
plasma	O
cortisol	O
in	O
the	O
same	O
group	O
(	O
r	O
=	O
0.74	O
)	O
.	O

A	O
high	O
expression	O
of	O
WT1	B-DNA
has	O
been	O
detected	O
in	O
a	O
range	O
of	O
acute	O
leukemias	O
,	O
and	O
WT1	B-DNA
is	O
downregulated	O
during	O
induced	O
differentiation	O
of	O
some	O
leukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Unlike	O
published	O
studies	O
with	O
pyrrolidinedithiocarbamate	O
,	O
which	O
specifically	O
inhibited	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
VCAM-1	B-protein
)	O
,	O
NAC	O
inhibited	O
IL-1	B-RNA
beta-induced	I-RNA
mRNA	I-RNA
and	O
cell	O
surface	O
expression	O
of	O
both	O
E-selectin	B-protein
and	O
VCAM-1	B-protein
.	O

We	O
have	O
found	O
that	O
,	O
in	O
the	O
human	O
pro-monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
,	O
the	O
lipopolysaccharide-induced	O
expression	O
of	O
interleukin	B-protein
1beta	I-protein
is	O
dependent	O
on	O
tyrosine	B-protein
kinase	I-protein
activation	O
.	O

These	O
results	O
suggest	O
that	O
HIV-TF1	B-protein
is	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
HIV-1	O
.	O

We	O
used	O
an	O
adenoviral	O
technique	O
of	O
blocking	O
NF-kappaB	B-protein
through	O
overexpression	O
of	O
the	O
inhibitory	B-protein
subunit	I-protein
IkappaBalpha	B-protein
,	O
which	O
has	O
the	O
advantage	O
that	O
it	O
can	O
be	O
used	O
in	O
the	O
diseased	O
tissue	O
itself	O
,	O
with	O
>	O
90	O
%	O
of	O
the	O
synovial	B-cell_type
macrophages	I-cell_type
,	O
fibroblasts	B-cell_type
,	O
and	O
T	B-cell_type
cells	I-cell_type
infected	O
.	O

Progesterone	O
effectively	O
blocked	O
a	O
broad	O
spectrum	O
of	O
K+	B-protein
channels	I-protein
,	O
reducing	O
both	O
Kv1.3	B-protein
and	O
charybdotoxin-resistant	B-protein
components	I-protein
of	O
KV	B-protein
current	O
and	O
KCa	B-protein
current	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
as	O
well	O
as	O
blocking	O
several	O
cloned	B-protein
KV	I-protein
channels	I-protein
expressed	O
in	O
cell	B-cell_line
lines	I-cell_line
.	O

The	O
effects	O
of	O
selenium	O
were	O
specific	O
for	O
NF-kappa	B-protein
B	I-protein
,	O
since	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
AP-1	B-protein
was	O
not	O
suppressed	O
.	O

Time-course	O
studies	O
revealed	O
a	O
biphasic	O
time-dependent	O
expression	O
after	O
0.5-	O
,	O
1-	O
and	O
2-Gy	O
exposures	O
.	O

Both	O
are	O
true	O
for	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O

Characterization	O
of	O
cytokine	B-protein
differential	O
induction	O
of	O
STAT	B-protein
complexes	I-protein
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
a	O
majority	O
of	O
these	O
genes	O
were	O
expressed	O
at	O
comparable	O
levels	O
in	O
U-937	B-cell_line
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O

PU.1	B-protein
is	O
completely	O
absent	O
from	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
most	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
based	O
on	O
sensitive	O
RT-PCR	O
assays	O
.	O

Human	O
myeloid	O
differentiation	O
is	O
accompanied	O
by	O
a	O
decrease	O
in	O
cell	O
proliferation	O
.	O

This	O
alteration	O
in	O
NFkappaB	B-protein
activation	O
occurred	O
in	O
the	O
presence	O
of	O
normal	O
expression	O
of	O
TCRzeta-associated	B-DNA
signaling	I-DNA
elements	I-DNA
.	O

They	O
involve	O
phosphorylation	O
and	O
proteolytic	O
reactions	O
and	O
seem	O
to	O
be	O
controlled	O
by	O
the	O
cells	O
'	O
redox	O
status	O
.	O

To	O
make	O
clear	O
the	O
roles	O
of	O
RA	O
and	O
RAR	B-protein
alpha	I-protein
in	O
the	O
normal	O
hematopoiesis	O
,	O
I	O
have	O
introduced	O
the	O
construct	O
of	O
human	B-protein
RAR	I-protein
alpha	I-protein
(	O
hRAR	B-protein
alpha	I-protein
)	O
into	O
murine	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
with	O
retroviral	O
vector	O
,	O
and	O
selected	O
infected	O
cells	O
with	O
drug	B-DNA
resistant	I-DNA
marker	I-DNA
(	O
Neo	B-DNA
(	I-DNA
r	I-DNA
)	I-DNA
)	O
cultured	O
on	O
the	O
stroma	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
PA6-neo	B-cell_line
)	O
,	O
and	O
analyzed	O
the	O
behavior	O
of	O
infected	B-cell_type
cells	I-cell_type
.	O

Studies	O
on	O
unicellular	B-cell_line
and	I-cell_line
paired	I-cell_line
daughter	I-cell_line
cell	I-cell_line
culture	I-cell_line
unequivocally	O
indicate	O
that	O
the	O
shift	O
is	O
mediated	O
by	O
modulation	O
of	O
the	O
HPC	O
differentiation	O
program	O
to	O
the	O
granulopoietic	O
pathway	O
(	O
rather	O
than	O
RA-induced	O
down-modulation	O
of	O
multipotent	O
/erythroid/monocytic	O
HPC	O
growth	O
coupled	O
with	O
recruitment	O
of	O
granulocytic	B-cell_type
HPCs	I-cell_type
)	O
.	O

One	O
site	O
is	O
similar	O
to	O
activated	O
TNFRII	B-protein
in	O
associating	O
with	O
TNFR-associated	B-protein
factors	I-protein
TRAF1	B-protein
and	O
TRAF2	B-protein
,	O
and	O
the	O
second	O
site	O
is	O
similar	O
to	O
TNFRI	B-protein
in	O
associating	O
with	O
the	O
TNFRI	B-protein
death	I-protein
domain	I-protein
interacting	I-protein
protein	I-protein
TRADD	B-protein
.	O

However	O
,	O
all	O
20	O
cases	O
lacked	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
and	O
17	O
cases	O
tested	O
lacked	O
the	O
promyelocytic/retinoic	B-RNA
acid	I-RNA
receptor	I-RNA
alpha	I-RNA
(	I-RNA
RAR	I-RNA
alpha	I-RNA
)	I-RNA
fusion	I-RNA
transcript	I-RNA
in	O
RT-PCR	O
assays	O
;	O
12	O
cases	O
had	O
46	O
,	O
XX	O
or	O
46	O
,	O
XY	O
karyotypes	O
,	O
whereas	O
2	O
cases	O
had	O
abnormalities	O
of	O
chromosome	B-DNA
17q	I-DNA
:	O
1	O
with	O
del	B-DNA
(	I-DNA
17	I-DNA
)	I-DNA
(	I-DNA
q25	I-DNA
)	I-DNA
and	O
the	O
other	O
with	O
t	B-DNA
(	I-DNA
11	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
(	I-DNA
q23	I-DNA
;	I-DNA
q21	I-DNA
)	I-DNA
and	O
the	O
promyelocytic	B-RNA
leukemia	I-RNA
zinc	I-RNA
finger/RAR	I-RNA
alpha	I-RNA
fusion	I-RNA
transcript	I-RNA
.	O

The	O
experiments	O
reported	O
in	O
this	O
study	O
were	O
designed	O
to	O
address	O
the	O
signaling	O
events	O
triggered	O
by	O
TCR	B-protein
engagement	O
that	O
are	O
important	O
for	O
regulating	O
CD95	B-protein
ligand	I-protein
gene	O
expression	O
.	O

We	O
previously	O
reported	O
that	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
a	O
synthetic	O
glucocorticoid	O
,	O
causes	O
apoptosis	O
in	O
mature	B-cell_line
Th	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
that	O
this	O
induction	O
of	O
cell	O
death	O
is	O
prevented	O
by	O
specific	O
cytokines	B-protein
,	O
namely	O
,	O
by	O
IL-2	B-protein
in	O
Th1	B-cell_type
cells	I-cell_type
and	O
by	O
IL-4	B-protein
in	O
Th2	B-cell_type
cells	I-cell_type
.	O

Murine	B-protein
and	I-protein
human	I-protein
T-lymphocyte	I-protein
GATA-3	I-protein
factors	I-protein
mediate	O
transcription	O
through	O
a	O
cis-regulatory	B-DNA
element	I-DNA
within	O
the	O
human	B-DNA
T-cell	I-DNA
receptor	I-DNA
delta	I-DNA
gene	I-DNA
enhancer	I-DNA
.	O

TSHR	B-protein
antibody	I-protein
and	O
microsomal	B-protein
antibody	I-protein
levels	O
decreased	O
after	O
surgery	O
,	O
but	O
increased	O
after	O
RAI	O
therapy	O
.	O

M-TAT	B-cell_line
is	O
a	O
cytokine-dependent	B-cell_line
cell	I-cell_line
line	I-cell_line
with	O
the	O
potential	O
to	O
differentiate	O
along	O
the	O
erythroid	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineages	I-cell_type
.	O

We	O
concluded	O
that	O
steroid	O
hormones	O
might	O
be	O
closely	O
related	O
to	O
tumor	O
cell	O
infiltration	O
of	O
some	O
malignant	B-cell_type
soft	I-cell_type
tissue	I-cell_type
tumors	I-cell_type
.	O

Improvement	O
in	O
urinary	O
protein	O
excretion	O
and	O
in	O
disease	O
activity	O
,	O
which	O
was	O
scored	O
according	O
to	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
system	O
of	O
the	O
University	O
of	O
Toronto	O
,	O
closely	O
related	O
to	O
the	O
glucocorticoid	B-protein
receptor	I-protein
concentrations	O
in	O
MNL	B-cell_type
isolated	O
from	O
the	O
corresponding	O
patients	O
.	O

Activation	O
of	O
individual	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
results	O
in	O
differential	O
lymphokine	B-protein
expression	O
:	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
is	O
preferentially	O
produced	O
by	O
T	B-cell_line
helper	I-cell_line
type	I-cell_line
1	I-cell_line
(	I-cell_line
TH1	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
which	O
are	O
involved	O
in	O
cell-mediated	O
immune	O
responses	O
,	O
whereas	O
IL-4	B-protein
is	O
synthesized	O
by	O
TH2	B-cell_line
cells	I-cell_line
,	O
which	O
are	O
essential	O
for	O
humoral	O
immunity	O
.	O

These	O
observations	O
suggest	O
that	O
TNF	B-protein
and	O
PMA	B-protein
do	O
not	O
lead	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
through	O
induction	O
of	O
changes	O
in	O
the	O
cell	O
redox	O
status	O
.	O

Inhibition	O
of	O
NF-kappaB	B-protein
has	O
been	O
achieved	O
by	O
pharmacological	O
and	O
genetic	O
approaches	O
;	O
however	O
,	O
monocyte	O
interactions	O
with	O
activated	O
endothelium	O
in	O
shear	O
flow	O
following	O
gene	O
transfer	O
of	O
the	O
NF-kappaB	B-protein
inhibitor	O
IkappaB-alpha	B-protein
have	O
not	O
been	O
studied	O
.	O

IL-1alpha	B-DNA
promoter	I-DNA
constructs	I-DNA
drive	O
transcription	O
of	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
in	O
HTLV-I-positive	B-cell_line
MT-2	I-cell_line
cells	I-cell_line
,	O
which	O
constitutively	O
produce	O
IL-1alpha	B-protein
.	O

Human	B-protein
RXR	I-protein
alpha	I-protein
was	O
significantly	O
expressed	O
in	O
U937	B-cell_line
and	I-cell_line
THP-1	I-cell_line
cells	I-cell_line
,	O
weakly	O
expressed	O
in	O
H9	B-cell_line
cells	I-cell_line
and	O
not	O
detectable	O
in	O
CEM	B-cell_line
cells	I-cell_line
.	O

They	O
also	O
provided	O
support	O
for	O
the	O
hypothesis	O
that	O
CBF	B-protein
is	O
a	O
factor	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
that	O
is	O
responsible	O
for	O
recognition	O
of	O
the	O
SL3	B-DNA
cores	I-DNA
.	O

A	O
novel	O
Ets	B-protein
protein	I-protein
was	O
isolated	O
by	O
yeast	O
one-hybrid	O
screening	O
of	O
a	O
cDNA	B-DNA
library	I-DNA
made	O
from	O
lipopolysaccharide-stimulated	B-cell_line
mouse	I-cell_line
splenic	I-cell_line
B	I-cell_line
cells	I-cell_line
,	O
using	O
the	O
SP6	B-DNA
kappa	I-DNA
promoter	I-DNA
kappaY	I-DNA
element	I-DNA
as	O
a	O
bait	O
.	O

DNA	O
band-shift	O
analysis	O
reveals	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
glial	O
cells	O
that	O
differs	O
from	O
that	O
present	O
in	O
T	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

Recent	O
studies	O
have	O
implicated	O
the	O
family	O
of	O
AP1	B-protein
factors	I-protein
as	O
components	O
of	O
the	O
murine	B-protein
NF-AT	I-protein
complex	I-protein
.	O

Nuclear	O
translocation	O
of	O
cytosolic	O
NF-kappa	O
B	O
is	O
correlated	O
with	O
a	O
number	O
of	O
LPS-inducible	O
responses	O
.	O

The	O
affinity	O
of	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
for	O
the	O
BAT	B-DNA
box	I-DNA
was	O
approximately	O
25-fold	O
less	O
than	O
for	O
the	O
octamer	B-DNA
sequence	I-DNA
and	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
dissociated	O
from	O
the	O
BAT	B-DNA
box	I-DNA
10-fold	O
more	O
rapidly	O
than	O
from	O
the	O
octamer	B-DNA
sequence	I-DNA
.	O

Cells	O
were	O
stimulated	O
with	O
endotoxin	B-protein
(	O
LPS	O
,	O
100	O
ng/mL	O
)	O
with	O
and	O
without	O
human	O
IL-10	B-protein
(	O
10	O
ng/mL	O
)	O
.	O

IFN-gamma	B-protein
has	O
potent	O
antiproliferative	O
and	O
apoptotic	O
effects	O
in	O
T	B-cell_type
cells	I-cell_type
that	O
are	O
important	O
in	O
determining	O
T	O
cell	O
development	O
and	O
polarized	O
differentiation	O
.	O

These	O
observations	O
were	O
corroborated	O
by	O
studies	O
on	O
Fas	B-protein
-mediated	O
death	O
in	O
primary	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
the	O
kinetics	O
of	O
the	O
two	O
phosphorylation	O
events	O
are	O
essentially	O
similar	O
.	O

We	O
have	O
cloned	O
the	O
mouse	O
and	O
human	O
GATA-1	B-DNA
genes	I-DNA
.	O

In	O
transfection	O
assays	O
,	O
TRADD	B-protein
and	O
TES2	B-protein
synergistically	O
mediated	O
high-level	O
NF-kappaB	B-protein
activation	O
.	O

The	O
addition	O
of	O
anti-CD28	B-protein
mAb	I-protein
to	O
anti-CD3-stimulated	B-cell_line
cells	I-cell_line
markedly	O
increased	O
IL-2	B-protein
production	O
in	O
both	O
cell	O
types	O
,	O
but	O
levels	O
of	O
IL-2	B-protein
in	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
remained	O
clearly	O
lower	O
than	O
those	O
of	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
respective	O
mean	O
values	O
:	O
385	O
+/-	O
109	O
pg/ml	O
and	O
4494	O
+/-	O
1199	O
pg/ml	O
)	O
.	O

When	O
all	O
three	O
sites	O
were	O
present	O
,	O
a	O
second	O
complex	O
``	O
a	O
''	O
was	O
detected	O
,	O
which	O
contains	O
an	O
unknown	O
member	O
of	O
the	O
Ets	B-protein
family	I-protein
.	O

These	O
concentrations	O
are	O
lower	O
than	O
concentrations	O
reported	O
to	O
activate	O
effector	O
function	O
of	O
CTL	O
recognizing	O
other	O
epithelial	B-protein
tumor	I-protein
Ag	I-protein
.	O

Apoptosis	O
induced	O
through	O
the	O
TCR	B-protein
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
mostly	O
mediated	O
by	O
the	O
inducible	O
expression	O
of	O
Fas	B-protein
ligand	I-protein
(	O
FasL	B-protein
)	O
as	O
a	O
primary	O
event	O
leading	O
to	O
the	O
commitment	O
to	O
death	O
.	O

Immediate	O
early	O
and	O
early	B-protein
lytic	I-protein
cycle	I-protein
proteins	I-protein
are	O
frequent	O
targets	O
of	O
the	O
Epstein-Barr	O
virus-induced	O
cytotoxic	O
T	O
cell	O
response	O
.	O

One	O
of	O
the	O
latter	O
elements	O
,	O
the	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
,	O
is	O
of	O
particular	O
interest	O
:	O
(	O
1	O
)	O
it	O
is	O
B	O
cell-specific	O
and	O
active	O
only	O
in	O
late	O
B	O
cell	O
development	O
;	O
(	O
2	O
)	O
in	O
rodent	O
plasmacytomas	O
and	O
in	O
some	O
human	O
Burkitt	O
's	O
lymphomas	O
it	O
is	O
part	O
of	O
a	O
locus	B-DNA
control	I-DNA
region	I-DNA
(	O
LCR	B-DNA
)	O
that	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
c-myc	B-DNA
oncogene	I-DNA
as	O
a	O
result	O
of	O
translocation	O
into	O
the	O
IgH	B-DNA
locus	I-DNA
;	O
and	O
(	O
3	O
)	O
it	O
has	O
been	O
implicated	O
in	O
the	O
mechanisms	O
that	O
control	O
Ig	B-DNA
gene	I-DNA
class	I-DNA
switch	O
recombination	O
.	O

Thus	O
,	O
despite	O
its	O
essential	O
role	O
for	O
releasing	O
an	O
elongation	B-protein
block	I-protein
,	O
Tat	B-protein
is	O
not	O
otherwise	O
absolutely	O
required	O
for	O
synthesis	O
of	O
full-length	B-RNA
HIV	I-RNA
transcripts	I-RNA
and	O
assembly	O
of	O
virus	O
particles	O
.	O

While	O
there	O
was	O
a	O
significant	O
increase	O
in	O
plasma	O
cortisol	O
levels	O
in	O
the	O
depressed	O
group	O
,	O
there	O
were	O
no	O
changes	O
in	O
the	O
lymphocyte	O
GR	B-protein
binding	O
parameters	O
(	O
K	O
(	O
m	O
)	O
and	O
Bmax	O
)	O
.	O

This	O
strategy	O
depends	O
on	O
a	O
separation	O
of	O
latency	O
and	O
the	O
lytic	O
replication	O
,	O
either	O
by	O
time	O
due	O
to	O
differentiation-dependent	O
mechanisms	O
or	O
by	O
spatial	O
separation	O
as	O
the	O
result	O
of	O
different	O
host	O
cell	O
types	O
.	O

Glucocorticoids	O
(	O
GCS	O
)	O
profoundly	O
inhibit	O
several	O
aspects	O
of	O
T	O
cell	O
immunity	O
largely	O
through	O
inhibition	O
of	O
cytokine	B-protein
expression	O
at	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

To	O
investigate	O
whether	O
the	O
molar	O
ratio	O
of	O
HSF2-alpha	B-protein
and	O
HSF2-beta	B-protein
isoforms	O
is	O
crucial	O
for	O
the	O
activation	O
of	O
HSF2	B-protein
and	O
whether	O
the	O
HSF2	B-protein
isoforms	O
play	O
functionally	O
distinct	O
roles	O
during	O
the	O
hemin-mediated	O
erythroid	O
differentiation	O
,	O
we	O
generated	O
cell	O
clones	O
expressing	O
different	O
levels	O
of	O
HSF2-alpha	B-protein
and	O
HSF2-beta	B-protein
.	O

We	O
have	O
used	O
immunolabeling	O
,	O
Western	O
blot	O
analysis	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
.	O

On	O
the	O
contrary	O
,	O
32Dcl3	B-cell_line
cells	I-cell_line
stably	O
expressing	O
AML1/ETO	B-DNA
were	O
completely	O
resistant	O
to	O
differentiation	O
and	O
continued	O
to	O
grow	O
in	O
the	O
presence	O
of	O
G-CSF	B-protein
.	O

Our	O
data	O
also	O
suggest	O
that	O
,	O
unlike	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
is	O
constitutively	O
phosphorylated	O
and	O
resynthesized	O
as	O
a	O
hypophosphorylated	B-protein
form	I-protein
.	O

However	O
,	O
viruses	O
containing	O
mutations	O
in	O
either	O
the	O
TAR	B-DNA
loop	I-DNA
sequences	I-DNA
or	O
stem	O
secondary	O
structure	O
which	O
were	O
very	O
defective	O
for	O
gene	O
expression	O
in	O
untreated	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
gave	O
nearly	O
wild-type	O
levels	O
of	O
gene	O
expression	O
in	O
phorbol	B-cell_line
ester-treated	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
but	O
not	O
in	O
phorbol	B-cell_line
ester-treated	I-cell_line
HeLa	I-cell_line
or	O
U937	B-cell_line
cells	I-cell_line
.	O

But	O
the	O
logarithmic	O
mean	O
of	O
ER	B-protein
content	O
in	O
lymphocytes	B-cell_type
,	O
expressed	O
by	O
fmol/mg	O
of	O
cytosolic	B-protein
protein	I-protein
,	O
in	O
14	O
patients	O
with	O
active	O
SLE	O
(	O
0.9356	O
+/-	O
0.31	O
)	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
13	O
patients	O
with	O
inactive	O
SLE	O
(	O
0.2979	O
+/-	O
0.23	O
,	O
P	O
less	O
than	O
0.001	O
)	O
and	O
in	O
the	O
controls	O
(	O
0.6204	O
+/-	O
0.52	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O

It	O
contains	O
a	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
motif	I-protein
contiguous	O
with	O
a	O
Per-Arnt-Sim	B-protein
(	I-protein
PAS	I-protein
)	I-protein
homology	I-protein
region	I-protein
.	O

CONCLUSIONS	O
.	O

Activation	O
of	O
Stat-3	B-protein
is	O
involved	O
in	O
the	O
induction	O
of	O
apoptosis	O
after	O
ligation	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
I	I-protein
molecules	I-protein
on	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
the	O
immunosuppressive	O
effect	O
of	O
oxLDLs	B-protein
might	O
operate	O
via	O
a	O
dysregulation	O
of	O
the	O
T-lymphocyte	B-cell_type
activation	O
mechanisms	O
.	O

Three	O
HSV/VZV	B-DNA
recombinants	I-DNA
were	O
generated	O
:	O
(	O
1	O
)	O
VZV	B-DNA
gE	I-DNA
protein	I-DNA
coding	I-DNA
sequences	I-DNA
along	O
with	O
the	O
promoter	B-protein
region	I-protein
were	O
inserted	O
into	O
the	O
thymidine	B-DNA
kinase	I-DNA
(	I-DNA
TK	I-DNA
)	I-DNA
gene	I-DNA
of	O
HSV-1	O
strain	O
KOS	O
;	O
(	O
2	O
)	O
VZV	B-protein
gE	I-protein
expressed	O
from	O
the	O
HSV-1	B-DNA
ICP4	I-DNA
promoter	I-DNA
was	O
inserted	O
into	O
the	O
glycoprotein	B-DNA
C	I-DNA
(	I-DNA
gC	I-DNA
)	I-DNA
gene	I-DNA
of	O
HSV-1	O
strain	O
F	O
;	O
and	O
(	O
3	O
)	O
VZV	B-DNA
IE62	I-DNA
protein	I-DNA
coding	I-DNA
sequences	I-DNA
under	O
the	O
control	O
of	O
the	O
HSV-1	B-DNA
ICP4	I-DNA
promoter	I-DNA
were	O
inserted	O
into	O
the	O
gC	B-DNA
gene	I-DNA
of	O
HSV-1	O
strain	O
F	O
.	O

Increased	O
glucocorticoid	O
responsiveness	O
of	O
CD4+	B-cell_line
T-cell	I-cell_line
clonal	I-cell_line
lines	I-cell_line
grown	O
in	O
serum-free	O
media	O
.	O

Redox	O
regulation	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathway	O
during	O
lymphocyte	O
activation	O
.	O

The	O
defensin	B-protein
sensitivities	O
of	O
Salmonella	O
typhimurium	O
strains	O
with	O
mutations	O
in	O
the	O
phoP/phoQ	B-DNA
two-component	I-DNA
virulence	I-DNA
regulon	I-DNA
were	O
tested	O
by	O
using	O
purified	B-protein
defensins	I-protein
NP-1	B-protein
and	O
NP-2	B-protein
.	O

IL-2R	O
chains	O
were	O
measured	O
by	O
flow	O
cytometry	O
,	O
and	O
Jaks/Stats	B-protein
by	O
sodium	O
dodecyl	O
sulfate	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS-PAGE	O
)	O
and	O
Western	O
blot	O
.	O

Constitutive	O
activation	O
of	O
NF-kB	B-protein
in	O
human	B-cell_type
thymocytes	I-cell_type
.	O

Proteins	O
of	O
the	O
ATF/	O
CREB	B-protein
class	O
of	O
transcription	B-protein
factors	I-protein
stimulate	O
gene	O
expression	O
of	O
several	O
cell	B-DNA
growth-related	I-DNA
genes	I-DNA
through	O
protein	B-DNA
kinase	I-DNA
A-related	I-DNA
cAMP	I-DNA
response	I-DNA
elements	I-DNA
.	O

Because	O
of	O
cell	O
type-specific	O
alternative	O
messenger	O
RNA	O
splicing	O
,	O
B-cell	B-protein
Fc	I-protein
gamma	I-protein
RII	I-protein
contains	O
an	O
insertion	O
of	O
47	O
amino	O
acids	O
that	O
participates	O
in	O
determining	O
receptor	O
function	O
in	O
these	O
cells	O
.	O

This	O
effect	O
is	O
blocked	O
by	O
anti-VCAM	B-protein
antibodies	I-protein
.	O

Application	O
of	O
this	O
form	O
of	O
testing	O
should	O
prove	O
valuable	O
in	O
screening	O
for	O
signaling	O
defects	O
in	O
selected	O
patients	O
with	O
recurrent	O
infections	O
.	O

Perhaps	O
murine	B-cell_type
thymocytes	I-cell_type
are	O
denied	O
this	O
form	O
of	O
rescue	O
because	O
they	O
shut	O
off	O
IL-2R	B-protein
beta	I-protein
chain	I-protein
expression	O
at	O
an	O
earlier	O
stage	O
or	O
because	O
they	O
may	O
be	O
uncommonly	O
Bcl-2	B-protein
deficient	O
(	O
cf.	O
Sentman	O
et	O
al.	O
,	O
1991	O
;	O
Strasser	O
et	O
al.	O
,	O
1991	O
)	O
.	O

We	O
further	O
show	O
that	O
subdominant	O
latent	O
cycle	O
reactivities	O
to	O
epitopes	O
in	O
the	O
latent	B-protein
membrane	I-protein
protein	I-protein
LMP2	I-protein
,	O
though	O
rarely	O
undetectable	O
in	O
LCL	B-cell_line
-stimulated	O
populations	O
,	O
can	O
be	O
reactivated	O
by	O
DC	O
stimulation	O
and	O
selectively	O
expanded	O
as	O
polyclonal	O
CTL	B-cell_line
lines	I-cell_line
;	O
the	O
adoptive	O
transfer	O
of	O
such	O
preparations	O
may	O
be	O
of	O
value	O
in	O
targeting	O
certain	O
EBV-positive	O
malignancies	O
.	O

When	O
peripheral	O
murine	O
monocytes	B-cell_type
that	O
do	O
not	O
express	O
the	O
lipoxygenase	B-protein
were	O
treated	O
with	O
IL-4	B-protein
expression	O
of	O
12/15-lipoxygenase	B-RNA
mRNA	I-RNA
was	O
induced	O
,	O
suggesting	O
pretranslational	O
control	O
mechanisms	O
.	O

Detailed	O
histogenetic	O
characterization	O
of	O
these	O
novel	O
PEL	B-cell_line
cell	I-cell_line
lines	I-cell_line
suggests	O
that	O
PEL	B-cell_line
may	O
derive	O
from	O
a	O
post-germinal	B-cell_line
centre	I-cell_line
B	I-cell_line
cell	I-cell_line
which	O
has	O
undergone	O
pre-terminal	O
differentiation	O
.	O

This	O
may	O
be	O
the	O
basis	O
of	O
the	O
therapeutic	O
effect	O
on	O
the	O
disease	O
.	O

Seventeen	O
cases	O
revealed	O
distinct	O
immunostaining	O
against	O
at	O
least	O
1	O
of	O
the	O
5	O
steroid	O
hormones	O
.	O

However	O
,	O
the	O
plasma	O
cortisol	O
was	O
high	O
(	O
66	O
microg/100	O
ml	O
at	O
10	O
:	O
00	O
h	O
;	O
N	O
:	O
8-15	O
)	O
and	O
the	O
ACTH	O
was	O
normal	O
(	O
13	O
pg/ml	O
,	O
N	O
:	O
10-60	O
)	O
;	O
there	O
was	O
a	O
marked	O
increase	O
in	O
plasma	O
renin	O
activity	O
(	O
>	O
37	O
ng/ml/h	O
;	O
N	O
supine	O
<	O
3	O
)	O
,	O
active	O
renin	O
(	O
869	O
pg/ml	O
;	O
N	O
supine	O
:	O
1.120	O
)	O
,	O
aldosterone	O
(	O
>	O
2000	O
pg/ml	O
;	O
N	O
supine	O
<	O
150	O
)	O
and	O
plasma	O
AVP	O
(	O
20	O
pmol/l	O
;	O
N	O
:	O
0.5-2.5	O
)	O
.	O

Functional	O
analysis	O
of	O
5	B-DNA
'	I-DNA
deletion	I-DNA
constructs	I-DNA
in	O
transfected	O
K562	B-cell_line
cells	I-cell_line
and	O
gel	O
mobility	O
shift	O
localized	O
the	O
major	O
phorbol	O
ester-responsive	O
motifs	O
in	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
promoter	O
to	O
a	O
cluster	O
of	O
activator	B-DNA
protein-2	I-DNA
(	I-DNA
AP-2	I-DNA
)	I-DNA
binding	I-DNA
consensus	I-DNA
sites	I-DNA
located	O
approximately	O
1.8	O
kb	O
5	O
'	O
from	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O

This	O
effect	O
can	O
be	O
associated	O
with	O
the	O
activation	O
of	O
specific	O
hormone	O
receptors	O
,	O
since	O
we	O
observed	O
the	O
expression	O
of	O
the	O
estrogen	B-RNA
receptor	I-RNA
alpha	I-RNA
(	I-RNA
ER-alpha	I-RNA
)	I-RNA
,	I-RNA
ER-beta	I-RNA
,	I-RNA
and	I-RNA
progesterone	I-RNA
receptor	I-RNA
(	I-RNA
PR	I-RNA
)	I-RNA
mRNAs	I-RNA
;	O
the	O
ER-alpha	B-protein
protein	O
expression	O
was	O
confirmed	O
by	O
immunocytochemical	O
analysis	O
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
plays	O
an	O
important	O
role	O
in	O
the	O
apoptotic	O
process	O
of	O
human	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
.	O

The	O
protein	O
components	O
of	O
this	O
complex	O
are	O
specifically	O
competed	O
by	O
an	O
AP1	B-DNA
consensus	I-DNA
motif	I-DNA
and	O
were	O
shown	O
by	O
supershift	O
to	O
include	O
c-Jun	B-protein
and	O
c-Fos	B-protein
,	O
suggesting	O
that	O
this	O
binding	B-DNA
site	I-DNA
is	O
an	O
AP1	B-DNA
motif	I-DNA
and	O
that	O
the	O
Jun	B-protein
and	I-protein
Fos	I-protein
families	I-protein
of	O
transcription	B-protein
factors	I-protein
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
the	O
kappa	B-DNA
light	I-DNA
chain	I-DNA
gene	I-DNA
.	O

Epo	B-protein
elicited	O
a	O
rapid	O
,	O
dose-related	O
increase	O
in	O
TAL1	B-RNA
mRNA	I-RNA
by	O
increasing	O
transcription	O
of	O
the	O
gene	O
and	O
stabilizing	O
one	O
of	O
its	O
mRNAs	B-RNA
.	O

Tax1	B-protein
,	O
a	O
potent	O
activator	O
of	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
transcription	O
,	O
has	O
been	O
shown	O
to	O
modulate	O
expression	O
of	O
many	O
cellular	B-DNA
genes	I-DNA
.	O

Pharmacological	O
control	O
of	O
antigen	O
responsiveness	O
in	O
genetically	B-cell_line
modified	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

The	O
addition	O
of	O
CD27	O
ligand	O
(	O
CD70	O
)	O
transfectants	O
to	O
B	B-cell_line
cell	I-cell_line
cultures	I-cell_line
increased	O
the	O
IgE	B-protein
synthesis	O
synergistically	O
in	O
the	O
presence	O
of	O
IL-4	B-protein
plus	O
anti-CD40	B-protein
mAb	I-protein
(	O
anti-CD40	B-protein
)	O
.	O

These	O
results	O
suggest	O
that	O
activation	O
of	O
the	O
protein	B-protein
kinase	I-protein
A	I-protein
pathway	O
inhibits	O
NF-kappaB	B-protein
transcription	O
by	O
phosphorylating	O
CREB	B-protein
,	O
which	O
competes	O
with	O
p65	B-protein
for	O
limiting	O
amounts	O
of	O
CBP	B-protein
.	O

Thus	O
,	O
HTLV-I	B-protein
Tax	I-protein
,	O
HTLV-II	B-protein
Tax	I-protein
,	O
and	O
c-jun	B-protein
transactivate	O
PTHrP	B-protein
and	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
hypercalcemia	O
in	O
adult	O
T-cell	O
leukemia	O
.	O

Various	O
stimuli	O
of	O
T	B-cell_type
cells	I-cell_type
that	O
induce	O
the	O
activity	O
of	O
TAD-A	B-protein
also	O
enhance	O
the	O
activity	O
of	O
TAD-B	B-protein
,	O
but	O
,	O
unlike	O
TAD-A	B-protein
,	O
TAD-B	B-protein
remains	O
unphosphorylated	O
by	O
protein	O
from	O
12-O-tetradecanoyl	B-cell_line
12-phorbol	I-cell_line
13-acetate-stimulated	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Binding	B-DNA
sites	I-DNA
at	O
the	O
core	O
region	O
show	O
little	O
conservation	O
with	O
consensus	B-DNA
sites	I-DNA
.	O

MHC-peptide	O
ligand	O
interactions	O
establish	O
a	O
functional	O
threshold	O
for	O
antigen-specific	O
T	O
cell	O
recognition	O
.	O

Amplified	O
c-erbB2	B-DNA
gene	I-DNA
sequences	I-DNA
were	O
present	O
in	O
21.5	O
%	O
of	O
all	O
samples	O
.	O

Three	O
cases	O
were	O
predicted	O
to	O
be	O
TSC2	B-DNA
mutations	I-DNA
on	O
the	O
basis	O
of	O
linkage	O
analysis	O
or	O
because	O
a	O
hamartoma	O
from	O
the	O
patient	O
showed	O
loss	O
of	O
heterozygosity	O
for	O
16p13.3	B-DNA
markers	I-DNA
.	O

In	O
addition	O
to	O
Zap-70	B-protein
,	O
the	O
3BP2	B-protein
SH2	I-protein
domain	I-protein
associated	O
in	O
vitro	O
with	O
LAT	B-protein
,	O
Grb2	B-protein
,	O
PLCgamma1	B-protein
,	O
and	O
Cbl	B-protein
from	O
activated	O
T	O
cell	O
lysates	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
aspirin	O
inhibits	O
NF-kappa	B-protein
B	I-protein
mobilization	O
,	O
induction	O
of	O
VCAM-1	B-protein
and	O
E-selectin	B-protein
,	O
and	O
subsequent	O
monocyte	O
adhesion	O
in	O
endothelial	B-cell_type
cells	I-cell_type
stimulated	O
by	O
TNF	B-protein
,	O
thereby	O
providing	O
an	O
additional	O
mechanism	O
for	O
therapeutic	O
effects	O
of	O
aspirin	O
.	O

A	O
mechanism	O
is	O
suggested	O
whereby	O
expression	O
of	O
c-jun	B-DNA
and	O
junB	B-DNA
,	O
in	O
the	O
absence	O
of	O
members	O
of	O
the	O
fos	B-DNA
family	I-DNA
,	O
can	O
prevent	O
inappropriate	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
caused	O
by	O
ligation	O
of	O
CD28	B-protein
in	O
the	O
absence	O
of	O
a	O
specific	O
antigenic	O
stimulus	O
.	O

In	O
summary	O
,	O
CD40	B-protein
signaling	O
preferentially	O
induces	O
SAPK	B-protein
but	O
not	O
MAPK	B-protein
.	O

These	O
protoenhancers	B-DNA
alone	O
are	O
weakly	O
or	O
not	O
responsive	O
to	O
R	B-protein
.	O

In	O
T	B-cell_type
cells	I-cell_type
,	O
HIV	O
transcription	O
is	O
poorly	O
detected	O
in	O
vivo	O
.	O

Overexpression	O
of	O
a	O
phosphorylation-defective	O
form	O
of	O
Rb	B-protein
inhibited	O
Elf-1	B-protein
-dependent	O
transcription	O
during	O
T	B-cell_type
cell	I-cell_type
activation	O
.	O

We	O
show	O
that	O
the	O
transcription	B-protein
factor	I-protein
NFATc	B-protein
was	O
sufficient	O
as	O
a	O
cellular	O
factor	O
to	O
induce	O
a	O
highly	O
permissive	O
state	O
for	O
HIV-1	O
replication	O
in	O
primary	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
retrodifferentiated	O
cells	O
detached	O
from	O
the	O
substrate	O
and	O
reinitiated	O
proliferation	O
.	O

Identification	O
of	O
a	O
major	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
located	O
5	O
'	O
to	O
the	O
human	B-DNA
zeta-globin	I-DNA
gene	I-DNA
.	O

We	O
found	O
that	O
in	O
both	O
cell	O
lines	O
,	O
both	O
phorbol	O
ester	O
and	O
TNF	B-protein
alpha	I-protein
were	O
able	O
to	O
activate	O
NF-kappa	B-protein
B	I-protein
.	O

In	O
uterine	O
decidua	O
,	O
we	O
found	O
29.9	O
%	O
CD3+	B-cell_type
cells	I-cell_type
(	O
2.2	O
%	O
of	O
CD3+	O
were	O
CD8+	O
)	O
,	O
51.6	O
%	O
CD56+	B-cell_type
cells	I-cell_type
and	O
18.5	O
%	O
CD68+	B-cell_type
cells	I-cell_type
.	O

Moreover	O
,	O
antisense	O
oligodeoxynucleotides	O
targeting	O
either	O
GATA-1	B-protein
or	O
p45	B-protein
NF-E2	I-protein
proteins	O
inhibited	O
both	O
protein	O
expression	O
and	O
BA-induced	O
differentiation	O
.	O

The	O
extent	O
to	O
which	O
analog	O
activity	O
was	O
increased	O
after	O
cotreatment	O
with	O
RA	O
was	O
inversely	O
related	O
to	O
potency	O
.	O

We	O
have	O
purified	O
the	O
RFX	B-protein
complex	I-protein
and	O
sequenced	O
its	O
three	O
subunits	O
.	O

Adhesion	O
of	O
monocytoid	B-cell_line
U937	I-cell_line
cells	I-cell_line
to	O
LPS-treated	O
endothelial	O
cells	O
was	O
reduced	O
concomitantly	O
.	O

The	O
mechanism	O
of	O
this	O
effect	O
is	O
that	O
Bcl-2	B-protein
prevents	O
the	O
nuclear	O
translocation	O
of	O
NFAT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
lymphocytes	I-protein
,	O
a	O
transcription	B-protein
factor	I-protein
activated	O
by	O
microtubule	B-protein
damage	O
)	O
by	O
binding	O
and	O
sequestering	O
calcineurin	O
,	O
a	O
calcium-dependent	O
phosphatase	O
that	O
must	O
dephosphorylate	O
NFAT	B-protein
to	O
move	O
to	O
the	O
nucleus	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
measured	O
levels	O
of	O
TF	B-protein
activity	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
highly	B-cell_type
purified	I-cell_type
monocytes/macrophages	I-cell_type
from	O
10	O
consecutive	O
cardiac	O
transplant	O
recipients	O
and	O
10	O
healthy	O
control	O
subjects	O
.	O

Clonal	O
analysis	O
revealed	O
individual	O
responses	O
to	O
the	O
two	O
immediate	B-protein
early	I-protein
proteins	I-protein
BZLF1	B-protein
and	O
BRLF1	B-protein
,	O
and	O
to	O
three	O
(	O
BMLF1	B-protein
,	O
BMRF1	B-protein
,	O
and	O
BALF2	B-protein
)	O
of	O
the	O
six	O
early	B-protein
proteins	I-protein
tested	O
.	O

Using	O
Western	O
blot	O
analysis	O
with	O
a	O
monoclonal	B-protein
antibody	I-protein
recognizing	O
a	O
17-amino	B-protein
acid	I-protein
epitope	I-protein
of	O
the	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3	I-protein
[	I-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
]	I-protein
receptor	I-protein
,	O
we	O
have	O
detected	O
two	O
crossreacting	B-protein
proteins	I-protein
in	O
activated	B-cell_type
normal	I-cell_type
human	I-cell_type
lymphocytes	I-cell_type
.	O

Using	O
human	B-cell_line
B-	I-cell_line
or	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
transfected	O
with	O
ZpCat	B-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
,	O
we	O
demonstrate	O
that	O
a	O
region	O
designated	O
the	O
ZII	B-DNA
domain	I-DNA
of	O
Zp	B-DNA
is	O
the	O
target	O
of	O
HHV-6	O
transactivation	O
.	O

We	O
sought	O
to	O
determine	O
the	O
activities	O
of	O
various	O
environmental	O
estrogens	O
on	O
the	O
modulation	O
of	O
the	O
interleukin-1beta	B-DNA
(	I-DNA
IL-1beta	I-DNA
)	I-DNA
gene	I-DNA
in	O
a	O
model	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
hER	B-cell_line
+	I-cell_line
IL-1beta-CAT+	I-cell_line
.	O

Mass	O
spectrometry	O
studies	O
performed	O
on	O
a	O
synthetic	O
peptide	O
mapping	O
over	O
the	O
cleavage	B-protein
domain	I-protein
of	O
alphaIIbH	B-protein
predicted	O
the	O
site	O
of	O
proteolysis	O
as	O
located	O
between	O
Val837	O
and	O
Asp838	O
.	O

UV	O
cross-linking	O
experiments	O
suggested	O
that	O
a	O
distinct	O
E2F	B-protein
DNA-binding	O
protein	O
is	O
uniquely	O
associated	O
with	O
the	O
S-phase	B-protein
p107	I-protein
complex	I-protein
and	O
is	O
not	O
associated	O
with	O
Rb	B-protein
.	O

Human	O
T	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
infects	O
T	B-cell_type
cells	I-cell_type
and	O
can	O
lead	O
to	O
increase	O
GM-CSF	B-protein
expression	O
.	O

These	O
data	O
indicate	O
that	O
TCL1	B-DNA
is	O
activated	O
in	O
preleukemic	B-cell_line
clonal	I-cell_line
cells	I-cell_line
as	O
a	O
consequence	O
of	O
chromosome	O
translocation	O
involving	O
sequences	O
from	O
the	O
TCR	B-DNA
locus	I-DNA
at	O
14q11	B-DNA
.	O

When	O
mouse	B-cell_line
MPC11	I-cell_line
plasmacytoma	I-cell_line
cells	I-cell_line
,	O
in	O
which	O
the	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
is	O
active	O
,	O
are	O
fused	O
with	O
fibroblasts	B-cell_type
,	O
Ig	O
expression	O
is	O
extinguished	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Thymic	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
mediate	O
negative	O
selection	O
at	O
a	O
relatively	O
late	O
stage	O
of	O
the	O
T-cell	O
developmental	O
pathway	O
.	O

IL-2R	B-protein
alpha	I-protein
transcription	O
is	O
at	O
least	O
in	O
part	O
controlled	O
by	O
two	O
positive	B-protein
regulatory	I-protein
regions	I-protein
,	O
PRRI	B-DNA
and	O
PRRII	B-DNA
.	O

Here	O
we	O
summarize	O
studies	O
which	O
investigate	O
the	O
mechanism	O
by	O
which	O
these	O
cytokines	B-protein
selectively	O
reprogramme	O
gene	O
expression	O
in	O
T-lymphocytes	B-cell_type
.	O

We	O
,	O
therefore	O
,	O
examined	O
glucocorticoid	B-protein
receptor	I-protein
characteristics	O
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
which	O
is	O
one	O
of	O
the	O
effects	O
of	O
glucocorticoid	B-protein
receptor	I-protein
activation	O
.	O

Using	O
mitogen	O
stimulated	O
and	O
quiescent	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
and	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
we	O
compared	O
differences	O
in	O
basal	O
transcription	O
and	O
amounts	O
and	O
binding	O
of	O
transcription	B-protein
factors	I-protein
with	O
TRE-1	B-DNA
.	O

The	O
position	O
of	O
the	O
ZEBRA	B-protein
activation	I-protein
domain	I-protein
does	O
not	O
influence	O
its	O
biological	O
activity	O
.	O

We	O
questioned	O
whether	O
these	O
differences	O
might	O
reflect	O
patterns	O
of	O
intracellular	O
signal	O
transduction	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
vincristine-selected	O
,	O
multidrug	O
resistance	O
on	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
-induced	O
HL-60	O
cell	O
differentiation	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
IVS1-10T	O
--	O
>	O
C	O
deleteriously	O
affected	O
BRCA1	B-DNA
splicing	O
or	O
expression	O
,	O
and	O
thereby	O
inactivated	O
the	O
other	O
BRCA1	B-DNA
allele	I-DNA
.	O

This	O
result	O
implies	O
that	O
development	O
of	O
anti-E.	B-protein
chaffeensis	I-protein
antibody	I-protein
in	O
patients	O
can	O
result	O
in	O
the	O
production	O
of	O
major	B-protein
proinflammatory	I-protein
cytokines	I-protein
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
ehrlichiosis	O
and	O
immune	O
responses	O
to	O
it	O
.	O

Competent	O
transcription	O
initiation	O
by	O
RNA	B-protein
polymerase	I-protein
II	I-protein
in	O
cell-free	B-cell_type
extracts	I-cell_type
from	O
xeroderma	O
pigmentosum	O
groups	O
B	O
and	O
D	O
in	O
an	O
optimized	O
RNA	O
transcription	O
assay	O
.	O

IL-4	B-protein
may	O
mediate	O
its	O
biological	O
effects	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
activating	O
a	O
tyrosine-phosphorylated	B-protein
DNA	I-protein
binding	I-protein
protein	I-protein
.	O

The	O
myb	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
has	O
been	O
strongly	O
implicated	O
in	O
the	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
in	O
the	O
haematopoietic	O
system	O
.	O

The	O
suppression	O
of	O
endogenous	O
corticosterone	O
in	O
plasma	B-cell_type
for	O
both	O
treatments	O
was	O
similar	O
with	O
values	O
from	O
L-MPL	O
rats	O
returning	O
to	O
baseline	O
after	O
24	O
h	O
.	O

In	O
contrast	O
,	O
AP-1	B-protein
generation	O
was	O
inhibited	O
by	O
wortmannin	O
and	O
was	O
also	O
variably	O
sensitive	O
to	O
chloroquine	O
.	O

Three	O
overlapping	O
PCR	B-DNA
products	I-DNA
,	O
covering	O
the	O
complete	O
coding	O
sequence	O
of	O
mRNA	B-RNA
,	O
were	O
generated	O
from	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
translated	O
into	O
35S-methionine	B-protein
labelled	I-protein
protein	I-protein
,	O
and	O
analysed	O
by	O
SDS-PAGE	O
.	O

Although	O
hypoxia	O
alone	O
did	O
not	O
induce	O
ICAM-1	B-protein
,	O
the	O
combination	O
of	O
LPS	O
and	O
hypoxia	O
enhanced	O
(	O
3	O
+/-	O
0.4-fold	O
over	O
normoxia	O
)	O
ICAM-1	B-protein
expression	O
.	O

HIV	B-DNA
enhancer	I-DNA
activity	O
perpetuated	O
by	O
NF-kappa	B-protein
B	I-protein
induction	O
on	O
infection	O
of	O
monocytes	B-cell_type
[	O
see	O
comments	O
]	O

These	O
data	O
demonstrate	O
that	O
DMDTC	O
is	O
a	O
potent	O
immunosuppressive	O
compound	O
in	O
vitro	O
.	O

We	O
compared	O
the	O
pattern	O
using	O
nuclear	O
extracts	O
from	O
human	O
brain	O
and	O
lymphocytes	B-cell_type
.	O

Abnormalities	O
of	O
I	O
or	O
more	O
signaling	B-protein
molecules	I-protein
were	O
found	O
in	O
9	O
of	O
14	O
patients	O
;	O
however	O
,	O
only	O
3	O
patients	O
had	O
T	B-cell_type
cells	I-cell_type
that	O
exhibited	O
all	O
5	O
defects	O
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
complementary	B-DNA
DNA	I-DNA
resulted	O
in	O
the	O
synthesis	O
of	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
size	O
of	O
65	B-protein
kilodaltons	I-protein
(	O
kD	O
)	O
.	O

NF-kappa	B-protein
B	I-protein
(	O
P65	B-protein
or	O
P65/P50	B-protein
heterodimer	I-protein
)	O
bound	O
to	O
the	O
P	B-DNA
sequence	I-DNA
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
and	O
activated	O
transcription	O
through	O
the	O
P	B-DNA
sequence	I-DNA
when	O
expression	B-DNA
plasmids	I-DNA
were	O
cotransfected	O
with	O
P	B-DNA
sequence-driven	I-DNA
reporter	I-DNA
plasmids	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Expression	O
of	O
the	O
protooncogene	B-DNA
c-fos	I-DNA
is	O
controlled	O
by	O
three	O
main	O
regulatory	O
pathways	O
involving	O
kinase	B-protein
C	I-protein
,	O
cAMP	O
,	O
and	O
calcium	O
.	O

ZAP-70	B-protein
will	O
then	O
be	O
able	O
to	O
effectively	O
control	O
phosphorylation	O
of	O
its	O
substrates	O
and	O
lead	O
to	O
gene	O
activation	O
.	O

In	O
myeloid	B-cell_type
cells	I-cell_type
,	O
CD38	B-protein
is	O
expressed	O
during	O
early	O
stages	O
of	O
differentiation	O
.	O

Zinc	O
is	O
an	O
important	O
trace	O
element	O
for	O
immune	O
function	O
.	O

Atopy	O
,	O
which	O
predisposes	O
individuals	O
to	O
develop	O
asthma	O
,	O
severe	O
systemic	O
anaphylaxis	O
,	O
and	O
atopic	O
dermatitis	O
,	O
is	O
usually	O
associated	O
with	O
dramatically	O
elevated	O
total	O
serum	O
IgE	B-protein
levels	O
and	O
is	O
thought	O
to	O
be	O
controlled	O
by	O
a	O
major	O
susceptibility	B-DNA
gene	I-DNA
and	O
multiple	O
minor	O
susceptibility	B-DNA
genes	I-DNA
.	O

This	O
effect	O
is	O
thought	O
to	O
be	O
largely	O
mediated	O
through	O
inactivation	O
of	O
the	O
phosphatase	O
calcineurin	B-protein
,	O
which	O
in	O
turn	O
inhibits	O
translocation	O
of	O
an	O
NFAT	B-protein
component	O
to	O
the	O
nucleus	O
.	O

Carboxylesterases	B-protein
play	O
an	O
important	O
role	O
in	O
defense	O
and	O
clearance	O
mechanisms	O
of	O
the	O
monocyte/macrophage	O
system	O
.	O

NF-AT	B-protein
and	O
NF-kappaB	B-protein
were	O
not	O
significantly	O
induced	O
by	O
IL-2	B-protein
stimulation	O
.	O

In	O
this	O
study	O
we	O
determined	O
the	O
effects	O
of	O
SAC	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
(	O
Jurkat	B-cell_line
cells	I-cell_line
)	O
induced	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-	B-protein
alpha	I-protein
)	O
and	O
H2O2	O
.	O

Natural	O
variants	O
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
:	O
analysis	O
of	O
promoters	B-DNA
with	O
duplicated	O
DNA	B-DNA
regulatory	I-DNA
motifs	I-DNA
.	O

PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
dropped	O
significantly	O
in	O
patients	O
who	O
received	O
adjuvant	O
chemotherapy	O
consisting	O
of	O
cyclophosphamide	O
,	O
methotrexate	O
and	O
fluorouracil	O
(	O
CMF	O
)	O
after	O
an	O
observation	O
period	O
of	O
6	O
months	O
(	O
P	O
<	O
0.01	O
)	O
,	O
but	O
not	O
in	O
patients	O
under	O
adjuvant	O
treatment	O
with	O
tamoxifen	O
only	O
.	O

Mutagenesis	O
studies	O
,	O
and	O
the	O
use	O
of	O
a	O
reporter	O
construct	O
containing	O
an	O
enhancerless	O
promoter	O
,	O
indicate	O
that	O
these	O
transcriptional	O
effects	O
are	O
due	O
principally	O
to	O
the	O
22-bp	B-DNA
sequence	I-DNA
duplication	I-DNA
and	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
contained	O
within	O
it	O
.	O

Adhesion	O
to	O
extracellular	O
matrices	O
is	O
known	O
to	O
modulate	O
leukocyte	O
activation	O
,	O
although	O
the	O
mechanisms	O
are	O
not	O
fully	O
understood	O
.	O

Activation	O
was	O
not	O
target-	O
or	O
cell-type	O
dependent	O
,	O
nor	O
was	O
it	O
dependent	O
on	O
the	O
presence	O
of	O
virus	O
.	O

We	O
,	O
therefore	O
,	O
conclude	O
that	O
signals	O
generated	O
by	O
the	O
convergence	O
of	O
the	O
MAPK	B-protein
and	O
the	O
calcineurin	B-protein
/NFAT	B-protein
pathway	O
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
Tpl-2	B-protein
.	O

Thus	O
,	O
BOB.1/OBF.1	B-protein
is	O
a	O
transcriptional	B-protein
coactivator	I-protein
that	O
is	O
critically	O
regulated	O
by	O
posttranslational	O
modifications	O
to	O
mediate	O
cell	O
type-specific	O
gene	O
expression	O
.	O

S6	B-protein
was	O
cleaved	O
with	O
CNBr	B-protein
and	O
three	O
internal	O
peptides	O
were	O
sequenced	O
.	O

Targeted	O
disruption	O
of	O
the	O
MyD88	B-DNA
gene	I-DNA
results	O
in	O
loss	O
of	O
IL-1-	O
and	O
IL-18-mediated	O
function	O
.	O

Here	O
,	O
we	O
report	O
that	O
stimulation	O
through	O
the	O
IL-2R	B-protein
induced	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B-protein
,	O
a	O
newly	O
identified	O
member	O
of	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
family	I-protein
of	O
proteins	O
.	O

We	O
demonstrate	O
here	O
the	O
interaction	O
of	O
RANK	B-protein
with	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factors	I-protein
(	I-protein
TRAFs	I-protein
)	I-protein
1	I-protein
,	I-protein
2	I-protein
,	I-protein
3	I-protein
,	I-protein
5	I-protein
,	I-protein
and	I-protein
6	I-protein
both	O
in	O
vitro	O
and	O
in	O
cells	O
.	O

In	O
this	O
investigation	O
an	O
enhanced	O
and	O
prolonged	O
IL-2	B-protein
and	O
IL-2	B-RNA
mRNA	I-RNA
response	O
was	O
also	O
detected	O
in	O
both	O
stimulated	O
(	O
T	B-protein
cell	I-protein
mitogens	I-protein
or	O
alloantigens	B-protein
)	O
murine	B-cell_type
splenocytes	I-cell_type
and	O
in	O
the	O
stimulated	O
murine	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
EL-4	I-cell_line
in	O
the	O
presence	O
of	O
ciprofloxacin	O
(	O
5-80	O
micrograms/ml	O
)	O
as	O
compared	O
to	O
control	O
cells	O
without	O
antibiotics	O
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
EBNA2	B-protein
)	O
,	O
a	O
protein	O
required	O
for	O
B	B-cell_type
lymphocyte	I-cell_type
immortalization	O
,	O
induces	O
the	O
synthesis	O
of	O
type	B-protein
I	I-protein
interferon	I-protein
in	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Using	O
retinoids	O
with	O
different	O
receptor	O
binding	O
specificity	O
(	O
CD336	O
,	O
CD437	O
,	O
CD2019	O
,	O
CD367	O
)	O
,	O
dose-dependent	O
inhibition	O
of	O
IgE	B-protein
synthesis	O
was	O
shown	O
by	O
all	O
four	O
derivates	O
,	O
but	O
was	O
most	O
marked	O
by	O
an	O
RA	O
binding	O
the	O
alpha	B-protein
receptor	I-protein
with	O
high	O
specificity	O
.	O

Furthermore	O
,	O
we	O
have	O
demonstrated	O
that	O
both	O
C/EBPbeta	B-protein
and	O
GATA-1	B-protein
can	O
bind	O
simultaneously	O
to	O
the	O
C/EBP-	O
and	O
GATA-binding	B-DNA
sites	I-DNA
in	O
the	O
MBP	B-DNA
promoter	I-DNA
.	O

When	O
levels	O
were	O
semiquantitated	O
using	O
densitometry	O
,	O
significant	O
decreases	O
of	O
TCRzeta	B-protein
(	O
P	O
=	O
0.029	O
)	O
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
(	O
P	O
=	O
0.029	O
)	O
but	O
not	O
CD3epsilon	B-protein
(	O
P	O
=	O
0.131	O
)	O
,	O
compared	O
with	O
control	O
levels	O
,	O
were	O
found	O
.	O

EBNA-2	B-protein
trans-activates	O
cellular	B-DNA
and	I-DNA
viral	I-DNA
genes	I-DNA
like	O
CD23	B-DNA
,	O
c-fgr	B-DNA
,	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
and	O
terminal	B-protein
protein	I-protein
1	I-protein
(	O
TP1	B-protein
)	O
.	O

The	O
other	O
major	O
subpopulation	O
expressing	O
the	O
CD4	B-protein
receptor	I-protein
,	O
namely	O
,	O
the	O
double-positive	B-cell_type
(	I-cell_type
DP	I-cell_type
)	I-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
+/-	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
,	O
despite	O
the	O
entry	O
of	O
the	O
virus	O
,	O
do	O
not	O
produce	O
a	O
significant	O
level	O
of	O
virus	O
,	O
presumably	O
because	O
they	O
are	O
unresponsive	O
to	O
TNF	B-protein
and	O
IL-7	B-protein
.	O

These	O
data	O
may	O
have	O
implications	O
for	O
the	O
stringent	O
control	O
of	O
IL-4	B-protein
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
several	O
cases	O
,	O
the	O
peptide	O
epitope	O
and	O
HLA-restricting	O
determinant	O
recognized	O
by	O
these	O
CTLs	B-cell_type
has	O
been	O
defined	O
,	O
one	O
unusual	O
feature	O
being	O
the	O
number	O
of	O
responses	O
restricted	O
through	O
HLA-C	B-DNA
alleles	I-DNA
.	O

The	O
results	O
indicate	O
that	O
stimulation	O
of	O
NK	B-cell_type
cells	I-cell_type
,	O
either	O
freshly	O
isolated	O
from	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
or	O
long-term	B-cell_line
cultured	I-cell_line
NK	I-cell_line
clones	I-cell_line
,	O
with	O
specific	O
cell	O
targets	O
results	O
in	O
an	O
increased	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
transcription	B-protein
factors	I-protein
measured	O
by	O
gel	O
retardation	O
.	O

This	O
suggests	O
that	O
CHEMR1	B-DNA
may	O
be	O
a	O
receptor	O
for	O
unidentified	O
C-C	B-protein
chemokine	I-protein
or	O
a	O
low-affinity	O
receptor	O
for	O
MIP-1alpha	B-protein
.	O

Altogether	O
,	O
these	O
results	O
indicate	O
that	O
the	O
IL-10	B-protein
-induced	O
up-regulation	O
of	O
cytokine	B-protein
production	O
depends	O
on	O
the	O
prevention	O
of	O
monocyte	O
adherence	O
by	O
red	B-cell_type
cells	I-cell_type
in	O
the	O
whole	O
blood	O
assays	O
or	O
by	O
cultures	O
of	O
PBMC	B-cell_type
on	O
Teflon	O
.	O

In	O
previous	O
studies	O
,	O
it	O
was	O
shown	O
that	O
the	O
fusion	O
region	O
of	O
the	O
pml/RAR-alpha	B-protein
protein	I-protein
,	O
expressed	O
by	O
acute	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
(	I-cell_line
APL	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
can	O
be	O
specifically	O
recognized	O
in	O
vitro	O
by	O
donor	O
(	O
D.	O
E.	O
)	O
CD4	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
a	O
HLA	B-protein
class	I-protein
II	I-protein
DR11-restricted	O
fashion	O
.	O

Transforming	B-protein
growth	I-protein
factor-beta	I-protein
suppresses	O
human	B-protein
B	I-protein
lymphocyte	I-protein
Ig	I-protein
production	O
by	O
inhibiting	O
synthesis	O
and	O
the	O
switch	O
from	O
the	O
membrane	B-RNA
form	I-RNA
to	O
the	O
secreted	B-RNA
form	I-RNA
of	O
Ig	B-RNA
mRNA	I-RNA
.	O

The	O
BCL6	B-DNA
gene	I-DNA
has	O
been	O
isolated	O
from	O
the	O
chromosomal	O
breakpoint	O
in	O
these	O
lymphomas	O
.	O

Regulation	O
of	O
M-CSF	B-protein
expression	O
by	O
M-CSF	B-protein
:	O
role	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
transcription	B-protein
factor	I-protein
NF	I-protein
kappa	I-protein
B	I-protein
.	O

The	O
results	O
obtained	O
suggest	O
that	O
two	O
Ad12	B-DNA
E1A	I-DNA
domains	I-DNA
are	O
required	O
to	O
induce	O
resistance	O
of	O
the	O
cell	B-cell_line
lines	I-cell_line
to	O
NK	B-cell_type
cells	I-cell_type
.	O

Northern	O
analyses	O
suggested	O
that	O
the	O
reiterated	B-DNA
splicing	I-DNA
sites	I-DNA
of	O
the	O
representative	O
mutants	O
were	O
all	O
used	O
in	O
RNA	O
splicing	O
,	O
and	O
the	O
closest	O
donor	O
and	O
recipient	O
joints	O
were	O
used	O
most	O
frequently	O
.	O

We	O
have	O
analyzed	O
the	O
effects	O
of	O
interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
on	O
the	O
entry	O
of	O
quiescent	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
into	O
the	O
cell	O
cycle	O
upon	O
stimulation	O
with	O
the	O
superantigen	B-protein
staphylococcal	B-protein
enterotoxin	I-protein
B	I-protein
(	O
SEB	B-protein
)	O
.	O

Human	O
RAR	O
alpha	O
expression	O
was	O
unchanged	O
in	O
H9	B-cell_line
and	O
CEM	B-cell_line
cells	I-cell_line
,	O
and	O
elevated	O
in	O
U937	B-cell_line
cells	I-cell_line
,	O
after	O
PMA	O
stimulation	O
.	O

Therefore	O
,	O
SR	O
asthma	O
may	O
be	O
due	O
to	O
more	O
than	O
one	O
abnormality	O
,	O
the	O
majority	O
related	O
to	O
a	O
reversible	O
cytokine	B-protein
-induced	O
reduction	O
in	O
GR	B-protein
binding	O
affinity	O
and	O
the	O
second	O
related	O
to	O
an	O
irreversible	O
reduction	O
in	O
GR	B-protein
number	O
.	O

High-dose	O
estrogen	O
administration	O
induces	O
anemia	O
in	O
mammals	O
.	O

Gel	O
mobility	O
shift	O
assays	O
and	O
transient	O
transfection	O
assays	O
demonstrate	O
that	O
AML1	B-protein
binds	O
specifically	O
to	O
this	O
site	O
in	O
the	O
blk	B-DNA
promoter	I-DNA
and	O
this	O
binding	O
site	O
is	O
important	O
for	O
blk	B-DNA
promoter	O
activity	O
.	O

Confirmation	O
of	O
a	O
model	O
.	O

The	O
promoter	B-DNA
of	O
the	O
human	O
major	O
histocompatibility	B-DNA
complex	I-DNA
class	I-DNA
II-associated	I-DNA
invariant-chain	I-DNA
gene	I-DNA
(	O
Ii	B-DNA
)	O
contains	O
two	O
NF-kappa	B-DNA
B/Rel	I-DNA
binding	I-DNA
sites	I-DNA
located	O
at	O
-109	B-DNA
to	I-DNA
-118	I-DNA
(	O
Ii	B-DNA
kappa	I-DNA
B-1	I-DNA
)	O
and	O
-163	B-DNA
to	I-DNA
-172	I-DNA
(	O
Ii	B-DNA
kappa	I-DNA
B-2	I-DNA
)	O
from	O
the	O
transcription	O
start	O
site	O
.	O

Interaction	O
of	O
HTLV-I	B-protein
Tax	I-protein
with	O
the	O
human	B-protein
proteasome	I-protein
:	O
implications	O
for	O
NF-kappa	B-protein
B	I-protein
induction	O
.	O

The	O
expression	O
of	O
TNF-alpha	B-RNA
and	I-RNA
IL-6	I-RNA
mRNAs	I-RNA
was	O
also	O
induced	O
.	O

In	O
addition	O
,	O
competitive	O
single-cell	O
RT-PCR	O
was	O
used	O
to	O
assay	O
CD34	B-RNA
mRNA	I-RNA
transcripts	I-RNA
in	O
sibling	B-cell_line
CD34	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
CD38	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
cells	I-cell_line
differentiating	O
in	O
unilineage	B-cell_line
erythroid	I-cell_line
cultures	I-cell_line
:	O
this	O
analysis	O
allowed	O
us	O
to	O
semiquantitate	O
the	O
gradual	O
downmodulation	O
of	O
CD34	B-RNA
mRNA	I-RNA
from	O
progenitor	B-cell_type
cells	I-cell_type
through	O
their	O
differentiating	B-cell_line
erythroid	I-cell_line
progeny	I-cell_line
.	O

OBJECTIVE	O
.	O

In	O
contrast	O
,	O
in	O
C57MG	B-cell_line
fibroblast	I-cell_line
cells	I-cell_line
,	O
lithium	O
inactivates	O
GSK-3beta	B-protein
and	O
induces	O
Tcf-controlled	O
transcription	O
.	O

Regulation	O
of	O
CD14	B-protein
expression	O
during	O
monocytic	O
differentiation	O
induced	O
with	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
.	O

The	O
data	O
indicate	O
that	O
10	O
(	O
-6	O
)	O
M	O
DM	O
increased	O
T	B-cell_type
cell	I-cell_type
p50	O
NF-kappa	B-RNA
B	I-RNA
mRNA	I-RNA
levels	O
by	O
four-fold	O
compared	O
to	O
the	O
levels	O
obtained	O
in	O
the	O
absence	O
of	O
DM	O
.	O

These	O
results	O
indicate	O
that	O
the	O
BCL-6	B-protein
protein	I-protein
can	O
function	O
as	O
a	O
sequence-specific	B-protein
transcriptional	I-protein
repressor	I-protein
and	O
have	O
implications	O
for	O
the	O
role	O
of	O
BCL6	B-protein
in	O
normal	O
lymphoid	O
development	O
and	O
lymphomagenesis	O
.	O

Thus	O
abnormalities	O
of	O
E2F	B-protein
function	O
are	O
unlikely	O
to	O
play	O
a	O
primary	O
pathogenic	O
role	O
in	O
AML	O
.	O

We	O
observed	O
that	O
FK506	O
suppressed	O
the	O
transcription	O
of	O
a	O
chemotactic	B-protein
cytokine	I-protein
,	O
interleukin-8	B-protein
(	O
IL-8	B-protein
)	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
(	O
Ca2+	O
)	O
ionophore	O
(	O
ionomycin	O
)	O
.	O

By	O
expressing	O
mutant	O
forms	O
of	O
the	O
human	O
protein	O
in	O
this	O
cell	B-cell_line
line	I-cell_line
,	O
we	O
have	O
been	O
able	O
to	O
delineate	O
the	O
sequences	O
responsible	O
for	O
both	O
the	O
ligand-induced	O
phosphorylation	O
and	O
the	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

These	O
data	O
imply	O
the	O
presence	O
of	O
common	O
structural	O
elements	O
within	O
the	O
core	O
of	O
each	O
LCR	B-DNA
HS	I-DNA
which	O
are	O
required	O
for	O
erythroid-specific	O
chromatin	O
structure	O
reorganization	O
.	O

We	O
examined	O
the	O
ability	O
of	O
nuclear	O
translocated	O
glucocorticoid	B-protein
receptors	I-protein
to	O
bind	O
to	O
their	O
DNA	B-DNA
binding	I-DNA
sites	I-DNA
(	O
GRE	B-DNA
)	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
in	O
PBMC	B-cell_type
from	O
patients	O
with	O
steroid-sensitive	O
and	O
steroid-resistant	O
asthma	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
undertook	O
a	O
biochemical	O
analysis	O
of	O
IL-10	B-protein
receptor	I-protein
expression	O
on	O
freshly	O
isolated	O
B-CLL	B-cell_line
cells	I-cell_line
and	O
characterized	O
the	O
functional	O
responsiveness	O
of	O
IL-10	B-protein
binding	O
to	O
its	O
constitutively	B-protein
expressed	I-protein
receptor	I-protein
.	O

Transcription	O
specific	O
differences	O
visualized	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
pattern	O
on	O
interphase	O
nuclei	O
of	O
different	O
cell	O
types	O
.	O

Expression	O
of	O
HLA-DO	B-protein
in	O
a	O
class	B-cell_line
II+	I-cell_line
and	I-cell_line
DM+	I-cell_line
,	I-cell_line
DO-	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
caused	O
the	O
accumulation	O
of	O
class	B-protein
II-CLIP	I-protein
complexes	I-protein
,	O
indicating	O
that	O
HLA-DO	B-protein
blocked	O
DM	O
function	O
in	O
vivo	O
and	O
suggesting	O
that	O
HLA-DO	B-protein
is	O
an	O
important	O
modulator	O
of	O
class	O
II-restricted	O
antigen	O
processing	O
.	O

Conversely	O
,	O
a	O
dominant	O
negative	O
version	O
of	O
TRAF6	B-protein
failed	O
to	O
block	O
hToll	B-protein
-induced	O
activation	O
of	O
stress-activated	B-protein
protein	I-protein
kinase/c-Jun	I-protein
NH2-terminal	I-protein
kinases	I-protein
,	O
thus	O
suggesting	O
an	O
early	O
divergence	O
of	O
the	O
two	O
pathways	O
.	O

These	O
results	O
explain	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
overproduction	O
in	O
granulomatoses	O
and	O
demonstrate	O
potent	O
inhibition	O
by	O
gamma-IFN	B-protein
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
action	O
in	O
immune	B-cell_type
cells	I-cell_type
.	O

We	O
searched	O
for	O
proteins	O
that	O
interact	O
with	O
Ras	B-protein
in	O
interleukin	B-cell_line
(	I-cell_line
IL	I-cell_line
)	I-cell_line
-2-stimulated	I-cell_line
or	I-cell_line
IL-2-deprived	I-cell_line
cells	I-cell_line
,	O
and	O
found	O
that	O
the	O
transcription	B-protein
factor	I-protein
Aiolos	B-protein
interacts	O
with	O
Ras	B-protein
.	O

NF-kappa	B-protein
B	I-protein
,	O
a	O
transcription	B-protein
factor	I-protein
controlling	O
the	O
expression	O
of	O
genes	B-DNA
involved	O
in	O
cell	O
activation	O
and	O
growth	O
control	O
,	O
has	O
been	O
shown	O
to	O
be	O
activated	O
by	O
LMP-1	B-protein
.	O

Moreover	O
,	O
Elf-1	B-protein
is	O
the	O
only	O
factor	O
present	O
in	O
activated	O
T-cell	O
nuclear	O
extracts	O
that	O
binds	O
to	O
these	O
sites	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
To	O
further	O
analyze	O
the	O
neonatal	O
immune	O
response	O
to	O
an	O
antigenic	O
challenge	O
such	O
as	O
blood	O
transfusion	O
,	O
c-fos	O
and	O
c-jun	O
mRNA	O
expression	O
were	O
analyzed	O
in	O
twelve	O
in-vitro-stimulated	O
normal	O
cord	O
blood	O
and	O
ten	O
in-vitro-stimulated	B-cell_type
normal	I-cell_type
adult	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocyte	I-cell_type
samples	I-cell_type
.	O

To	O
determine	O
why	O
alveolar	B-cell_type
macrophages	I-cell_type
do	O
not	O
express	O
AP-1	B-protein
DNA	O
binding	O
activity	O
,	O
we	O
first	O
showed	O
that	O
there	O
was	O
not	O
a	O
decrease	O
in	O
expression	O
of	O
the	O
FOS	B-protein
and	I-protein
JUN	I-protein
proteins	I-protein
that	O
make	O
up	O
the	O
AP-1	B-protein
complex	O
.	O

Dex	O
inhibited	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
the	O
AP-1	B-DNA
,	O
but	O
not	O
the	O
NF-AT	B-DNA
and	O
NF-kB	B-DNA
plasmids	I-DNA
.	O

The	O
effect	O
was	O
abrogated	O
by	O
the	O
PKC	B-protein
inhibitor	O
staurosporine	O
,	O
suggesting	O
a	O
role	O
for	O
PKC	B-protein
.	O

S107	B-cell_line
plasmacytoma	I-cell_line
cells	I-cell_line
,	O
which	O
express	O
CD40	B-protein
but	O
are	O
defective	O
for	O
the	O
nuclear	O
appearance	O
of	O
p50/p65-NF-kappaB	B-protein
,	O
do	O
not	O
express	O
RelB	B-protein
after	O
CD40	B-protein
stimulation	O
.	O

However	O
,	O
the	O
intensity	O
of	O
the	O
complex	O
formed	O
appeared	O
to	O
increase	O
when	O
nuclear	O
extracts	O
from	O
PMA-treated	B-cell_line
cells	I-cell_line
were	O
used	O
.	O

Selenium-mediated	O
inhibition	O
of	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
and	O
HIV-1	B-DNA
LTR	I-DNA
promoter	I-DNA
activity	O
.	O

Cells	O
were	O
separated	O
from	O
blood	O
samples	O
on	O
a	O
Ficoll	O
gradient	O
and	O
incubated	O
with	O
different	O
concentrations	O
of	O
[	O
3H	O
]	O
testosterone	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
400-fold	O
excess	O
of	O
unlabelled	O
testosterone	O
.	O

ICSAT	B-protein
was	O
demonstrated	O
to	O
possess	O
repressive	O
function	O
over	O
the	O
gene	O
activation	O
induced	O
by	O
IFN	B-protein
stimulation	O
or	O
by	O
IRF-1	B-protein
cotransfection	O
.	O

Decreased	O
adhesion	B-protein
molecule	I-protein
expression	O
was	O
associated	O
with	O
a	O
reduction	O
of	O
monocytic	O
cell	O
adhesion	O
.	O

This	O
review	O
focuses	O
on	O
the	O
roles	O
of	O
transcription	B-protein
factors	I-protein
in	O
hematopoietic	O
lineage	O
commitment	O
.	O

Partial	O
cortisol	O
receptor	O
resistance	O
might	O
be	O
less	O
rare	O
than	O
previously	O
thought	O
.	O

Nuclear	O
p65	B-protein
and	O
c-Rel	B-protein
proteins	O
were	O
found	O
in	O
all	O
cell	O
types	O
including	O
lymphocytes	B-cell_type
.	O

Together	O
,	O
these	O
results	O
show	O
that	O
NF-kappa	B-protein
B	I-protein
controls	O
the	O
expression	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
by	O
means	O
of	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

Trans-activation	O
of	O
the	O
TP1	B-DNA
promoter	I-DNA
and	O
of	O
the	O
BamHI	B-DNA
C	I-DNA
promoter	I-DNA
has	O
already	O
been	O
investigated	O
in	O
detail	O
and	O
appears	O
to	O
be	O
mediated	O
via	O
protein-protein	O
interactions	O
and	O
not	O
by	O
direct	O
binding	O
of	O
EBNA-2	B-protein
type	I-protein
A	I-protein
(	O
of	O
EBV	O
type	O
1	O
)	O
to	O
the	O
DNA	O
.	O

Deoxycholate	O
treatment	O
of	O
cytoplasmic	O
extracts	O
from	O
these	O
subclones	O
released	O
much	O
reduced	O
NF-kB	B-protein
binding	I-protein
proteins	I-protein
from	O
their	O
cytoplasmic	O
pools	O
.	O

HS	B-DNA
III	I-DNA
was	O
weak	O
in	O
HEL	B-cell_line
and	O
Jurkat	B-cell_line
,	O
and	O
greatly	O
enhanced	O
in	O
DU528	B-cell_line
,	O
a	O
T-cell	B-cell_line
line	I-cell_line
that	O
bears	O
a	B-DNA
t	I-DNA
(	I-DNA
1	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
and	O
initiates	O
tal-1	B-DNA
transcription	O
within	O
exon	B-DNA
4	I-DNA
.	O

Various	O
stimuli	O
,	O
typically	O
those	O
associated	O
with	O
stress	O
or	O
pathogens	O
,	O
rapidly	O
inactivate	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
binding	O
of	O
a	O
myeloid-specific	B-protein
factor	I-protein
(	O
PU.1	B-protein
)	O
allows	O
a	O
general	O
factor	O
(	O
Sp1	B-protein
)	O
to	O
bind	O
in	O
a	O
tissue-specific	O
fashion	O
thereby	O
contributing	O
to	O
the	O
myeloid-specific	O
expression	O
of	O
CD11b	B-cell_line
.	O

Translocated	B-protein
hormone/receptor	I-protein
complexes	I-protein
compete	O
for	O
a	O
limited	O
number	O
of	O
specific	O
nuclear	O
binding	O
sites	O
.	O

This	O
cDNA	B-DNA
clone	I-DNA
was	O
isolated	O
by	O
expression	O
cDNA	B-DNA
cloning	O
,	O
and	O
encodes	O
the	O
human	B-protein
c-Jun	I-protein
protein	I-protein
,	O
which	O
together	O
with	O
c-Fos	B-protein
forms	O
the	O
heterodimeric	B-protein
activator	I-protein
protein-1	I-protein
transcription	I-protein
complex	I-protein
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
expression	O
of	O
a	O
dominant-negative	B-protein
form	I-protein
of	O
TRAF2	B-protein
was	O
found	O
to	O
potentiate	O
TNFR1	B-protein
-mediated	O
death	O
.	O

There	O
were	O
two	O
main	O
goals	O
:	O
(	O
1	O
)	O
to	O
evaluate	O
whether	O
workers	O
with	O
a	O
moderately	O
increased	O
PCDD/PCDF-body	O
burden	O
[	O
25-140	O
ppt	O
TCDD	O
or	O
104-522	O
ppt	O
I-TE	O
in	O
blood	O
fat	O
]	O
exhibit	O
changes	O
in	O
the	O
surface	B-protein
receptors	I-protein
of	O
white	B-cell_type
blood	I-cell_type
cells	I-cell_type
,	O
as	O
observed	O
in	O
previous	O
studies	O
in	O
non-human	O
primates	O
,	O
and	O
(	O
2	O
)	O
to	O
clarify	O
whether	O
persons	O
at	O
the	O
upper	O
range	O
[	O
10-23	O
ppt	O
TCDD	O
or	O
30-90	O
ppt	O
I-TE	O
in	O
blood	O
fat	O
]	O
of	O
the	O
body	O
burden	O
reference	O
values	O
of	O
a	O
not	O
particularly	O
exposed	O
population	O
show	O
detectable	O
deviations	O
in	O
these	O
immunological	O
variables	O
,	O
when	O
compared	O
with	O
persons	O
at	O
the	O
lower	O
and	O
medium	O
range	O
[	O
1-3	O
ppt	O
TCDD	O
or	O
9-29	O
ppt	O
I-TE	O
]	O
of	O
these	O
body	O
burden	O
reference	O
values	O
.	O

In	O
fact	O
,	O
IFNs	B-protein
inhibit	O
growth	O
of	O
various	O
normal	B-cell_type
and	O
transformed	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O

RESULTS	O
:	O
In	O
preliminary	O
studies	O
,	O
we	O
demonstrated	O
that	O
transfection	O
of	O
the	O
PIEC	B-cell_line
line	I-cell_line
with	O
full-length	O
human	O
CIITA	B-DNA
constructs	I-DNA
resulted	O
in	O
strong	O
expression	O
of	O
SLA-DR	B-protein
and	O
SLA-DQ	B-protein
antigens	O
,	O
thus	O
establishing	O
the	O
cross-species	O
effectiveness	O
of	O
human	B-protein
CIITA	I-protein
in	O
the	O
pig	O
.	O

Because	O
the	O
primed	B-cell_line
T	I-cell_line
cells	I-cell_line
contain	O
higher	O
levels	O
of	O
nuclear	B-protein
NF-ATp	I-protein
,	O
capable	O
of	O
binding	O
to	O
P	B-DNA
elements	I-DNA
of	O
the	O
IL-4	B-DNA
and	I-DNA
IL-13	I-DNA
promoters	I-DNA
,	O
than	O
do	O
freshly-isolated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
the	O
NF-AT-binding	B-DNA
P	I-DNA
elements	I-DNA
are	O
attractive	O
candidates	O
to	O
mediate	O
the	O
coordinate	O
expression	O
of	O
these	O
two	O
cytokine	B-DNA
genes	I-DNA
.	O

A	O
second	O
hypersensitive	O
site	O
(	O
HS	O
2	O
)	O
was	O
identified	O
within	O
the	O
first	O
intron	O
in	O
pre-monocytic	O
cells	O
,	O
which	O
express	O
Elk-1	O
only	O
when	O
differentiating	O
to	O
monocytes	B-cell_type
.	O

Probucol	O
(	O
50	O
microM	O
)	O
and	O
N-acetylcysteine	O
(	O
20	O
mM	O
)	O
also	O
inhibited	O
agonist-induced	O
monocytic	O
cell	O
adhesion	O
;	O
whereas	O
,	O
several	O
other	O
antioxidants	O
had	O
no	O
significant	O
effect	O
.	O

This	O
led	O
to	O
the	O
hypothesis	O
that	O
some	O
of	O
the	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	I-protein
were	O
key	O
nuclear	B-protein
factors	I-protein
in	O
functions	O
of	O
accessory	B-cell_type
cells	I-cell_type
of	O
the	O
immune	O
response	O
.	O

Enzymatic	O
assay	O
of	O
alpha-galactosidase	B-protein
in	O
blood	B-cell_type
leucocytes	I-cell_type
,	O
skin	B-cell_type
fibroblasts	I-cell_type
,	O
Epstein-Barr	B-cell_line
virus	I-cell_line
transformed	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
hair	O
follicles	O
of	O
the	O
twins	O
and	O
their	O
parents	O
confirmed	O
the	O
heterozygous	O
status	O
of	O
the	O
twins	O
and	O
indicated	O
that	O
Fabry	O
disease	O
had	O
occurred	O
as	O
a	O
result	O
of	O
a	O
de	O
novo	O
mutation	O
.	O

Although	O
it	O
can	O
be	O
incorporated	O
into	O
the	O
DNA	O
of	O
dividing	O
cells	O
,	O
fludarabine	O
is	O
also	O
a	O
potent	O
inhibitor	O
of	O
cells	O
with	O
a	O
low	O
growth	O
fraction	O
,	O
thus	O
it	O
must	O
have	O
other	O
mechanisms	O
of	O
action	O
.	O

This	O
higher	O
NF-kappa	B-protein
B	I-protein
activity	O
was	O
restricted	O
to	O
the	O
CD4+	B-cell_type
T-cell	I-cell_type
subset	I-cell_type
.	O

Transcriptional	O
regulation	O
of	O
interleukin	B-protein
3	I-protein
(	O
IL3	B-protein
)	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Low	O
proliferative	O
capacity	O
was	O
observed	O
after	O
1	O
week	O
in	O
culture	O
in	O
the	O
presence	O
of	O
stem	B-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
+	O
Flt-3	B-protein
ligand	I-protein
(	O
FL	B-protein
)	O
+	O
G-CSF	B-protein
.	O

Proteins	O
involved	O
in	O
repression	O
of	O
the	O
human	B-DNA
beta-globin	I-DNA
gene	I-DNA
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
sickle	O
cell	O
anemia	O
,	O
in	O
conjunction	O
with	O
therapy	O
to	O
reactivate	O
fetal	B-DNA
globin	I-DNA
genes	I-DNA
.	O

In	O
conclusion	O
,	O
we	O
have	O
characterized	O
a	O
novel	O
continuous	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
line	I-cell_line
presenting	O
a	O
hierarchical	O
structure	O
similar	O
to	O
that	O
of	O
the	O
bone	B-cell_line
marrow	I-cell_line
progenitor	I-cell_line
cell	I-cell_line
compartment	I-cell_line
.	O

Differential	O
responsiveness	O
of	O
the	O
IL-5	B-DNA
and	I-DNA
IL-4	I-DNA
genes	I-DNA
to	O
transcription	B-protein
factor	I-protein
GATA-3	I-protein
.	O

A	O
7-base-pair	O
mutation	O
in	O
the	O
site	B-DNA
B	I-DNA
palindrome	I-DNA
,	O
which	O
destroyed	O
protein	O
binding	O
,	O
resulted	O
in	O
increased	O
expression	O
from	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Within	O
2	O
to	O
4	O
h	O
of	O
PMA	O
exposure	O
,	O
steady	O
state	O
levels	O
of	O
TNF	B-RNA
mRNA	I-RNA
are	O
markedly	O
elevated	O
in	O
all	O
myelomonocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
studied	O
.	O

This	O
shows	O
that	O
the	O
induction	O
of	O
gene	O
expression	O
by	O
FICZ	O
and	O
UV	O
is	O
Ah	B-protein
receptor	I-protein
dependent	O
.	O

The	O
protein	O
shows	O
significant	O
sequence	O
similarities	O
to	O
the	O
family	O
of	O
G-protein	B-protein
coupled	I-protein
chemokine	I-protein
receptors	I-protein
and	O
turned	O
out	O
to	O
be	O
identical	O
to	O
the	O
recently	O
described	O
receptor	B-protein
EBI1	I-protein
.	O

Changes	O
in	O
c-fos	B-DNA
expression	O
induced	O
by	O
radiation	O
therapy	O
in	O
tumor	O
tissues	O
have	O
not	O
yet	O
been	O
reported	O
.	O

Defective	O
transcription	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
is	O
associated	O
with	O
impaired	O
expression	O
of	O
c-Fos	B-protein
,	O
FosB	B-protein
,	O
and	O
JunB	B-protein
in	O
anergic	B-cell_line
T	I-cell_line
helper	I-cell_line
1	I-cell_line
cells	I-cell_line
.	O

RESULTS	O
:	O
Co-culture	O
of	O
NK	B-cell_type
cells	I-cell_type
with	O
transfected	O
EC	B-cell_type
enhanced	O
E-selectin	B-protein
,	O
IL-8	B-protein
,	O
and	O
NF-kappaB	B-protein
-dependent	O
promoter	O
activity	O
.	O

A	O
slower	O
initial	O
decline	O
in	O
blood	O
histamine	O
after	O
the	O
divided	O
regimen	O
may	O
be	O
related	O
to	O
incomplete	O
suppression	O
of	O
basophil	B-cell_type
cell	I-cell_type
return	O
to	O
blood	O
.	O

Activation	O
of	O
CD40	B-protein
is	O
essential	O
for	O
thymus-dependent	O
humoral	O
immune	O
responses	O
and	O
rescuing	O
B	B-cell_type
cells	I-cell_type
from	O
apoptosis	O
.	O

Although	O
statistical	O
evaluation	O
of	O
the	O
data	O
showed	O
a	O
significant	O
difference	O
between	O
patients	O
with	O
a	O
chronic	O
MPD	O
and	O
control	O
subjects	O
,	O
proof	O
of	O
clonality	O
in	O
individual	O
,	O
especially	O
elderly	O
,	O
patients	O
is	O
difficult	O
.	O

We	O
also	O
showed	O
that	O
this	O
silencer	B-DNA
has	O
stronger	O
inhibitory	O
activity	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
as	O
compared	O
to	O
K562	B-cell_line
human	I-cell_line
erythroleukemia	I-cell_line
cells	I-cell_line
.	O

In	O
contrast	O
,	O
we	O
found	O
that	O
AR	B-protein
can	O
initiate	O
apoptosis	O
in	O
S49	B-cell_line
cells	I-cell_line
after	O
treatment	O
with	O
5	O
alpha-dihydrotestosterone	O
,	O
despite	O
its	O
relative	O
inability	O
to	O
induce	O
high	O
level	O
expression	O
of	O
MMTV	O
.	O

Transcriptional	O
repression	O
of	O
the	O
interleukin-2	B-DNA
gene	I-DNA
by	O
vitamin	O
D3	O
:	O
direct	O
inhibition	O
of	O
NFATp/AP-1	B-protein
complex	I-protein
formation	O
by	O
a	O
nuclear	B-protein
hormone	I-protein
receptor	I-protein
.	O

Ctx	B-protein
combined	O
with	O
TNFalpha	B-protein
or	O
IL-1beta	B-protein
to	O
produce	O
a	O
synergistic	O
increase	O
in	O
p24	B-protein
antigen	I-protein
production	O
in	O
U1	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
.	O

Five	O
major	O
DNase-I	B-DNA
hypersensitive	I-DNA
sites	I-DNA
(	O
HS	B-DNA
)	O
were	O
mapped	O
in	O
the	O
tal-1	B-DNA
locus	O
.	O

Likewise	O
,	O
activation	O
of	O
this	O
reporter	O
construct	O
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
depended	O
on	O
the	O
SP-1	B-DNA
site	I-DNA
.	O

Anti-rheumatic	O
compound	O
aurothioglucose	O
inhibits	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
-induced	O
HIV-1	O
replication	O
in	O
latently	O
infected	O
OM10.1	B-cell_line
and	I-cell_line
Ach2	I-cell_line
cells	I-cell_line
.	O

Peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
are	O
a	O
good	O
model	O
for	O
studies	O
of	O
GR	B-protein
in	O
humans	O
.	O

In	O
consequence	O
,	O
the	O
alternative	B-RNA
La	I-RNA
mRNA	I-RNA
is	O
the	O
result	O
of	O
a	O
promoter	O
switching	O
combined	O
with	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

Interactions	O
between	O
the	O
canonical	O
and	O
unique	O
GATA	B-DNA
site	I-DNA
3	I-DNA
and	O
nuclear	O
extracts	O
were	O
also	O
studied	O
in	O
real	O
time	O
and	O
provided	O
information	O
on	O
its	O
association	O
and	O
dissociation	O
rates	O
for	O
native	O
huGATA-3	B-protein
.	O

Since	O
a	O
mutation	O
of	O
CBP	B-protein
abolishing	O
HAT	O
activity	O
is	O
almost	O
as	O
active	O
as	O
wild-type	B-protein
CBP	I-protein
in	O
T	B-cell_type
cells	I-cell_type
,	O
functions	O
of	O
CBP/p300	B-protein
other	O
than	O
histone	O
acetylation	O
appear	O
to	O
control	O
the	O
NF-AT	B-protein
-dependent	O
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Construction	O
and	O
biological	O
characterization	O
of	O
an	O
interleukin-12	B-protein
fusion	I-protein
protein	I-protein
(	O
Flexi-12	B-protein
)	O
:	O
delivery	O
to	O
acute	B-cell_type
myeloid	I-cell_type
leukemic	I-cell_type
blasts	I-cell_type
using	O
adeno-associated	O
virus	O
.	O

Moreover	O
,	O
tyrosine-phosphorylated	B-protein
LAT/pp36/38	I-protein
in	O
detergent	O
lysates	O
prepared	O
from	O
anti-CD3	B-cell_type
stimulated	I-cell_type
T	I-cell_type
cells	I-cell_type
associated	O
with	O
Grb2	B-protein
but	O
not	O
GrpL	B-protein
.	O

The	O
DNA-binding	B-protein
domain	I-protein
(	O
amino	B-protein
acids	I-protein
421-486	I-protein
)	O
is	O
completely	O
conserved	O
among	O
human	B-protein
,	I-protein
squirrel	I-protein
monkey	I-protein
,	I-protein
owl	I-protein
monkey	I-protein
,	I-protein
and	I-protein
cotton-top	I-protein
tamarin	I-protein
receptors	I-protein
.	O

Upregulation	O
of	O
bcl-2	B-DNA
by	O
the	O
Epstein-Barr	B-protein
virus	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
:	O
a	O
B-cell-specific	O
response	O
that	O
is	O
delayed	O
relative	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
to	O
induction	O
of	O
cell	B-protein
surface	I-protein
markers	I-protein
.	O

After	O
stimulation	O
of	O
progesterone	O
the	O
expression	O
of	O
receptors	O
was	O
augmented	O
2-3	O
times	O
.	O

These	O
two	O
anthracyclines	O
,	O
although	O
closely	O
related	O
in	O
their	O
structures	O
,	O
appeared	O
to	O
act	O
as	O
differentiation	O
inducers	O
by	O
distinct	O
mechanisms	O
.	O

It	O
also	O
discusses	O
new	O
insights	O
into	O
how	O
the	O
structure	O
of	O
these	O
tissues	O
supports	O
effective	O
immune	O
responses	O
.	O

Using	O
synthetic	O
ligands	O
to	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
and	O
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
)	O
that	O
selectively	O
bind	O
and	O
activate	O
RAR-RXR	B-protein
or	O
RXR-RXR	B-protein
dimers	O
,	O
respectively	O
,	O
we	O
dissected	O
the	O
involvement	O
of	O
the	O
two	O
retinoid	O
response	O
pathways	O
in	O
the	O
regulation	O
of	O
normal	O
myeloid	O
and	O
erythroid	O
progenitor	O
cell	O
growth	O
.	O

The	O
unusual	O
CD56+	B-cell_type
CD16-	I-cell_type
eGLs	I-cell_type
present	O
in	O
large	O
numbers	O
in	O
late	O
secretory	O
phase	O
eutopic	O
endometrium	O
were	O
highly	O
purified	O
(	O
>	O
98	O
%	O
)	O
by	O
immunomagnetic	O
separation	O
.	O

In	O
order	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
regulation	O
of	O
cdc2	B-RNA
mRNA	I-RNA
expression	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
we	O
isolated	O
the	O
5'-flanking	B-DNA
sequence	I-DNA
of	O
the	O
cdc2	B-DNA
gene	I-DNA
and	O
found	O
the	O
putative	O
E2F	O
binding	B-DNA
site	I-DNA
at	O
the	O
position	O
of	O
nucleotides	B-DNA
-124	I-DNA
to	I-DNA
-117	I-DNA
.	O

PBMC	O
obtained	O
from	O
these	O
two	O
groups	O
,	O
17	O
SR	O
and	O
12	O
SS	O
,	O
as	O
well	O
as	O
12	O
normal	O
controls	O
were	O
analyzed.	O
SR	O
patients	O
had	O
two	O
distinguishable	O
GR	B-protein
binding	O
abnormalities	O
:	O
15	O
of	O
the	O
17	O
SR	O
patients	O
demonstrated	O
a	O
significantly	O
reduced	O
GR	B-protein
binding	O
affinity	O
,	O
as	O
compared	O
with	O
SS	O
patients	O
(	O
P	O
=	O
0.0001	O
)	O
and	O
normal	O
controls	O
(	O
P	O
=	O
0.0001	O
)	O
.	O

These	O
findings	O
may	O
help	O
in	O
understanding	O
the	O
pathogenesis	O
of	O
the	O
immunodeficiency	O
that	O
occurs	O
with	O
mutations	O
of	O
JAK3	B-protein
and	O
may	O
suggest	O
a	O
mechanism	O
for	O
the	O
pleiotropic	O
effects	O
of	O
IL-4	B-protein
.	O

These	O
data	O
suggest	O
that	O
in	O
activated	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
CD28	B-protein
-derived	O
signals	O
can	O
stimulate	O
proliferation	O
at	O
least	O
in	O
part	O
via	O
NF-kappaB	O
and	O
AP-1	O
generation	O
,	O
and	O
that	O
this	O
response	O
uses	O
both	O
acidic	B-protein
sphingomyelinase	I-protein
and	O
phosphatidylinositol	B-protein
3-kinase	I-protein
-linked	O
pathways	O
.	O

We	O
now	O
report	O
that	O
PO-B	B-protein
DNA-binding	O
in	O
HL-60	B-cell_line
cells	I-cell_line
is	O
similarly	O
induced	O
during	O
differentiation	O
to	O
the	O
granulocytic	B-cell_type
lineage	I-cell_type
(	O
with	O
either	O
retinoic	O
acid	O
or	O
dimethylsulfoxide	O
)	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
determine	O
whether	O
CD14	B-protein
is	O
expressed	O
in	O
gingival	B-cell_type
fibroblasts	I-cell_type
and	O
to	O
define	O
the	O
P-LPS-mediated	O
signal-transducing	B-protein
mechanism	O
in	O
the	O
cells	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
were	O
investigated	O
in	O
a	O
whole	O
cell	O
dexamethasone	O
binding	O
assay	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
.	O

In	O
addition	O
,	O
IL-13	B-protein
phosphorylated	O
insulin	B-protein
response	I-protein
substrate-1	I-protein
,	O
IL-4R	B-protein
p140	I-protein
,	O
JAK1	B-protein
,	O
and	O
Tyk2	B-protein
,	O
but	O
not	O
JAK3	B-protein
kinase	I-protein
.	O

The	O
proto-oncoprotein	B-protein
c-Rel	I-protein
is	O
a	O
member	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
transcription	I-protein
factor	I-protein
family	I-protein
,	O
which	O
includes	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
.	O

IL-10	B-protein
treatment	O
of	O
both	O
T	B-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
results	O
in	O
the	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B-protein
and	O
Jak1	B-protein
,	O
but	O
not	O
Jak2	B-protein
or	O
Jak3	B-protein
.	O

In	O
this	O
study	O
we	O
present	O
a	O
deletion	O
analysis	O
of	O
the	O
N-terminal	B-protein
region	I-protein
of	O
Oct-2a	B-protein
to	O
determine	O
the	O
minimal	B-protein
repression	I-protein
domain	I-protein
.	O

The	O
increases	O
in	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
induced	O
by	O
PA	O
or	O
anti-CD3	B-protein
mAb	I-protein
were	O
efficiently	O
abrogated	O
by	O
the	O
presence	O
of	O
propranolol	O
,	O
an	O
inhibitor	O
of	O
PA	O
phosphohydrolase	B-protein
and	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O

Evidence	O
for	O
a	O
trans-acting	B-protein
activator	I-protein
function	O
regulating	O
the	O
expression	O
of	O
the	O
human	B-protein
CD5	I-protein
antigen	I-protein
.	O

The	O
role	O
of	O
interleukin-11	B-protein
(	O
IL-11	B-protein
)	O
was	O
evaluated	O
in	O
the	O
IgG	B-protein
immune	I-protein
complex	I-protein
model	O
of	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

In	O
the	O
third	O
series	O
physical	O
exercises	O
that	O
induced	O
an	O
activation	O
of	O
the	O
hypothalamic-hypophyseal-adrenocortical	O
system	O
(	O
maximal	O
physical	O
exercises	O
and	O
prolonged	O
submaximal	O
exercises	O
at	O
70	O
%	O
of	O
maximal	O
oxygen	O
uptake	O
)	O
led	O
to	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
without	O
changes	O
of	O
dissociation	O
constant	O
.	O

The	O
model	O
should	O
be	O
useful	O
for	O
exploring	O
the	O
molecular	O
pathogenesis	O
of	O
APL	O
and	O
the	O
mechanisms	O
of	O
the	O
therapeutic	O
response	O
to	O
retinoic	O
acid	O
,	O
as	O
well	O
as	O
for	O
preclinical	O
studies	O
of	O
therapeutic	O
regimens	O
.	O

Comparison	O
of	O
the	O
different	O
combinations	O
of	O
GC	O
and	O
cytokines	B-protein
/LPS	O
revealed	O
differences	O
in	O
the	O
level	O
of	O
GC-dependent	O
enhancement	O
of	O
sialoadhesin	B-protein
expression	O
,	O
with	O
IFN-beta	B-protein
and	O
IL-4	B-protein
being	O
more	O
potent	O
than	O
IFN-gamma	B-protein
and	O
LPS	O
.	O

These	O
data	O
are	O
most	O
consistent	O
with	O
NOTCH1	B-protein
oncogenesis	O
and	O
transcriptional	O
activation	O
being	O
independent	O
of	O
association	O
with	O
RBP-Jkappa	B-protein
at	O
promoter	B-DNA
sites	I-DNA
.	O

Complementary	B-DNA
DNA	I-DNA
encoding	O
the	O
human	B-protein
T-cell	I-protein
FK506-binding	I-protein
protein	I-protein
,	O
a	O
peptidylprolyl	B-protein
cis-trans	I-protein
isomerase	I-protein
distinct	O
from	O
cyclophilin	B-protein
.	O

The	O
clinical	O
relevance	O
of	O
these	O
alterations	O
was	O
studied	O
by	O
comparing	O
the	O
FISH	O
results	O
with	O
several	O
parameters	O
currently	O
used	O
in	O
breast-cancer	O
pathology	O
.	O

Activation	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
after	O
antigen	O
recognition	O
is	O
a	O
critical	O
event	O
for	O
T	O
cell	O
proliferation	O
and	O
effector	O
function	O
.	O

This	O
was	O
also	O
true	O
for	O
KBF	O
(	O
p50	O
homodimer	O
)	O
binding	O
activity	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

When	O
all	O
the	O
asthmatic	O
patients	O
were	O
analyzed	O
together	O
,	O
there	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
degree	O
of	O
sensitivity	O
of	O
T	B-cell_type
cells	I-cell_type
to	O
dexamethasone	O
and	O
the	O
clinical	O
responsiveness	O
to	O
prednisolone	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

Their	O
different	O
activities	O
on	O
the	O
RA	O
signalling	O
pathway	O
might	O
underlie	O
the	O
different	O
responses	O
of	O
PML-RAR	B-protein
alpha	I-protein
and	O
PLZF-RAR	B-protein
alpha	I-protein
APLs	O
to	O
RA	O
treatment	O
.	O

Immunohistochemical	O
staining	O
demonstrated	O
RelB	B-protein
within	O
the	O
differentiated	B-cell_type
lymph	I-cell_type
node	I-cell_type
interdigitating	I-cell_type
DC	I-cell_type
and	O
follicular	B-cell_type
DC	I-cell_type
,	O
but	O
not	O
undifferentiated	B-cell_type
DC	I-cell_type
in	O
normal	O
skin	O
.	O

Transfection	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
the	O
NF-kappaB	B-protein
subunits	I-protein
p50	B-protein
and	O
p65	B-protein
confers	O
resistance	O
against	O
Fas-mediated	O
apoptosis	O
.	O

This	O
is	O
most	O
likely	O
due	O
to	O
the	O
presence	O
of	O
the	O
lymphoid-specific	B-protein
OTF-2	I-protein
factor	I-protein
.	O

The	O
v-erb	B-protein
A	I-protein
protein	I-protein
has	O
sustained	O
two	O
amino	O
acid	O
alterations	O
within	O
its	O
DNA-binding	B-protein
domain	I-protein
relative	O
to	O
that	O
of	O
c-erb	B-protein
A	I-protein
,	O
one	O
of	O
which	O
,	O
at	O
serine	O
61	O
,	O
is	O
known	O
to	O
be	O
important	O
for	O
v-erb	B-protein
A	I-protein
function	O
in	O
the	O
neoplastic	B-cell_type
cell	I-cell_type
.	O

Comparative	O
studies	O
showed	O
that	O
Fli-1	B-protein
was	O
also	O
able	O
to	O
transactivate	O
the	O
GPIbalpha	B-DNA
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
the	O
GPIIb	B-DNA
promoter	I-DNA
.	O

In	O
addition	O
,	O
negative	O
correlations	O
were	O
observed	O
between	O
FECa2+	O
in	O
the	O
dense	O
tubules	O
and	O
age	O
.	O

Cytokine	O
modulation	O
of	O
HIV	O
expression	O
.	O

Nevertheless	O
,	O
this	O
hyperaldosteronism	O
may	O
be	O
associated	O
with	O
hyponatremia	O
and	O
hyperkalemia	O
suggesting	O
PHA	O
related	O
to	O
the	O
major	O
importance	O
of	O
the	O
colon	O
for	O
the	O
absorption	O
of	O
sodium	O
.	O

Lipopolysaccharide	O
induction	O
of	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
promoter	I-DNA
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
a	O
failure	O
to	O
degrade	O
IkappaB-alpha	B-protein
in	O
cytosols	O
of	O
TNF-treated	B-cell_type
T	I-cell_type
cells	I-cell_type
pretreated	O
with	O
PAO	O
is	O
due	O
to	O
its	O
interference	O
with	O
the	O
phosphorylation	O
of	O
IkappaB-alpha	B-protein
and	O
not	O
due	O
to	O
its	O
inhibitory	O
effect	O
on	O
proteasomal	O
degradation	O
.	O

Furthermore	O
,	O
a	O
TAL1	B-protein
mutant	O
not	O
binding	O
to	O
DNA	O
also	O
activated	O
the	O
transcription	O
of	O
RALDH2	B-protein
in	O
the	O
presence	O
of	O
LMO	B-protein
and	O
GATA3	B-protein
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Absent	O
or	O
greatly	O
diminished	O
type	O
I	B-protein
aldosterone	I-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leucocytes	I-cell_type
have	O
been	O
recently	O
demonstrated	O
and	O
explain	O
the	O
lack	O
of	O
response	O
to	O
mineralocorticoids	O
.	O

Sequence-specific	O
DNA	O
binding	O
of	O
the	O
proto-oncoprotein	B-protein
ets-1	B-protein
defines	O
a	O
transcriptional	B-DNA
activator	I-DNA
sequence	I-DNA
within	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
of	O
the	O
Moloney	O
murine	O
sarcoma	O
virus	O
.	O

T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
cross-linking	O
is	O
in	O
part	O
required	O
for	O
activation	O
of	O
NF-kappaB	B-protein
,	O
which	O
is	O
dependent	O
on	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaBalpha	B-protein
.	O

Cutting	O
edge	O
:	O
TCR	B-protein
stimulation	O
by	O
antibody	O
and	O
bacterial	O
superantigen	O
induces	O
Stat3	B-protein
activation	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Protein	B-protein
kinase	I-protein
C	I-protein
activation	O
and	O
protooncogene	B-DNA
expression	O
in	O
differentiation/retrodifferentiation	O
of	O
human	B-cell_line
U-937	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

(	O
5	O
)	O
Some	O
neoplastic	O
cells	O
in	O
AITL	O
stained	O
for	O
Bcl-6	B-protein
,	O
suggesting	O
up-regulation	O
of	O
Bcl-6	B-protein
expression	O
in	O
this	O
tumor	O
.	O

Calcineurin	B-protein
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
inactivate	O
I	B-protein
kappa	I-protein
B/MAD3	I-protein
,	O
an	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

A	O
mutant	B-DNA
LTR	I-DNA
containing	O
four	O
base	O
pair	O
substitutions	O
in	O
the	O
ets-1	B-DNA
binding	I-DNA
site	I-DNA
was	O
constructed	O
and	O
was	O
shown	O
to	O
have	O
reduced	O
binding	O
in	O
vitro	O
.	O

Transient	O
expression	O
analyses	O
in	O
cells	O
of	O
neuroglial	O
and	O
lymphocytic	O
origin	O
demonstrated	O
that	O
some	O
of	O
these	O
LTRs	B-DNA
had	O
activities	O
which	O
varied	O
significantly	O
from	O
the	O
LAI	B-DNA
LTR	I-DNA
in	O
U-373	B-cell_line
MG	I-cell_line
cells	I-cell_line
(	O
an	O
astrocytoma	B-cell_line
cell	I-cell_line
line	I-cell_line
)	O
as	O
well	O
as	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
(	O
a	O
CD4-positive	B-cell_line
lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
)	O
.	O

The	O
percentage	O
of	O
cells	O
expressing	O
CD40	B-protein
in	O
T	B-cell_line
and	I-cell_line
B	I-cell_line
cell	I-cell_line
co-cultures	I-cell_line
increased	O
from	O
4.2	O
%	O
to	O
13.8	O
%	O
after	O
oligo	O
stimulation	O
in	O
patients	O
,	O
while	O
it	O
increased	O
form	O
4.7	O
%	O
to	O
48.6	O
%	O
in	O
healthy	O
controls	O
.	O

Expression	O
of	O
LMP1	B-protein
was	O
seen	O
in	O
variable	O
proportions	O
of	O
tumor	B-cell_type
cells	I-cell_type
in	O
two	O
cases	O
and	O
EBNA2	B-protein
was	O
detected	O
in	O
some	O
tumor	B-cell_type
cells	I-cell_type
in	O
three	O
other	O
cases	O
.	O

Inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
by	O
anetholdithiolthione	O
.	O

We	O
prepared	O
nuclear	O
extracts	O
from	O
two	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
levels	O
correlated	O
with	O
increased	O
phosphorylation	O
of	O
the	O
Ets-1	B-protein
protein	O
.	O

Treatment	O
of	O
cells	O
expressing	O
the	O
chimeric	B-protein
receptor	I-protein
kit/IL-4R	B-protein
alpha	I-protein
with	O
SCF	B-protein
induces	O
activation	O
of	O
the	O
IL-4R	B-protein
alpha-associated	I-protein
kinase	I-protein
JAK-1	B-protein
and	O
the	O
transcription	B-protein
factor	I-protein
STAT6	B-protein
.	O

In	O
addition	O
,	O
recombinant	O
IL-1beta	B-protein
was	O
able	O
to	O
replace	O
MCM	O
for	O
the	O
inhibition	O
of	O
proliferation	O
and	O
down-regulation	O
of	O
AR	B-protein
and	O
PSA	B-protein
proteins	O
.	O

We	O
further	O
characterize	O
which	O
AP1	B-protein
family	I-protein
members	I-protein
can	O
assume	O
this	O
role	O
.	O

Impaired	O
myelopoiesis	O
in	O
vivo	O
was	O
shown	O
by	O
stressing	O
these	O
mice	O
with	O
sublethal	O
irradiation	O
.	O

Overall	O
,	O
these	O
results	O
indicate	O
that	O
the	O
integrity	O
of	O
domain	B-protein
E	I-protein
is	O
necessary	O
and	O
sufficient	O
to	O
bind	O
steroid	O
ligands	O
,	O
agonists	O
or	O
antagonists	O
,	O
with	O
characteristics	O
similar	O
to	O
the	O
entire	O
native	O
MR	B-protein
.	O

PCR	O
analysis	O
of	O
spontaneous	B-cell_line
EBV-transformed	I-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
LCL	B-cell_line
)	O
from	O
three	O
individuals	O
with	O
primary	O
infection	O
showed	O
that	O
two	O
were	O
infected	O
with	O
type	O
A	O
and	O
one	O
with	O
type	O
B	O
EBV	O
.	O

The	O
findings	O
suggest	O
that	O
when	O
SOCS-3	B-protein
is	O
rapidly	O
induced	O
by	O
IL-2	B-protein
in	O
T	B-cell_type
cells	I-cell_type
,	O
it	O
acts	O
to	O
inhibit	O
IL-2	B-protein
responses	O
in	O
a	O
classical	O
negative	O
feedback	O
loop	O
.	O

NF-kB	B-protein
is	O
a	O
eukaryotic	B-protein
transcription	I-protein
regulatory	I-protein
factor	I-protein
.	O

Secreted	O
TNF-alpha	B-protein
mediated	O
the	O
enhancement	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
and	O
activator	O
protein-1	O
(	O
AP-1	B-protein
)	O
binding	O
activity	O
;	O
in	O
fact	O
,	O
the	O
triggering	O
of	O
HLA-DR	B-protein
antigens	I-protein
in	O
the	O
presence	O
of	O
antihuman	B-protein
TNF-alpha-neutralizing	I-protein
antibodies	I-protein
did	O
not	O
upregulate	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
.	O

But	O
many	O
puzzles	O
of	O
the	O
drugs	O
remain	O
.	O

Finally	O
,	O
the	O
addition	O
of	O
anti-CD28	B-protein
mAb	I-protein
to	O
anti-CD3	B-cell_type
mAb-stimulated	I-cell_type
T	I-cell_type
cells	I-cell_type
overcame	O
much	O
of	O
the	O
suppression	O
of	O
proliferation	O
induced	O
by	O
PGE2	O
or	O
ISO	O
but	O
less	O
so	O
than	O
that	O
induced	O
by	O
DEX	O
.	O

CD30	B-protein
,	O
however	O
,	O
has	O
also	O
been	O
implicated	O
in	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
of	O
lymphocytes	B-cell_type
.	O

The	O
correlation	O
is	O
specific	O
as	O
the	O
level	O
of	O
at	O
least	O
three	O
other	O
transcription	B-protein
factors	I-protein
did	O
not	O
change	O
.	O

Replication	O
of	O
human	O
immunodeficiency	O
virus-1	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
is	O
dependent	O
on	O
the	O
autocrine	O
secretion	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
through	O
the	O
control	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activation	O
.	O

AP-1	B-protein
,	O
the	O
polypeptide	O
product	O
of	O
c-jun	B-DNA
,	O
recognizes	O
and	O
binds	O
to	O
specific	O
DNA	O
sequences	O
and	O
stimulates	O
transcription	O
of	O
genes	B-DNA
responsive	O
to	O
certain	O
growth	O
factors	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

However	O
,	O
the	O
two	O
SH2	B-protein
domains	I-protein
of	O
SHP1	B-protein
did	O
not	O
facilitate	O
its	O
recognition	O
of	O
ZAP-70	B-protein
and	O
Syk	B-protein
as	O
substrates	O
in	O
intact	O
cells	O
.	O

A	O
candidate	O
gene	O
to	O
control	O
thymocyte	B-cell_type
differentiation	O
,	O
T	B-protein
cell	I-protein
factor-1	I-protein
(	O
TCF-1	B-protein
)	O
*	O
encodes	O
a	O
DNA-binding	B-protein
protein	I-protein
.	O

Expression	O
studies	O
on	O
TCF-1	B-protein
protein	I-protein
have	O
been	O
hampered	O
by	O
the	O
difficulty	O
to	O
raise	O
antibodies	B-protein
due	O
to	O
extreme	O
evolutionary	O
conservation	O
.	O

Both	O
groups	O
showed	O
substantial	O
decreases	O
in	O
mineralocorticoid	O
(	O
MR	O
)	O
and	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
levels	O
in	O
the	O
hippocampus	O
,	O
a	O
limbic	O
brain	O
structure	O
critical	O
for	O
HPA	O
axis	O
regulation	O
,	O
whereas	O
GR	B-protein
concentrations	O
in	O
the	O
hypothalamus	O
were	O
unchanged	O
and	O
in	O
anterior	O
pituitary	O
were	O
slightly	O
increased	O
.	O

The	O
15-LO	B-protein
promoter	O
is	O
associated	O
with	O
a	O
CpG	O
island	O
at	O
the	O
5'-end	B-DNA
of	O
the	O
gene	O
,	O
and	O
sequence	O
analysis	O
reveals	O
putative	O
Sp1	B-DNA
and	I-DNA
Ap2	I-DNA
binding	I-DNA
site/s	I-DNA
and	O
absence	O
of	O
TATA	B-DNA
or	I-DNA
CAAT	I-DNA
motifs	I-DNA
.	O

It	O
is	O
our	O
contention	O
that	O
CD	O
is	O
triggered	O
by	O
the	O
binding	O
of	O
one	O
or	O
more	O
gliadin	O
peptides	O
to	O
CD-associated	B-protein
HLA	I-protein
class	I-protein
II	I-protein
molecules	I-protein
.	O

CONCLUSIONS	O
Hypercortisolaemia	O
does	O
not	O
down-regulate	O
the	O
lymphocyte	O
glucocorticoid	B-protein
receptors	I-protein
in	O
anorexia	O
nervosa	O
and	O
a	O
post-receptor	O
defect	O
might	O
be	O
involved	O
in	O
peripheral	O
tissue	O
resistance	O
to	O
the	O
effects	O
of	O
glucocorticoid	O
hormones	O
in	O
undernutrition	O
.	O

To	O
explore	O
the	O
receptor	O
signaling	O
pathways	O
involved	O
in	O
RA-induced	O
apoptosis	O
,	O
we	O
used	O
selective	O
ligands	O
for	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RARs	O
;	O
RO13-7410	O
)	O
and	O
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
;	O
RO	O
25-6603	O
)	O
.	O

The	O
T	B-protein
cell	I-protein
activation	I-protein
factor	I-protein
NF-ATc	B-protein
positively	O
regulates	O
HIV-1	O
replication	O
and	O
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Staurosporine	O
,	O
a	O
nonspecific	O
inhibitor	O
of	O
PKC	B-protein
,	O
partially	O
blocked	O
TPA-induced	O
adherence	O
and	O
growth	O
inhibition	O
and	O
concomitantly	O
prevented	O
TPA-induced	O
c-fos	O
and	O
c-jun	O
gene	O
expression	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
Nef	O
protein	O
down-regulates	O
transcription	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vitro	O
after	O
T-cell	O
receptor	O
stimulation	O
.	O

Kinase	O
activity	O
was	O
reduced	O
in	O
lysates	O
preadsorbed	O
using	O
an	O
antibody	B-protein
specific	O
for	O
CaM	B-protein
kinase	I-protein
II	I-protein
.	O

Induction	O
of	O
HL-60	B-cell_line
and	O
U-937	B-cell_line
cell	O
differentiation	O
into	O
monocytes/macrophages	B-cell_type
by	O
IFN-gamma	B-protein
or	O
PMA	O
results	O
in	O
a	O
dephosphorylation	O
and	O
consequent	O
activation	O
of	O
4E-BP1	B-protein
.	O

Positive	O
autoregulation	O
of	O
GR	B-protein
expression	O
was	O
also	O
observed	O
in	O
glucocorticoid-resistant	B-cell_line
CEM-C1	I-cell_line
cells	I-cell_line
,	O
which	O
contain	O
functional	O
GR	B-protein
,	O
but	O
whose	O
growth	O
is	O
unaffected	O
by	O
glucocorticoids	O
.	O

It	O
appears	O
that	O
the	O
B	O
cell-specific	O
expression	O
of	O
Ig	B-DNA
genes	I-DNA
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
cell	O
type-specific	B-protein
Oct	I-protein
factors	I-protein
,	O
and	O
that	O
there	O
are	O
both	O
quantitative	O
and	O
qualitative	O
differences	O
between	O
Oct-1	B-protein
and	O
Oct-2	B-protein
factors	I-protein
.	O

Both	O
IL-4	B-protein
and	O
anti-	O
CD40	B-protein
mAb	I-protein
induced	O
activation	O
of	O
phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI3-kinase	B-protein
)	O
,	O
translocation	O
of	O
a	O
zeta	O
isoform	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
and	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Oxidative	O
stress	O
enhances	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activity	O
,	O
and	O
NF-kappa	B-protein
B	I-protein
activity	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
expression	O
of	O
cytotoxic	B-protein
cytokines	I-protein
.	O

Chemical	O
cross-linking	O
with	O
125I-labeled	B-protein
TGF-beta	I-protein
1	I-protein
showed	O
an	O
essentially	O
normal	O
TGF-beta	B-protein
receptor	I-protein
profile	O
in	O
EBV-positive	B-cell_line
and	I-cell_line
EBV-negative	I-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
these	O
receptors	O
were	O
shown	O
to	O
be	O
functional	O
in	O
transducing	O
signals	O
,	O
as	O
evidenced	O
by	O
the	O
TGF-beta	B-protein
1	I-protein
-mediated	O
modulation	O
of	O
junB	B-DNA
gene	I-DNA
expression	O
.	O

These	O
data	O
indicate	O
a	O
highly	O
polarized	O
functional	O
architecture	O
for	O
antigen	O
processing	O
and	O
presentation	O
by	O
intestinal	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
,	O
and	O
suggest	O
that	O
the	O
functional	O
outcome	O
of	O
antigen	O
processing	O
by	O
the	O
intestinal	O
epithelium	O
is	O
both	O
dependent	O
on	O
the	O
cellular	O
surface	O
at	O
which	O
the	O
foreign	O
antigen	O
is	O
internalized	O
and	O
by	O
the	O
underlying	O
degree	O
of	O
mucosal	O
inflammation	O

We	O
have	O
used	O
Western	O
blotting	O
to	O
investigate	O
the	O
presence	O
of	O
these	O
proteins	O
during	O
the	O
cell	O
cycles	O
of	O
two	O
different	O
cellular	B-cell_line
systems	I-cell_line
:	O
a	O
continuously	B-cell_line
growing	I-cell_line
myeloid	I-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
HL60	B-cell_line
,	O
and	O
normal	B-cell_type
cells	I-cell_type
stimulated	O
into	O
cycle	O
,	O
phyto-	B-cell_line
hemagglutinin	I-cell_line
(	I-cell_line
PHA	I-cell_line
)	I-cell_line
-stimulated	I-cell_line
normal	I-cell_line
human	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
(	O
PBL	B-cell_type
)	O
.	O

Nuclear	B-protein
Rel-A	I-protein
and	I-protein
c-Rel	I-protein
protein	I-protein
complexes	I-protein
are	O
differentially	O
distributed	O
within	O
human	B-cell_type
thymocytes	I-cell_type
.	O

Cotransfection	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B-protein
largely	O
substituted	O
for	O
the	O
Ca2+	O
requirement	O
and	O
reversed	O
the	O
blockade	O
by	O
SK	O
&	O
F	O
96365	O
.	O

MEASUREMENTS	O
:	O
The	O
binding	O
capacity	O
and	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
were	O
measured	O
and	O
compared	O
to	O
clinical	O
data	O
and	O
the	O
plasma	O
cortisol	O
concentrations	O
.	O

TNF-alpha	B-protein
release	O
in	O
culture	O
supernatants	O
was	O
measured	O
by	O
an	O
ELISA	O
.	O

All	O
the	O
isoforms	B-protein
retain	O
the	O
previously	O
characterized	O
POU-domain	O
and	O
are	O
therefore	O
able	O
to	O
bind	O
to	O
the	O
octamer	B-DNA
motif	I-DNA
.	O

Additionally	O
,	O
we	O
show	O
that	O
SLAP-130	B-protein
is	O
a	O
substrate	O
of	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor-induced	I-protein
protein	I-protein
tyrosine	B-protein
kinases	I-protein
.	O

Interestingly	O
,	O
microtubule	B-protein
disruption	O
also	O
decreased	O
monocyte	B-cell_type
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
,	O
not	O
by	O
decreasing	O
the	O
Vmax	O
of	O
monocyte	B-protein
mitochondrial	I-protein
1	I-protein
alpha-hydroxylase	I-protein
but	O
through	O
an	O
increase	O
in	O
the	O
Km	O
for	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

Isolation	O
and	O
utilization	O
of	O
human	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
from	O
peripheral	O
blood	O
to	O
assay	O
an	O
in	O
vitro	O
primary	O
immune	O
response	O
to	O
varicella-zoster	O
virus	O
peptides	O
.	O

In	O
contrast	O
,	O
treatment	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
was	O
associated	O
with	O
stabilization	O
(	O
t	O
1/2	O
=	O
90	O
min	O
)	O
of	O
c-jun	B-protein
transcripts	I-protein
.	O

These	O
results	O
strongly	O
suggest	O
that	O
HU	O
induces	O
both	O
transcriptional	O
and	O
post-transcription	O
regulation	O
of	O
c-jun	B-DNA
during	O
erythroid	O
differentiation	O
.	O

Dual	O
action	O
of	O
retinoic	O
acid	O
on	O
human	O
embryonic/fetal	O
hematopoiesis	O
:	O
blockade	O
of	O
primitive	O
progenitor	O
proliferation	O
and	O
shift	O
from	O
multipotent/erythroid/monocytic	O
to	O
granulocytic	O
differentiation	O
program	O
.	O

This	O
indicates	O
that	O
functional	O
differences	O
observed	O
in	O
IL-2-	B-cell_line
and	I-cell_line
IL-12-stimulated	I-cell_line
cells	I-cell_line
may	O
depend	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
differential	O
gene	O
regulation	O
.	O

In	O
the	O
bone	O
marrow	O
,	O
it	O
is	O
preferentially	O
expressed	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

The	O
same	O
pattern	O
of	O
inhibition	O
was	O
observed	O
using	O
anti-human	O
LT	O
sera	O
.	O

Expression	O
of	O
c-fos	B-DNA
correlates	O
with	O
IFN-alpha	B-protein
responsiveness	O
in	O
Philadelphia	O
chromosome	O
positive	O
chronic	O
myelogenous	O
leukemia	O
.	O

Plasma	O
cortisol	O
and	O
aldosterone	O
levels	O
and	O
number	O
of	O
related	O
receptors	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
were	O
measured	O
in	O
49	O
healthy	O
aged	O
subjects	O
(	O
62-97	O
yr	O
)	O
and	O
in	O
21	O
adult	O
controls	O
(	O
21-50	O
yr	O
)	O
.	O

The	O
phosphorylation	O
appears	O
to	O
be	O
related	O
to	O
the	O
signaling	O
events	O
that	O
are	O
activated	O
by	O
TRAF2	B-protein
under	O
these	O
circumstances	O
,	O
since	O
two	O
nonfunctional	O
mutants	O
were	O
found	O
to	O
be	O
phosphorylated	O
significantly	O
less	O
than	O
the	O
wild-type	B-protein
protein	I-protein
.	O

bcl-2	B-protein
expression	O
is	O
increased	O
following	O
phorbol	O
ester	O
treatment	O
,	O
and	O
the	O
increased	O
expression	O
is	O
dependent	O
on	O
the	O
CRE	B-DNA
site	I-DNA
.	O

One	O
gene	O
product	O
,	O
when	O
overexpressed	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
specifically	O
induced	O
transcription	O
from	O
the	O
interleukin-2	B-DNA
enhancer	I-DNA
,	O
by	O
activating	O
the	O
T-cell-specific	B-protein
transcription	I-protein
factors	I-protein
NF-AT	B-protein
and	O
NF-IL2A	B-protein
.	O

Five	O
patients	O
were	O
found	O
with	O
repeated	O
maximal	O
responses	O
to	O
adenovirus	B-protein
antigen	I-protein
;	O
in	O
one	O
of	O
these	O
adenovirus	B-DNA
nucleotide	I-DNA
sequences	I-DNA
were	O
present	O
in	O
a	O
synovial	O
biopsy	O
specimen	O
.	O

These	O
data	O
suggest	O
that	O
USF/c-Myc	B-protein
and	O
YY1	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
HIV-1-replicative	O
cycle	O
,	O
by	O
modulating	O
both	O
the	O
viral	O
fusion/entry	O
process	O
and	O
viral	O
expression	O
.	O

Deletions	O
of	O
a	O
relatively	O
short	O
amino-	B-protein
(	I-protein
729-766	I-protein
)	I-protein
or	I-protein
carboxy-	I-protein
terminal	I-protein
(	I-protein
940-984	I-protein
)	I-protein
region	I-protein
of	O
the	O
HBD	B-protein
fragment	I-protein
eliminated	O
all	O
steroid-binding	O
properties	O
.	O

The	O
type	O
I	O
human	O
T-cell	O
leukemia	O
virus	O
(	O
HTLV-I	O
)	O
induces	O
abnormal	O
growth	O
and	O
subsequent	O
transformation	O
of	O
T	B-cell_type
cells	I-cell_type
,	O
which	O
is	O
associated	O
with	O
the	O
development	O
of	O
an	O
acute	O
T-cell	O
malignancy	O
termed	O
adult	O
T-cell	O
leukemia	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
indicate	O
that	O
the	O
lack	O
of	O
cushingoid	O
features	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
is	O
not	O
ascribable	O
to	O
a	O
reduced	O
sensitivity	O
to	O
glucocorticoids	O
but	O
is	O
more	O
likely	O
due	O
to	O
the	O
paucity	O
of	O
metabolic	O
substrates	O
.	O

In	O
an	O
open-label	O
study	O
,	O
adolescents	O
(	O
n	O
=	O
20	O
)	O
meeting	O
DSM-III-R	O
criteria	O
for	O
MDD	O
showed	O
baseline	O
lymphocyte	B-protein
GCII	I-protein
sites	I-protein
per	O
cell	O
(	O
sites/cell	O
)	O
values	O
of	O
793	O
+/-	O
106	O
versus	O
2	O
,	O
563	O
+/-	O
499	O
(	O
+/-	O
SEM	O
)	O
for	O
matched	O
controls	O
(	O
n	O
=	O
18	O
)	O
(	O
t	O
=	O
3.5	O
;	O
df	O
=	O
36	O
;	O
p	O
<	O
.001	O
)	O
.	O

Human	B-protein
TAFII	I-protein
105	I-protein
is	O
a	O
cell	B-protein
type-specific	I-protein
TFIID	I-protein
subunit	I-protein
related	O
to	O
hTAFII130	B-protein
.	O

A	O
common	O
feature	O
of	O
all	O
stages	O
of	O
atherosclerosis	O
is	O
inflammation	O
of	O
the	O
vessel	O
wall	O
.	O

Several	O
criteria	O
indicated	O
that	O
the	O
defect	O
in	O
this	O
cell	O
line	O
influences	O
the	O
activity	O
of	O
an	O
isotype-specific	B-protein
transcription	I-protein
factor	I-protein
.	O

Processing	O
of	O
the	O
precursor	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
the	O
HIV-1	B-protein
protease	I-protein
during	O
acute	O
infection	O
.	O

Our	O
present	O
study	O
shows	O
that	O
IFN-alpha	B-protein
and	I-protein
-beta	I-protein
mediate	O
anti-apoptotic	O
effect	O
through	O
other	O
pathways	O
than	O
that	O
of	O
IL-2	B-protein
in	O
growth	O
factor	O
deprivation	O
apoptosis	O
.	O

Inhibition	O
of	O
HIV-1	O
replication	O
by	O
combination	O
of	O
a	O
novel	O
inhibitor	O
of	O
TNF-alpha	B-protein
with	O
AZT	O
.	O

By	O
employing	O
a	O
derivative	O
E	B-DNA
box	I-DNA
that	O
binds	O
ZEB	B-protein
but	O
not	O
E2A	B-protein
,	O
we	O
have	O
shown	O
that	O
the	O
repressor	B-protein
is	O
active	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
the	O
IgH	B-DNA
enhancer	I-DNA
is	O
silenced	O
in	O
the	O
absence	O
of	O
binding	O
competition	O
by	O
bHLH	B-protein
proteins	I-protein
.	O

T	O
cell	O
recognition	O
of	O
specific	O
peptides	O
was	O
concordant	O
between	O
naive	O
,	O
DC	B-cell_type
-mediated	O
responses	O
,	O
and	O
postvaccine	O
responses	O
using	O
monocytes	B-cell_type
as	O
APC	B-cell_type
in	O
69	O
%	O
of	O
comparisons	O
(	O
p	O
=	O
0.05	O
;	O
chi2	O
)	O
;	O
the	O
predictive	O
value	O
of	O
a	O
positive	O
response	O
to	O
an	O
IE62	O
peptide	O
before	O
immunization	O
for	O
T	O
cell	O
sensitization	O
in	O
vivo	O
was	O
82	O
%	O
.	O

However	O
,	O
the	O
change	O
in	O
p130	B-protein
phosphorylation	O
in	O
response	O
to	O
alpha-IFN	B-protein
occurs	O
before	O
dephosphorylation	O
of	O
pRb	B-protein
is	O
complete	O
because	O
loss	O
of	O
p130	B-protein
Form	I-protein
3	I-protein
occurs	O
throughout	O
the	O
cell	O
cycle	O
prior	O
to	O
complete	O
arrest	O
in	O
G1	O
,	O
whereas	O
pRb	B-protein
is	O
dephosphorylated	O
only	O
in	O
G1	O
.	O

The	O
expression	O
of	O
the	O
murine	B-protein
interleukin	I-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
receptor	I-protein
alpha	I-protein
chain/CD25	I-protein
is	O
strongly	O
induced	O
at	O
the	O
transcriptional	O
level	O
after	O
T	O
cell	O
activation	O
.	O

In	O
contrast	O
,	O
intracytoplasmic	O
TNFalpha	B-protein
levels	O
were	O
strongly	O
reduced	O
in	O
transfected	B-cell_line
clones	I-cell_line
.	O

In	O
T	O
cell	O
areas	O
,	O
p50	B-protein
,	O
p52	B-protein
,	O
and	O
RelB	B-protein
were	O
found	O
in	O
the	O
nuclei	O
of	O
HLA-DR+	B-cell_line
cells	I-cell_line
with	O
an	O
antigen-presenting	O
cell	O
(	O
APC	O
)	O
morphology	O
.	O

The	O
formation	O
of	O
a	O
stable	O
tetrameric	B-protein
DCoH-HNF-1	I-protein
alpha	I-protein
complex	I-protein
,	O
which	O
required	O
the	O
dimerization	B-protein
domain	I-protein
of	O
HNF-1	B-protein
alpha	I-protein
,	O
did	O
not	O
change	O
the	O
DNA	O
binding	O
characteristics	O
of	O
HNF-1	B-protein
alpha	I-protein
,	O
but	O
enhanced	O
its	O
transcriptional	O
activity	O
.	O

Thus	O
,	O
OBF-1	B-protein
has	O
all	O
the	O
properties	O
expected	O
for	O
a	O
B	B-protein
cell-specific	I-protein
transcriptional	I-protein
coactivator	I-protein
protein	I-protein
.	O

6.	O
Partitioning	O
of	O
SMX-NHOH	O
into	O
red	B-cell_type
blood	I-cell_type
cells	I-cell_type
was	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
lower	O
than	O
with	O
the	O
hydroxylamine	O
of	O
dapsone	O
.	O

The	O
close	O
homology	O
of	O
the	O
basic	B-protein
region/leucine	I-protein
zipper	I-protein
(	O
bZIP	B-protein
)	O
DNA-binding	O
and	O
dimerization	B-protein
domain	I-protein
of	O
HLF	B-protein
to	O
that	O
of	O
the	O
CES-2	B-protein
cell-death	I-protein
specification	I-protein
protein	I-protein
of	O
Caenorhabditis	O
elegans	O
suggests	O
a	O
model	O
of	O
leukaemogenesis	O
in	O
which	O
E2A-HLF	B-protein
blocks	O
an	O
early	O
step	O
within	O
an	O
evolutionarily	O
conserved	O
cell-death	O
pathway	O
.	O

We	O
have	O
now	O
investigated	O
the	O
effect	O
of	O
oxLDLs	B-protein
on	O
blast	O
differentiation	O
,	O
on	O
IL-2	B-protein
synthesis	O
and	O
on	O
the	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
system	O
in	O
activated	O
lymphocytes	O
.	O

After	O
cellular	O
activation	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
rapidly	O
degraded	O
in	O
concert	O
with	O
the	O
induced	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

However	O
,	O
activation	O
from	O
a	O
remote	O
position	O
could	O
only	O
be	O
achieved	O
with	O
the	O
C-terminus	B-protein
of	O
Oct-2a	B-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O

We	O
studied	O
the	O
ability	O
of	O
N-acetylglucosaminyl-1	O
,	O
6-anhydro-N-acetylmuramyl-L-alanyl-D-	O
isoglutamyl-m-diaminopimelyl-D-alanine	O
(	O
G	O
(	O
Anh	O
)	O
MTetra	O
)	O
,	O
a	O
naturally	O
occurring	O
breakdown	O
product	O
of	O
peptidoglycan	O
that	O
is	O
produced	O
by	O
soluble	O
lytic	B-protein
transglycosylase	I-protein
of	O
Escherichia	O
coli	O
,	O
to	O
induce	O
cytokine	B-protein
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Tissue	O
transglutaminase-dependent	O
posttranslational	O
modification	O
of	O
the	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
in	O
promonocytic	B-cell_line
cells	I-cell_line
undergoing	O
apoptosis	O
.	O

In	O
contrast	O
,	O
anergic	B-cell_type
T	I-cell_type
cells	I-cell_type
express	O
approximately	O
eightfold	O
lower	O
amounts	O
of	O
NF-AT	B-protein
,	O
a	O
member	O
of	O
the	O
class	O
of	O
inducible	B-protein
factors	I-protein
that	O
regulates	O
IL-2	B-DNA
gene	I-DNA
transcription	O
.	O

FGF-1	B-protein
alone	O
induces	O
modest	O
nuclear	O
translocation	O
of	O
kappaB-binding	B-protein
proteins	I-protein
,	O
and	O
this	O
translocation	O
is	O
enhanced	O
by	O
the	O
combination	O
of	O
anti-CD3	B-protein
and	O
FGF-1	B-protein
.	O

We	O
have	O
now	O
raised	O
a	O
monoclonal	B-protein
antibody	I-protein
to	O
document	O
expression	O
and	O
biochemistry	O
of	O
the	O
human	B-protein
TCF-1	I-protein
protein	I-protein
.	O

17beta-estradiol	O
(	O
E2	O
)	O
markedly	O
enhanced	O
lipopolysaccharide	O
-	O
(	O
LPS	O
)	O
induced	O
IL-1beta	B-DNA
promoter	I-DNA
-driven	O
CAT	B-protein
activity	O
in	O
a	O
dose-dependent	O
manner	O
.	O

The	O
murine	B-DNA
fra-1	I-DNA
gene	I-DNA
,	O
encoding	O
Fos-related	B-protein
Ag	I-protein
1	I-protein
,	O
was	O
isolated	O
from	O
a	O
splenic	B-DNA
cDNA	I-DNA
library	I-DNA
and	O
sequenced	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
stress-activated	B-protein
protein	I-protein
kinases	I-protein
(	O
SAPK	B-protein
)	O
are	O
activated	O
after	O
CD40	B-protein
cross-linking	O
on	O
various	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
or	O
human	B-cell_type
tonsillar	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Inducible	O
nitric	O
oxide	O
:	O
an	O
autoregulatory	O
feedback	O
inhibitor	O
of	O
vascular	O
inflammation	O
.	O

Therefore	O
we	O
conclude	O
that	O
flavonoids	O
may	O
be	O
of	O
therapeutic	O
value	O
for	O
vascular	O
disease	O
through	O
down	O
regulation	O
of	O
NFkappaB	B-protein
/IkappaB	B-protein
system	O
.	O

In	O
the	O
adult	O
,	O
however	O
,	O
lymphoid	B-cell_type
lineages	I-cell_type
rely	O
on	O
Ikaros	B-DNA
at	O
distinct	O
phases	O
of	O
their	O
development	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
3-carboranyl-substituted	O
compounds	O
(	O
8	O
,	O
12	O
)	O
showed	O
potential	O
agonistic	O
activity	O
,	O
but	O
no	O
antagonistic	O
activity	O
.	O

In	O
contrast	O
,	O
a	O
high	O
level	O
of	O
bcl-2	B-protein
protects	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
from	O
the	O
viral	B-protein
protease	I-protein
and	O
prevents	O
cell	O
death	O
following	O
HIV	O
infection	O
of	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
while	O
reducing	O
the	O
yields	O
of	O
viral	B-protein
structural	I-protein
proteins	I-protein
,	O
infectivity	O
,	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
.	O

However	O
,	O
while	O
HUVECs	B-cell_line
contained	O
endothelial	O
NOS	B-protein
protein	I-protein
,	O
no	O
inducible	O
NOS	B-protein
was	O
detected	O
in	O
either	O
tolerant	O
or	O
nontolerant	B-cell_type
cells	I-cell_type
.	O

Although	O
the	O
mechanism	O
of	O
LTR	B-DNA
activation	O
remains	O
obscure	O
,	O
several	O
lines	O
of	O
investigation	O
have	O
suggested	O
that	O
it	O
is	O
a	O
result	O
of	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factor	I-protein
(	O
s	O
)	O
following	O
signaling	O
events	O
related	O
to	O
generalized	O
DNA	O
damage	O
.	O

In	O
different	O
genes	B-DNA
,	O
the	O
core	B-DNA
sequences	I-DNA
are	O
separated	O
by	O
integer	O
numbers	O
of	O
helical	O
turns	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
and	O
3-O-methyl-D	O
glucose	O
(	O
3-O-MG	O
)	O
transport	O
were	O
determined	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
(	O
MNL	B-cell_type
)	O
from	O
11	O
abdominal	O
obese	O
subjects	O
,	O
10	O
pituitary-dependent	O
Cushing	O
's	O
syndrome	O
(	O
Cushing	O
's	O
disease	O
)	O
and	O
10	O
healthy	O
controls	O
.	O
